{
  "Version": 76,
  "Individuals": [
    {
      "Name": "Standard_Adult_UGT",
      "Seed": 965997659,
      "OriginData": {
        "CalculationMethods": [
          "SurfaceAreaPlsInt_VAR1",
          "Body surface area - Mosteller"
        ],
        "Species": "Human",
        "Population": "European_ICRP_2002",
        "Gender": "MALE",
        "Age": {
          "Value": 30.0,
          "Unit": "year(s)"
        }
      },
      "Parameters": [
        {
          "Path": "Organism|Liver|EHC continuous fraction",
          "Value": 1.0,
          "ValueOrigin": {
            "Source": "Unknown"
          }
        },
        {
          "Path": "Organism|Lumen|Caecum|Effective surface area enhancement factor",
          "Value": 0.3067717772,
          "ValueOrigin": {
            "Source": "ParameterIdentification",
            "Method": "ParameterIdentification",
            "Description": "Value updated from 'Parameter Identification-17457' on 2019-08-02 13:57"
          }
        },
        {
          "Path": "Organism|Lumen|ColonAscendens|Effective surface area enhancement factor",
          "Value": 0.4260719128,
          "ValueOrigin": {
            "Source": "ParameterIdentification",
            "Method": "ParameterIdentification",
            "Description": "Value updated from 'Parameter Identification-17457' on 2019-08-02 13:57"
          }
        },
        {
          "Path": "Organism|Lumen|ColonDescendens|Effective surface area enhancement factor",
          "Value": 0.4260719128,
          "ValueOrigin": {
            "Source": "ParameterIdentification",
            "Method": "ParameterIdentification",
            "Description": "Value updated from 'Parameter Identification-17457' on 2019-08-02 13:57"
          }
        },
        {
          "Path": "Organism|Lumen|ColonSigmoid|Effective surface area enhancement factor",
          "Value": 0.4260719128,
          "ValueOrigin": {
            "Source": "ParameterIdentification",
            "Method": "ParameterIdentification",
            "Description": "Value updated from 'Parameter Identification-17457' on 2019-08-02 13:57"
          }
        },
        {
          "Path": "Organism|Lumen|ColonTransversum|Effective surface area enhancement factor",
          "Value": 0.4260719128,
          "ValueOrigin": {
            "Source": "ParameterIdentification",
            "Method": "ParameterIdentification",
            "Description": "Value updated from 'Parameter Identification-17457' on 2019-08-02 13:57"
          }
        },
        {
          "Path": "Organism|Lumen|Rectum|Effective surface area enhancement factor",
          "Value": 0.6067264038,
          "ValueOrigin": {
            "Source": "ParameterIdentification",
            "Method": "ParameterIdentification",
            "Description": "Value updated from 'Parameter Identification-17457' on 2019-08-02 13:57"
          }
        }
      ],
      "Molecules": [
        {
          "Name": "CYP3A4",
          "Type": "Enzyme",
          "MembraneLocation": "Apical",
          "TissueLocation": "Intracellular",
          "IntracellularVascularEndoLocation": "Endosomal",
          "Expression": [
            {
              "Name": "Brain",
              "Value": 0.0041682898325
            },
            {
              "Name": "Gonads",
              "Value": 0.00078691079081
            },
            {
              "Name": "Kidney",
              "Value": 0.0053603428126
            },
            {
              "Name": "Periportal",
              "Value": 1.0
            },
            {
              "Name": "Pericentral",
              "Value": 1.0
            },
            {
              "Name": "Lung",
              "Value": 0.00042695753798
            },
            {
              "Name": "SmallIntestine",
              "Value": 0.0727697702
            },
            {
              "Name": "Duodenum",
              "Value": 0.0727697702
            },
            {
              "Name": "UpperJejunum",
              "Value": 0.0727697702
            },
            {
              "Name": "LowerJejunum",
              "Value": 0.0727697702
            },
            {
              "Name": "UpperIleum",
              "Value": 0.0727697702
            },
            {
              "Name": "LowerIleum",
              "Value": 0.0727697702
            }
          ],
          "Ontogeny": {
            "Name": "CYP3A4"
          }
        },
        {
          "Name": "CYP1A1",
          "Type": "Enzyme",
          "MembraneLocation": "Apical",
          "TissueLocation": "Intracellular",
          "IntracellularVascularEndoLocation": "Endosomal",
          "Expression": [
            {
              "Name": "Brain",
              "Value": 0.0057142857143
            },
            {
              "Name": "Gonads",
              "Value": 0.0316642121
            },
            {
              "Name": "Kidney",
              "Value": 0.0035198821797
            },
            {
              "Name": "Periportal",
              "Value": 0.4394108984
            },
            {
              "Name": "Pericentral",
              "Value": 0.4394108984
            },
            {
              "Name": "Lung",
              "Value": 1.0
            },
            {
              "Name": "SmallIntestine",
              "Value": 0.0259204713
            },
            {
              "Name": "Duodenum",
              "Value": 0.0259204713
            },
            {
              "Name": "UpperJejunum",
              "Value": 0.0259204713
            },
            {
              "Name": "LowerJejunum",
              "Value": 0.0259204713
            },
            {
              "Name": "UpperIleum",
              "Value": 0.0259204713
            },
            {
              "Name": "LowerIleum",
              "Value": 0.0259204713
            }
          ],
          "Parameters": [
            {
              "Name": "Reference concentration",
              "Value": 0.8454956,
              "Unit": "µmol/l",
              "ValueOrigin": {
                "Source": "Other",
                "Description": "Riociguat PBPK report"
              }
            }
          ]
        },
        {
          "Name": "UGT1A1",
          "Type": "Enzyme",
          "MembraneLocation": "Apical",
          "TissueLocation": "Intracellular",
          "IntracellularVascularEndoLocation": "Endosomal",
          "Expression": [
            {
              "Name": "Gonads",
              "Value": 0.0013585313175
            },
            {
              "Name": "Kidney",
              "Value": 0.0788336933
            },
            {
              "Name": "Periportal",
              "Value": 1.0
            },
            {
              "Name": "Pericentral",
              "Value": 1.0
            },
            {
              "Name": "Lung",
              "Value": 0.00027429805616
            },
            {
              "Name": "Stomach",
              "Value": 0.016349892
            },
            {
              "Name": "SmallIntestine",
              "Value": 0.3239740821
            },
            {
              "Name": "LargeIntestine",
              "Value": 0.0349892009
            },
            {
              "Name": "Duodenum",
              "Value": 0.3239740821
            },
            {
              "Name": "UpperJejunum",
              "Value": 0.3239740821
            },
            {
              "Name": "LowerJejunum",
              "Value": 0.3239740821
            },
            {
              "Name": "UpperIleum",
              "Value": 0.3239740821
            },
            {
              "Name": "LowerIleum",
              "Value": 0.3239740821
            },
            {
              "Name": "Caecum",
              "Value": 0.0349892009
            },
            {
              "Name": "ColonAscendens",
              "Value": 0.0349892009
            },
            {
              "Name": "ColonTransversum",
              "Value": 0.0349892009
            },
            {
              "Name": "ColonDescendens",
              "Value": 0.0349892009
            },
            {
              "Name": "ColonSigmoid",
              "Value": 0.0349892009
            }
          ],
          "Ontogeny": {
            "Name": "UGT1A1"
          },
          "Parameters": [
            {
              "Name": "Reference concentration",
              "Value": 1.328,
              "Unit": "µmol/l",
              "ValueOrigin": {
                "Source": "Publication",
                "Description": "Ohtsuki et al."
              }
            }
          ]
        },
        {
          "Name": "UGT1A9",
          "Type": "Enzyme",
          "MembraneLocation": "Apical",
          "TissueLocation": "Intracellular",
          "IntracellularVascularEndoLocation": "Endosomal",
          "Expression": [
            {
              "Name": "Gonads",
              "Value": 0.00016153846154
            },
            {
              "Name": "Kidney",
              "Value": 1.0
            },
            {
              "Name": "Periportal",
              "Value": 0.0982905983
            },
            {
              "Name": "Pericentral",
              "Value": 0.0982905983
            },
            {
              "Name": "Stomach",
              "Value": 0.0017264957265
            },
            {
              "Name": "SmallIntestine",
              "Value": 0.0041282051282
            },
            {
              "Name": "LargeIntestine",
              "Value": 0.0079487179487
            },
            {
              "Name": "Duodenum",
              "Value": 0.0041282051282
            },
            {
              "Name": "UpperJejunum",
              "Value": 0.0041282051282
            },
            {
              "Name": "LowerJejunum",
              "Value": 0.0041282051282
            },
            {
              "Name": "UpperIleum",
              "Value": 0.0041282051282
            },
            {
              "Name": "LowerIleum",
              "Value": 0.0041282051282
            },
            {
              "Name": "Caecum",
              "Value": 0.0079487179487
            },
            {
              "Name": "ColonAscendens",
              "Value": 0.0079487179487
            },
            {
              "Name": "ColonTransversum",
              "Value": 0.0079487179487
            },
            {
              "Name": "ColonDescendens",
              "Value": 0.0079487179487
            },
            {
              "Name": "ColonSigmoid",
              "Value": 0.0079487179487
            }
          ],
          "Ontogeny": {
            "Name": "UGT1A9"
          },
          "Parameters": [
            {
              "Name": "Reference concentration",
              "Value": 10.36,
              "Unit": "µmol/l",
              "ValueOrigin": {
                "Source": "Publication",
                "Description": "Rodriguez-Antona et al."
              }
            }
          ]
        },
        {
          "Name": "Cleavage-protein",
          "Type": "Enzyme",
          "MembraneLocation": "Apical",
          "TissueLocation": "Intracellular",
          "IntracellularVascularEndoLocation": "Endosomal",
          "Expression": [
            {
              "Name": "Lumen-Caecum",
              "Value": 1.0
            },
            {
              "Name": "Lumen-ColonAscendens",
              "Value": 1.0
            },
            {
              "Name": "Lumen-ColonTransversum",
              "Value": 1.0
            },
            {
              "Name": "Lumen-ColonDescendens",
              "Value": 1.0
            },
            {
              "Name": "Lumen-ColonSigmoid",
              "Value": 1.0
            },
            {
              "Name": "Lumen-Rectum",
              "Value": 1.0
            }
          ]
        },
        {
          "Name": "ABCG2",
          "Type": "Transporter",
          "TransportType": "Efflux",
          "Expression": [
            {
              "Name": "Bone",
              "MembraneLocation": "Basolateral",
              "Value": 0.2113821138
            },
            {
              "Name": "Brain",
              "MembraneLocation": "BloodBrainBarrier",
              "Value": 0.4552845528
            },
            {
              "Name": "Gonads",
              "MembraneLocation": "Basolateral",
              "Value": 0.2703252033
            },
            {
              "Name": "Heart",
              "MembraneLocation": "Basolateral",
              "Value": 0.1099593496
            },
            {
              "Name": "Kidney",
              "MembraneLocation": "Apical",
              "Value": 0.0941056911
            },
            {
              "Name": "Periportal",
              "MembraneLocation": "Apical",
              "Value": 0.2825203252
            },
            {
              "Name": "Pericentral",
              "MembraneLocation": "Apical",
              "Value": 0.2825203252
            },
            {
              "Name": "Lung",
              "MembraneLocation": "Basolateral",
              "Value": 0.2154471545
            },
            {
              "Name": "Muscle",
              "MembraneLocation": "Basolateral",
              "Value": 0.0331300813
            },
            {
              "Name": "Pancreas",
              "MembraneLocation": "Basolateral",
              "Value": 0.0054268292683
            },
            {
              "Name": "Spleen",
              "MembraneLocation": "Basolateral",
              "Value": 0.0585365854
            },
            {
              "Name": "Stomach",
              "MembraneLocation": "Basolateral",
              "Value": 0.0404471545
            },
            {
              "Name": "SmallIntestine",
              "MembraneLocation": "Basolateral",
              "Value": 1.0
            },
            {
              "Name": "LargeIntestine",
              "MembraneLocation": "Basolateral",
              "Value": 0.1593495935
            },
            {
              "Name": "Duodenum",
              "MembraneLocation": "Apical",
              "Value": 1.0
            },
            {
              "Name": "UpperJejunum",
              "MembraneLocation": "Apical",
              "Value": 1.0
            },
            {
              "Name": "LowerJejunum",
              "MembraneLocation": "Apical",
              "Value": 1.0
            },
            {
              "Name": "UpperIleum",
              "MembraneLocation": "Apical",
              "Value": 1.0
            },
            {
              "Name": "LowerIleum",
              "MembraneLocation": "Apical",
              "Value": 1.0
            },
            {
              "Name": "Caecum",
              "MembraneLocation": "Apical",
              "Value": 0.1593495935
            },
            {
              "Name": "ColonAscendens",
              "MembraneLocation": "Apical",
              "Value": 0.1593495935
            },
            {
              "Name": "ColonTransversum",
              "MembraneLocation": "Apical",
              "Value": 0.1593495935
            },
            {
              "Name": "ColonDescendens",
              "MembraneLocation": "Apical",
              "Value": 0.1593495935
            },
            {
              "Name": "ColonSigmoid",
              "MembraneLocation": "Apical",
              "Value": 0.1593495935
            }
          ],
          "Parameters": [
            {
              "Name": "Reference concentration",
              "Value": 9.2028777,
              "Unit": "nmol/l",
              "ValueOrigin": {
                "Source": "Publication",
                "Description": "Tucker et al."
              }
            }
          ]
        },
        {
          "Name": "ABCB1",
          "Type": "Transporter",
          "TransportType": "PgpLike",
          "Expression": [
            {
              "Name": "Bone",
              "MembraneLocation": "Basolateral",
              "Value": 0.0341950646
            },
            {
              "Name": "Brain",
              "MembraneLocation": "BloodBrainBarrier",
              "Value": 0.1072855464
            },
            {
              "Name": "Gonads",
              "MembraneLocation": "Basolateral",
              "Value": 0.024559342
            },
            {
              "Name": "Heart",
              "MembraneLocation": "Basolateral",
              "Value": 0.059106933
            },
            {
              "Name": "Kidney",
              "MembraneLocation": "Apical",
              "Value": 1.0
            },
            {
              "Name": "Periportal",
              "MembraneLocation": "Apical",
              "Value": 0.2702702703
            },
            {
              "Name": "Pericentral",
              "MembraneLocation": "Apical",
              "Value": 0.2702702703
            },
            {
              "Name": "Lung",
              "MembraneLocation": "Basolateral",
              "Value": 0.0927144536
            },
            {
              "Name": "Muscle",
              "MembraneLocation": "Basolateral",
              "Value": 0.0180963572
            },
            {
              "Name": "Pancreas",
              "MembraneLocation": "Basolateral",
              "Value": 0.0200940071
            },
            {
              "Name": "Spleen",
              "MembraneLocation": "Basolateral",
              "Value": 0.1047003525
            },
            {
              "Name": "Stomach",
              "MembraneLocation": "Basolateral",
              "Value": 0.0367802585
            },
            {
              "Name": "SmallIntestine",
              "MembraneLocation": "Basolateral",
              "Value": 0.3960047004
            },
            {
              "Name": "LargeIntestine",
              "MembraneLocation": "Basolateral",
              "Value": 0.1562867215
            },
            {
              "Name": "Duodenum",
              "MembraneLocation": "Apical",
              "Value": 0.3960047004
            },
            {
              "Name": "UpperJejunum",
              "MembraneLocation": "Apical",
              "Value": 0.3960047004
            },
            {
              "Name": "LowerJejunum",
              "MembraneLocation": "Apical",
              "Value": 0.3960047004
            },
            {
              "Name": "UpperIleum",
              "MembraneLocation": "Apical",
              "Value": 0.3960047004
            },
            {
              "Name": "LowerIleum",
              "MembraneLocation": "Apical",
              "Value": 0.3960047004
            },
            {
              "Name": "Caecum",
              "MembraneLocation": "Apical",
              "Value": 0.1562867215
            },
            {
              "Name": "ColonAscendens",
              "MembraneLocation": "Apical",
              "Value": 0.1562867215
            },
            {
              "Name": "ColonTransversum",
              "MembraneLocation": "Apical",
              "Value": 0.1562867215
            },
            {
              "Name": "ColonDescendens",
              "MembraneLocation": "Apical",
              "Value": 0.1562867215
            },
            {
              "Name": "ColonSigmoid",
              "MembraneLocation": "Apical",
              "Value": 0.1562867215
            }
          ],
          "Ontogeny": {
            "Name": "Ontogeny for ABCB1.Edginton_2006.Table",
            "Table": {
              "Name": "TableFormula",
              "Percentile": 0.0,
              "DistributionMetaData": [
                {
                  "Mean": 1E-14,
                  "Deviation": 1.6,
                  "Distribution": "LogNormal"
                },
                {
                  "Mean": 1.915059E-05,
                  "Deviation": 1.6,
                  "Distribution": "LogNormal"
                },
                {
                  "Mean": 5.486795E-05,
                  "Deviation": 1.6,
                  "Distribution": "LogNormal"
                },
                {
                  "Mean": 0.0001571905,
                  "Deviation": 1.6,
                  "Distribution": "LogNormal"
                },
                {
                  "Mean": 0.0004502473,
                  "Deviation": 1.6,
                  "Distribution": "LogNormal"
                },
                {
                  "Mean": 0.001288958,
                  "Deviation": 1.6,
                  "Distribution": "LogNormal"
                },
                {
                  "Mean": 0.00368424,
                  "Deviation": 1.6,
                  "Distribution": "LogNormal"
                },
                {
                  "Mean": 0.01048397,
                  "Deviation": 1.6,
                  "Distribution": "LogNormal"
                },
                {
                  "Mean": 0.02946235,
                  "Deviation": 1.6,
                  "Distribution": "LogNormal"
                },
                {
                  "Mean": 0.0800178,
                  "Deviation": 1.6,
                  "Distribution": "LogNormal"
                },
                {
                  "Mean": 0.1994918,
                  "Deviation": 1.6,
                  "Distribution": "LogNormal"
                },
                {
                  "Mean": 0.4165768,
                  "Deviation": 1.6,
                  "Distribution": "LogNormal"
                },
                {
                  "Mean": 0.6716791,
                  "Deviation": 1.6,
                  "Distribution": "LogNormal"
                },
                {
                  "Mean": 0.8542612,
                  "Deviation": 1.6,
                  "Distribution": "LogNormal"
                },
                {
                  "Mean": 0.943803,
                  "Deviation": 1.6,
                  "Distribution": "LogNormal"
                },
                {
                  "Mean": 0.9796414,
                  "Deviation": 1.6,
                  "Distribution": "LogNormal"
                },
                {
                  "Mean": 0.992799,
                  "Deviation": 1.6,
                  "Distribution": "LogNormal"
                },
                {
                  "Mean": 0.9974749,
                  "Deviation": 1.6,
                  "Distribution": "LogNormal"
                },
                {
                  "Mean": 0.9991173,
                  "Deviation": 1.6,
                  "Distribution": "LogNormal"
                },
                {
                  "Mean": 0.9996917,
                  "Deviation": 1.6,
                  "Distribution": "LogNormal"
                },
                {
                  "Mean": 0.9998924,
                  "Deviation": 1.6,
                  "Distribution": "LogNormal"
                },
                {
                  "Mean": 0.9999624,
                  "Deviation": 1.6,
                  "Distribution": "LogNormal"
                },
                {
                  "Mean": 0.9999869,
                  "Deviation": 1.6,
                  "Distribution": "LogNormal"
                },
                {
                  "Mean": 1.0,
                  "Deviation": 1.6,
                  "Distribution": "LogNormal"
                }
              ],
              "XName": "Postmenstrual age",
              "XDimension": "Age in years",
              "XUnit": "year(s)",
              "YName": "Ontogeny for ABCB1.Edginton_2006.Table",
              "YDimension": "Fraction",
              "UseDerivedValues": false,
              "Points": [
                {
                  "X": 0.0,
                  "Y": 1E-14,
                  "RestartSolver": false
                },
                {
                  "X": 0.08333334,
                  "Y": 1.915059E-05,
                  "RestartSolver": false
                },
                {
                  "X": 0.1666667,
                  "Y": 5.486795E-05,
                  "RestartSolver": false
                },
                {
                  "X": 0.25,
                  "Y": 0.0001571905,
                  "RestartSolver": false
                },
                {
                  "X": 0.3333333,
                  "Y": 0.0004502473,
                  "RestartSolver": false
                },
                {
                  "X": 0.4166667,
                  "Y": 0.001288958,
                  "RestartSolver": false
                },
                {
                  "X": 0.5,
                  "Y": 0.00368424,
                  "RestartSolver": false
                },
                {
                  "X": 0.5833333,
                  "Y": 0.01048397,
                  "RestartSolver": false
                },
                {
                  "X": 0.6666667,
                  "Y": 0.02946235,
                  "RestartSolver": false
                },
                {
                  "X": 0.75,
                  "Y": 0.0800178,
                  "RestartSolver": false
                },
                {
                  "X": 0.8333333,
                  "Y": 0.1994918,
                  "RestartSolver": false
                },
                {
                  "X": 0.9166667,
                  "Y": 0.4165768,
                  "RestartSolver": false
                },
                {
                  "X": 1.0,
                  "Y": 0.6716791,
                  "RestartSolver": false
                },
                {
                  "X": 1.083333,
                  "Y": 0.8542612,
                  "RestartSolver": false
                },
                {
                  "X": 1.166667,
                  "Y": 0.943803,
                  "RestartSolver": false
                },
                {
                  "X": 1.25,
                  "Y": 0.9796414,
                  "RestartSolver": false
                },
                {
                  "X": 1.333333,
                  "Y": 0.992799,
                  "RestartSolver": false
                },
                {
                  "X": 1.416667,
                  "Y": 0.9974749,
                  "RestartSolver": false
                },
                {
                  "X": 1.5,
                  "Y": 0.9991173,
                  "RestartSolver": false
                },
                {
                  "X": 1.583333,
                  "Y": 0.9996917,
                  "RestartSolver": false
                },
                {
                  "X": 1.666667,
                  "Y": 0.9998924,
                  "RestartSolver": false
                },
                {
                  "X": 1.75,
                  "Y": 0.9999624,
                  "RestartSolver": false
                },
                {
                  "X": 1.833333,
                  "Y": 0.9999869,
                  "RestartSolver": false
                },
                {
                  "X": 3.333333,
                  "Y": 1.0,
                  "RestartSolver": false
                }
              ]
            }
          },
          "Parameters": [
            {
              "Name": "Reference concentration",
              "Value": 96.57,
              "Unit": "nmol/l",
              "ValueOrigin": {
                "Source": "Publication",
                "Description": "Tucker et al."
              }
            }
          ]
        },
        {
          "Name": "M-1 TS",
          "Type": "Transporter",
          "TransportType": "Efflux",
          "Expression": [
            {
              "Name": "Kidney",
              "MembraneLocation": "Apical",
              "Value": 1.0
            }
          ]
        },
        {
          "Name": "UGT2B7",
          "Type": "Enzyme",
          "MembraneLocation": "Apical",
          "TissueLocation": "Intracellular",
          "IntracellularVascularEndoLocation": "Endosomal",
          "Expression": [
            {
              "Name": "Gonads",
              "Value": 0.00094468085106
            },
            {
              "Name": "Periportal",
              "Value": 1.0
            },
            {
              "Name": "Pericentral",
              "Value": 1.0
            },
            {
              "Name": "Pancreas",
              "Value": 0.0354468085
            },
            {
              "Name": "SmallIntestine",
              "Value": 0.5361702128
            },
            {
              "Name": "LargeIntestine",
              "Value": 0.0049787234043
            },
            {
              "Name": "Duodenum",
              "Value": 0.5361702128
            },
            {
              "Name": "UpperJejunum",
              "Value": 0.5361702128
            },
            {
              "Name": "LowerJejunum",
              "Value": 0.5361702128
            },
            {
              "Name": "UpperIleum",
              "Value": 0.5361702128
            },
            {
              "Name": "LowerIleum",
              "Value": 0.5361702128
            },
            {
              "Name": "Caecum",
              "Value": 0.0049787234043
            },
            {
              "Name": "ColonAscendens",
              "Value": 0.0049787234043
            },
            {
              "Name": "ColonTransversum",
              "Value": 0.0049787234043
            },
            {
              "Name": "ColonDescendens",
              "Value": 0.0049787234043
            },
            {
              "Name": "ColonSigmoid",
              "Value": 0.0049787234043
            },
            {
              "Name": "Rectum",
              "Value": 0.0049787234043
            }
          ],
          "Ontogeny": {
            "Name": "UGT2B7"
          },
          "Parameters": [
            {
              "Name": "Reference concentration",
              "Value": 3.372,
              "Unit": "µmol/l",
              "ValueOrigin": {
                "Source": "Publication",
                "Description": "Ohtsuki et al. 2011"
              }
            }
          ]
        },
        {
          "Name": "Hepatic-CYP",
          "Type": "Enzyme",
          "MembraneLocation": "Apical",
          "TissueLocation": "Intracellular",
          "IntracellularVascularEndoLocation": "Endosomal",
          "Expression": [
            {
              "Name": "Periportal",
              "Value": 1.0
            },
            {
              "Name": "Pericentral",
              "Value": 1.0
            }
          ]
        }
      ]
    }
  ],
  "Compounds": [
    {
      "Name": "Dapagliflozin",
      "IsSmallMolecule": true,
      "PlasmaProteinBindingPartner": "Albumin",
      "Lipophilicity": [
        {
          "Name": "Optimized",
          "Parameters": [
            {
              "Name": "Lipophilicity",
              "Value": 2.6495139838,
              "Unit": "Log Units",
              "ValueOrigin": {
                "Source": "ParameterIdentification",
                "Method": "ParameterIdentification",
                "Description": "Value updated from 'PI full  (perm)' on 2019-08-06 14:46"
              }
            }
          ]
        }
      ],
      "FractionUnbound": [
        {
          "Name": "Human",
          "Species": "Human",
          "Parameters": [
            {
              "Name": "Fraction unbound (plasma, reference value)",
              "Value": 0.09,
              "ValueOrigin": {
                "Source": "Publication",
                "Description": "Kasichayanula et al. 2014"
              }
            }
          ]
        }
      ],
      "Solubility": [
        {
          "Name": "Water solubility",
          "Parameters": [
            {
              "Name": "Solubility at reference pH",
              "Value": 0.2100844168,
              "Unit": "mg/ml",
              "ValueOrigin": {
                "Source": "ParameterIdentification",
                "Method": "ParameterIdentification",
                "Description": "Value updated from 'PI full  (perm)' on 2019-08-06 14:46"
              }
            },
            {
              "Name": "Reference pH",
              "Value": 7.0,
              "ValueOrigin": {
                "Source": "Database",
                "Description": "DrugBank DB06292"
              }
            }
          ]
        }
      ],
      "IntestinalPermeability": [
        {
          "Name": "Optimized",
          "IsDefault": false,
          "Parameters": [
            {
              "Name": "Specific intestinal permeability (transcellular)",
              "Value": 3.8347545732E-05,
              "Unit": "cm/min",
              "ValueOrigin": {
                "Source": "ParameterIdentification",
                "Method": "ParameterIdentification",
                "Description": "Value updated from 'PI full  (perm)' on 2019-08-06 14:46"
              }
            }
          ]
        }
      ],
      "Permeability": [
        {
          "Name": "Optimized",
          "IsDefault": false,
          "Parameters": [
            {
              "Name": "Permeability",
              "Value": 0.00041657167125,
              "Unit": "cm/min",
              "ValueOrigin": {
                "Source": "ParameterIdentification",
                "Method": "ParameterIdentification",
                "Description": "Value updated from 'PI full  (perm)' on 2019-08-06 14:46"
              }
            }
          ]
        }
      ],
      "PkaTypes": [
        {
          "Type": "Acid",
          "Pka": 12.75,
          "ValueOrigin": {
            "Source": "Database",
            "Description": "DrugBank DB06292"
          }
        }
      ],
      "Processes": [
        {
          "InternalName": "MetabolizationSpecific_FirstOrder",
          "DataSource": "Optimized",
          "Molecule": "UGT1A9",
          "Metabolite": "Dapagliflozin-3-O-glucuronide",
          "Parameters": [
            {
              "Name": "Enzyme concentration",
              "Value": 1.0,
              "Unit": "µmol/l"
            },
            {
              "Name": "Specific clearance",
              "Value": 0.0,
              "Unit": "1/min"
            },
            {
              "Name": "CLspec/[Enzyme]",
              "Value": 0.402175146,
              "Unit": "l/µmol/min",
              "ValueOrigin": {
                "Source": "ParameterIdentification",
                "Method": "ParameterIdentification",
                "Description": "Value updated from 'PI full  (perm)' on 2019-08-06 14:46"
              }
            }
          ]
        },
        {
          "InternalName": "MetabolizationSpecific_FirstOrder",
          "DataSource": "Optimized",
          "Molecule": "UGT2B7",
          "Metabolite": "Dapagliflozin-2-O-glucuronide",
          "Parameters": [
            {
              "Name": "Enzyme concentration",
              "Value": 1.0,
              "Unit": "µmol/l"
            },
            {
              "Name": "Specific clearance",
              "Value": 0.0,
              "Unit": "1/min"
            },
            {
              "Name": "CLspec/[Enzyme]",
              "Value": 0.0072288071857,
              "Unit": "l/µmol/min",
              "ValueOrigin": {
                "Source": "ParameterIdentification",
                "Method": "ParameterIdentification",
                "Description": "Value updated from 'PI full  (perm)' on 2019-08-06 14:46"
              }
            }
          ]
        },
        {
          "InternalName": "GlomerularFiltration",
          "DataSource": "assumed",
          "Species": "Human",
          "Parameters": [
            {
              "Name": "GFR fraction",
              "Value": 0.8944188606,
              "ValueOrigin": {
                "Source": "ParameterIdentification",
                "Method": "ParameterIdentification",
                "Description": "Value updated from 'PI full  (perm)' on 2019-08-06 14:46"
              }
            }
          ]
        },
        {
          "InternalName": "MetabolizationSpecific_FirstOrder",
          "DataSource": "Optimized",
          "Molecule": "Hepatic-CYP",
          "Parameters": [
            {
              "Name": "Enzyme concentration",
              "Value": 1.0,
              "Unit": "µmol/l"
            },
            {
              "Name": "Specific clearance",
              "Value": 0.0,
              "Unit": "1/min"
            },
            {
              "Name": "CLspec/[Enzyme]",
              "Value": 0.1397810065,
              "Unit": "l/µmol/min",
              "ValueOrigin": {
                "Source": "ParameterIdentification",
                "Method": "ParameterIdentification",
                "Description": "Value updated from 'PI full  (perm)' on 2019-08-06 14:46"
              }
            }
          ]
        }
      ],
      "CalculationMethods": [
        "Cellular partition coefficient method - Rodgers and Rowland",
        "Cellular permeability - PK-Sim Standard"
      ],
      "Parameters": [
        {
          "Name": "Cl",
          "Value": 1.0
        },
        {
          "Name": "Molecular weight",
          "Value": 408.873,
          "Unit": "g/mol"
        }
      ]
    }
  ],
  "Formulations": [
    {
      "Name": "Solution",
      "FormulationType": "Formulation_Dissolved"
    },
    {
      "Name": "IR tablet",
      "FormulationType": "Formulation_Tablet_Weibull",
      "Parameters": [
        {
          "Name": "Dissolution time (50% dissolved)",
          "Value": 30.0,
          "Unit": "min"
        },
        {
          "Name": "Lag time",
          "Value": 0.0,
          "Unit": "min"
        },
        {
          "Name": "Dissolution shape",
          "Value": 0.6
        },
        {
          "Name": "Use as suspension",
          "Value": 1.0
        }
      ]
    }
  ],
  "Protocols": [
    {
      "Name": "IV 0.08 mg",
      "DosingInterval": "Single",
      "Schemas": [
        {
          "Name": "Schema 1",
          "SchemaItems": [
            {
              "Name": "Schema Item 1",
              "ApplicationType": "Intravenous",
              "Parameters": [
                {
                  "Name": "Start time",
                  "Value": 0.0,
                  "Unit": "h"
                },
                {
                  "Name": "InputDose",
                  "Value": 0.08,
                  "Unit": "mg"
                },
                {
                  "Name": "Infusion time",
                  "Value": 1.0,
                  "Unit": "min"
                }
              ]
            }
          ],
          "Parameters": [
            {
              "Name": "Start time",
              "Value": 1.0,
              "Unit": "h",
              "ValueOrigin": {
                "Source": "Unknown"
              }
            }
          ]
        }
      ],
      "TimeUnit": "h"
    },
    {
      "Name": "PO SD 50 mg",
      "ApplicationType": "Oral",
      "DosingInterval": "Single",
      "Parameters": [
        {
          "Name": "Start time",
          "Value": 0.0,
          "Unit": "h"
        },
        {
          "Name": "InputDose",
          "Value": 50.0,
          "Unit": "mg"
        },
        {
          "Name": "Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        }
      ]
    },
    {
      "Name": "PO SD 2.5 mg",
      "ApplicationType": "Oral",
      "DosingInterval": "Single",
      "Parameters": [
        {
          "Name": "Start time",
          "Value": 0.0,
          "Unit": "h"
        },
        {
          "Name": "InputDose",
          "Value": 2.5,
          "Unit": "mg"
        },
        {
          "Name": "Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        }
      ]
    },
    {
      "Name": "PO SD 5 mg",
      "ApplicationType": "Oral",
      "DosingInterval": "Single",
      "Parameters": [
        {
          "Name": "Start time",
          "Value": 0.0,
          "Unit": "h"
        },
        {
          "Name": "InputDose",
          "Value": 5.0,
          "Unit": "mg"
        },
        {
          "Name": "Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        }
      ]
    },
    {
      "Name": "PO SD 10 mg",
      "ApplicationType": "Oral",
      "DosingInterval": "Single",
      "Parameters": [
        {
          "Name": "Start time",
          "Value": 0.0,
          "Unit": "h"
        },
        {
          "Name": "InputDose",
          "Value": 10.0,
          "Unit": "mg"
        },
        {
          "Name": "Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        }
      ]
    },
    {
      "Name": "PO SD 20 mg",
      "ApplicationType": "Oral",
      "DosingInterval": "Single",
      "Parameters": [
        {
          "Name": "Start time",
          "Value": 0.0,
          "Unit": "h"
        },
        {
          "Name": "InputDose",
          "Value": 20.0,
          "Unit": "mg"
        },
        {
          "Name": "Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        }
      ]
    },
    {
      "Name": "PO SD 100 mg",
      "ApplicationType": "Oral",
      "DosingInterval": "Single",
      "Parameters": [
        {
          "Name": "Start time",
          "Value": 0.0,
          "Unit": "h"
        },
        {
          "Name": "InputDose",
          "Value": 100.0,
          "Unit": "mg"
        },
        {
          "Name": "Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        }
      ]
    },
    {
      "Name": "PO SD 250 mg",
      "ApplicationType": "Oral",
      "DosingInterval": "Single",
      "Parameters": [
        {
          "Name": "Start time",
          "Value": 0.0,
          "Unit": "h"
        },
        {
          "Name": "InputDose",
          "Value": 250.0,
          "Unit": "mg"
        },
        {
          "Name": "Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        }
      ]
    },
    {
      "Name": "PO SD 500 mg",
      "ApplicationType": "Oral",
      "DosingInterval": "Single",
      "Parameters": [
        {
          "Name": "Start time",
          "Value": 0.0,
          "Unit": "h"
        },
        {
          "Name": "InputDose",
          "Value": 500.0,
          "Unit": "mg"
        },
        {
          "Name": "Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        }
      ]
    },
    {
      "Name": "PO MD 2.5 mg",
      "DosingInterval": "Single",
      "Schemas": [
        {
          "Name": "Schema 1",
          "SchemaItems": [
            {
              "Name": "Schema Item 1",
              "ApplicationType": "Oral",
              "FormulationKey": "Formulation",
              "Parameters": [
                {
                  "Name": "Start time",
                  "Value": 0.0,
                  "Unit": "h"
                },
                {
                  "Name": "InputDose",
                  "Value": 2.5,
                  "Unit": "mg"
                },
                {
                  "Name": "Volume of water/body weight",
                  "Value": 3.5,
                  "Unit": "ml/kg"
                }
              ]
            }
          ],
          "Parameters": [
            {
              "Name": "NumberOfRepetitions",
              "Value": 14.0,
              "ValueOrigin": {
                "Source": "Unknown"
              }
            },
            {
              "Name": "TimeBetweenRepetitions",
              "Value": 24.0,
              "Unit": "h",
              "ValueOrigin": {
                "Source": "Unknown"
              }
            }
          ]
        }
      ],
      "TimeUnit": "h"
    },
    {
      "Name": "PO MD 10 mg",
      "DosingInterval": "Single",
      "Schemas": [
        {
          "Name": "Schema 1",
          "SchemaItems": [
            {
              "Name": "Schema Item 1",
              "ApplicationType": "Oral",
              "FormulationKey": "Formulation",
              "Parameters": [
                {
                  "Name": "Start time",
                  "Value": 0.0,
                  "Unit": "h"
                },
                {
                  "Name": "InputDose",
                  "Value": 10.0,
                  "Unit": "mg"
                },
                {
                  "Name": "Volume of water/body weight",
                  "Value": 3.5,
                  "Unit": "ml/kg"
                }
              ]
            }
          ],
          "Parameters": [
            {
              "Name": "NumberOfRepetitions",
              "Value": 14.0,
              "ValueOrigin": {
                "Source": "Unknown"
              }
            },
            {
              "Name": "TimeBetweenRepetitions",
              "Value": 24.0,
              "Unit": "h",
              "ValueOrigin": {
                "Source": "Unknown"
              }
            }
          ]
        }
      ],
      "TimeUnit": "h"
    },
    {
      "Name": "PO MD 20 mg",
      "DosingInterval": "Single",
      "Schemas": [
        {
          "Name": "Schema 1",
          "SchemaItems": [
            {
              "Name": "Schema Item 1",
              "ApplicationType": "Oral",
              "FormulationKey": "Formulation",
              "Parameters": [
                {
                  "Name": "Start time",
                  "Value": 0.0,
                  "Unit": "h"
                },
                {
                  "Name": "InputDose",
                  "Value": 20.0,
                  "Unit": "mg"
                },
                {
                  "Name": "Volume of water/body weight",
                  "Value": 3.5,
                  "Unit": "ml/kg"
                }
              ]
            }
          ],
          "Parameters": [
            {
              "Name": "NumberOfRepetitions",
              "Value": 14.0,
              "ValueOrigin": {
                "Source": "Unknown"
              }
            },
            {
              "Name": "TimeBetweenRepetitions",
              "Value": 24.0,
              "Unit": "h",
              "ValueOrigin": {
                "Source": "Unknown"
              }
            }
          ]
        }
      ],
      "TimeUnit": "h"
    },
    {
      "Name": "PO MD 50 mg",
      "DosingInterval": "Single",
      "Schemas": [
        {
          "Name": "Schema 1",
          "SchemaItems": [
            {
              "Name": "Schema Item 1",
              "ApplicationType": "Oral",
              "FormulationKey": "Formulation",
              "Parameters": [
                {
                  "Name": "Start time",
                  "Value": 0.0,
                  "Unit": "h"
                },
                {
                  "Name": "InputDose",
                  "Value": 50.0,
                  "Unit": "mg"
                },
                {
                  "Name": "Volume of water/body weight",
                  "Value": 3.5,
                  "Unit": "ml/kg"
                }
              ]
            }
          ],
          "Parameters": [
            {
              "Name": "NumberOfRepetitions",
              "Value": 14.0,
              "ValueOrigin": {
                "Source": "Unknown"
              }
            },
            {
              "Name": "TimeBetweenRepetitions",
              "Value": 24.0,
              "Unit": "h",
              "ValueOrigin": {
                "Source": "Unknown"
              }
            }
          ]
        }
      ],
      "TimeUnit": "h"
    },
    {
      "Name": "PO MD 100 mg",
      "DosingInterval": "Single",
      "Schemas": [
        {
          "Name": "Schema 1",
          "SchemaItems": [
            {
              "Name": "Schema Item 1",
              "ApplicationType": "Oral",
              "FormulationKey": "Formulation",
              "Parameters": [
                {
                  "Name": "Start time",
                  "Value": 0.0,
                  "Unit": "h"
                },
                {
                  "Name": "InputDose",
                  "Value": 100.0,
                  "Unit": "mg"
                },
                {
                  "Name": "Volume of water/body weight",
                  "Value": 3.5,
                  "Unit": "ml/kg"
                }
              ]
            }
          ],
          "Parameters": [
            {
              "Name": "NumberOfRepetitions",
              "Value": 14.0,
              "ValueOrigin": {
                "Source": "Unknown"
              }
            },
            {
              "Name": "TimeBetweenRepetitions",
              "Value": 24.0,
              "Unit": "h",
              "ValueOrigin": {
                "Source": "Unknown"
              }
            }
          ]
        }
      ],
      "TimeUnit": "h"
    }
  ],
  "Events": [
    {
      "Name": "breakfast",
      "Template": "Meal: High-fat breakfast (Human)"
    }
  ],
  "Simulations": [
    {
      "Name": "IV 0.08 mg (perm)",
      "Model": "4Comp",
      "ObservedData": [
        "Boulton 2013 - 14C-dapagliflozin iv - Dapagliflozin - IV - 0.08 mg - Plasma - agg. (n=7)"
      ],
      "Solver": {},
      "OutputSchema": [
        {
          "Parameters": [
            {
              "Name": "Start time",
              "Value": 0.0,
              "Unit": "h"
            },
            {
              "Name": "End time",
              "Value": 2.0,
              "Unit": "h"
            },
            {
              "Name": "Resolution",
              "Value": 20.0,
              "Unit": "pts/h"
            }
          ]
        },
        {
          "Parameters": [
            {
              "Name": "Start time",
              "Value": 2.0,
              "Unit": "h"
            },
            {
              "Name": "End time",
              "Value": 50.0,
              "Unit": "h",
              "ValueOrigin": {
                "Source": "Unknown"
              }
            },
            {
              "Name": "Resolution",
              "Value": 4.0,
              "Unit": "pts/h"
            }
          ]
        }
      ],
      "Parameters": [
        {
          "Path": "Applications|IV 0.08 mg|Application_1|ProtocolSchemaItem|Infusion time",
          "Value": 1.0,
          "Unit": "min"
        },
        {
          "Path": "Dapagliflozin|Blood/Plasma concentration ratio",
          "Value": 0.88,
          "ValueOrigin": {
            "Source": "ParameterIdentification",
            "Method": "ParameterIdentification",
            "Description": "Value updated from 'PI full  (perm)' on 2019-08-06 14:46"
          }
        },
        {
          "Path": "Dapagliflozin|logP (veg.oil/water)",
          "Value": 2.0765619283,
          "Unit": "Log Units",
          "ValueOrigin": {
            "Source": "ParameterIdentification",
            "Method": "ParameterIdentification",
            "Description": "Value updated from 'PI full  (perm)' on 2019-08-06 14:46"
          }
        }
      ],
      "OutputSelections": [
        "Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)"
      ],
      "Individual": "Standard_Adult_UGT",
      "Compounds": [
        {
          "Name": "Dapagliflozin",
          "CalculationMethods": [
            "Cellular partition coefficient method - Rodgers and Rowland",
            "Cellular permeability - PK-Sim Standard"
          ],
          "Alternatives": [
            {
              "AlternativeName": "Optimized",
              "GroupName": "COMPOUND_PERMEABILITY"
            },
            {
              "AlternativeName": "Optimized",
              "GroupName": "COMPOUND_INTESTINAL_PERMEABILITY"
            }
          ],
          "Processes": [
            {
              "Name": "UGT1A9-Optimized",
              "MoleculeName": "UGT1A9"
            },
            {
              "Name": "UGT2B7-Optimized",
              "MoleculeName": "UGT2B7"
            },
            {
              "Name": "Hepatic-CYP-Optimized",
              "MoleculeName": "Hepatic-CYP"
            },
            {
              "Name": "Glomerular Filtration-assumed"
            }
          ],
          "Protocol": {
            "Name": "IV 0.08 mg"
          }
        }
      ],
      "HasResults": true,
      "IndividualAnalyses": [
        {
          "Axes": [
            {
              "Unit": "h",
              "Dimension": "Time",
              "Type": "X",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "None",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            },
            {
              "Unit": "µg/l",
              "Dimension": "Concentration (molar)",
              "Type": "Y",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Solid",
              "Scaling": "Log",
              "NumberMode": "Normal"
            }
          ],
          "Curves": [
            {
              "Name": "IV 0.08 mg (perm)-Dapagliflozin-Peripheral Venous Blood-Plasma-Concentration",
              "X": "Time",
              "Y": "IV 0.08 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
              "CurveOptions": {
                "Color": "#FF0000",
                "LegendIndex": 1
              }
            },
            {
              "Name": "Boulton 2013 - 14C-dapagliflozin iv - Dapagliflozin - IV - 0.08 mg - Plasma - agg. (n=7)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
              "X": "Boulton 2013 - 14C-dapagliflozin iv - Dapagliflozin - IV - 0.08 mg - Plasma - agg. (n=7)|Time",
              "Y": "Boulton 2013 - 14C-dapagliflozin iv - Dapagliflozin - IV - 0.08 mg - Plasma - agg. (n=7)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "Color": "#0000FF",
                "LegendIndex": 2,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            }
          ],
          "Name": "IV 0.08 mg (perm)",
          "Title": "IV 0.08 mg (perm)",
          "OriginText": "Dapagliflozin\nIV 0.08 mg (perm)\n2019-08-05 17:52"
        },
        {
          "Axes": [
            {
              "Unit": "h",
              "Dimension": "Time",
              "Type": "X",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "None",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            },
            {
              "Unit": "µg/l",
              "Dimension": "Concentration (molar)",
              "Type": "Y",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Solid",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            }
          ],
          "Curves": [
            {
              "Name": "IV 0.08 mg (perm)-Dapagliflozin-Peripheral Venous Blood-Plasma-Concentration",
              "X": "Time",
              "Y": "IV 0.08 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
              "CurveOptions": {
                "Color": "#FF0000",
                "LegendIndex": 1
              }
            },
            {
              "Name": "Boulton 2013 - 14C-dapagliflozin iv - Dapagliflozin - IV - 0.08 mg - Plasma - agg. (n=7)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
              "X": "Boulton 2013 - 14C-dapagliflozin iv - Dapagliflozin - IV - 0.08 mg - Plasma - agg. (n=7)|Time",
              "Y": "Boulton 2013 - 14C-dapagliflozin iv - Dapagliflozin - IV - 0.08 mg - Plasma - agg. (n=7)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "Color": "#0000FF",
                "LegendIndex": 2,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            }
          ],
          "Name": "Time Profile Analysis 1",
          "Title": "IV 0.08 mg (perm)",
          "OriginText": "Dapagliflozin\nIV 0.08 mg (perm)\n2019-08-05 17:52"
        }
      ]
    },
    {
      "Name": "PO SD 10 mg (perm)",
      "Model": "4Comp",
      "ObservedData": [
        "Boulton 2013 - Dapagliflozin po - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=7)",
        "Imamura 2013 - Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=22)",
        "Kasichayanula 2011a - fasted - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=14)",
        "Kasichayanula 2013a - Study 1: Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=14)",
        "Kasichayanula 2013a - Study 2: Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=16)",
        "Vakkalagadda 2016 - Dapagliflozin - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=42)",
        "Kasichayanula 2011c - Healthy Volunteers - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=6)",
        "Komoroski 2009 - SAD 10 mg - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=6)",
        "Komoroski 2009 - SAD 10 mg (Urine) - Dapagliflozin - PO - 10 mg - Urine - agg. (n=6)",
        "Komoroski 2009 - MAD 10 mg (day 1) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=6)"
      ],
      "Solver": {},
      "OutputSchema": [
        {
          "Parameters": [
            {
              "Name": "Start time",
              "Value": 0.0,
              "Unit": "h"
            },
            {
              "Name": "End time",
              "Value": 2.0,
              "Unit": "h"
            },
            {
              "Name": "Resolution",
              "Value": 20.0,
              "Unit": "pts/h"
            }
          ]
        },
        {
          "Parameters": [
            {
              "Name": "Start time",
              "Value": 2.0,
              "Unit": "h"
            },
            {
              "Name": "End time",
              "Value": 120.0,
              "Unit": "h",
              "ValueOrigin": {
                "Source": "Unknown"
              }
            },
            {
              "Name": "Resolution",
              "Value": 4.0,
              "Unit": "pts/h"
            }
          ]
        }
      ],
      "Parameters": [
        {
          "Path": "Applications|PO SD 10 mg|Solution|Application_1|ProtocolSchemaItem|Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        },
        {
          "Path": "Dapagliflozin|Blood/Plasma concentration ratio",
          "Value": 0.88,
          "ValueOrigin": {
            "Source": "ParameterIdentification",
            "Method": "ParameterIdentification",
            "Description": "Value updated from 'PI full  (perm)' on 2019-08-06 14:46"
          }
        },
        {
          "Path": "Dapagliflozin|logP (veg.oil/water)",
          "Value": 2.0765619283,
          "Unit": "Log Units",
          "ValueOrigin": {
            "Source": "ParameterIdentification",
            "Method": "ParameterIdentification",
            "Description": "Value updated from 'PI full  (perm)' on 2019-08-06 14:46"
          }
        }
      ],
      "OutputSelections": [
        "Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
        "Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine"
      ],
      "Individual": "Standard_Adult_UGT",
      "Compounds": [
        {
          "Name": "Dapagliflozin",
          "CalculationMethods": [
            "Cellular partition coefficient method - Rodgers and Rowland",
            "Cellular permeability - PK-Sim Standard"
          ],
          "Alternatives": [
            {
              "AlternativeName": "Optimized",
              "GroupName": "COMPOUND_PERMEABILITY"
            },
            {
              "AlternativeName": "Optimized",
              "GroupName": "COMPOUND_INTESTINAL_PERMEABILITY"
            }
          ],
          "Processes": [
            {
              "Name": "UGT1A9-Optimized",
              "MoleculeName": "UGT1A9"
            },
            {
              "Name": "UGT2B7-Optimized",
              "MoleculeName": "UGT2B7"
            },
            {
              "Name": "Hepatic-CYP-Optimized",
              "MoleculeName": "Hepatic-CYP"
            },
            {
              "Name": "Glomerular Filtration-assumed"
            }
          ],
          "Protocol": {
            "Name": "PO SD 10 mg",
            "Formulations": [
              {
                "Name": "Solution",
                "Key": "Formulation"
              }
            ]
          }
        }
      ],
      "HasResults": true,
      "IndividualAnalyses": [
        {
          "Axes": [
            {
              "Unit": "h",
              "Dimension": "Time",
              "Type": "X",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "None",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            },
            {
              "Unit": "µg/l",
              "Dimension": "Concentration (molar)",
              "Type": "Y",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Solid",
              "Scaling": "Log",
              "NumberMode": "Normal"
            },
            {
              "Unit": "",
              "Dimension": "Fraction",
              "Type": "Y2",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Dash",
              "Scaling": "Log",
              "NumberMode": "Normal"
            }
          ],
          "Curves": [
            {
              "Name": "PO SD 10 mg (perm)-Dapagliflozin-Peripheral Venous Blood-Plasma-Concentration",
              "X": "Time",
              "Y": "PO SD 10 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
              "CurveOptions": {
                "Color": "#FF0000",
                "LegendIndex": 1
              }
            },
            {
              "Name": "Boulton 2013 - Dapagliflozin po - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=7)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
              "X": "Boulton 2013 - Dapagliflozin po - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=7)|Time",
              "Y": "Boulton 2013 - Dapagliflozin po - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=7)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "Color": "#0000FF",
                "LegendIndex": 2,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            },
            {
              "Name": "Imamura 2013 - Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=22)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
              "X": "Imamura 2013 - Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=22)|Time",
              "Y": "Imamura 2013 - Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=22)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "Color": "#008000",
                "LegendIndex": 3,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            },
            {
              "Name": "Kasichayanula 2011a - fasted - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=14)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
              "X": "Kasichayanula 2011a - fasted - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=14)|Time",
              "Y": "Kasichayanula 2011a - fasted - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=14)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "Color": "#FF00FF",
                "LegendIndex": 4,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            },
            {
              "Name": "Kasichayanula 2013a - Study 1: Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=14)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
              "X": "Kasichayanula 2013a - Study 1: Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=14)|Time",
              "Y": "Kasichayanula 2013a - Study 1: Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=14)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "Color": "#FF8000",
                "LegendIndex": 5,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            },
            {
              "Name": "Kasichayanula 2013a - Study 2: Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=16)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
              "X": "Kasichayanula 2013a - Study 2: Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=16)|Time",
              "Y": "Kasichayanula 2013a - Study 2: Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=16)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "Color": "#00C0C0",
                "LegendIndex": 6,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            },
            {
              "Name": "Vakkalagadda 2016 - Dapagliflozin - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=42)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
              "X": "Vakkalagadda 2016 - Dapagliflozin - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=42)|Time",
              "Y": "Vakkalagadda 2016 - Dapagliflozin - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=42)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "Color": "#C000C0",
                "LegendIndex": 7,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            },
            {
              "Name": "Kasichayanula 2011c - Healthy Volunteers - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=6)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
              "X": "Kasichayanula 2011c - Healthy Volunteers - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=6)|Time",
              "Y": "Kasichayanula 2011c - Healthy Volunteers - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "Color": "#C04000",
                "LegendIndex": 8,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            },
            {
              "Name": "Komoroski 2009 - SAD 10 mg - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=6)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
              "X": "Komoroski 2009 - SAD 10 mg - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=6)|Time",
              "Y": "Komoroski 2009 - SAD 10 mg - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "Color": "#00FF00",
                "LegendIndex": 9,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            },
            {
              "Name": "Komoroski 2009 - SAD 10 mg (Urine) - Dapagliflozin - PO - 10 mg - Urine - agg. (n=6)-Dapagliflozin-Kidney-Urine-ArithmeticMean",
              "X": "Komoroski 2009 - SAD 10 mg (Urine) - Dapagliflozin - PO - 10 mg - Urine - agg. (n=6)|Time",
              "Y": "Komoroski 2009 - SAD 10 mg (Urine) - Dapagliflozin - PO - 10 mg - Urine - agg. (n=6)|ObservedData|Kidney|Urine|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "yAxisType": "Y2",
                "Color": "#808080",
                "LegendIndex": 10,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            },
            {
              "Name": "Komoroski 2009 - MAD 10 mg (day 1) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=6)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
              "X": "Komoroski 2009 - MAD 10 mg (day 1) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=6)|Time",
              "Y": "Komoroski 2009 - MAD 10 mg (day 1) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "Color": "#C0C000",
                "LegendIndex": 11,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            },
            {
              "Name": "PO SD 10 mg (perm)-Dapagliflozin-Kidney-Urine-Fraction excreted to urine",
              "X": "Time",
              "Y": "PO SD 10 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
              "CurveOptions": {
                "yAxisType": "Y2",
                "Color": "#A5A5A5",
                "LegendIndex": 12,
                "LineStyle": "Dash"
              }
            }
          ],
          "Name": "PO SD 10 mg (perm)",
          "Settings": {
            "SideMarginsEnabled": true,
            "LegendPosition": "None",
            "BackColor": "#FFFFFF",
            "DiagramBackColor": "#FFFFFF"
          },
          "Title": "PO SD 10 mg (perm)",
          "OriginText": "Dapagliflozin\nPO SD 10 mg (perm)\n2019-08-06 11:22"
        },
        {
          "Axes": [
            {
              "Unit": "h",
              "Dimension": "Time",
              "Type": "X",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "None",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            },
            {
              "Unit": "µg/l",
              "Dimension": "Concentration (molar)",
              "Type": "Y",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Solid",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            },
            {
              "Unit": "",
              "Dimension": "Fraction",
              "Type": "Y2",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Dash",
              "Scaling": "Log",
              "NumberMode": "Normal"
            }
          ],
          "Curves": [
            {
              "Name": "PO SD 10 mg (perm)-Dapagliflozin-Peripheral Venous Blood-Plasma-Concentration",
              "X": "Time",
              "Y": "PO SD 10 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
              "CurveOptions": {
                "Color": "#FF0000",
                "LegendIndex": 1
              }
            },
            {
              "Name": "Boulton 2013 - Dapagliflozin po - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=7)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
              "X": "Boulton 2013 - Dapagliflozin po - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=7)|Time",
              "Y": "Boulton 2013 - Dapagliflozin po - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=7)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "Color": "#0000FF",
                "LegendIndex": 2,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            },
            {
              "Name": "Imamura 2013 - Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=22)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
              "X": "Imamura 2013 - Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=22)|Time",
              "Y": "Imamura 2013 - Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=22)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "Color": "#008000",
                "LegendIndex": 3,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            },
            {
              "Name": "Kasichayanula 2011a - fasted - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=14)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
              "X": "Kasichayanula 2011a - fasted - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=14)|Time",
              "Y": "Kasichayanula 2011a - fasted - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=14)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "Color": "#FF00FF",
                "LegendIndex": 4,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            },
            {
              "Name": "Kasichayanula 2013a - Study 1: Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=14)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
              "X": "Kasichayanula 2013a - Study 1: Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=14)|Time",
              "Y": "Kasichayanula 2013a - Study 1: Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=14)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "Color": "#FF8000",
                "LegendIndex": 5,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            },
            {
              "Name": "Kasichayanula 2013a - Study 2: Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=16)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
              "X": "Kasichayanula 2013a - Study 2: Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=16)|Time",
              "Y": "Kasichayanula 2013a - Study 2: Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=16)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "Color": "#00C0C0",
                "LegendIndex": 6,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            },
            {
              "Name": "Vakkalagadda 2016 - Dapagliflozin - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=42)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
              "X": "Vakkalagadda 2016 - Dapagliflozin - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=42)|Time",
              "Y": "Vakkalagadda 2016 - Dapagliflozin - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=42)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "Color": "#C000C0",
                "LegendIndex": 7,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            },
            {
              "Name": "Kasichayanula 2011c - Healthy Volunteers - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=6)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
              "X": "Kasichayanula 2011c - Healthy Volunteers - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=6)|Time",
              "Y": "Kasichayanula 2011c - Healthy Volunteers - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "Color": "#C04000",
                "LegendIndex": 8,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            },
            {
              "Name": "Komoroski 2009 - SAD 10 mg - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=6)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
              "X": "Komoroski 2009 - SAD 10 mg - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=6)|Time",
              "Y": "Komoroski 2009 - SAD 10 mg - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "Color": "#00FF00",
                "LegendIndex": 9,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            },
            {
              "Name": "Komoroski 2009 - SAD 10 mg (Urine) - Dapagliflozin - PO - 10 mg - Urine - agg. (n=6)-Dapagliflozin-Kidney-Urine-ArithmeticMean",
              "X": "Komoroski 2009 - SAD 10 mg (Urine) - Dapagliflozin - PO - 10 mg - Urine - agg. (n=6)|Time",
              "Y": "Komoroski 2009 - SAD 10 mg (Urine) - Dapagliflozin - PO - 10 mg - Urine - agg. (n=6)|ObservedData|Kidney|Urine|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "yAxisType": "Y2",
                "Color": "#808080",
                "LegendIndex": 10,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            },
            {
              "Name": "Komoroski 2009 - MAD 10 mg (day 1) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=6)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
              "X": "Komoroski 2009 - MAD 10 mg (day 1) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=6)|Time",
              "Y": "Komoroski 2009 - MAD 10 mg (day 1) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "Color": "#C0C000",
                "LegendIndex": 11,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            },
            {
              "Name": "PO SD 10 mg (perm)-Dapagliflozin-Kidney-Urine-Fraction excreted to urine",
              "X": "Time",
              "Y": "PO SD 10 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
              "CurveOptions": {
                "yAxisType": "Y2",
                "Color": "#A5A5A5",
                "LegendIndex": 12,
                "LineStyle": "Dash"
              }
            }
          ],
          "Name": "Time Profile Analysis 1",
          "Settings": {
            "SideMarginsEnabled": true,
            "LegendPosition": "None",
            "BackColor": "#FFFFFF",
            "DiagramBackColor": "#FFFFFF"
          },
          "Title": "PO SD 10 mg (perm)",
          "OriginText": "Dapagliflozin\nPO SD 10 mg (perm)\n2019-08-06 11:22"
        }
      ]
    },
    {
      "Name": "PO SD 50 mg (perm)",
      "Model": "4Comp",
      "ObservedData": [
        "Kasichayanula 2011b - Study 1: 50 mg Control (Perpetrator Placebo) - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=24)",
        "Kasichayanula 2013b - Healthy subjects with normal kidney function - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=8)",
        "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin Urine - Dapagliflozin - PO - 50 mg - Urine - agg. (n=6)",
        "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin Feces - Dapagliflozin - PO - 50 mg - Feces - agg. (n=6)",
        "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin 3OG Gluc - Dapagliflozin-3-O-glucuronide - PO - 50 mg - Fraction - agg. (n=6)",
        "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin 2OG Gluc - Dapagliflozin-2-O-glucuronide - PO - 50 mg - Fraction - agg. (n=6)",
        "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin oxid Metab - Dapagliflozin oxidative metabolites - PO - 50 mg - Fraction - agg. (n=6)",
        "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin 3OG Gluc (incl. unchanged feces exret.) - Dapagliflozin-3-O-glucuronide - PO - 50 mg - Fraction - agg. (n=6)",
        "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin 2OG Gluc (incl. unchanged feces exret.) - Dapagliflozin-2-O-glucuronide - PO - 50 mg - Fraction - agg. (n=6)",
        "Komoroski 2009 - SAD 50 mg - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=6)",
        "Komoroski 2009 - SAD 50 mg (Urine) - Dapagliflozin - PO - 50 mg - Urine - agg. (n=6)",
        "Komoroski 2009 - MAD 50 mg (day 1) - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=6)"
      ],
      "Solver": {},
      "OutputSchema": [
        {
          "Parameters": [
            {
              "Name": "Start time",
              "Value": 0.0,
              "Unit": "h"
            },
            {
              "Name": "End time",
              "Value": 2.0,
              "Unit": "h"
            },
            {
              "Name": "Resolution",
              "Value": 20.0,
              "Unit": "pts/h"
            }
          ]
        },
        {
          "Parameters": [
            {
              "Name": "Start time",
              "Value": 2.0,
              "Unit": "h"
            },
            {
              "Name": "End time",
              "Value": 320.0,
              "Unit": "h",
              "ValueOrigin": {
                "Source": "Unknown"
              }
            },
            {
              "Name": "Resolution",
              "Value": 4.0,
              "Unit": "pts/h"
            }
          ]
        }
      ],
      "Parameters": [
        {
          "Path": "Applications|PO SD 50 mg|Solution|Application_1|ProtocolSchemaItem|Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        },
        {
          "Path": "Dapagliflozin|Blood/Plasma concentration ratio",
          "Value": 0.88,
          "ValueOrigin": {
            "Source": "ParameterIdentification",
            "Method": "ParameterIdentification",
            "Description": "Value updated from 'PI full  (perm)' on 2019-08-06 14:46"
          }
        },
        {
          "Path": "Dapagliflozin|logP (veg.oil/water)",
          "Value": 2.0765619283,
          "Unit": "Log Units",
          "ValueOrigin": {
            "Source": "ParameterIdentification",
            "Method": "ParameterIdentification",
            "Description": "Value updated from 'PI full  (perm)' on 2019-08-06 14:46"
          }
        }
      ],
      "OutputSelections": [
        "Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
        "Organism|Dapagliflozin-UGT1A9-Optimized Metabolite|Total fraction of dose-Dapagliflozin",
        "Organism|Dapagliflozin-UGT2B7-Optimized Metabolite|Total fraction of dose-Dapagliflozin",
        "Organism|Dapagliflozin-Hepatic-CYP-Optimized Metabolite|Total fraction of dose-Dapagliflozin",
        "Organism|Lumen|Feces|Dapagliflozin|Fraction excreted to feces",
        "Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine"
      ],
      "Individual": "Standard_Adult_UGT",
      "Compounds": [
        {
          "Name": "Dapagliflozin",
          "CalculationMethods": [
            "Cellular partition coefficient method - Rodgers and Rowland",
            "Cellular permeability - PK-Sim Standard"
          ],
          "Alternatives": [
            {
              "AlternativeName": "Optimized",
              "GroupName": "COMPOUND_PERMEABILITY"
            },
            {
              "AlternativeName": "Optimized",
              "GroupName": "COMPOUND_INTESTINAL_PERMEABILITY"
            }
          ],
          "Processes": [
            {
              "Name": "UGT1A9-Optimized",
              "MoleculeName": "UGT1A9"
            },
            {
              "Name": "UGT2B7-Optimized",
              "MoleculeName": "UGT2B7"
            },
            {
              "Name": "Hepatic-CYP-Optimized",
              "MoleculeName": "Hepatic-CYP"
            },
            {
              "Name": "Glomerular Filtration-assumed"
            }
          ],
          "Protocol": {
            "Name": "PO SD 50 mg",
            "Formulations": [
              {
                "Name": "Solution",
                "Key": "Formulation"
              }
            ]
          }
        }
      ],
      "HasResults": true,
      "IndividualAnalyses": [
        {
          "Axes": [
            {
              "Unit": "h",
              "Dimension": "Time",
              "Type": "X",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "None",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            },
            {
              "Unit": "µg/l",
              "Dimension": "Concentration (molar)",
              "Type": "Y",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Solid",
              "Scaling": "Log",
              "NumberMode": "Normal"
            },
            {
              "Unit": "%",
              "Dimension": "Fraction",
              "Type": "Y2",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Dash",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            }
          ],
          "Curves": [
            {
              "Name": "PO SD 50 mg (perm)-Dapagliflozin-Peripheral Venous Blood-Plasma-Concentration",
              "X": "Time",
              "Y": "PO SD 50 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
              "CurveOptions": {
                "Color": "#FF0000",
                "LegendIndex": 1
              }
            },
            {
              "Name": "PO SD 50 mg (perm)-Dapagliflozin-Kidney-Urine-Fraction excreted to urine",
              "X": "Time",
              "Y": "PO SD 50 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
              "CurveOptions": {
                "yAxisType": "Y2",
                "Color": "#0000FF",
                "LegendIndex": 2,
                "LineStyle": "Dash"
              }
            },
            {
              "Name": "PO SD 50 mg (perm)-Dapagliflozin-Lumen-Feces-Fraction excreted to feces",
              "X": "Time",
              "Y": "PO SD 50 mg (perm)|Organism|Lumen|Feces|Dapagliflozin|Fraction excreted to feces",
              "CurveOptions": {
                "yAxisType": "Y2",
                "Color": "#008000",
                "LegendIndex": 3,
                "LineStyle": "Dash"
              }
            },
            {
              "Name": "PO SD 50 mg (perm)-Dapagliflozin-UGT1A9-Optimized Metabolite-Organism-Total fraction of dose-Dapagliflozin",
              "X": "Time",
              "Y": "PO SD 50 mg (perm)|Organism|Dapagliflozin-UGT1A9-Optimized Metabolite|Total fraction of dose-Dapagliflozin",
              "CurveOptions": {
                "yAxisType": "Y2",
                "Color": "#FF00FF",
                "LegendIndex": 5,
                "LineStyle": "Dash"
              }
            },
            {
              "Name": "PO SD 50 mg (perm)-Dapagliflozin-UGT2B7-Optimized Metabolite-Organism-Total fraction of dose-Dapagliflozin",
              "X": "Time",
              "Y": "PO SD 50 mg (perm)|Organism|Dapagliflozin-UGT2B7-Optimized Metabolite|Total fraction of dose-Dapagliflozin",
              "CurveOptions": {
                "yAxisType": "Y2",
                "Color": "#FF8000",
                "LegendIndex": 6,
                "LineStyle": "Dash"
              }
            },
            {
              "Name": "Kasichayanula 2011b - Study 1: 50 mg Control (Perpetrator Placebo) - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=24)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
              "X": "Kasichayanula 2011b - Study 1: 50 mg Control (Perpetrator Placebo) - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=24)|Time",
              "Y": "Kasichayanula 2011b - Study 1: 50 mg Control (Perpetrator Placebo) - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=24)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "Color": "#FF0000",
                "LegendIndex": 9,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            },
            {
              "Name": "Kasichayanula 2013b - Healthy subjects with normal kidney function - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=8)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
              "X": "Kasichayanula 2013b - Healthy subjects with normal kidney function - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=8)|Time",
              "Y": "Kasichayanula 2013b - Healthy subjects with normal kidney function - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=8)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "Color": "#FF0000",
                "LegendIndex": 11,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            },
            {
              "Name": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin Urine - Dapagliflozin - PO - 50 mg - Urine - agg. (n=6)-Dapagliflozin-Kidney-Urine-ArithmeticMean",
              "X": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin Urine - Dapagliflozin - PO - 50 mg - Urine - agg. (n=6)|Time",
              "Y": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin Urine - Dapagliflozin - PO - 50 mg - Urine - agg. (n=6)|ObservedData|Kidney|Urine|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "yAxisType": "Y2",
                "Color": "#0000FF",
                "LegendIndex": 14,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            },
            {
              "Name": "Komoroski 2009 - SAD 50 mg - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=6)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
              "X": "Komoroski 2009 - SAD 50 mg - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=6)|Time",
              "Y": "Komoroski 2009 - SAD 50 mg - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "Color": "#FF0000",
                "LegendIndex": 10,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            },
            {
              "Name": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin 2OG Gluc (incl. unchanged feces exret.) - Dapagliflozin-2-O-glucuronide - PO - 50 mg - Fraction - agg. (n=6)-Dapagliflozin-2-O-glucuronide-Undefined-Undefined-ArithmeticMean",
              "X": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin 2OG Gluc (incl. unchanged feces exret.) - Dapagliflozin-2-O-glucuronide - PO - 50 mg - Fraction - agg. (n=6)|Time",
              "Y": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin 2OG Gluc (incl. unchanged feces exret.) - Dapagliflozin-2-O-glucuronide - PO - 50 mg - Fraction - agg. (n=6)|ObservedData|Undefined|Undefined|Dapagliflozin-2-O-glucuronide|ArithmeticMean",
              "CurveOptions": {
                "yAxisType": "Y2",
                "Color": "#FF8000",
                "LegendIndex": 19,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            },
            {
              "Name": "Komoroski 2009 - SAD 50 mg (Urine) - Dapagliflozin - PO - 50 mg - Urine - agg. (n=6)-Dapagliflozin-Kidney-Urine-ArithmeticMean",
              "X": "Komoroski 2009 - SAD 50 mg (Urine) - Dapagliflozin - PO - 50 mg - Urine - agg. (n=6)|Time",
              "Y": "Komoroski 2009 - SAD 50 mg (Urine) - Dapagliflozin - PO - 50 mg - Urine - agg. (n=6)|ObservedData|Kidney|Urine|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "yAxisType": "Y2",
                "Color": "#0000FF",
                "LegendIndex": 16,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            },
            {
              "Name": "PO SD 50 mg (perm)-Dapagliflozin-Hepatic-CYP-Optimized Metabolite-Organism-Total fraction of dose-Dapagliflozin",
              "X": "Time",
              "Y": "PO SD 50 mg (perm)|Organism|Dapagliflozin-Hepatic-CYP-Optimized Metabolite|Total fraction of dose-Dapagliflozin",
              "CurveOptions": {
                "yAxisType": "Y2",
                "Color": "#00C0C0",
                "LegendIndex": 7,
                "LineStyle": "Dash"
              }
            },
            {
              "Name": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin oxid Metab - Dapagliflozin oxidative metabolites - PO - 50 mg - Fraction - agg. (n=6)-Dapagliflozin oxidative metabolites-Undefined-Undefined-ArithmeticMean",
              "X": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin oxid Metab - Dapagliflozin oxidative metabolites - PO - 50 mg - Fraction - agg. (n=6)|Time",
              "Y": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin oxid Metab - Dapagliflozin oxidative metabolites - PO - 50 mg - Fraction - agg. (n=6)|ObservedData|Undefined|Undefined|Dapagliflozin oxidative metabolites|ArithmeticMean",
              "CurveOptions": {
                "yAxisType": "Y2",
                "Color": "#00C0C0",
                "LegendIndex": 21,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            },
            {
              "Name": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin 3OG Gluc (incl. unchanged feces exret.) - Dapagliflozin-3-O-glucuronide - PO - 50 mg - Fraction - agg. (n=6)-Dapagliflozin-3-O-glucuronide-Undefined-Undefined-ArithmeticMean",
              "X": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin 3OG Gluc (incl. unchanged feces exret.) - Dapagliflozin-3-O-glucuronide - PO - 50 mg - Fraction - agg. (n=6)|Time",
              "Y": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin 3OG Gluc (incl. unchanged feces exret.) - Dapagliflozin-3-O-glucuronide - PO - 50 mg - Fraction - agg. (n=6)|ObservedData|Undefined|Undefined|Dapagliflozin-3-O-glucuronide|ArithmeticMean",
              "CurveOptions": {
                "yAxisType": "Y2",
                "Color": "#FF00FF",
                "LegendIndex": 17,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            },
            {
              "Name": "Komoroski 2009 - MAD 50 mg (day 1) - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=6)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
              "X": "Komoroski 2009 - MAD 50 mg (day 1) - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=6)|Time",
              "Y": "Komoroski 2009 - MAD 50 mg (day 1) - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "Color": "#FF0000",
                "LegendIndex": 13,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            }
          ],
          "Name": "PO SD 50 mg (perm)",
          "Settings": {
            "SideMarginsEnabled": true,
            "LegendPosition": "None",
            "BackColor": "#FFFFFF",
            "DiagramBackColor": "#FFFFFF"
          },
          "Title": "PO SD 50 mg (perm)",
          "OriginText": "Dapagliflozin\nPO SD 50 mg (perm)\n2019-08-06 08:59"
        },
        {
          "Axes": [
            {
              "Unit": "h",
              "Dimension": "Time",
              "Type": "X",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "None",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            },
            {
              "Unit": "µg/l",
              "Dimension": "Concentration (molar)",
              "Type": "Y",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Solid",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            },
            {
              "Unit": "%",
              "Dimension": "Fraction",
              "Type": "Y2",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Dash",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            }
          ],
          "Curves": [
            {
              "Name": "PO SD 50 mg (perm)-Dapagliflozin-Peripheral Venous Blood-Plasma-Concentration",
              "X": "Time",
              "Y": "PO SD 50 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
              "CurveOptions": {
                "Color": "#FF0000",
                "LegendIndex": 1
              }
            },
            {
              "Name": "PO SD 50 mg (perm)-Dapagliflozin-Kidney-Urine-Fraction excreted to urine",
              "X": "Time",
              "Y": "PO SD 50 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
              "CurveOptions": {
                "yAxisType": "Y2",
                "Color": "#0000FF",
                "LegendIndex": 2,
                "LineStyle": "Dash"
              }
            },
            {
              "Name": "PO SD 50 mg (perm)-Dapagliflozin-Lumen-Feces-Fraction excreted to feces",
              "X": "Time",
              "Y": "PO SD 50 mg (perm)|Organism|Lumen|Feces|Dapagliflozin|Fraction excreted to feces",
              "CurveOptions": {
                "yAxisType": "Y2",
                "Color": "#008000",
                "LegendIndex": 3,
                "LineStyle": "Dash"
              }
            },
            {
              "Name": "PO SD 50 mg (perm)-Dapagliflozin-UGT1A9-Optimized Metabolite-Organism-Total fraction of dose-Dapagliflozin",
              "X": "Time",
              "Y": "PO SD 50 mg (perm)|Organism|Dapagliflozin-UGT1A9-Optimized Metabolite|Total fraction of dose-Dapagliflozin",
              "CurveOptions": {
                "yAxisType": "Y2",
                "Color": "#FF00FF",
                "LegendIndex": 5,
                "LineStyle": "Dash"
              }
            },
            {
              "Name": "PO SD 50 mg (perm)-Dapagliflozin-UGT2B7-Optimized Metabolite-Organism-Total fraction of dose-Dapagliflozin",
              "X": "Time",
              "Y": "PO SD 50 mg (perm)|Organism|Dapagliflozin-UGT2B7-Optimized Metabolite|Total fraction of dose-Dapagliflozin",
              "CurveOptions": {
                "yAxisType": "Y2",
                "Color": "#FF8000",
                "LegendIndex": 6,
                "LineStyle": "Dash"
              }
            },
            {
              "Name": "Kasichayanula 2011b - Study 1: 50 mg Control (Perpetrator Placebo) - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=24)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
              "X": "Kasichayanula 2011b - Study 1: 50 mg Control (Perpetrator Placebo) - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=24)|Time",
              "Y": "Kasichayanula 2011b - Study 1: 50 mg Control (Perpetrator Placebo) - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=24)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "Color": "#FF0000",
                "LegendIndex": 9,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            },
            {
              "Name": "Kasichayanula 2013b - Healthy subjects with normal kidney function - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=8)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
              "X": "Kasichayanula 2013b - Healthy subjects with normal kidney function - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=8)|Time",
              "Y": "Kasichayanula 2013b - Healthy subjects with normal kidney function - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=8)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "Color": "#FF0000",
                "LegendIndex": 11,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            },
            {
              "Name": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin Urine - Dapagliflozin - PO - 50 mg - Urine - agg. (n=6)-Dapagliflozin-Kidney-Urine-ArithmeticMean",
              "X": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin Urine - Dapagliflozin - PO - 50 mg - Urine - agg. (n=6)|Time",
              "Y": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin Urine - Dapagliflozin - PO - 50 mg - Urine - agg. (n=6)|ObservedData|Kidney|Urine|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "yAxisType": "Y2",
                "Color": "#0000FF",
                "LegendIndex": 14,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            },
            {
              "Name": "Komoroski 2009 - SAD 50 mg - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=6)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
              "X": "Komoroski 2009 - SAD 50 mg - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=6)|Time",
              "Y": "Komoroski 2009 - SAD 50 mg - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "Color": "#FF0000",
                "LegendIndex": 10,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            },
            {
              "Name": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin 2OG Gluc (incl. unchanged feces exret.) - Dapagliflozin-2-O-glucuronide - PO - 50 mg - Fraction - agg. (n=6)-Dapagliflozin-2-O-glucuronide-Undefined-Undefined-ArithmeticMean",
              "X": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin 2OG Gluc (incl. unchanged feces exret.) - Dapagliflozin-2-O-glucuronide - PO - 50 mg - Fraction - agg. (n=6)|Time",
              "Y": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin 2OG Gluc (incl. unchanged feces exret.) - Dapagliflozin-2-O-glucuronide - PO - 50 mg - Fraction - agg. (n=6)|ObservedData|Undefined|Undefined|Dapagliflozin-2-O-glucuronide|ArithmeticMean",
              "CurveOptions": {
                "yAxisType": "Y2",
                "Color": "#FF8000",
                "LegendIndex": 19,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            },
            {
              "Name": "Komoroski 2009 - SAD 50 mg (Urine) - Dapagliflozin - PO - 50 mg - Urine - agg. (n=6)-Dapagliflozin-Kidney-Urine-ArithmeticMean",
              "X": "Komoroski 2009 - SAD 50 mg (Urine) - Dapagliflozin - PO - 50 mg - Urine - agg. (n=6)|Time",
              "Y": "Komoroski 2009 - SAD 50 mg (Urine) - Dapagliflozin - PO - 50 mg - Urine - agg. (n=6)|ObservedData|Kidney|Urine|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "yAxisType": "Y2",
                "Color": "#0000FF",
                "LegendIndex": 16,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            },
            {
              "Name": "PO SD 50 mg (perm)-Dapagliflozin-Hepatic-CYP-Optimized Metabolite-Organism-Total fraction of dose-Dapagliflozin",
              "X": "Time",
              "Y": "PO SD 50 mg (perm)|Organism|Dapagliflozin-Hepatic-CYP-Optimized Metabolite|Total fraction of dose-Dapagliflozin",
              "CurveOptions": {
                "yAxisType": "Y2",
                "Color": "#00C0C0",
                "LegendIndex": 7,
                "LineStyle": "Dash"
              }
            },
            {
              "Name": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin oxid Metab - Dapagliflozin oxidative metabolites - PO - 50 mg - Fraction - agg. (n=6)-Dapagliflozin oxidative metabolites-Undefined-Undefined-ArithmeticMean",
              "X": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin oxid Metab - Dapagliflozin oxidative metabolites - PO - 50 mg - Fraction - agg. (n=6)|Time",
              "Y": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin oxid Metab - Dapagliflozin oxidative metabolites - PO - 50 mg - Fraction - agg. (n=6)|ObservedData|Undefined|Undefined|Dapagliflozin oxidative metabolites|ArithmeticMean",
              "CurveOptions": {
                "yAxisType": "Y2",
                "Color": "#00C0C0",
                "LegendIndex": 21,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            },
            {
              "Name": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin 3OG Gluc (incl. unchanged feces exret.) - Dapagliflozin-3-O-glucuronide - PO - 50 mg - Fraction - agg. (n=6)-Dapagliflozin-3-O-glucuronide-Undefined-Undefined-ArithmeticMean",
              "X": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin 3OG Gluc (incl. unchanged feces exret.) - Dapagliflozin-3-O-glucuronide - PO - 50 mg - Fraction - agg. (n=6)|Time",
              "Y": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin 3OG Gluc (incl. unchanged feces exret.) - Dapagliflozin-3-O-glucuronide - PO - 50 mg - Fraction - agg. (n=6)|ObservedData|Undefined|Undefined|Dapagliflozin-3-O-glucuronide|ArithmeticMean",
              "CurveOptions": {
                "yAxisType": "Y2",
                "Color": "#FF00FF",
                "LegendIndex": 17,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            },
            {
              "Name": "Komoroski 2009 - MAD 50 mg (day 1) - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=6)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
              "X": "Komoroski 2009 - MAD 50 mg (day 1) - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=6)|Time",
              "Y": "Komoroski 2009 - MAD 50 mg (day 1) - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "Color": "#FF0000",
                "LegendIndex": 13,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            }
          ],
          "Name": "PO SD 50 mg (perm) 1",
          "Settings": {
            "SideMarginsEnabled": true,
            "LegendPosition": "None",
            "BackColor": "#FFFFFF",
            "DiagramBackColor": "#FFFFFF"
          },
          "Title": "PO SD 50 mg (perm)",
          "OriginText": "Dapagliflozin\nPO SD 50 mg (perm)\n2019-08-06 08:59"
        }
      ]
    },
    {
      "Name": "PO SD 2.5 mg (perm)",
      "Model": "4Comp",
      "ObservedData": [
        "Komoroski 2009 - SAD 2.5 mg - Dapagliflozin - PO - 2.5 mg - Plasma - agg. (n=6)",
        "Komoroski 2009 - SAD 2.5 mg (Urine) - Dapagliflozin - PO - 2.5 mg - Urine - agg. (n=6)",
        "Komoroski 2009 - MAD 2.5 mg (day 1) - Dapagliflozin - PO - 2.5 mg - Plasma - agg. (n=6)"
      ],
      "Solver": {},
      "OutputSchema": [
        {
          "Parameters": [
            {
              "Name": "Start time",
              "Value": 0.0,
              "Unit": "h"
            },
            {
              "Name": "End time",
              "Value": 2.0,
              "Unit": "h"
            },
            {
              "Name": "Resolution",
              "Value": 20.0,
              "Unit": "pts/h"
            }
          ]
        },
        {
          "Parameters": [
            {
              "Name": "Start time",
              "Value": 2.0,
              "Unit": "h"
            },
            {
              "Name": "End time",
              "Value": 120.0,
              "Unit": "h",
              "ValueOrigin": {
                "Source": "Unknown"
              }
            },
            {
              "Name": "Resolution",
              "Value": 4.0,
              "Unit": "pts/h"
            }
          ]
        }
      ],
      "Parameters": [
        {
          "Path": "Applications|PO SD 2.5 mg|Solution|Application_1|ProtocolSchemaItem|Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        },
        {
          "Path": "Dapagliflozin|Blood/Plasma concentration ratio",
          "Value": 0.88,
          "ValueOrigin": {
            "Source": "ParameterIdentification",
            "Method": "ParameterIdentification",
            "Description": "Value updated from 'PI full  (perm)' on 2019-08-06 14:46"
          }
        },
        {
          "Path": "Dapagliflozin|logP (veg.oil/water)",
          "Value": 2.0765619283,
          "Unit": "Log Units",
          "ValueOrigin": {
            "Source": "ParameterIdentification",
            "Method": "ParameterIdentification",
            "Description": "Value updated from 'PI full  (perm)' on 2019-08-06 14:46"
          }
        }
      ],
      "OutputSelections": [
        "Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
        "Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine"
      ],
      "Individual": "Standard_Adult_UGT",
      "Compounds": [
        {
          "Name": "Dapagliflozin",
          "CalculationMethods": [
            "Cellular partition coefficient method - Rodgers and Rowland",
            "Cellular permeability - PK-Sim Standard"
          ],
          "Alternatives": [
            {
              "AlternativeName": "Optimized",
              "GroupName": "COMPOUND_PERMEABILITY"
            },
            {
              "AlternativeName": "Optimized",
              "GroupName": "COMPOUND_INTESTINAL_PERMEABILITY"
            }
          ],
          "Processes": [
            {
              "Name": "UGT1A9-Optimized",
              "MoleculeName": "UGT1A9"
            },
            {
              "Name": "UGT2B7-Optimized",
              "MoleculeName": "UGT2B7"
            },
            {
              "Name": "Hepatic-CYP-Optimized",
              "MoleculeName": "Hepatic-CYP"
            },
            {
              "Name": "Glomerular Filtration-assumed"
            }
          ],
          "Protocol": {
            "Name": "PO SD 2.5 mg",
            "Formulations": [
              {
                "Name": "Solution",
                "Key": "Formulation"
              }
            ]
          }
        }
      ],
      "HasResults": true,
      "IndividualAnalyses": [
        {
          "Axes": [
            {
              "Unit": "h",
              "Dimension": "Time",
              "Type": "X",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "None",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            },
            {
              "Unit": "µg/l",
              "Dimension": "Concentration (molar)",
              "Type": "Y",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Solid",
              "Scaling": "Log",
              "NumberMode": "Normal"
            },
            {
              "Unit": "",
              "Dimension": "Fraction",
              "Type": "Y2",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Dash",
              "Scaling": "Log",
              "NumberMode": "Normal"
            }
          ],
          "Curves": [
            {
              "Name": "PO SD 2.5 mg (perm)-Dapagliflozin-Peripheral Venous Blood-Plasma-Concentration",
              "X": "Time",
              "Y": "PO SD 2.5 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
              "CurveOptions": {
                "Color": "#FF0000",
                "LegendIndex": 1
              }
            },
            {
              "Name": "Komoroski 2009 - SAD 2.5 mg (Urine) - Dapagliflozin - PO - 2.5 mg - Urine - agg. (n=6)-Dapagliflozin-Kidney-Urine-ArithmeticMean",
              "X": "Komoroski 2009 - SAD 2.5 mg (Urine) - Dapagliflozin - PO - 2.5 mg - Urine - agg. (n=6)|Time",
              "Y": "Komoroski 2009 - SAD 2.5 mg (Urine) - Dapagliflozin - PO - 2.5 mg - Urine - agg. (n=6)|ObservedData|Kidney|Urine|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "yAxisType": "Y2",
                "Color": "#FF00FF",
                "LegendIndex": 4,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            },
            {
              "Name": "PO SD 2.5 mg (perm)-Dapagliflozin-Kidney-Urine-Fraction excreted to urine",
              "X": "Time",
              "Y": "PO SD 2.5 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
              "CurveOptions": {
                "yAxisType": "Y2",
                "Color": "#FF00FF",
                "LegendIndex": 3,
                "LineStyle": "Dash"
              }
            },
            {
              "Name": "Komoroski 2009 - SAD 2.5 mg - Dapagliflozin - PO - 2.5 mg - Plasma - agg. (n=6)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
              "X": "Komoroski 2009 - SAD 2.5 mg - Dapagliflozin - PO - 2.5 mg - Plasma - agg. (n=6)|Time",
              "Y": "Komoroski 2009 - SAD 2.5 mg - Dapagliflozin - PO - 2.5 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "Color": "#0000FF",
                "LegendIndex": 2,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            },
            {
              "Name": "Komoroski 2009 - MAD 2.5 mg (day 1) - Dapagliflozin - PO - 2.5 mg - Plasma - agg. (n=6)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
              "X": "Komoroski 2009 - MAD 2.5 mg (day 1) - Dapagliflozin - PO - 2.5 mg - Plasma - agg. (n=6)|Time",
              "Y": "Komoroski 2009 - MAD 2.5 mg (day 1) - Dapagliflozin - PO - 2.5 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "Color": "#FF8000",
                "LegendIndex": 5,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            }
          ],
          "Name": "PO SD 2.5 mg (perm)",
          "Title": "PO SD 2.5 mg (perm)",
          "OriginText": "Dapagliflozin\nPO SD 2.5 mg (perm)\n2019-08-06 11:20"
        },
        {
          "Axes": [
            {
              "Unit": "h",
              "Dimension": "Time",
              "Type": "X",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "None",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            },
            {
              "Unit": "µg/l",
              "Dimension": "Concentration (molar)",
              "Type": "Y",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Solid",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            },
            {
              "Unit": "",
              "Dimension": "Fraction",
              "Type": "Y2",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Dash",
              "Scaling": "Log",
              "NumberMode": "Normal"
            }
          ],
          "Curves": [
            {
              "Name": "PO SD 2.5 mg (perm)-Dapagliflozin-Peripheral Venous Blood-Plasma-Concentration",
              "X": "Time",
              "Y": "PO SD 2.5 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
              "CurveOptions": {
                "Color": "#FF0000",
                "LegendIndex": 1
              }
            },
            {
              "Name": "Komoroski 2009 - SAD 2.5 mg (Urine) - Dapagliflozin - PO - 2.5 mg - Urine - agg. (n=6)-Dapagliflozin-Kidney-Urine-ArithmeticMean",
              "X": "Komoroski 2009 - SAD 2.5 mg (Urine) - Dapagliflozin - PO - 2.5 mg - Urine - agg. (n=6)|Time",
              "Y": "Komoroski 2009 - SAD 2.5 mg (Urine) - Dapagliflozin - PO - 2.5 mg - Urine - agg. (n=6)|ObservedData|Kidney|Urine|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "yAxisType": "Y2",
                "Color": "#FF00FF",
                "LegendIndex": 4,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            },
            {
              "Name": "PO SD 2.5 mg (perm)-Dapagliflozin-Kidney-Urine-Fraction excreted to urine",
              "X": "Time",
              "Y": "PO SD 2.5 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
              "CurveOptions": {
                "yAxisType": "Y2",
                "Color": "#FF00FF",
                "LegendIndex": 3,
                "LineStyle": "Dash"
              }
            },
            {
              "Name": "Komoroski 2009 - SAD 2.5 mg - Dapagliflozin - PO - 2.5 mg - Plasma - agg. (n=6)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
              "X": "Komoroski 2009 - SAD 2.5 mg - Dapagliflozin - PO - 2.5 mg - Plasma - agg. (n=6)|Time",
              "Y": "Komoroski 2009 - SAD 2.5 mg - Dapagliflozin - PO - 2.5 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "Color": "#0000FF",
                "LegendIndex": 2,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            },
            {
              "Name": "Komoroski 2009 - MAD 2.5 mg (day 1) - Dapagliflozin - PO - 2.5 mg - Plasma - agg. (n=6)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
              "X": "Komoroski 2009 - MAD 2.5 mg (day 1) - Dapagliflozin - PO - 2.5 mg - Plasma - agg. (n=6)|Time",
              "Y": "Komoroski 2009 - MAD 2.5 mg (day 1) - Dapagliflozin - PO - 2.5 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "Color": "#FF8000",
                "LegendIndex": 5,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            }
          ],
          "Name": "PO SD 2.5 mg (perm) 1",
          "Title": "PO SD 2.5 mg (perm)",
          "OriginText": "Dapagliflozin\nPO SD 2.5 mg (perm)\n2019-08-06 11:20"
        }
      ]
    },
    {
      "Name": "PO SD 5 mg (perm)",
      "Model": "4Comp",
      "ObservedData": [
        "Komoroski 2009 - SAD 5 mg - Dapagliflozin - PO - 5 mg - Plasma - agg. (n=6)",
        "Komoroski 2009 - SAD 5 mg (Urine) - Dapagliflozin - PO - 5 mg - Urine - agg. (n=6)"
      ],
      "Solver": {},
      "OutputSchema": [
        {
          "Parameters": [
            {
              "Name": "Start time",
              "Value": 0.0,
              "Unit": "h"
            },
            {
              "Name": "End time",
              "Value": 2.0,
              "Unit": "h"
            },
            {
              "Name": "Resolution",
              "Value": 20.0,
              "Unit": "pts/h"
            }
          ]
        },
        {
          "Parameters": [
            {
              "Name": "Start time",
              "Value": 2.0,
              "Unit": "h"
            },
            {
              "Name": "End time",
              "Value": 120.0,
              "Unit": "h",
              "ValueOrigin": {
                "Source": "Unknown"
              }
            },
            {
              "Name": "Resolution",
              "Value": 4.0,
              "Unit": "pts/h"
            }
          ]
        }
      ],
      "Parameters": [
        {
          "Path": "Applications|PO SD 5 mg|Solution|Application_1|ProtocolSchemaItem|Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        },
        {
          "Path": "Dapagliflozin|Blood/Plasma concentration ratio",
          "Value": 0.88,
          "ValueOrigin": {
            "Source": "ParameterIdentification",
            "Method": "ParameterIdentification",
            "Description": "Value updated from 'PI full  (perm)' on 2019-08-06 14:46"
          }
        },
        {
          "Path": "Dapagliflozin|logP (veg.oil/water)",
          "Value": 2.0765619283,
          "Unit": "Log Units",
          "ValueOrigin": {
            "Source": "ParameterIdentification",
            "Method": "ParameterIdentification",
            "Description": "Value updated from 'PI full  (perm)' on 2019-08-06 14:46"
          }
        }
      ],
      "OutputSelections": [
        "Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
        "Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine"
      ],
      "Individual": "Standard_Adult_UGT",
      "Compounds": [
        {
          "Name": "Dapagliflozin",
          "CalculationMethods": [
            "Cellular partition coefficient method - Rodgers and Rowland",
            "Cellular permeability - PK-Sim Standard"
          ],
          "Alternatives": [
            {
              "AlternativeName": "Optimized",
              "GroupName": "COMPOUND_PERMEABILITY"
            },
            {
              "AlternativeName": "Optimized",
              "GroupName": "COMPOUND_INTESTINAL_PERMEABILITY"
            }
          ],
          "Processes": [
            {
              "Name": "UGT1A9-Optimized",
              "MoleculeName": "UGT1A9"
            },
            {
              "Name": "UGT2B7-Optimized",
              "MoleculeName": "UGT2B7"
            },
            {
              "Name": "Hepatic-CYP-Optimized",
              "MoleculeName": "Hepatic-CYP"
            },
            {
              "Name": "Glomerular Filtration-assumed"
            }
          ],
          "Protocol": {
            "Name": "PO SD 5 mg",
            "Formulations": [
              {
                "Name": "Solution",
                "Key": "Formulation"
              }
            ]
          }
        }
      ],
      "HasResults": true,
      "IndividualAnalyses": [
        {
          "Axes": [
            {
              "Unit": "h",
              "Dimension": "Time",
              "Type": "X",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "None",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            },
            {
              "Unit": "µg/l",
              "Dimension": "Concentration (molar)",
              "Type": "Y",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Solid",
              "Scaling": "Log",
              "NumberMode": "Normal"
            },
            {
              "Unit": "",
              "Dimension": "Fraction",
              "Type": "Y2",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Dash",
              "Scaling": "Log",
              "NumberMode": "Normal"
            }
          ],
          "Curves": [
            {
              "Name": "PO SD 5 mg (perm)-Dapagliflozin-Peripheral Venous Blood-Plasma-Concentration",
              "X": "Time",
              "Y": "PO SD 5 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
              "CurveOptions": {
                "Color": "#FF0000",
                "LegendIndex": 1
              }
            },
            {
              "Name": "PO SD 5 mg (perm)-Dapagliflozin-Kidney-Urine-Fraction excreted to urine",
              "X": "Time",
              "Y": "PO SD 5 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
              "CurveOptions": {
                "yAxisType": "Y2",
                "Color": "#008000",
                "LegendIndex": 4,
                "LineStyle": "Dash"
              }
            },
            {
              "Name": "Komoroski 2009 - SAD 5 mg (Urine) - Dapagliflozin - PO - 5 mg - Urine - agg. (n=6)-Dapagliflozin-Kidney-Urine-ArithmeticMean",
              "X": "Komoroski 2009 - SAD 5 mg (Urine) - Dapagliflozin - PO - 5 mg - Urine - agg. (n=6)|Time",
              "Y": "Komoroski 2009 - SAD 5 mg (Urine) - Dapagliflozin - PO - 5 mg - Urine - agg. (n=6)|ObservedData|Kidney|Urine|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "yAxisType": "Y2",
                "Color": "#008000",
                "LegendIndex": 3,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            },
            {
              "Name": "Komoroski 2009 - SAD 5 mg - Dapagliflozin - PO - 5 mg - Plasma - agg. (n=6)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
              "X": "Komoroski 2009 - SAD 5 mg - Dapagliflozin - PO - 5 mg - Plasma - agg. (n=6)|Time",
              "Y": "Komoroski 2009 - SAD 5 mg - Dapagliflozin - PO - 5 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "Color": "#0000FF",
                "LegendIndex": 2,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            }
          ],
          "Name": "PO SD 5 mg (perm)",
          "Title": "PO SD 5 mg (perm)",
          "OriginText": "Dapagliflozin\nPO SD 5 mg (perm)\n2019-08-06 11:20"
        },
        {
          "Axes": [
            {
              "Unit": "h",
              "Dimension": "Time",
              "Type": "X",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "None",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            },
            {
              "Unit": "µg/l",
              "Dimension": "Concentration (molar)",
              "Type": "Y",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Solid",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            },
            {
              "Unit": "",
              "Dimension": "Fraction",
              "Type": "Y2",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Dash",
              "Scaling": "Log",
              "NumberMode": "Normal"
            }
          ],
          "Curves": [
            {
              "Name": "PO SD 5 mg (perm)-Dapagliflozin-Peripheral Venous Blood-Plasma-Concentration",
              "X": "Time",
              "Y": "PO SD 5 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
              "CurveOptions": {
                "Color": "#FF0000",
                "LegendIndex": 1
              }
            },
            {
              "Name": "PO SD 5 mg (perm)-Dapagliflozin-Kidney-Urine-Fraction excreted to urine",
              "X": "Time",
              "Y": "PO SD 5 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
              "CurveOptions": {
                "yAxisType": "Y2",
                "Color": "#008000",
                "LegendIndex": 4,
                "LineStyle": "Dash"
              }
            },
            {
              "Name": "Komoroski 2009 - SAD 5 mg (Urine) - Dapagliflozin - PO - 5 mg - Urine - agg. (n=6)-Dapagliflozin-Kidney-Urine-ArithmeticMean",
              "X": "Komoroski 2009 - SAD 5 mg (Urine) - Dapagliflozin - PO - 5 mg - Urine - agg. (n=6)|Time",
              "Y": "Komoroski 2009 - SAD 5 mg (Urine) - Dapagliflozin - PO - 5 mg - Urine - agg. (n=6)|ObservedData|Kidney|Urine|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "yAxisType": "Y2",
                "Color": "#008000",
                "LegendIndex": 3,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            },
            {
              "Name": "Komoroski 2009 - SAD 5 mg - Dapagliflozin - PO - 5 mg - Plasma - agg. (n=6)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
              "X": "Komoroski 2009 - SAD 5 mg - Dapagliflozin - PO - 5 mg - Plasma - agg. (n=6)|Time",
              "Y": "Komoroski 2009 - SAD 5 mg - Dapagliflozin - PO - 5 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "Color": "#0000FF",
                "LegendIndex": 2,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            }
          ],
          "Name": "PO SD 5 mg (perm) 1",
          "Title": "PO SD 5 mg (perm)",
          "OriginText": "Dapagliflozin\nPO SD 5 mg (perm)\n2019-08-06 11:20"
        }
      ]
    },
    {
      "Name": "PO SD 20 mg (perm)",
      "Model": "4Comp",
      "ObservedData": [
        "Kasichayanula 2012 - Study 1: Control (Perpetrator Placebo) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=24)",
        "Komoroski 2009 - SAD 20 mg - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=6)",
        "Komoroski 2009 - SAD 20 mg (Urine) - Dapagliflozin - PO - 20 mg - Urine - agg. (n=6)",
        "Komoroski 2009 - MAD 20 mg (day 1) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=6)"
      ],
      "Solver": {},
      "OutputSchema": [
        {
          "Parameters": [
            {
              "Name": "Start time",
              "Value": 0.0,
              "Unit": "h"
            },
            {
              "Name": "End time",
              "Value": 2.0,
              "Unit": "h"
            },
            {
              "Name": "Resolution",
              "Value": 20.0,
              "Unit": "pts/h"
            }
          ]
        },
        {
          "Parameters": [
            {
              "Name": "Start time",
              "Value": 2.0,
              "Unit": "h"
            },
            {
              "Name": "End time",
              "Value": 120.0,
              "Unit": "h",
              "ValueOrigin": {
                "Source": "Unknown"
              }
            },
            {
              "Name": "Resolution",
              "Value": 4.0,
              "Unit": "pts/h"
            }
          ]
        }
      ],
      "Parameters": [
        {
          "Path": "Applications|PO SD 20 mg|Solution|Application_1|ProtocolSchemaItem|Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        },
        {
          "Path": "Dapagliflozin|Blood/Plasma concentration ratio",
          "Value": 0.88,
          "ValueOrigin": {
            "Source": "ParameterIdentification",
            "Method": "ParameterIdentification",
            "Description": "Value updated from 'PI full  (perm)' on 2019-08-06 14:46"
          }
        },
        {
          "Path": "Dapagliflozin|logP (veg.oil/water)",
          "Value": 2.0765619283,
          "Unit": "Log Units",
          "ValueOrigin": {
            "Source": "ParameterIdentification",
            "Method": "ParameterIdentification",
            "Description": "Value updated from 'PI full  (perm)' on 2019-08-06 14:46"
          }
        }
      ],
      "OutputSelections": [
        "Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
        "Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine"
      ],
      "Individual": "Standard_Adult_UGT",
      "Compounds": [
        {
          "Name": "Dapagliflozin",
          "CalculationMethods": [
            "Cellular partition coefficient method - Rodgers and Rowland",
            "Cellular permeability - PK-Sim Standard"
          ],
          "Alternatives": [
            {
              "AlternativeName": "Optimized",
              "GroupName": "COMPOUND_PERMEABILITY"
            },
            {
              "AlternativeName": "Optimized",
              "GroupName": "COMPOUND_INTESTINAL_PERMEABILITY"
            }
          ],
          "Processes": [
            {
              "Name": "UGT1A9-Optimized",
              "MoleculeName": "UGT1A9"
            },
            {
              "Name": "UGT2B7-Optimized",
              "MoleculeName": "UGT2B7"
            },
            {
              "Name": "Hepatic-CYP-Optimized",
              "MoleculeName": "Hepatic-CYP"
            },
            {
              "Name": "Glomerular Filtration-assumed"
            }
          ],
          "Protocol": {
            "Name": "PO SD 20 mg",
            "Formulations": [
              {
                "Name": "Solution",
                "Key": "Formulation"
              }
            ]
          }
        }
      ],
      "HasResults": true,
      "IndividualAnalyses": [
        {
          "Axes": [
            {
              "Unit": "h",
              "Dimension": "Time",
              "Type": "X",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "None",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            },
            {
              "Unit": "µg/l",
              "Dimension": "Concentration (molar)",
              "Type": "Y",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Solid",
              "Scaling": "Log",
              "NumberMode": "Normal"
            },
            {
              "Unit": "",
              "Dimension": "Fraction",
              "Type": "Y2",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Dash",
              "Scaling": "Log",
              "NumberMode": "Normal"
            }
          ],
          "Curves": [
            {
              "Name": "PO SD 20 mg (perm)-Dapagliflozin-Peripheral Venous Blood-Plasma-Concentration",
              "X": "Time",
              "Y": "PO SD 20 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
              "CurveOptions": {
                "Color": "#FF0000",
                "LegendIndex": 1
              }
            },
            {
              "Name": "Komoroski 2009 - SAD 20 mg (Urine) - Dapagliflozin - PO - 20 mg - Urine - agg. (n=6)-Dapagliflozin-Kidney-Urine-ArithmeticMean",
              "X": "Komoroski 2009 - SAD 20 mg (Urine) - Dapagliflozin - PO - 20 mg - Urine - agg. (n=6)|Time",
              "Y": "Komoroski 2009 - SAD 20 mg (Urine) - Dapagliflozin - PO - 20 mg - Urine - agg. (n=6)|ObservedData|Kidney|Urine|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "yAxisType": "Y2",
                "Color": "#FF8000",
                "LegendIndex": 5,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            },
            {
              "Name": "PO SD 20 mg (perm)-Dapagliflozin-Kidney-Urine-Fraction excreted to urine",
              "X": "Time",
              "Y": "PO SD 20 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
              "CurveOptions": {
                "yAxisType": "Y2",
                "Color": "#F79646",
                "LegendIndex": 4,
                "LineStyle": "Dash"
              }
            },
            {
              "Name": "Kasichayanula 2012 - Study 1: Control (Perpetrator Placebo) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=24)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
              "X": "Kasichayanula 2012 - Study 1: Control (Perpetrator Placebo) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=24)|Time",
              "Y": "Kasichayanula 2012 - Study 1: Control (Perpetrator Placebo) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=24)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "Color": "#008000",
                "LegendIndex": 3,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            },
            {
              "Name": "Komoroski 2009 - SAD 20 mg - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=6)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
              "X": "Komoroski 2009 - SAD 20 mg - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=6)|Time",
              "Y": "Komoroski 2009 - SAD 20 mg - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "Color": "#0000FF",
                "LegendIndex": 2,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            },
            {
              "Name": "Komoroski 2009 - MAD 20 mg (day 1) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=6)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
              "X": "Komoroski 2009 - MAD 20 mg (day 1) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=6)|Time",
              "Y": "Komoroski 2009 - MAD 20 mg (day 1) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "Color": "#00C0C0",
                "LegendIndex": 6,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            }
          ],
          "Name": "PO SD 20 mg (perm)",
          "Settings": {
            "SideMarginsEnabled": true,
            "LegendPosition": "None",
            "BackColor": "#FFFFFF",
            "DiagramBackColor": "#FFFFFF"
          },
          "Title": "PO SD 20 mg (perm)",
          "OriginText": "Dapagliflozin\nPO SD 20 mg (perm)\n2019-08-06 11:24"
        },
        {
          "Axes": [
            {
              "Unit": "h",
              "Dimension": "Time",
              "Type": "X",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "None",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            },
            {
              "Unit": "µg/l",
              "Dimension": "Concentration (molar)",
              "Type": "Y",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Solid",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            },
            {
              "Unit": "",
              "Dimension": "Fraction",
              "Type": "Y2",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Dash",
              "Scaling": "Log",
              "NumberMode": "Normal"
            }
          ],
          "Curves": [
            {
              "Name": "PO SD 20 mg (perm)-Dapagliflozin-Peripheral Venous Blood-Plasma-Concentration",
              "X": "Time",
              "Y": "PO SD 20 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
              "CurveOptions": {
                "Color": "#FF0000",
                "LegendIndex": 1
              }
            },
            {
              "Name": "Komoroski 2009 - SAD 20 mg (Urine) - Dapagliflozin - PO - 20 mg - Urine - agg. (n=6)-Dapagliflozin-Kidney-Urine-ArithmeticMean",
              "X": "Komoroski 2009 - SAD 20 mg (Urine) - Dapagliflozin - PO - 20 mg - Urine - agg. (n=6)|Time",
              "Y": "Komoroski 2009 - SAD 20 mg (Urine) - Dapagliflozin - PO - 20 mg - Urine - agg. (n=6)|ObservedData|Kidney|Urine|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "yAxisType": "Y2",
                "Color": "#FF8000",
                "LegendIndex": 5,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            },
            {
              "Name": "PO SD 20 mg (perm)-Dapagliflozin-Kidney-Urine-Fraction excreted to urine",
              "X": "Time",
              "Y": "PO SD 20 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
              "CurveOptions": {
                "yAxisType": "Y2",
                "Color": "#F79646",
                "LegendIndex": 4,
                "LineStyle": "Dash"
              }
            },
            {
              "Name": "Kasichayanula 2012 - Study 1: Control (Perpetrator Placebo) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=24)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
              "X": "Kasichayanula 2012 - Study 1: Control (Perpetrator Placebo) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=24)|Time",
              "Y": "Kasichayanula 2012 - Study 1: Control (Perpetrator Placebo) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=24)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "Color": "#008000",
                "LegendIndex": 3,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            },
            {
              "Name": "Komoroski 2009 - SAD 20 mg - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=6)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
              "X": "Komoroski 2009 - SAD 20 mg - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=6)|Time",
              "Y": "Komoroski 2009 - SAD 20 mg - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "Color": "#0000FF",
                "LegendIndex": 2,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            },
            {
              "Name": "Komoroski 2009 - MAD 20 mg (day 1) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=6)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
              "X": "Komoroski 2009 - MAD 20 mg (day 1) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=6)|Time",
              "Y": "Komoroski 2009 - MAD 20 mg (day 1) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "Color": "#00C0C0",
                "LegendIndex": 6,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            }
          ],
          "Name": "PO SD 20 mg (perm) 1",
          "Settings": {
            "SideMarginsEnabled": true,
            "LegendPosition": "None",
            "BackColor": "#FFFFFF",
            "DiagramBackColor": "#FFFFFF"
          },
          "Title": "PO SD 20 mg (perm)",
          "OriginText": "Dapagliflozin\nPO SD 20 mg (perm)\n2019-08-06 11:24"
        }
      ]
    },
    {
      "Name": "PO SD 100 mg (perm)",
      "Model": "4Comp",
      "ObservedData": [
        "Komoroski 2009 - SAD 100 mg - Dapagliflozin - PO - 100 mg - Plasma - agg. (n=6)",
        "Komoroski 2009 - SAD 100 mg (Urine) - Dapagliflozin - PO - 100 mg - Urine - agg. (n=6)",
        "Komoroski 2009 - MAD 100 mg (day 1) - Dapagliflozin - PO - 100 mg - Plasma - agg. (n=6)"
      ],
      "Solver": {},
      "OutputSchema": [
        {
          "Parameters": [
            {
              "Name": "Start time",
              "Value": 0.0,
              "Unit": "h"
            },
            {
              "Name": "End time",
              "Value": 2.0,
              "Unit": "h"
            },
            {
              "Name": "Resolution",
              "Value": 20.0,
              "Unit": "pts/h"
            }
          ]
        },
        {
          "Parameters": [
            {
              "Name": "Start time",
              "Value": 2.0,
              "Unit": "h"
            },
            {
              "Name": "End time",
              "Value": 24.0,
              "Unit": "h",
              "ValueOrigin": {
                "Source": "Unknown"
              }
            },
            {
              "Name": "Resolution",
              "Value": 4.0,
              "Unit": "pts/h"
            }
          ]
        }
      ],
      "Parameters": [
        {
          "Path": "Applications|PO SD 100 mg|Solution|Application_1|ProtocolSchemaItem|Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        },
        {
          "Path": "Dapagliflozin|Blood/Plasma concentration ratio",
          "Value": 0.88,
          "ValueOrigin": {
            "Source": "ParameterIdentification",
            "Method": "ParameterIdentification",
            "Description": "Value updated from 'PI full  (perm)' on 2019-08-06 14:46"
          }
        },
        {
          "Path": "Dapagliflozin|logP (veg.oil/water)",
          "Value": 2.0765619283,
          "Unit": "Log Units",
          "ValueOrigin": {
            "Source": "ParameterIdentification",
            "Method": "ParameterIdentification",
            "Description": "Value updated from 'PI full  (perm)' on 2019-08-06 14:46"
          }
        }
      ],
      "OutputSelections": [
        "Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
        "Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine"
      ],
      "Individual": "Standard_Adult_UGT",
      "Compounds": [
        {
          "Name": "Dapagliflozin",
          "CalculationMethods": [
            "Cellular partition coefficient method - Rodgers and Rowland",
            "Cellular permeability - PK-Sim Standard"
          ],
          "Alternatives": [
            {
              "AlternativeName": "Optimized",
              "GroupName": "COMPOUND_PERMEABILITY"
            },
            {
              "AlternativeName": "Optimized",
              "GroupName": "COMPOUND_INTESTINAL_PERMEABILITY"
            }
          ],
          "Processes": [
            {
              "Name": "UGT1A9-Optimized",
              "MoleculeName": "UGT1A9"
            },
            {
              "Name": "UGT2B7-Optimized",
              "MoleculeName": "UGT2B7"
            },
            {
              "Name": "Hepatic-CYP-Optimized",
              "MoleculeName": "Hepatic-CYP"
            },
            {
              "Name": "Glomerular Filtration-assumed"
            }
          ],
          "Protocol": {
            "Name": "PO SD 100 mg",
            "Formulations": [
              {
                "Name": "Solution",
                "Key": "Formulation"
              }
            ]
          }
        }
      ],
      "HasResults": true,
      "IndividualAnalyses": [
        {
          "Axes": [
            {
              "Unit": "h",
              "Dimension": "Time",
              "Type": "X",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "None",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            },
            {
              "Unit": "µg/l",
              "Dimension": "Concentration (molar)",
              "Type": "Y",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Solid",
              "Scaling": "Log",
              "NumberMode": "Normal"
            },
            {
              "Unit": "",
              "Dimension": "Fraction",
              "Type": "Y2",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Dash",
              "Scaling": "Log",
              "NumberMode": "Normal"
            }
          ],
          "Curves": [
            {
              "Name": "PO SD 100 mg (perm)-Dapagliflozin-Peripheral Venous Blood-Plasma-Concentration",
              "X": "Time",
              "Y": "PO SD 100 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
              "CurveOptions": {
                "Color": "#FF0000",
                "LegendIndex": 1
              }
            },
            {
              "Name": "Komoroski 2009 - SAD 100 mg (Urine) - Dapagliflozin - PO - 100 mg - Urine - agg. (n=6)-Dapagliflozin-Kidney-Urine-ArithmeticMean",
              "X": "Komoroski 2009 - SAD 100 mg (Urine) - Dapagliflozin - PO - 100 mg - Urine - agg. (n=6)|Time",
              "Y": "Komoroski 2009 - SAD 100 mg (Urine) - Dapagliflozin - PO - 100 mg - Urine - agg. (n=6)|ObservedData|Kidney|Urine|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "yAxisType": "Y2",
                "Color": "#FF00FF",
                "LegendIndex": 4,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            },
            {
              "Name": "PO SD 100 mg (perm)-Dapagliflozin-Kidney-Urine-Fraction excreted to urine",
              "X": "Time",
              "Y": "PO SD 100 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
              "CurveOptions": {
                "yAxisType": "Y2",
                "Color": "#FF00FF",
                "LegendIndex": 3,
                "LineStyle": "Dash"
              }
            },
            {
              "Name": "Komoroski 2009 - SAD 100 mg - Dapagliflozin - PO - 100 mg - Plasma - agg. (n=6)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
              "X": "Komoroski 2009 - SAD 100 mg - Dapagliflozin - PO - 100 mg - Plasma - agg. (n=6)|Time",
              "Y": "Komoroski 2009 - SAD 100 mg - Dapagliflozin - PO - 100 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "Color": "#0000FF",
                "LegendIndex": 2,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            },
            {
              "Name": "Komoroski 2009 - MAD 100 mg (day 1) - Dapagliflozin - PO - 100 mg - Plasma - agg. (n=6)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
              "X": "Komoroski 2009 - MAD 100 mg (day 1) - Dapagliflozin - PO - 100 mg - Plasma - agg. (n=6)|Time",
              "Y": "Komoroski 2009 - MAD 100 mg (day 1) - Dapagliflozin - PO - 100 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "Color": "#FF8000",
                "LegendIndex": 5,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            }
          ],
          "Name": "PO SD 100 mg (perm)",
          "Title": "PO SD 100 mg (perm)",
          "OriginText": "Dapagliflozin\nPO SD 100 mg (perm)\n2019-08-06 11:25"
        },
        {
          "Axes": [
            {
              "Unit": "h",
              "Dimension": "Time",
              "Type": "X",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "None",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            },
            {
              "Unit": "µg/l",
              "Dimension": "Concentration (molar)",
              "Type": "Y",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Solid",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            },
            {
              "Unit": "",
              "Dimension": "Fraction",
              "Type": "Y2",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Dash",
              "Scaling": "Log",
              "NumberMode": "Normal"
            }
          ],
          "Curves": [
            {
              "Name": "PO SD 100 mg (perm)-Dapagliflozin-Peripheral Venous Blood-Plasma-Concentration",
              "X": "Time",
              "Y": "PO SD 100 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
              "CurveOptions": {
                "Color": "#FF0000",
                "LegendIndex": 1
              }
            },
            {
              "Name": "Komoroski 2009 - SAD 100 mg (Urine) - Dapagliflozin - PO - 100 mg - Urine - agg. (n=6)-Dapagliflozin-Kidney-Urine-ArithmeticMean",
              "X": "Komoroski 2009 - SAD 100 mg (Urine) - Dapagliflozin - PO - 100 mg - Urine - agg. (n=6)|Time",
              "Y": "Komoroski 2009 - SAD 100 mg (Urine) - Dapagliflozin - PO - 100 mg - Urine - agg. (n=6)|ObservedData|Kidney|Urine|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "yAxisType": "Y2",
                "Color": "#FF00FF",
                "LegendIndex": 4,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            },
            {
              "Name": "PO SD 100 mg (perm)-Dapagliflozin-Kidney-Urine-Fraction excreted to urine",
              "X": "Time",
              "Y": "PO SD 100 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
              "CurveOptions": {
                "yAxisType": "Y2",
                "Color": "#FF00FF",
                "LegendIndex": 3,
                "LineStyle": "Dash"
              }
            },
            {
              "Name": "Komoroski 2009 - SAD 100 mg - Dapagliflozin - PO - 100 mg - Plasma - agg. (n=6)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
              "X": "Komoroski 2009 - SAD 100 mg - Dapagliflozin - PO - 100 mg - Plasma - agg. (n=6)|Time",
              "Y": "Komoroski 2009 - SAD 100 mg - Dapagliflozin - PO - 100 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "Color": "#0000FF",
                "LegendIndex": 2,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            },
            {
              "Name": "Komoroski 2009 - MAD 100 mg (day 1) - Dapagliflozin - PO - 100 mg - Plasma - agg. (n=6)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
              "X": "Komoroski 2009 - MAD 100 mg (day 1) - Dapagliflozin - PO - 100 mg - Plasma - agg. (n=6)|Time",
              "Y": "Komoroski 2009 - MAD 100 mg (day 1) - Dapagliflozin - PO - 100 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "Color": "#FF8000",
                "LegendIndex": 5,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            }
          ],
          "Name": "PO SD 100 mg (perm) 1",
          "Title": "PO SD 100 mg (perm)",
          "OriginText": "Dapagliflozin\nPO SD 100 mg (perm)\n2019-08-06 11:25"
        }
      ]
    },
    {
      "Name": "PO SD 250 mg (perm)",
      "Model": "4Comp",
      "ObservedData": [
        "Komoroski 2009 - SAD 250 mg fasted - Dapagliflozin - PO - 250 mg - Plasma - agg. (n=6)",
        "Komoroski 2009 - SAD 250 mg fasted (Urine) - Dapagliflozin - PO - 250 mg - Urine - agg. (n=6)"
      ],
      "Solver": {},
      "OutputSchema": [
        {
          "Parameters": [
            {
              "Name": "Start time",
              "Value": 0.0,
              "Unit": "h"
            },
            {
              "Name": "End time",
              "Value": 2.0,
              "Unit": "h"
            },
            {
              "Name": "Resolution",
              "Value": 20.0,
              "Unit": "pts/h"
            }
          ]
        },
        {
          "Parameters": [
            {
              "Name": "Start time",
              "Value": 2.0,
              "Unit": "h"
            },
            {
              "Name": "End time",
              "Value": 120.0,
              "Unit": "h",
              "ValueOrigin": {
                "Source": "Unknown"
              }
            },
            {
              "Name": "Resolution",
              "Value": 4.0,
              "Unit": "pts/h"
            }
          ]
        }
      ],
      "Parameters": [
        {
          "Path": "Applications|PO SD 250 mg|Solution|Application_1|ProtocolSchemaItem|Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        },
        {
          "Path": "Dapagliflozin|Blood/Plasma concentration ratio",
          "Value": 0.88,
          "ValueOrigin": {
            "Source": "ParameterIdentification",
            "Method": "ParameterIdentification",
            "Description": "Value updated from 'PI full  (perm)' on 2019-08-06 14:46"
          }
        },
        {
          "Path": "Dapagliflozin|logP (veg.oil/water)",
          "Value": 2.0765619283,
          "Unit": "Log Units",
          "ValueOrigin": {
            "Source": "ParameterIdentification",
            "Method": "ParameterIdentification",
            "Description": "Value updated from 'PI full  (perm)' on 2019-08-06 14:46"
          }
        }
      ],
      "OutputSelections": [
        "Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
        "Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine"
      ],
      "Individual": "Standard_Adult_UGT",
      "Compounds": [
        {
          "Name": "Dapagliflozin",
          "CalculationMethods": [
            "Cellular partition coefficient method - Rodgers and Rowland",
            "Cellular permeability - PK-Sim Standard"
          ],
          "Alternatives": [
            {
              "AlternativeName": "Optimized",
              "GroupName": "COMPOUND_PERMEABILITY"
            },
            {
              "AlternativeName": "Optimized",
              "GroupName": "COMPOUND_INTESTINAL_PERMEABILITY"
            }
          ],
          "Processes": [
            {
              "Name": "UGT1A9-Optimized",
              "MoleculeName": "UGT1A9"
            },
            {
              "Name": "UGT2B7-Optimized",
              "MoleculeName": "UGT2B7"
            },
            {
              "Name": "Hepatic-CYP-Optimized",
              "MoleculeName": "Hepatic-CYP"
            },
            {
              "Name": "Glomerular Filtration-assumed"
            }
          ],
          "Protocol": {
            "Name": "PO SD 250 mg",
            "Formulations": [
              {
                "Name": "Solution",
                "Key": "Formulation"
              }
            ]
          }
        }
      ],
      "HasResults": true,
      "IndividualAnalyses": [
        {
          "Axes": [
            {
              "Unit": "h",
              "Dimension": "Time",
              "Type": "X",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "None",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            },
            {
              "Unit": "µg/l",
              "Dimension": "Concentration (molar)",
              "Type": "Y",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Solid",
              "Scaling": "Log",
              "NumberMode": "Normal"
            },
            {
              "Unit": "",
              "Dimension": "Fraction",
              "Type": "Y2",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Dash",
              "Scaling": "Log",
              "NumberMode": "Normal"
            }
          ],
          "Curves": [
            {
              "Name": "PO SD 250 mg (perm)-Dapagliflozin-Peripheral Venous Blood-Plasma-Concentration",
              "X": "Time",
              "Y": "PO SD 250 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
              "CurveOptions": {
                "Color": "#FF0000",
                "LegendIndex": 1
              }
            },
            {
              "Name": "Komoroski 2009 - SAD 250 mg fasted - Dapagliflozin - PO - 250 mg - Plasma - agg. (n=6)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
              "X": "Komoroski 2009 - SAD 250 mg fasted - Dapagliflozin - PO - 250 mg - Plasma - agg. (n=6)|Time",
              "Y": "Komoroski 2009 - SAD 250 mg fasted - Dapagliflozin - PO - 250 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "Color": "#0000FF",
                "LegendIndex": 2,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            },
            {
              "Name": "Komoroski 2009 - SAD 250 mg fasted (Urine) - Dapagliflozin - PO - 250 mg - Urine - agg. (n=6)-Dapagliflozin-Kidney-Urine-ArithmeticMean",
              "X": "Komoroski 2009 - SAD 250 mg fasted (Urine) - Dapagliflozin - PO - 250 mg - Urine - agg. (n=6)|Time",
              "Y": "Komoroski 2009 - SAD 250 mg fasted (Urine) - Dapagliflozin - PO - 250 mg - Urine - agg. (n=6)|ObservedData|Kidney|Urine|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "yAxisType": "Y2",
                "Color": "#008000",
                "LegendIndex": 3,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            },
            {
              "Name": "PO SD 250 mg (perm)-Dapagliflozin-Kidney-Urine-Fraction excreted to urine",
              "X": "Time",
              "Y": "PO SD 250 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
              "CurveOptions": {
                "yAxisType": "Y2",
                "Color": "#008000",
                "LegendIndex": 4,
                "LineStyle": "Dash"
              }
            }
          ],
          "Name": "PO SD 250 mg (perm)",
          "Title": "PO SD 250 mg (perm)",
          "OriginText": "Dapagliflozin\nPO SD 250 mg (perm)\n2019-08-06 11:26"
        },
        {
          "Axes": [
            {
              "Unit": "h",
              "Dimension": "Time",
              "Type": "X",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "None",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            },
            {
              "Unit": "µg/l",
              "Dimension": "Concentration (molar)",
              "Type": "Y",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Solid",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            },
            {
              "Unit": "",
              "Dimension": "Fraction",
              "Type": "Y2",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Dash",
              "Scaling": "Log",
              "NumberMode": "Normal"
            }
          ],
          "Curves": [
            {
              "Name": "PO SD 250 mg (perm)-Dapagliflozin-Peripheral Venous Blood-Plasma-Concentration",
              "X": "Time",
              "Y": "PO SD 250 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
              "CurveOptions": {
                "Color": "#FF0000",
                "LegendIndex": 1
              }
            },
            {
              "Name": "Komoroski 2009 - SAD 250 mg fasted - Dapagliflozin - PO - 250 mg - Plasma - agg. (n=6)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
              "X": "Komoroski 2009 - SAD 250 mg fasted - Dapagliflozin - PO - 250 mg - Plasma - agg. (n=6)|Time",
              "Y": "Komoroski 2009 - SAD 250 mg fasted - Dapagliflozin - PO - 250 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "Color": "#0000FF",
                "LegendIndex": 2,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            },
            {
              "Name": "Komoroski 2009 - SAD 250 mg fasted (Urine) - Dapagliflozin - PO - 250 mg - Urine - agg. (n=6)-Dapagliflozin-Kidney-Urine-ArithmeticMean",
              "X": "Komoroski 2009 - SAD 250 mg fasted (Urine) - Dapagliflozin - PO - 250 mg - Urine - agg. (n=6)|Time",
              "Y": "Komoroski 2009 - SAD 250 mg fasted (Urine) - Dapagliflozin - PO - 250 mg - Urine - agg. (n=6)|ObservedData|Kidney|Urine|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "yAxisType": "Y2",
                "Color": "#008000",
                "LegendIndex": 3,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            },
            {
              "Name": "PO SD 250 mg (perm)-Dapagliflozin-Kidney-Urine-Fraction excreted to urine",
              "X": "Time",
              "Y": "PO SD 250 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
              "CurveOptions": {
                "yAxisType": "Y2",
                "Color": "#008000",
                "LegendIndex": 4,
                "LineStyle": "Dash"
              }
            }
          ],
          "Name": "PO SD 250 mg (perm)",
          "Title": "PO SD 250 mg (perm)",
          "OriginText": "Dapagliflozin\nPO SD 250 mg (perm)\n2019-08-06 11:26"
        }
      ]
    },
    {
      "Name": "PO SD 500 mg (perm)",
      "Model": "4Comp",
      "ObservedData": [
        "Komoroski 2009 - SAD 500 mg - Dapagliflozin - PO - 500 mg - Plasma - agg. (n=6)",
        "Komoroski 2009 - SAD 500 mg (Urine) - Dapagliflozin - PO - 500 mg - Urine - agg. (n=6)"
      ],
      "Solver": {},
      "OutputSchema": [
        {
          "Parameters": [
            {
              "Name": "Start time",
              "Value": 0.0,
              "Unit": "h"
            },
            {
              "Name": "End time",
              "Value": 2.0,
              "Unit": "h"
            },
            {
              "Name": "Resolution",
              "Value": 20.0,
              "Unit": "pts/h"
            }
          ]
        },
        {
          "Parameters": [
            {
              "Name": "Start time",
              "Value": 2.0,
              "Unit": "h"
            },
            {
              "Name": "End time",
              "Value": 120.0,
              "Unit": "h",
              "ValueOrigin": {
                "Source": "Unknown"
              }
            },
            {
              "Name": "Resolution",
              "Value": 4.0,
              "Unit": "pts/h"
            }
          ]
        }
      ],
      "Parameters": [
        {
          "Path": "Applications|PO SD 500 mg|Solution|Application_1|ProtocolSchemaItem|Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        },
        {
          "Path": "Dapagliflozin|Blood/Plasma concentration ratio",
          "Value": 0.88,
          "ValueOrigin": {
            "Source": "ParameterIdentification",
            "Method": "ParameterIdentification",
            "Description": "Value updated from 'PI full  (perm)' on 2019-08-06 14:46"
          }
        },
        {
          "Path": "Dapagliflozin|logP (veg.oil/water)",
          "Value": 2.0765619283,
          "Unit": "Log Units",
          "ValueOrigin": {
            "Source": "ParameterIdentification",
            "Method": "ParameterIdentification",
            "Description": "Value updated from 'PI full  (perm)' on 2019-08-06 14:46"
          }
        }
      ],
      "OutputSelections": [
        "Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
        "Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine"
      ],
      "Individual": "Standard_Adult_UGT",
      "Compounds": [
        {
          "Name": "Dapagliflozin",
          "CalculationMethods": [
            "Cellular partition coefficient method - Rodgers and Rowland",
            "Cellular permeability - PK-Sim Standard"
          ],
          "Alternatives": [
            {
              "AlternativeName": "Optimized",
              "GroupName": "COMPOUND_PERMEABILITY"
            },
            {
              "AlternativeName": "Optimized",
              "GroupName": "COMPOUND_INTESTINAL_PERMEABILITY"
            }
          ],
          "Processes": [
            {
              "Name": "UGT1A9-Optimized",
              "MoleculeName": "UGT1A9"
            },
            {
              "Name": "UGT2B7-Optimized",
              "MoleculeName": "UGT2B7"
            },
            {
              "Name": "Hepatic-CYP-Optimized",
              "MoleculeName": "Hepatic-CYP"
            },
            {
              "Name": "Glomerular Filtration-assumed"
            }
          ],
          "Protocol": {
            "Name": "PO SD 500 mg",
            "Formulations": [
              {
                "Name": "Solution",
                "Key": "Formulation"
              }
            ]
          }
        }
      ],
      "HasResults": true,
      "IndividualAnalyses": [
        {
          "Axes": [
            {
              "Unit": "h",
              "Dimension": "Time",
              "Type": "X",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "None",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            },
            {
              "Unit": "µg/l",
              "Dimension": "Concentration (molar)",
              "Type": "Y",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Solid",
              "Scaling": "Log",
              "NumberMode": "Normal"
            },
            {
              "Unit": "",
              "Dimension": "Fraction",
              "Type": "Y2",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Dash",
              "Scaling": "Log",
              "NumberMode": "Normal"
            }
          ],
          "Curves": [
            {
              "Name": "PO SD 500 mg (perm)-Dapagliflozin-Peripheral Venous Blood-Plasma-Concentration",
              "X": "Time",
              "Y": "PO SD 500 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
              "CurveOptions": {
                "Color": "#FF0000",
                "LegendIndex": 1
              }
            },
            {
              "Name": "Komoroski 2009 - SAD 500 mg - Dapagliflozin - PO - 500 mg - Plasma - agg. (n=6)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
              "X": "Komoroski 2009 - SAD 500 mg - Dapagliflozin - PO - 500 mg - Plasma - agg. (n=6)|Time",
              "Y": "Komoroski 2009 - SAD 500 mg - Dapagliflozin - PO - 500 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "Color": "#0000FF",
                "LegendIndex": 2,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            },
            {
              "Name": "PO SD 500 mg (perm)-Dapagliflozin-Kidney-Urine-Fraction excreted to urine",
              "X": "Time",
              "Y": "PO SD 500 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
              "CurveOptions": {
                "yAxisType": "Y2",
                "Color": "#FF00FF",
                "LegendIndex": 3,
                "LineStyle": "Dash"
              }
            },
            {
              "Name": "Komoroski 2009 - SAD 500 mg (Urine) - Dapagliflozin - PO - 500 mg - Urine - agg. (n=6)-Dapagliflozin-Kidney-Urine-ArithmeticMean",
              "X": "Komoroski 2009 - SAD 500 mg (Urine) - Dapagliflozin - PO - 500 mg - Urine - agg. (n=6)|Time",
              "Y": "Komoroski 2009 - SAD 500 mg (Urine) - Dapagliflozin - PO - 500 mg - Urine - agg. (n=6)|ObservedData|Kidney|Urine|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "yAxisType": "Y2",
                "Color": "#FF00FF",
                "LegendIndex": 4,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            }
          ],
          "Name": "PO SD 500 mg (perm)",
          "Title": "PO SD 500 mg (perm)",
          "OriginText": "Dapagliflozin\nPO SD 500 mg (perm)\n2019-08-06 11:27"
        },
        {
          "Axes": [
            {
              "Unit": "h",
              "Dimension": "Time",
              "Type": "X",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "None",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            },
            {
              "Unit": "µg/l",
              "Dimension": "Concentration (molar)",
              "Type": "Y",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Solid",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            },
            {
              "Unit": "",
              "Dimension": "Fraction",
              "Type": "Y2",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Dash",
              "Scaling": "Log",
              "NumberMode": "Normal"
            }
          ],
          "Curves": [
            {
              "Name": "PO SD 500 mg (perm)-Dapagliflozin-Peripheral Venous Blood-Plasma-Concentration",
              "X": "Time",
              "Y": "PO SD 500 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
              "CurveOptions": {
                "Color": "#FF0000",
                "LegendIndex": 1
              }
            },
            {
              "Name": "Komoroski 2009 - SAD 500 mg - Dapagliflozin - PO - 500 mg - Plasma - agg. (n=6)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
              "X": "Komoroski 2009 - SAD 500 mg - Dapagliflozin - PO - 500 mg - Plasma - agg. (n=6)|Time",
              "Y": "Komoroski 2009 - SAD 500 mg - Dapagliflozin - PO - 500 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "Color": "#0000FF",
                "LegendIndex": 2,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            },
            {
              "Name": "PO SD 500 mg (perm)-Dapagliflozin-Kidney-Urine-Fraction excreted to urine",
              "X": "Time",
              "Y": "PO SD 500 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
              "CurveOptions": {
                "yAxisType": "Y2",
                "Color": "#FF00FF",
                "LegendIndex": 3,
                "LineStyle": "Dash"
              }
            },
            {
              "Name": "Komoroski 2009 - SAD 500 mg (Urine) - Dapagliflozin - PO - 500 mg - Urine - agg. (n=6)-Dapagliflozin-Kidney-Urine-ArithmeticMean",
              "X": "Komoroski 2009 - SAD 500 mg (Urine) - Dapagliflozin - PO - 500 mg - Urine - agg. (n=6)|Time",
              "Y": "Komoroski 2009 - SAD 500 mg (Urine) - Dapagliflozin - PO - 500 mg - Urine - agg. (n=6)|ObservedData|Kidney|Urine|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "yAxisType": "Y2",
                "Color": "#FF00FF",
                "LegendIndex": 4,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            }
          ],
          "Name": "PO SD 500 mg (perm) 1",
          "Title": "PO SD 500 mg (perm)",
          "OriginText": "Dapagliflozin\nPO SD 500 mg (perm)\n2019-08-06 11:27"
        }
      ]
    },
    {
      "Name": "PO SD 20 mg IR tablet (perm)",
      "Model": "4Comp",
      "ObservedData": [
        "Kasichayanula 2011b - Study 3: 20 mg Control (Perpetrator Placebo) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=18)",
        "Kasichayanula 2011b - Study 2: 20 mg Control (Perpetrator Placebo) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=18)"
      ],
      "Solver": {},
      "OutputSchema": [
        {
          "Parameters": [
            {
              "Name": "Start time",
              "Value": 0.0,
              "Unit": "h"
            },
            {
              "Name": "End time",
              "Value": 2.0,
              "Unit": "h"
            },
            {
              "Name": "Resolution",
              "Value": 20.0,
              "Unit": "pts/h"
            }
          ]
        },
        {
          "Parameters": [
            {
              "Name": "Start time",
              "Value": 2.0,
              "Unit": "h"
            },
            {
              "Name": "End time",
              "Value": 75.0,
              "Unit": "h",
              "ValueOrigin": {
                "Source": "Unknown"
              }
            },
            {
              "Name": "Resolution",
              "Value": 4.0,
              "Unit": "pts/h"
            }
          ]
        }
      ],
      "Parameters": [
        {
          "Path": "Applications|PO SD 20 mg|IR tablet|Application_1|ProtocolSchemaItem|Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        },
        {
          "Path": "Dapagliflozin|Blood/Plasma concentration ratio",
          "Value": 0.88,
          "ValueOrigin": {
            "Source": "Unknown"
          }
        },
        {
          "Path": "Dapagliflozin|logP (veg.oil/water)",
          "Value": 2.0765619283,
          "Unit": "Log Units",
          "ValueOrigin": {
            "Source": "Unknown"
          }
        }
      ],
      "OutputSelections": [
        "Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)"
      ],
      "Individual": "Standard_Adult_UGT",
      "Compounds": [
        {
          "Name": "Dapagliflozin",
          "CalculationMethods": [
            "Cellular partition coefficient method - Rodgers and Rowland",
            "Cellular permeability - PK-Sim Standard"
          ],
          "Alternatives": [
            {
              "AlternativeName": "Optimized",
              "GroupName": "COMPOUND_PERMEABILITY"
            },
            {
              "AlternativeName": "Optimized",
              "GroupName": "COMPOUND_INTESTINAL_PERMEABILITY"
            }
          ],
          "Processes": [
            {
              "Name": "UGT1A9-Optimized",
              "MoleculeName": "UGT1A9"
            },
            {
              "Name": "UGT2B7-Optimized",
              "MoleculeName": "UGT2B7"
            },
            {
              "Name": "Hepatic-CYP-Optimized",
              "MoleculeName": "Hepatic-CYP"
            },
            {
              "Name": "Glomerular Filtration-assumed"
            }
          ],
          "Protocol": {
            "Name": "PO SD 20 mg",
            "Formulations": [
              {
                "Name": "IR tablet",
                "Key": "Formulation"
              }
            ]
          }
        }
      ],
      "HasResults": true,
      "IndividualAnalyses": [
        {
          "Axes": [
            {
              "Unit": "h",
              "Dimension": "Time",
              "Type": "X",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "None",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            },
            {
              "Unit": "µg/l",
              "Dimension": "Concentration (molar)",
              "Type": "Y",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Solid",
              "Scaling": "Log",
              "NumberMode": "Normal"
            }
          ],
          "Curves": [
            {
              "Name": "PO SD 20 mg IR tablet (perm)-Dapagliflozin-Peripheral Venous Blood-Plasma-Concentration",
              "X": "Time",
              "Y": "PO SD 20 mg IR tablet (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
              "CurveOptions": {
                "Color": "#FF0000",
                "LegendIndex": 1
              }
            },
            {
              "Name": "Kasichayanula 2011b - Study 3: 20 mg Control (Perpetrator Placebo) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=18)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
              "X": "Kasichayanula 2011b - Study 3: 20 mg Control (Perpetrator Placebo) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=18)|Time",
              "Y": "Kasichayanula 2011b - Study 3: 20 mg Control (Perpetrator Placebo) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=18)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "Color": "#FF00FF",
                "LegendIndex": 4,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            },
            {
              "Name": "Kasichayanula 2011b - Study 2: 20 mg Control (Perpetrator Placebo) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=18)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
              "X": "Kasichayanula 2011b - Study 2: 20 mg Control (Perpetrator Placebo) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=18)|Time",
              "Y": "Kasichayanula 2011b - Study 2: 20 mg Control (Perpetrator Placebo) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=18)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "Color": "#008000",
                "LegendIndex": 3,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            }
          ],
          "Name": "PO SD 20 mg IR tablet (perm)",
          "Title": "PO SD 20 mg IR tablet (perm)",
          "OriginText": "Dapagliflozin\nPO SD 20 mg IR tablet (perm)\n2019-08-06 14:59"
        },
        {
          "Axes": [
            {
              "Unit": "h",
              "Dimension": "Time",
              "Type": "X",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "None",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            },
            {
              "Unit": "µg/l",
              "Dimension": "Concentration (molar)",
              "Type": "Y",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Solid",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            }
          ],
          "Curves": [
            {
              "Name": "PO SD 20 mg IR tablet (perm)-Dapagliflozin-Peripheral Venous Blood-Plasma-Concentration",
              "X": "Time",
              "Y": "PO SD 20 mg IR tablet (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
              "CurveOptions": {
                "Color": "#FF0000",
                "LegendIndex": 1
              }
            },
            {
              "Name": "Kasichayanula 2011b - Study 3: 20 mg Control (Perpetrator Placebo) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=18)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
              "X": "Kasichayanula 2011b - Study 3: 20 mg Control (Perpetrator Placebo) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=18)|Time",
              "Y": "Kasichayanula 2011b - Study 3: 20 mg Control (Perpetrator Placebo) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=18)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "Color": "#FF00FF",
                "LegendIndex": 4,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            },
            {
              "Name": "Kasichayanula 2011b - Study 2: 20 mg Control (Perpetrator Placebo) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=18)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
              "X": "Kasichayanula 2011b - Study 2: 20 mg Control (Perpetrator Placebo) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=18)|Time",
              "Y": "Kasichayanula 2011b - Study 2: 20 mg Control (Perpetrator Placebo) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=18)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "Color": "#008000",
                "LegendIndex": 3,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            }
          ],
          "Name": "PO SD 20 mg IR tablet (perm) 1",
          "Title": "PO SD 20 mg IR tablet (perm)",
          "OriginText": "Dapagliflozin\nPO SD 20 mg IR tablet (perm)\n2019-08-06 14:59"
        }
      ]
    },
    {
      "Name": "PO SD 5 mg IR tablet (perm)",
      "Model": "4Comp",
      "ObservedData": [
        "Chang 2015 - Study 1 Treatment A (single oral doses) - Dapagliflozin - PO - 5 mg - Plasma - agg. (n=36)"
      ],
      "Solver": {},
      "OutputSchema": [
        {
          "Parameters": [
            {
              "Name": "Start time",
              "Value": 0.0,
              "Unit": "h"
            },
            {
              "Name": "End time",
              "Value": 2.0,
              "Unit": "h"
            },
            {
              "Name": "Resolution",
              "Value": 20.0,
              "Unit": "pts/h"
            }
          ]
        },
        {
          "Parameters": [
            {
              "Name": "Start time",
              "Value": 2.0,
              "Unit": "h"
            },
            {
              "Name": "End time",
              "Value": 24.0,
              "Unit": "h",
              "ValueOrigin": {
                "Source": "Unknown"
              }
            },
            {
              "Name": "Resolution",
              "Value": 4.0,
              "Unit": "pts/h"
            }
          ]
        }
      ],
      "Parameters": [
        {
          "Path": "Applications|PO SD 5 mg|IR tablet|Application_1|ProtocolSchemaItem|Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        },
        {
          "Path": "Dapagliflozin|Blood/Plasma concentration ratio",
          "Value": 0.88,
          "ValueOrigin": {
            "Source": "Unknown"
          }
        },
        {
          "Path": "Dapagliflozin|logP (veg.oil/water)",
          "Value": 2.0765619283,
          "Unit": "Log Units",
          "ValueOrigin": {
            "Source": "Unknown"
          }
        }
      ],
      "OutputSelections": [
        "Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)"
      ],
      "Individual": "Standard_Adult_UGT",
      "Compounds": [
        {
          "Name": "Dapagliflozin",
          "CalculationMethods": [
            "Cellular partition coefficient method - Rodgers and Rowland",
            "Cellular permeability - PK-Sim Standard"
          ],
          "Alternatives": [
            {
              "AlternativeName": "Optimized",
              "GroupName": "COMPOUND_PERMEABILITY"
            },
            {
              "AlternativeName": "Optimized",
              "GroupName": "COMPOUND_INTESTINAL_PERMEABILITY"
            }
          ],
          "Processes": [
            {
              "Name": "UGT1A9-Optimized",
              "MoleculeName": "UGT1A9"
            },
            {
              "Name": "UGT2B7-Optimized",
              "MoleculeName": "UGT2B7"
            },
            {
              "Name": "Hepatic-CYP-Optimized",
              "MoleculeName": "Hepatic-CYP"
            },
            {
              "Name": "Glomerular Filtration-assumed"
            }
          ],
          "Protocol": {
            "Name": "PO SD 5 mg",
            "Formulations": [
              {
                "Name": "IR tablet",
                "Key": "Formulation"
              }
            ]
          }
        }
      ],
      "HasResults": true,
      "IndividualAnalyses": [
        {
          "Axes": [
            {
              "Unit": "h",
              "Dimension": "Time",
              "Type": "X",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "None",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            },
            {
              "Unit": "µg/l",
              "Dimension": "Concentration (molar)",
              "Type": "Y",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Solid",
              "Scaling": "Log",
              "NumberMode": "Normal"
            }
          ],
          "Curves": [
            {
              "Name": "PO SD 5 mg IR tablet (perm)-Dapagliflozin-Peripheral Venous Blood-Plasma-Concentration",
              "X": "Time",
              "Y": "PO SD 5 mg IR tablet (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
              "CurveOptions": {
                "Color": "#FF0000",
                "LegendIndex": 1
              }
            },
            {
              "Name": "Chang 2015 - Study 1 Treatment A (single oral doses) - Dapagliflozin - PO - 5 mg - Plasma - agg. (n=36)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
              "X": "Chang 2015 - Study 1 Treatment A (single oral doses) - Dapagliflozin - PO - 5 mg - Plasma - agg. (n=36)|Time",
              "Y": "Chang 2015 - Study 1 Treatment A (single oral doses) - Dapagliflozin - PO - 5 mg - Plasma - agg. (n=36)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "Color": "#0000FF",
                "LegendIndex": 2,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            }
          ],
          "Name": "PO SD 5 mg IR tablet (perm)",
          "Title": "PO SD 5 mg IR tablet (perm)",
          "OriginText": "Dapagliflozin\nPO SD 5 mg IR tablet (perm)\n2019-08-06 14:59"
        },
        {
          "Axes": [
            {
              "Unit": "h",
              "Dimension": "Time",
              "Type": "X",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "None",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            },
            {
              "Unit": "µg/l",
              "Dimension": "Concentration (molar)",
              "Type": "Y",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Solid",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            }
          ],
          "Curves": [
            {
              "Name": "PO SD 5 mg IR tablet (perm)-Dapagliflozin-Peripheral Venous Blood-Plasma-Concentration",
              "X": "Time",
              "Y": "PO SD 5 mg IR tablet (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
              "CurveOptions": {
                "Color": "#FF0000",
                "LegendIndex": 1
              }
            },
            {
              "Name": "Chang 2015 - Study 1 Treatment A (single oral doses) - Dapagliflozin - PO - 5 mg - Plasma - agg. (n=36)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
              "X": "Chang 2015 - Study 1 Treatment A (single oral doses) - Dapagliflozin - PO - 5 mg - Plasma - agg. (n=36)|Time",
              "Y": "Chang 2015 - Study 1 Treatment A (single oral doses) - Dapagliflozin - PO - 5 mg - Plasma - agg. (n=36)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "Color": "#0000FF",
                "LegendIndex": 2,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            }
          ],
          "Name": "PO SD 5 mg IR tablet (perm) 1",
          "Title": "PO SD 5 mg IR tablet (perm)",
          "OriginText": "Dapagliflozin\nPO SD 5 mg IR tablet (perm)\n2019-08-06 14:59"
        }
      ]
    },
    {
      "Name": "PO SD 250 mg fed (perm)",
      "Model": "4Comp",
      "ObservedData": [
        "Komoroski 2009 - SAD 250 mg fed - Dapagliflozin - PO - 250 mg - Plasma - agg. (n=6)"
      ],
      "Solver": {},
      "OutputSchema": [
        {
          "Parameters": [
            {
              "Name": "Start time",
              "Value": 0.0,
              "Unit": "h"
            },
            {
              "Name": "End time",
              "Value": 2.0,
              "Unit": "h"
            },
            {
              "Name": "Resolution",
              "Value": 20.0,
              "Unit": "pts/h"
            }
          ]
        },
        {
          "Parameters": [
            {
              "Name": "Start time",
              "Value": 2.0,
              "Unit": "h"
            },
            {
              "Name": "End time",
              "Value": 24.0,
              "Unit": "h",
              "ValueOrigin": {
                "Source": "Unknown"
              }
            },
            {
              "Name": "Resolution",
              "Value": 4.0,
              "Unit": "pts/h"
            }
          ]
        }
      ],
      "Parameters": [
        {
          "Path": "Applications|PO SD 250 mg|Solution|Application_1|ProtocolSchemaItem|Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        },
        {
          "Path": "Dapagliflozin|Blood/Plasma concentration ratio",
          "Value": 0.88,
          "ValueOrigin": {
            "Source": "Unknown"
          }
        },
        {
          "Path": "Dapagliflozin|logP (veg.oil/water)",
          "Value": 2.0765619283,
          "Unit": "Log Units",
          "ValueOrigin": {
            "Source": "Unknown"
          }
        }
      ],
      "OutputSelections": [
        "Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
        "Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine"
      ],
      "Individual": "Standard_Adult_UGT",
      "Compounds": [
        {
          "Name": "Dapagliflozin",
          "CalculationMethods": [
            "Cellular partition coefficient method - Rodgers and Rowland",
            "Cellular permeability - PK-Sim Standard"
          ],
          "Alternatives": [
            {
              "AlternativeName": "Optimized",
              "GroupName": "COMPOUND_PERMEABILITY"
            },
            {
              "AlternativeName": "Optimized",
              "GroupName": "COMPOUND_INTESTINAL_PERMEABILITY"
            }
          ],
          "Processes": [
            {
              "Name": "UGT1A9-Optimized",
              "MoleculeName": "UGT1A9"
            },
            {
              "Name": "UGT2B7-Optimized",
              "MoleculeName": "UGT2B7"
            },
            {
              "Name": "Hepatic-CYP-Optimized",
              "MoleculeName": "Hepatic-CYP"
            },
            {
              "Name": "Glomerular Filtration-assumed"
            }
          ],
          "Protocol": {
            "Name": "PO SD 250 mg",
            "Formulations": [
              {
                "Name": "Solution",
                "Key": "Formulation"
              }
            ]
          }
        }
      ],
      "Events": [
        {
          "Name": "breakfast",
          "StartTime": {
            "Value": 0.0,
            "Unit": "h"
          }
        }
      ],
      "HasResults": true,
      "IndividualAnalyses": [
        {
          "Axes": [
            {
              "Unit": "h",
              "Dimension": "Time",
              "Type": "X",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "None",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            },
            {
              "Unit": "µg/l",
              "Dimension": "Concentration (molar)",
              "Type": "Y",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Solid",
              "Scaling": "Log",
              "NumberMode": "Normal"
            },
            {
              "Unit": "",
              "Type": "Y2",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Dash",
              "Scaling": "Log",
              "NumberMode": "Normal"
            }
          ],
          "Curves": [
            {
              "Name": "PO SD 250 mg fed (perm)-Dapagliflozin-Peripheral Venous Blood-Plasma-Concentration",
              "X": "Time",
              "Y": "PO SD 250 mg fed (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
              "CurveOptions": {
                "Color": "#FF0000",
                "LegendIndex": 1
              }
            },
            {
              "Name": "Komoroski 2009 - SAD 250 mg fed - Dapagliflozin - PO - 250 mg - Plasma - agg. (n=6)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
              "X": "Komoroski 2009 - SAD 250 mg fed - Dapagliflozin - PO - 250 mg - Plasma - agg. (n=6)|Time",
              "Y": "Komoroski 2009 - SAD 250 mg fed - Dapagliflozin - PO - 250 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "Color": "#0000FF",
                "LegendIndex": 2,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            }
          ],
          "Name": "PO SD 250 mg fed (perm)",
          "OriginText": "Dapagliflozin\nPO SD 250 mg fed (perm)\n2019-08-06 14:47"
        },
        {
          "Axes": [
            {
              "Unit": "h",
              "Dimension": "Time",
              "Type": "X",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "None",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            },
            {
              "Unit": "µg/l",
              "Dimension": "Concentration (molar)",
              "Type": "Y",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Solid",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            },
            {
              "Unit": "",
              "Type": "Y2",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Dash",
              "Scaling": "Log",
              "NumberMode": "Normal"
            }
          ],
          "Curves": [
            {
              "Name": "PO SD 250 mg fed (perm)-Dapagliflozin-Peripheral Venous Blood-Plasma-Concentration",
              "X": "Time",
              "Y": "PO SD 250 mg fed (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
              "CurveOptions": {
                "Color": "#FF0000",
                "LegendIndex": 1
              }
            },
            {
              "Name": "Komoroski 2009 - SAD 250 mg fed - Dapagliflozin - PO - 250 mg - Plasma - agg. (n=6)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
              "X": "Komoroski 2009 - SAD 250 mg fed - Dapagliflozin - PO - 250 mg - Plasma - agg. (n=6)|Time",
              "Y": "Komoroski 2009 - SAD 250 mg fed - Dapagliflozin - PO - 250 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "Color": "#0000FF",
                "LegendIndex": 2,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            }
          ],
          "Name": "PO SD 250 mg fed (perm) 1",
          "Title": "PO SD 250 mg fed (perm)",
          "OriginText": "Dapagliflozin\nPO SD 250 mg fed (perm)\n2019-08-06 14:47"
        }
      ]
    },
    {
      "Name": "PO SD 10 mg IR tablet (perm)",
      "Model": "4Comp",
      "ObservedData": [
        "Chang 2015 - Study 2 Treatment A (single oral doses) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=36)"
      ],
      "Solver": {},
      "OutputSchema": [
        {
          "Parameters": [
            {
              "Name": "Start time",
              "Value": 0.0,
              "Unit": "h"
            },
            {
              "Name": "End time",
              "Value": 2.0,
              "Unit": "h"
            },
            {
              "Name": "Resolution",
              "Value": 20.0,
              "Unit": "pts/h"
            }
          ]
        },
        {
          "Parameters": [
            {
              "Name": "Start time",
              "Value": 2.0,
              "Unit": "h"
            },
            {
              "Name": "End time",
              "Value": 24.0,
              "Unit": "h",
              "ValueOrigin": {
                "Source": "Unknown"
              }
            },
            {
              "Name": "Resolution",
              "Value": 4.0,
              "Unit": "pts/h"
            }
          ]
        }
      ],
      "Parameters": [
        {
          "Path": "Applications|PO SD 10 mg|IR tablet|Application_1|ProtocolSchemaItem|Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        },
        {
          "Path": "Dapagliflozin|Blood/Plasma concentration ratio",
          "Value": 0.88,
          "ValueOrigin": {
            "Source": "Unknown"
          }
        },
        {
          "Path": "Dapagliflozin|logP (veg.oil/water)",
          "Value": 2.0765619283,
          "Unit": "Log Units",
          "ValueOrigin": {
            "Source": "Unknown"
          }
        }
      ],
      "OutputSelections": [
        "Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)"
      ],
      "Individual": "Standard_Adult_UGT",
      "Compounds": [
        {
          "Name": "Dapagliflozin",
          "CalculationMethods": [
            "Cellular partition coefficient method - Rodgers and Rowland",
            "Cellular permeability - PK-Sim Standard"
          ],
          "Alternatives": [
            {
              "AlternativeName": "Optimized",
              "GroupName": "COMPOUND_PERMEABILITY"
            },
            {
              "AlternativeName": "Optimized",
              "GroupName": "COMPOUND_INTESTINAL_PERMEABILITY"
            }
          ],
          "Processes": [
            {
              "Name": "UGT1A9-Optimized",
              "MoleculeName": "UGT1A9"
            },
            {
              "Name": "UGT2B7-Optimized",
              "MoleculeName": "UGT2B7"
            },
            {
              "Name": "Hepatic-CYP-Optimized",
              "MoleculeName": "Hepatic-CYP"
            },
            {
              "Name": "Glomerular Filtration-assumed"
            }
          ],
          "Protocol": {
            "Name": "PO SD 10 mg",
            "Formulations": [
              {
                "Name": "IR tablet",
                "Key": "Formulation"
              }
            ]
          }
        }
      ],
      "HasResults": true,
      "IndividualAnalyses": [
        {
          "Axes": [
            {
              "Unit": "h",
              "Dimension": "Time",
              "Type": "X",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "None",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            },
            {
              "Unit": "µg/l",
              "Dimension": "Concentration (molar)",
              "Type": "Y",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Solid",
              "Scaling": "Log",
              "NumberMode": "Normal"
            }
          ],
          "Curves": [
            {
              "Name": "PO SD 10 mg IR tablet (perm)-Dapagliflozin-Peripheral Venous Blood-Plasma-Concentration",
              "X": "Time",
              "Y": "PO SD 10 mg IR tablet (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
              "CurveOptions": {
                "Color": "#FF0000",
                "LegendIndex": 1
              }
            },
            {
              "Name": "Chang 2015 - Study 2 Treatment A (single oral doses) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=36)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
              "X": "Chang 2015 - Study 2 Treatment A (single oral doses) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=36)|Time",
              "Y": "Chang 2015 - Study 2 Treatment A (single oral doses) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=36)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "Color": "#0000FF",
                "LegendIndex": 2,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            }
          ],
          "Name": "PO SD 10 mg IR tablet (perm)",
          "Title": "PO SD 10 mg IR tablet (perm)",
          "OriginText": "Dapagliflozin\nPO SD 10 mg IR tablet (perm)\n2019-08-07 13:04"
        },
        {
          "Axes": [
            {
              "Unit": "h",
              "Dimension": "Time",
              "Type": "X",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "None",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            },
            {
              "Unit": "µg/l",
              "Dimension": "Concentration (molar)",
              "Type": "Y",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Solid",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            }
          ],
          "Curves": [
            {
              "Name": "PO SD 10 mg IR tablet (perm)-Dapagliflozin-Peripheral Venous Blood-Plasma-Concentration",
              "X": "Time",
              "Y": "PO SD 10 mg IR tablet (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
              "CurveOptions": {
                "Color": "#FF0000",
                "LegendIndex": 1
              }
            },
            {
              "Name": "Chang 2015 - Study 2 Treatment A (single oral doses) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=36)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
              "X": "Chang 2015 - Study 2 Treatment A (single oral doses) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=36)|Time",
              "Y": "Chang 2015 - Study 2 Treatment A (single oral doses) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=36)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "Color": "#0000FF",
                "LegendIndex": 2,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            }
          ],
          "Name": "PO SD 10 mg IR tablet (perm) 1",
          "Title": "PO SD 10 mg IR tablet (perm)",
          "OriginText": "Dapagliflozin\nPO SD 10 mg IR tablet (perm)\n2019-08-07 13:04"
        }
      ]
    },
    {
      "Name": "PO MD 10 mg (perm)",
      "Model": "4Comp",
      "ObservedData": [
        "Komoroski 2009 - MAD 10 mg (day 1) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=6)",
        "Komoroski 2009 - MAD 10 mg (day 7 and day 14) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=6)"
      ],
      "Solver": {},
      "OutputSchema": [
        {
          "Parameters": [
            {
              "Name": "Start time",
              "Value": 0.0,
              "Unit": "h"
            },
            {
              "Name": "End time",
              "Value": 2.0,
              "Unit": "h"
            },
            {
              "Name": "Resolution",
              "Value": 20.0,
              "Unit": "pts/h"
            }
          ]
        },
        {
          "Parameters": [
            {
              "Name": "Start time",
              "Value": 2.0,
              "Unit": "h"
            },
            {
              "Name": "End time",
              "Value": 336.0,
              "Unit": "h",
              "ValueOrigin": {
                "Source": "Unknown"
              }
            },
            {
              "Name": "Resolution",
              "Value": 4.0,
              "Unit": "pts/h"
            }
          ]
        }
      ],
      "Parameters": [
        {
          "Path": "Applications|PO MD 10 mg|Solution|Application_1|ProtocolSchemaItem|Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        },
        {
          "Path": "Applications|PO MD 10 mg|Solution|Application_10|ProtocolSchemaItem|Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        },
        {
          "Path": "Applications|PO MD 10 mg|Solution|Application_11|ProtocolSchemaItem|Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        },
        {
          "Path": "Applications|PO MD 10 mg|Solution|Application_12|ProtocolSchemaItem|Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        },
        {
          "Path": "Applications|PO MD 10 mg|Solution|Application_13|ProtocolSchemaItem|Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        },
        {
          "Path": "Applications|PO MD 10 mg|Solution|Application_14|ProtocolSchemaItem|Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        },
        {
          "Path": "Applications|PO MD 10 mg|Solution|Application_2|ProtocolSchemaItem|Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        },
        {
          "Path": "Applications|PO MD 10 mg|Solution|Application_3|ProtocolSchemaItem|Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        },
        {
          "Path": "Applications|PO MD 10 mg|Solution|Application_4|ProtocolSchemaItem|Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        },
        {
          "Path": "Applications|PO MD 10 mg|Solution|Application_5|ProtocolSchemaItem|Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        },
        {
          "Path": "Applications|PO MD 10 mg|Solution|Application_6|ProtocolSchemaItem|Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        },
        {
          "Path": "Applications|PO MD 10 mg|Solution|Application_7|ProtocolSchemaItem|Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        },
        {
          "Path": "Applications|PO MD 10 mg|Solution|Application_8|ProtocolSchemaItem|Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        },
        {
          "Path": "Applications|PO MD 10 mg|Solution|Application_9|ProtocolSchemaItem|Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        },
        {
          "Path": "Dapagliflozin|Blood/Plasma concentration ratio",
          "Value": 0.88,
          "ValueOrigin": {
            "Source": "Unknown"
          }
        },
        {
          "Path": "Dapagliflozin|logP (veg.oil/water)",
          "Value": 2.0765619283,
          "Unit": "Log Units",
          "ValueOrigin": {
            "Source": "Unknown"
          }
        }
      ],
      "OutputSelections": [
        "Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
        "Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine"
      ],
      "Individual": "Standard_Adult_UGT",
      "Compounds": [
        {
          "Name": "Dapagliflozin",
          "CalculationMethods": [
            "Cellular partition coefficient method - Rodgers and Rowland",
            "Cellular permeability - PK-Sim Standard"
          ],
          "Alternatives": [
            {
              "AlternativeName": "Optimized",
              "GroupName": "COMPOUND_PERMEABILITY"
            },
            {
              "AlternativeName": "Optimized",
              "GroupName": "COMPOUND_INTESTINAL_PERMEABILITY"
            }
          ],
          "Processes": [
            {
              "Name": "UGT1A9-Optimized",
              "MoleculeName": "UGT1A9"
            },
            {
              "Name": "UGT2B7-Optimized",
              "MoleculeName": "UGT2B7"
            },
            {
              "Name": "Hepatic-CYP-Optimized",
              "MoleculeName": "Hepatic-CYP"
            },
            {
              "Name": "Glomerular Filtration-assumed"
            }
          ],
          "Protocol": {
            "Name": "PO MD 10 mg",
            "Formulations": [
              {
                "Name": "Solution",
                "Key": "Formulation"
              }
            ]
          }
        }
      ],
      "HasResults": true,
      "IndividualAnalyses": [
        {
          "Axes": [
            {
              "Unit": "h",
              "Dimension": "Time",
              "Type": "X",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "None",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            },
            {
              "Unit": "µg/l",
              "Dimension": "Concentration (molar)",
              "Type": "Y",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Solid",
              "Scaling": "Log",
              "NumberMode": "Normal"
            },
            {
              "Unit": "",
              "Type": "Y2",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Dash",
              "Scaling": "Log",
              "NumberMode": "Normal"
            }
          ],
          "Curves": [
            {
              "Name": "PO MD 10 mg (perm)-Dapagliflozin-Peripheral Venous Blood-Plasma-Concentration",
              "X": "Time",
              "Y": "PO MD 10 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
              "CurveOptions": {
                "Color": "#FF0000",
                "LegendIndex": 1
              }
            },
            {
              "Name": "Komoroski 2009 - MAD 10 mg (day 1) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=6)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
              "X": "Komoroski 2009 - MAD 10 mg (day 1) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=6)|Time",
              "Y": "Komoroski 2009 - MAD 10 mg (day 1) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "Color": "#0000FF",
                "LegendIndex": 2,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            },
            {
              "Name": "Komoroski 2009 - MAD 10 mg (day 7 and day 14) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=6)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
              "X": "Komoroski 2009 - MAD 10 mg (day 7 and day 14) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=6)|Time",
              "Y": "Komoroski 2009 - MAD 10 mg (day 7 and day 14) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "Color": "#0000FF",
                "LegendIndex": 3,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            }
          ],
          "Name": "PO MD 10 mg (perm)",
          "Title": "PO MD 10 mg (perm)",
          "OriginText": "Dapagliflozin\nPO MD 10 mg (perm)\n2019-08-19 17:37"
        },
        {
          "Axes": [
            {
              "Unit": "h",
              "Dimension": "Time",
              "Type": "X",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "None",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            },
            {
              "Unit": "µg/l",
              "Dimension": "Concentration (molar)",
              "Type": "Y",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Solid",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            },
            {
              "Unit": "",
              "Type": "Y2",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Dash",
              "Scaling": "Log",
              "NumberMode": "Normal"
            }
          ],
          "Curves": [
            {
              "Name": "PO MD 10 mg (perm)-Dapagliflozin-Peripheral Venous Blood-Plasma-Concentration",
              "X": "Time",
              "Y": "PO MD 10 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
              "CurveOptions": {
                "Color": "#FF0000",
                "LegendIndex": 1
              }
            },
            {
              "Name": "Komoroski 2009 - MAD 10 mg (day 1) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=6)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
              "X": "Komoroski 2009 - MAD 10 mg (day 1) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=6)|Time",
              "Y": "Komoroski 2009 - MAD 10 mg (day 1) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "Color": "#0000FF",
                "LegendIndex": 2,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            },
            {
              "Name": "Komoroski 2009 - MAD 10 mg (day 7 and day 14) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=6)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
              "X": "Komoroski 2009 - MAD 10 mg (day 7 and day 14) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=6)|Time",
              "Y": "Komoroski 2009 - MAD 10 mg (day 7 and day 14) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "Color": "#0000FF",
                "LegendIndex": 3,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            }
          ],
          "Name": "PO MD 10 mg (perm) 1",
          "Title": "PO MD 10 mg (perm)",
          "OriginText": "Dapagliflozin\nPO MD 10 mg (perm)\n2019-08-19 17:37"
        }
      ]
    },
    {
      "Name": "PO MD 100 mg (perm)",
      "Model": "4Comp",
      "ObservedData": [
        "Komoroski 2009 - MAD 100 mg (day 1) - Dapagliflozin - PO - 100 mg - Plasma - agg. (n=6)",
        "Komoroski 2009 - MAD 100 mg (day 7 and day 14) - Dapagliflozin - PO - 100 mg - Plasma - agg. (n=6)"
      ],
      "Solver": {},
      "OutputSchema": [
        {
          "Parameters": [
            {
              "Name": "Start time",
              "Value": 0.0,
              "Unit": "h"
            },
            {
              "Name": "End time",
              "Value": 2.0,
              "Unit": "h"
            },
            {
              "Name": "Resolution",
              "Value": 20.0,
              "Unit": "pts/h"
            }
          ]
        },
        {
          "Parameters": [
            {
              "Name": "Start time",
              "Value": 2.0,
              "Unit": "h"
            },
            {
              "Name": "End time",
              "Value": 336.0,
              "Unit": "h",
              "ValueOrigin": {
                "Source": "Unknown"
              }
            },
            {
              "Name": "Resolution",
              "Value": 4.0,
              "Unit": "pts/h"
            }
          ]
        }
      ],
      "Parameters": [
        {
          "Path": "Applications|PO MD 100 mg|Solution|Application_1|ProtocolSchemaItem|Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        },
        {
          "Path": "Applications|PO MD 100 mg|Solution|Application_10|ProtocolSchemaItem|Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        },
        {
          "Path": "Applications|PO MD 100 mg|Solution|Application_11|ProtocolSchemaItem|Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        },
        {
          "Path": "Applications|PO MD 100 mg|Solution|Application_12|ProtocolSchemaItem|Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        },
        {
          "Path": "Applications|PO MD 100 mg|Solution|Application_13|ProtocolSchemaItem|Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        },
        {
          "Path": "Applications|PO MD 100 mg|Solution|Application_14|ProtocolSchemaItem|Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        },
        {
          "Path": "Applications|PO MD 100 mg|Solution|Application_2|ProtocolSchemaItem|Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        },
        {
          "Path": "Applications|PO MD 100 mg|Solution|Application_3|ProtocolSchemaItem|Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        },
        {
          "Path": "Applications|PO MD 100 mg|Solution|Application_4|ProtocolSchemaItem|Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        },
        {
          "Path": "Applications|PO MD 100 mg|Solution|Application_5|ProtocolSchemaItem|Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        },
        {
          "Path": "Applications|PO MD 100 mg|Solution|Application_6|ProtocolSchemaItem|Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        },
        {
          "Path": "Applications|PO MD 100 mg|Solution|Application_7|ProtocolSchemaItem|Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        },
        {
          "Path": "Applications|PO MD 100 mg|Solution|Application_8|ProtocolSchemaItem|Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        },
        {
          "Path": "Applications|PO MD 100 mg|Solution|Application_9|ProtocolSchemaItem|Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        },
        {
          "Path": "Dapagliflozin|Blood/Plasma concentration ratio",
          "Value": 0.88,
          "ValueOrigin": {
            "Source": "Unknown"
          }
        },
        {
          "Path": "Dapagliflozin|logP (veg.oil/water)",
          "Value": 2.0765619283,
          "Unit": "Log Units",
          "ValueOrigin": {
            "Source": "Unknown"
          }
        }
      ],
      "OutputSelections": [
        "Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
        "Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine"
      ],
      "Individual": "Standard_Adult_UGT",
      "Compounds": [
        {
          "Name": "Dapagliflozin",
          "CalculationMethods": [
            "Cellular partition coefficient method - Rodgers and Rowland",
            "Cellular permeability - PK-Sim Standard"
          ],
          "Alternatives": [
            {
              "AlternativeName": "Optimized",
              "GroupName": "COMPOUND_PERMEABILITY"
            },
            {
              "AlternativeName": "Optimized",
              "GroupName": "COMPOUND_INTESTINAL_PERMEABILITY"
            }
          ],
          "Processes": [
            {
              "Name": "UGT1A9-Optimized",
              "MoleculeName": "UGT1A9"
            },
            {
              "Name": "UGT2B7-Optimized",
              "MoleculeName": "UGT2B7"
            },
            {
              "Name": "Hepatic-CYP-Optimized",
              "MoleculeName": "Hepatic-CYP"
            },
            {
              "Name": "Glomerular Filtration-assumed"
            }
          ],
          "Protocol": {
            "Name": "PO MD 100 mg",
            "Formulations": [
              {
                "Name": "Solution",
                "Key": "Formulation"
              }
            ]
          }
        }
      ],
      "HasResults": true,
      "IndividualAnalyses": [
        {
          "Axes": [
            {
              "Unit": "h",
              "Dimension": "Time",
              "Type": "X",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "None",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            },
            {
              "Unit": "µg/l",
              "Dimension": "Concentration (molar)",
              "Type": "Y",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Solid",
              "Scaling": "Log",
              "NumberMode": "Normal"
            },
            {
              "Unit": "",
              "Type": "Y2",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Dash",
              "Scaling": "Log",
              "NumberMode": "Normal"
            }
          ],
          "Curves": [
            {
              "Name": "PO MD 100 mg (perm)-Dapagliflozin-Peripheral Venous Blood-Plasma-Concentration",
              "X": "Time",
              "Y": "PO MD 100 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
              "CurveOptions": {
                "Color": "#FF0000",
                "LegendIndex": 1
              }
            },
            {
              "Name": "Komoroski 2009 - MAD 100 mg (day 1) - Dapagliflozin - PO - 100 mg - Plasma - agg. (n=6)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
              "X": "Komoroski 2009 - MAD 100 mg (day 1) - Dapagliflozin - PO - 100 mg - Plasma - agg. (n=6)|Time",
              "Y": "Komoroski 2009 - MAD 100 mg (day 1) - Dapagliflozin - PO - 100 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "Color": "#0000FF",
                "LegendIndex": 2,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            },
            {
              "Name": "Komoroski 2009 - MAD 100 mg (day 7 and day 14) - Dapagliflozin - PO - 100 mg - Plasma - agg. (n=6)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
              "X": "Komoroski 2009 - MAD 100 mg (day 7 and day 14) - Dapagliflozin - PO - 100 mg - Plasma - agg. (n=6)|Time",
              "Y": "Komoroski 2009 - MAD 100 mg (day 7 and day 14) - Dapagliflozin - PO - 100 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "Color": "#0000FF",
                "LegendIndex": 3,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            }
          ],
          "Name": "PO MD 100 mg (perm)",
          "Title": "PO MD 100 mg (perm)",
          "OriginText": "Dapagliflozin\nPO MD 100 mg (perm)\n2019-08-19 17:43"
        },
        {
          "Axes": [
            {
              "Unit": "h",
              "Dimension": "Time",
              "Type": "X",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "None",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            },
            {
              "Unit": "µg/l",
              "Dimension": "Concentration (molar)",
              "Type": "Y",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Solid",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            },
            {
              "Unit": "",
              "Type": "Y2",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Dash",
              "Scaling": "Log",
              "NumberMode": "Normal"
            }
          ],
          "Curves": [
            {
              "Name": "PO MD 100 mg (perm)-Dapagliflozin-Peripheral Venous Blood-Plasma-Concentration",
              "X": "Time",
              "Y": "PO MD 100 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
              "CurveOptions": {
                "Color": "#FF0000",
                "LegendIndex": 1
              }
            },
            {
              "Name": "Komoroski 2009 - MAD 100 mg (day 1) - Dapagliflozin - PO - 100 mg - Plasma - agg. (n=6)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
              "X": "Komoroski 2009 - MAD 100 mg (day 1) - Dapagliflozin - PO - 100 mg - Plasma - agg. (n=6)|Time",
              "Y": "Komoroski 2009 - MAD 100 mg (day 1) - Dapagliflozin - PO - 100 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "Color": "#0000FF",
                "LegendIndex": 2,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            },
            {
              "Name": "Komoroski 2009 - MAD 100 mg (day 7 and day 14) - Dapagliflozin - PO - 100 mg - Plasma - agg. (n=6)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
              "X": "Komoroski 2009 - MAD 100 mg (day 7 and day 14) - Dapagliflozin - PO - 100 mg - Plasma - agg. (n=6)|Time",
              "Y": "Komoroski 2009 - MAD 100 mg (day 7 and day 14) - Dapagliflozin - PO - 100 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "Color": "#0000FF",
                "LegendIndex": 3,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            }
          ],
          "Name": "PO MD 100 mg (perm) 1",
          "Title": "PO MD 100 mg (perm)",
          "OriginText": "Dapagliflozin\nPO MD 100 mg (perm)\n2019-08-19 17:43"
        }
      ]
    },
    {
      "Name": "PO MD 2.5 mg (perm)",
      "Model": "4Comp",
      "ObservedData": [
        "Komoroski 2009 - MAD 2.5 mg (day 7 and day 14) - Dapagliflozin - PO - 2.5 mg - Plasma - agg. (n=6)",
        "Komoroski 2009 - MAD 2.5 mg (day 1) - Dapagliflozin - PO - 2.5 mg - Plasma - agg. (n=6)"
      ],
      "Solver": {},
      "OutputSchema": [
        {
          "Parameters": [
            {
              "Name": "Start time",
              "Value": 0.0,
              "Unit": "h"
            },
            {
              "Name": "End time",
              "Value": 2.0,
              "Unit": "h"
            },
            {
              "Name": "Resolution",
              "Value": 20.0,
              "Unit": "pts/h"
            }
          ]
        },
        {
          "Parameters": [
            {
              "Name": "Start time",
              "Value": 2.0,
              "Unit": "h"
            },
            {
              "Name": "End time",
              "Value": 336.0,
              "Unit": "h",
              "ValueOrigin": {
                "Source": "Unknown"
              }
            },
            {
              "Name": "Resolution",
              "Value": 4.0,
              "Unit": "pts/h"
            }
          ]
        }
      ],
      "Parameters": [
        {
          "Path": "Applications|PO MD 2.5 mg|Solution|Application_1|ProtocolSchemaItem|Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        },
        {
          "Path": "Applications|PO MD 2.5 mg|Solution|Application_10|ProtocolSchemaItem|Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        },
        {
          "Path": "Applications|PO MD 2.5 mg|Solution|Application_11|ProtocolSchemaItem|Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        },
        {
          "Path": "Applications|PO MD 2.5 mg|Solution|Application_12|ProtocolSchemaItem|Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        },
        {
          "Path": "Applications|PO MD 2.5 mg|Solution|Application_13|ProtocolSchemaItem|Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        },
        {
          "Path": "Applications|PO MD 2.5 mg|Solution|Application_14|ProtocolSchemaItem|Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        },
        {
          "Path": "Applications|PO MD 2.5 mg|Solution|Application_2|ProtocolSchemaItem|Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        },
        {
          "Path": "Applications|PO MD 2.5 mg|Solution|Application_3|ProtocolSchemaItem|Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        },
        {
          "Path": "Applications|PO MD 2.5 mg|Solution|Application_4|ProtocolSchemaItem|Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        },
        {
          "Path": "Applications|PO MD 2.5 mg|Solution|Application_5|ProtocolSchemaItem|Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        },
        {
          "Path": "Applications|PO MD 2.5 mg|Solution|Application_6|ProtocolSchemaItem|Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        },
        {
          "Path": "Applications|PO MD 2.5 mg|Solution|Application_7|ProtocolSchemaItem|Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        },
        {
          "Path": "Applications|PO MD 2.5 mg|Solution|Application_8|ProtocolSchemaItem|Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        },
        {
          "Path": "Applications|PO MD 2.5 mg|Solution|Application_9|ProtocolSchemaItem|Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        },
        {
          "Path": "Dapagliflozin|Blood/Plasma concentration ratio",
          "Value": 0.88,
          "ValueOrigin": {
            "Source": "Unknown"
          }
        },
        {
          "Path": "Dapagliflozin|logP (veg.oil/water)",
          "Value": 2.0765619283,
          "Unit": "Log Units",
          "ValueOrigin": {
            "Source": "Unknown"
          }
        }
      ],
      "OutputSelections": [
        "Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
        "Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine"
      ],
      "Individual": "Standard_Adult_UGT",
      "Compounds": [
        {
          "Name": "Dapagliflozin",
          "CalculationMethods": [
            "Cellular partition coefficient method - Rodgers and Rowland",
            "Cellular permeability - PK-Sim Standard"
          ],
          "Alternatives": [
            {
              "AlternativeName": "Optimized",
              "GroupName": "COMPOUND_PERMEABILITY"
            },
            {
              "AlternativeName": "Optimized",
              "GroupName": "COMPOUND_INTESTINAL_PERMEABILITY"
            }
          ],
          "Processes": [
            {
              "Name": "UGT1A9-Optimized",
              "MoleculeName": "UGT1A9"
            },
            {
              "Name": "UGT2B7-Optimized",
              "MoleculeName": "UGT2B7"
            },
            {
              "Name": "Hepatic-CYP-Optimized",
              "MoleculeName": "Hepatic-CYP"
            },
            {
              "Name": "Glomerular Filtration-assumed"
            }
          ],
          "Protocol": {
            "Name": "PO MD 2.5 mg",
            "Formulations": [
              {
                "Name": "Solution",
                "Key": "Formulation"
              }
            ]
          }
        }
      ],
      "HasResults": true,
      "IndividualAnalyses": [
        {
          "Axes": [
            {
              "Unit": "h",
              "Dimension": "Time",
              "Type": "X",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "None",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            },
            {
              "Unit": "µg/l",
              "Dimension": "Concentration (molar)",
              "Type": "Y",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Solid",
              "Scaling": "Log",
              "NumberMode": "Normal"
            },
            {
              "Unit": "",
              "Type": "Y2",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Dash",
              "Scaling": "Log",
              "NumberMode": "Normal"
            }
          ],
          "Curves": [
            {
              "Name": "PO MD 2.5 mg (perm)-Dapagliflozin-Peripheral Venous Blood-Plasma-Concentration",
              "X": "Time",
              "Y": "PO MD 2.5 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
              "CurveOptions": {
                "Color": "#FF0000",
                "LegendIndex": 1
              }
            },
            {
              "Name": "Komoroski 2009 - MAD 2.5 mg (day 1) - Dapagliflozin - PO - 2.5 mg - Plasma - agg. (n=6)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
              "X": "Komoroski 2009 - MAD 2.5 mg (day 1) - Dapagliflozin - PO - 2.5 mg - Plasma - agg. (n=6)|Time",
              "Y": "Komoroski 2009 - MAD 2.5 mg (day 1) - Dapagliflozin - PO - 2.5 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "Color": "#0000FF",
                "LegendIndex": 2,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            },
            {
              "Name": "Komoroski 2009 - MAD 2.5 mg (day 7 and day 14) - Dapagliflozin - PO - 2.5 mg - Plasma - agg. (n=6)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
              "X": "Komoroski 2009 - MAD 2.5 mg (day 7 and day 14) - Dapagliflozin - PO - 2.5 mg - Plasma - agg. (n=6)|Time",
              "Y": "Komoroski 2009 - MAD 2.5 mg (day 7 and day 14) - Dapagliflozin - PO - 2.5 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "Color": "#0000FF",
                "LegendIndex": 3,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            }
          ],
          "Name": "PO MD 2.5 mg (perm)",
          "Title": "PO MD 2.5 mg (perm)",
          "OriginText": "Dapagliflozin\nPO MD 2.5 mg (perm)\n2019-08-19 17:44"
        },
        {
          "Axes": [
            {
              "Unit": "h",
              "Dimension": "Time",
              "Type": "X",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "None",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            },
            {
              "Unit": "µg/l",
              "Dimension": "Concentration (molar)",
              "Type": "Y",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Solid",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            },
            {
              "Unit": "",
              "Type": "Y2",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Dash",
              "Scaling": "Log",
              "NumberMode": "Normal"
            }
          ],
          "Curves": [
            {
              "Name": "PO MD 2.5 mg (perm)-Dapagliflozin-Peripheral Venous Blood-Plasma-Concentration",
              "X": "Time",
              "Y": "PO MD 2.5 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
              "CurveOptions": {
                "Color": "#FF0000",
                "LegendIndex": 1
              }
            },
            {
              "Name": "Komoroski 2009 - MAD 2.5 mg (day 1) - Dapagliflozin - PO - 2.5 mg - Plasma - agg. (n=6)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
              "X": "Komoroski 2009 - MAD 2.5 mg (day 1) - Dapagliflozin - PO - 2.5 mg - Plasma - agg. (n=6)|Time",
              "Y": "Komoroski 2009 - MAD 2.5 mg (day 1) - Dapagliflozin - PO - 2.5 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "Color": "#0000FF",
                "LegendIndex": 2,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            },
            {
              "Name": "Komoroski 2009 - MAD 2.5 mg (day 7 and day 14) - Dapagliflozin - PO - 2.5 mg - Plasma - agg. (n=6)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
              "X": "Komoroski 2009 - MAD 2.5 mg (day 7 and day 14) - Dapagliflozin - PO - 2.5 mg - Plasma - agg. (n=6)|Time",
              "Y": "Komoroski 2009 - MAD 2.5 mg (day 7 and day 14) - Dapagliflozin - PO - 2.5 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "Color": "#0000FF",
                "LegendIndex": 3,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            }
          ],
          "Name": "PO MD 2.5 mg (perm) 1",
          "Title": "PO MD 2.5 mg (perm)",
          "OriginText": "Dapagliflozin\nPO MD 2.5 mg (perm)\n2019-08-19 17:44"
        }
      ]
    },
    {
      "Name": "PO MD 20 mg (perm)",
      "Model": "4Comp",
      "ObservedData": [
        "Komoroski 2009 - MAD 20 mg (day 1) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=6)",
        "Komoroski 2009 - MAD 20 mg (day 7 and day 14) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=6)"
      ],
      "Solver": {},
      "OutputSchema": [
        {
          "Parameters": [
            {
              "Name": "Start time",
              "Value": 0.0,
              "Unit": "h"
            },
            {
              "Name": "End time",
              "Value": 2.0,
              "Unit": "h"
            },
            {
              "Name": "Resolution",
              "Value": 20.0,
              "Unit": "pts/h"
            }
          ]
        },
        {
          "Parameters": [
            {
              "Name": "Start time",
              "Value": 2.0,
              "Unit": "h"
            },
            {
              "Name": "End time",
              "Value": 336.0,
              "Unit": "h",
              "ValueOrigin": {
                "Source": "Unknown"
              }
            },
            {
              "Name": "Resolution",
              "Value": 4.0,
              "Unit": "pts/h"
            }
          ]
        }
      ],
      "Parameters": [
        {
          "Path": "Applications|PO MD 20 mg|Solution|Application_1|ProtocolSchemaItem|Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        },
        {
          "Path": "Applications|PO MD 20 mg|Solution|Application_10|ProtocolSchemaItem|Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        },
        {
          "Path": "Applications|PO MD 20 mg|Solution|Application_11|ProtocolSchemaItem|Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        },
        {
          "Path": "Applications|PO MD 20 mg|Solution|Application_12|ProtocolSchemaItem|Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        },
        {
          "Path": "Applications|PO MD 20 mg|Solution|Application_13|ProtocolSchemaItem|Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        },
        {
          "Path": "Applications|PO MD 20 mg|Solution|Application_14|ProtocolSchemaItem|Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        },
        {
          "Path": "Applications|PO MD 20 mg|Solution|Application_2|ProtocolSchemaItem|Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        },
        {
          "Path": "Applications|PO MD 20 mg|Solution|Application_3|ProtocolSchemaItem|Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        },
        {
          "Path": "Applications|PO MD 20 mg|Solution|Application_4|ProtocolSchemaItem|Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        },
        {
          "Path": "Applications|PO MD 20 mg|Solution|Application_5|ProtocolSchemaItem|Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        },
        {
          "Path": "Applications|PO MD 20 mg|Solution|Application_6|ProtocolSchemaItem|Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        },
        {
          "Path": "Applications|PO MD 20 mg|Solution|Application_7|ProtocolSchemaItem|Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        },
        {
          "Path": "Applications|PO MD 20 mg|Solution|Application_8|ProtocolSchemaItem|Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        },
        {
          "Path": "Applications|PO MD 20 mg|Solution|Application_9|ProtocolSchemaItem|Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        },
        {
          "Path": "Dapagliflozin|Blood/Plasma concentration ratio",
          "Value": 0.88,
          "ValueOrigin": {
            "Source": "Unknown"
          }
        },
        {
          "Path": "Dapagliflozin|logP (veg.oil/water)",
          "Value": 2.0765619283,
          "Unit": "Log Units",
          "ValueOrigin": {
            "Source": "Unknown"
          }
        }
      ],
      "OutputSelections": [
        "Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
        "Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine"
      ],
      "Individual": "Standard_Adult_UGT",
      "Compounds": [
        {
          "Name": "Dapagliflozin",
          "CalculationMethods": [
            "Cellular partition coefficient method - Rodgers and Rowland",
            "Cellular permeability - PK-Sim Standard"
          ],
          "Alternatives": [
            {
              "AlternativeName": "Optimized",
              "GroupName": "COMPOUND_PERMEABILITY"
            },
            {
              "AlternativeName": "Optimized",
              "GroupName": "COMPOUND_INTESTINAL_PERMEABILITY"
            }
          ],
          "Processes": [
            {
              "Name": "UGT1A9-Optimized",
              "MoleculeName": "UGT1A9"
            },
            {
              "Name": "UGT2B7-Optimized",
              "MoleculeName": "UGT2B7"
            },
            {
              "Name": "Hepatic-CYP-Optimized",
              "MoleculeName": "Hepatic-CYP"
            },
            {
              "Name": "Glomerular Filtration-assumed"
            }
          ],
          "Protocol": {
            "Name": "PO MD 20 mg",
            "Formulations": [
              {
                "Name": "Solution",
                "Key": "Formulation"
              }
            ]
          }
        }
      ],
      "HasResults": true,
      "IndividualAnalyses": [
        {
          "Axes": [
            {
              "Unit": "h",
              "Dimension": "Time",
              "Type": "X",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "None",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            },
            {
              "Unit": "µg/l",
              "Dimension": "Concentration (molar)",
              "Type": "Y",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Solid",
              "Scaling": "Log",
              "NumberMode": "Normal"
            },
            {
              "Unit": "",
              "Type": "Y2",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Dash",
              "Scaling": "Log",
              "NumberMode": "Normal"
            }
          ],
          "Curves": [
            {
              "Name": "PO MD 20 mg (perm)-Dapagliflozin-Peripheral Venous Blood-Plasma-Concentration",
              "X": "Time",
              "Y": "PO MD 20 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
              "CurveOptions": {
                "Color": "#FF0000",
                "LegendIndex": 1
              }
            },
            {
              "Name": "Komoroski 2009 - MAD 20 mg (day 1) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=6)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
              "X": "Komoroski 2009 - MAD 20 mg (day 1) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=6)|Time",
              "Y": "Komoroski 2009 - MAD 20 mg (day 1) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "Color": "#0000FF",
                "LegendIndex": 2,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            },
            {
              "Name": "Komoroski 2009 - MAD 20 mg (day 7 and day 14) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=6)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
              "X": "Komoroski 2009 - MAD 20 mg (day 7 and day 14) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=6)|Time",
              "Y": "Komoroski 2009 - MAD 20 mg (day 7 and day 14) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "Color": "#0000FF",
                "LegendIndex": 3,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            }
          ],
          "Name": "PO MD 20 mg (perm)",
          "Title": "PO MD 20 mg (perm)",
          "OriginText": "Dapagliflozin\nPO MD 20 mg (perm)\n2019-08-19 17:47"
        },
        {
          "Axes": [
            {
              "Unit": "h",
              "Dimension": "Time",
              "Type": "X",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "None",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            },
            {
              "Unit": "µg/l",
              "Dimension": "Concentration (molar)",
              "Type": "Y",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Solid",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            },
            {
              "Unit": "",
              "Type": "Y2",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Dash",
              "Scaling": "Log",
              "NumberMode": "Normal"
            }
          ],
          "Curves": [
            {
              "Name": "PO MD 20 mg (perm)-Dapagliflozin-Peripheral Venous Blood-Plasma-Concentration",
              "X": "Time",
              "Y": "PO MD 20 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
              "CurveOptions": {
                "Color": "#FF0000",
                "LegendIndex": 1
              }
            },
            {
              "Name": "Komoroski 2009 - MAD 20 mg (day 1) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=6)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
              "X": "Komoroski 2009 - MAD 20 mg (day 1) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=6)|Time",
              "Y": "Komoroski 2009 - MAD 20 mg (day 1) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "Color": "#0000FF",
                "LegendIndex": 2,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            },
            {
              "Name": "Komoroski 2009 - MAD 20 mg (day 7 and day 14) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=6)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
              "X": "Komoroski 2009 - MAD 20 mg (day 7 and day 14) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=6)|Time",
              "Y": "Komoroski 2009 - MAD 20 mg (day 7 and day 14) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "Color": "#0000FF",
                "LegendIndex": 3,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            }
          ],
          "Name": "PO MD 20 mg (perm) 1",
          "Title": "PO MD 20 mg (perm)",
          "OriginText": "Dapagliflozin\nPO MD 20 mg (perm)\n2019-08-19 17:47"
        }
      ]
    },
    {
      "Name": "PO MD 50 mg (perm)",
      "Model": "4Comp",
      "ObservedData": [
        "Komoroski 2009 - MAD 50 mg (day 1) - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=6)",
        "Komoroski 2009 - MAD 50 mg (day 7 and day 14) - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=6)"
      ],
      "Solver": {},
      "OutputSchema": [
        {
          "Parameters": [
            {
              "Name": "Start time",
              "Value": 0.0,
              "Unit": "h"
            },
            {
              "Name": "End time",
              "Value": 2.0,
              "Unit": "h"
            },
            {
              "Name": "Resolution",
              "Value": 20.0,
              "Unit": "pts/h"
            }
          ]
        },
        {
          "Parameters": [
            {
              "Name": "Start time",
              "Value": 2.0,
              "Unit": "h"
            },
            {
              "Name": "End time",
              "Value": 336.0,
              "Unit": "h",
              "ValueOrigin": {
                "Source": "Unknown"
              }
            },
            {
              "Name": "Resolution",
              "Value": 4.0,
              "Unit": "pts/h"
            }
          ]
        }
      ],
      "Parameters": [
        {
          "Path": "Applications|PO MD 50 mg|Solution|Application_1|ProtocolSchemaItem|Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        },
        {
          "Path": "Applications|PO MD 50 mg|Solution|Application_10|ProtocolSchemaItem|Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        },
        {
          "Path": "Applications|PO MD 50 mg|Solution|Application_11|ProtocolSchemaItem|Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        },
        {
          "Path": "Applications|PO MD 50 mg|Solution|Application_12|ProtocolSchemaItem|Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        },
        {
          "Path": "Applications|PO MD 50 mg|Solution|Application_13|ProtocolSchemaItem|Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        },
        {
          "Path": "Applications|PO MD 50 mg|Solution|Application_14|ProtocolSchemaItem|Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        },
        {
          "Path": "Applications|PO MD 50 mg|Solution|Application_2|ProtocolSchemaItem|Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        },
        {
          "Path": "Applications|PO MD 50 mg|Solution|Application_3|ProtocolSchemaItem|Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        },
        {
          "Path": "Applications|PO MD 50 mg|Solution|Application_4|ProtocolSchemaItem|Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        },
        {
          "Path": "Applications|PO MD 50 mg|Solution|Application_5|ProtocolSchemaItem|Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        },
        {
          "Path": "Applications|PO MD 50 mg|Solution|Application_6|ProtocolSchemaItem|Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        },
        {
          "Path": "Applications|PO MD 50 mg|Solution|Application_7|ProtocolSchemaItem|Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        },
        {
          "Path": "Applications|PO MD 50 mg|Solution|Application_8|ProtocolSchemaItem|Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        },
        {
          "Path": "Applications|PO MD 50 mg|Solution|Application_9|ProtocolSchemaItem|Volume of water/body weight",
          "Value": 3.5,
          "Unit": "ml/kg"
        },
        {
          "Path": "Dapagliflozin|Blood/Plasma concentration ratio",
          "Value": 0.88,
          "ValueOrigin": {
            "Source": "Unknown"
          }
        },
        {
          "Path": "Dapagliflozin|logP (veg.oil/water)",
          "Value": 2.0765619283,
          "Unit": "Log Units",
          "ValueOrigin": {
            "Source": "Unknown"
          }
        }
      ],
      "OutputSelections": [
        "Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
        "Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine"
      ],
      "Individual": "Standard_Adult_UGT",
      "Compounds": [
        {
          "Name": "Dapagliflozin",
          "CalculationMethods": [
            "Cellular partition coefficient method - Rodgers and Rowland",
            "Cellular permeability - PK-Sim Standard"
          ],
          "Alternatives": [
            {
              "AlternativeName": "Optimized",
              "GroupName": "COMPOUND_PERMEABILITY"
            },
            {
              "AlternativeName": "Optimized",
              "GroupName": "COMPOUND_INTESTINAL_PERMEABILITY"
            }
          ],
          "Processes": [
            {
              "Name": "UGT1A9-Optimized",
              "MoleculeName": "UGT1A9"
            },
            {
              "Name": "UGT2B7-Optimized",
              "MoleculeName": "UGT2B7"
            },
            {
              "Name": "Hepatic-CYP-Optimized",
              "MoleculeName": "Hepatic-CYP"
            },
            {
              "Name": "Glomerular Filtration-assumed"
            }
          ],
          "Protocol": {
            "Name": "PO MD 50 mg",
            "Formulations": [
              {
                "Name": "Solution",
                "Key": "Formulation"
              }
            ]
          }
        }
      ],
      "HasResults": true,
      "IndividualAnalyses": [
        {
          "Axes": [
            {
              "Unit": "h",
              "Dimension": "Time",
              "Type": "X",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "None",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            },
            {
              "Unit": "µg/l",
              "Dimension": "Concentration (molar)",
              "Type": "Y",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Solid",
              "Scaling": "Log",
              "NumberMode": "Normal"
            },
            {
              "Unit": "",
              "Type": "Y2",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Dash",
              "Scaling": "Log",
              "NumberMode": "Normal"
            }
          ],
          "Curves": [
            {
              "Name": "PO MD 50 mg (perm)-Dapagliflozin-Peripheral Venous Blood-Plasma-Concentration",
              "X": "Time",
              "Y": "PO MD 50 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
              "CurveOptions": {
                "Color": "#FF0000",
                "LegendIndex": 1
              }
            },
            {
              "Name": "Komoroski 2009 - MAD 50 mg (day 1) - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=6)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
              "X": "Komoroski 2009 - MAD 50 mg (day 1) - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=6)|Time",
              "Y": "Komoroski 2009 - MAD 50 mg (day 1) - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "Color": "#0000FF",
                "LegendIndex": 2,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            },
            {
              "Name": "Komoroski 2009 - MAD 50 mg (day 7 and day 14) - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=6)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
              "X": "Komoroski 2009 - MAD 50 mg (day 7 and day 14) - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=6)|Time",
              "Y": "Komoroski 2009 - MAD 50 mg (day 7 and day 14) - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "Color": "#0000FF",
                "LegendIndex": 3,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            }
          ],
          "Name": "PO MD 50 mg (perm)",
          "Title": "PO MD 20 mg (perm)",
          "OriginText": "Dapagliflozin\nPO MD 50 mg (perm)\n2019-08-19 17:46"
        },
        {
          "Axes": [
            {
              "Unit": "h",
              "Dimension": "Time",
              "Type": "X",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "None",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            },
            {
              "Unit": "µg/l",
              "Dimension": "Concentration (molar)",
              "Type": "Y",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Solid",
              "Scaling": "Linear",
              "NumberMode": "Normal"
            },
            {
              "Unit": "",
              "Type": "Y2",
              "GridLines": false,
              "Visible": true,
              "DefaultColor": "#FFFFFF",
              "DefaultLineStyle": "Dash",
              "Scaling": "Log",
              "NumberMode": "Normal"
            }
          ],
          "Curves": [
            {
              "Name": "PO MD 50 mg (perm)-Dapagliflozin-Peripheral Venous Blood-Plasma-Concentration",
              "X": "Time",
              "Y": "PO MD 50 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
              "CurveOptions": {
                "Color": "#FF0000",
                "LegendIndex": 1
              }
            },
            {
              "Name": "Komoroski 2009 - MAD 50 mg (day 1) - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=6)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
              "X": "Komoroski 2009 - MAD 50 mg (day 1) - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=6)|Time",
              "Y": "Komoroski 2009 - MAD 50 mg (day 1) - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "Color": "#0000FF",
                "LegendIndex": 2,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            },
            {
              "Name": "Komoroski 2009 - MAD 50 mg (day 7 and day 14) - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=6)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
              "X": "Komoroski 2009 - MAD 50 mg (day 7 and day 14) - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=6)|Time",
              "Y": "Komoroski 2009 - MAD 50 mg (day 7 and day 14) - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
              "CurveOptions": {
                "Color": "#0000FF",
                "LegendIndex": 3,
                "LineStyle": "None",
                "Symbol": "Circle"
              }
            }
          ],
          "Name": "PO MD 50 mg (perm) 1",
          "Title": "PO MD 50 mg (perm)",
          "OriginText": "Dapagliflozin\nPO MD 50 mg (perm)\n2019-08-19 17:46"
        }
      ]
    }
  ],
  "ParameterIdentifications": [
    {
      "Name": "PI full  (perm)",
      "Simulations": [
        "IV 0.08 mg (perm)",
        "PO SD 10 mg (perm)",
        "PO SD 50 mg (perm)",
        "PO SD 100 mg (perm)",
        "PO SD 2.5 mg (perm)",
        "PO SD 20 mg (perm)",
        "PO SD 250 mg (perm)",
        "PO SD 5 mg (perm)",
        "PO SD 500 mg (perm)"
      ],
      "Configuration": {
        "LLOQMode": "OnlyObservedData",
        "RemoveLLOQMode": "Never",
        "CalculateJacobian": true,
        "Algorithm": {
          "Name": "Levenberg - Marquardt (MPFit)",
          "Properties": [
            {
              "Name": "ftol",
              "Value": 0.001
            },
            {
              "Name": "xtol",
              "Value": 1E-06
            },
            {
              "Name": "gtol",
              "Value": 1E-10
            },
            {
              "Name": "stepfactor",
              "Value": 100.0
            },
            {
              "Name": "maxiter",
              "Value": 200.0
            },
            {
              "Name": "maxfev",
              "Value": 0.0
            },
            {
              "Name": "epsfcn",
              "Value": 1E-09
            }
          ]
        }
      },
      "OutputMappings": [
        {
          "Scaling": "Log",
          "Path": "PO SD 50 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Kasichayanula 2013b - Healthy subjects with normal kidney function - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=8)"
        },
        {
          "Scaling": "Log",
          "Path": "PO SD 50 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Kasichayanula 2011b - Study 1: 50 mg Control (Perpetrator Placebo) - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=24)"
        },
        {
          "Scaling": "Linear",
          "Weight": 0.0,
          "Path": "PO SD 50 mg (perm)|Organism|Lumen|Feces|Dapagliflozin|Fraction excreted to feces",
          "ObservedData": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin Feces - Dapagliflozin - PO - 50 mg - Feces - agg. (n=6)"
        },
        {
          "Scaling": "Linear",
          "Weight": 10.0,
          "Path": "PO SD 50 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
          "ObservedData": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin Urine - Dapagliflozin - PO - 50 mg - Urine - agg. (n=6)"
        },
        {
          "Scaling": "Log",
          "Path": "PO SD 10 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Kasichayanula 2011c - Healthy Volunteers - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=6)"
        },
        {
          "Scaling": "Log",
          "Path": "PO SD 10 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Vakkalagadda 2016 - Dapagliflozin - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=42)"
        },
        {
          "Scaling": "Log",
          "Path": "PO SD 10 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Kasichayanula 2013a - Study 2: Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=16)"
        },
        {
          "Scaling": "Log",
          "Path": "PO SD 10 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Kasichayanula 2013a - Study 1: Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=14)"
        },
        {
          "Scaling": "Log",
          "Path": "PO SD 10 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Kasichayanula 2011a - fasted - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=14)"
        },
        {
          "Scaling": "Log",
          "Path": "PO SD 10 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Imamura 2013 - Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=22)"
        },
        {
          "Scaling": "Log",
          "Path": "PO SD 10 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Boulton 2013 - Dapagliflozin po - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=7)"
        },
        {
          "Scaling": "Log",
          "Path": "IV 0.08 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Boulton 2013 - 14C-dapagliflozin iv - Dapagliflozin - IV - 0.08 mg - Plasma - agg. (n=7)"
        },
        {
          "Scaling": "Linear",
          "Weight": 10.0,
          "Path": "PO SD 50 mg (perm)|Organism|Dapagliflozin-UGT1A9-Optimized Metabolite|Total fraction of dose-Dapagliflozin",
          "ObservedData": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin 3OG Gluc (incl. unchanged feces exret.) - Dapagliflozin-3-O-glucuronide - PO - 50 mg - Fraction - agg. (n=6)"
        },
        {
          "Scaling": "Linear",
          "Weight": 10.0,
          "Path": "PO SD 50 mg (perm)|Organism|Dapagliflozin-UGT2B7-Optimized Metabolite|Total fraction of dose-Dapagliflozin",
          "ObservedData": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin 2OG Gluc (incl. unchanged feces exret.) - Dapagliflozin-2-O-glucuronide - PO - 50 mg - Fraction - agg. (n=6)"
        },
        {
          "Scaling": "Linear",
          "Weight": 10.0,
          "Path": "PO SD 50 mg (perm)|Organism|Dapagliflozin-Hepatic-CYP-Optimized Metabolite|Total fraction of dose-Dapagliflozin",
          "ObservedData": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin oxid Metab - Dapagliflozin oxidative metabolites - PO - 50 mg - Fraction - agg. (n=6)"
        },
        {
          "Scaling": "Log",
          "Path": "PO SD 100 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Komoroski 2009 - SAD 100 mg - Dapagliflozin - PO - 100 mg - Plasma - agg. (n=6)"
        },
        {
          "Scaling": "Log",
          "Path": "PO SD 2.5 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Komoroski 2009 - SAD 2.5 mg - Dapagliflozin - PO - 2.5 mg - Plasma - agg. (n=6)"
        },
        {
          "Scaling": "Log",
          "Path": "PO SD 20 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Kasichayanula 2012 - Study 1: Control (Perpetrator Placebo) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=24)"
        },
        {
          "Scaling": "Log",
          "Path": "PO SD 20 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Komoroski 2009 - SAD 20 mg - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=6)"
        },
        {
          "Scaling": "Log",
          "Path": "PO SD 250 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Komoroski 2009 - SAD 250 mg fasted - Dapagliflozin - PO - 250 mg - Plasma - agg. (n=6)"
        },
        {
          "Scaling": "Log",
          "Path": "PO SD 5 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Komoroski 2009 - SAD 5 mg - Dapagliflozin - PO - 5 mg - Plasma - agg. (n=6)"
        },
        {
          "Scaling": "Log",
          "Path": "PO SD 500 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Komoroski 2009 - SAD 500 mg - Dapagliflozin - PO - 500 mg - Plasma - agg. (n=6)"
        },
        {
          "Scaling": "Linear",
          "Path": "PO SD 2.5 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
          "ObservedData": "Komoroski 2009 - SAD 2.5 mg (Urine) - Dapagliflozin - PO - 2.5 mg - Urine - agg. (n=6)"
        },
        {
          "Scaling": "Linear",
          "Path": "PO SD 5 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
          "ObservedData": "Komoroski 2009 - SAD 5 mg (Urine) - Dapagliflozin - PO - 5 mg - Urine - agg. (n=6)"
        },
        {
          "Scaling": "Linear",
          "Path": "PO SD 10 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
          "ObservedData": "Komoroski 2009 - SAD 10 mg (Urine) - Dapagliflozin - PO - 10 mg - Urine - agg. (n=6)"
        },
        {
          "Scaling": "Linear",
          "Path": "PO SD 20 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
          "ObservedData": "Komoroski 2009 - SAD 20 mg (Urine) - Dapagliflozin - PO - 20 mg - Urine - agg. (n=6)"
        },
        {
          "Scaling": "Linear",
          "Path": "PO SD 50 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
          "ObservedData": "Komoroski 2009 - SAD 50 mg (Urine) - Dapagliflozin - PO - 50 mg - Urine - agg. (n=6)"
        },
        {
          "Scaling": "Linear",
          "Path": "PO SD 100 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
          "ObservedData": "Komoroski 2009 - SAD 100 mg (Urine) - Dapagliflozin - PO - 100 mg - Urine - agg. (n=6)"
        },
        {
          "Scaling": "Linear",
          "Path": "PO SD 250 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
          "ObservedData": "Komoroski 2009 - SAD 250 mg fasted (Urine) - Dapagliflozin - PO - 250 mg - Urine - agg. (n=6)"
        },
        {
          "Scaling": "Linear",
          "Path": "PO SD 500 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
          "ObservedData": "Komoroski 2009 - SAD 500 mg (Urine) - Dapagliflozin - PO - 500 mg - Urine - agg. (n=6)"
        },
        {
          "Scaling": "Log",
          "Path": "PO SD 2.5 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Komoroski 2009 - MAD 2.5 mg (day 1) - Dapagliflozin - PO - 2.5 mg - Plasma - agg. (n=6)"
        },
        {
          "Scaling": "Log",
          "Path": "PO SD 10 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Komoroski 2009 - MAD 10 mg (day 1) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=6)"
        },
        {
          "Scaling": "Log",
          "Path": "PO SD 20 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Komoroski 2009 - MAD 20 mg (day 1) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=6)"
        },
        {
          "Scaling": "Log",
          "Path": "PO SD 50 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Komoroski 2009 - MAD 50 mg (day 1) - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=6)"
        },
        {
          "Scaling": "Log",
          "Path": "PO SD 100 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Komoroski 2009 - MAD 100 mg (day 1) - Dapagliflozin - PO - 100 mg - Plasma - agg. (n=6)"
        }
      ],
      "IdentificationParameters": [
        {
          "Name": "Lipophilicity",
          "Scaling": "Linear",
          "LinkedParameters": [
            "IV 0.08 mg (perm)|Dapagliflozin|Lipophilicity",
            "PO SD 10 mg (perm)|Dapagliflozin|Lipophilicity",
            "PO SD 50 mg (perm)|Dapagliflozin|Lipophilicity",
            "PO SD 100 mg (perm)|Dapagliflozin|Lipophilicity",
            "PO SD 2.5 mg (perm)|Dapagliflozin|Lipophilicity",
            "PO SD 20 mg (perm)|Dapagliflozin|Lipophilicity",
            "PO SD 250 mg (perm)|Dapagliflozin|Lipophilicity",
            "PO SD 5 mg (perm)|Dapagliflozin|Lipophilicity",
            "PO SD 500 mg (perm)|Dapagliflozin|Lipophilicity"
          ],
          "Parameters": [
            {
              "Name": "Start value",
              "Value": 2.546,
              "Unit": "Log Units"
            },
            {
              "Name": "MinValue",
              "Value": 1.0,
              "Unit": "Log Units"
            },
            {
              "Name": "MaxValue",
              "Value": 4.0,
              "Unit": "Log Units"
            }
          ]
        },
        {
          "Name": "P int",
          "Scaling": "Log",
          "LinkedParameters": [
            "IV 0.08 mg (perm)|Dapagliflozin|Specific intestinal permeability (transcellular)",
            "PO SD 10 mg (perm)|Dapagliflozin|Specific intestinal permeability (transcellular)",
            "PO SD 50 mg (perm)|Dapagliflozin|Specific intestinal permeability (transcellular)",
            "PO SD 100 mg (perm)|Dapagliflozin|Specific intestinal permeability (transcellular)",
            "PO SD 2.5 mg (perm)|Dapagliflozin|Specific intestinal permeability (transcellular)",
            "PO SD 20 mg (perm)|Dapagliflozin|Specific intestinal permeability (transcellular)",
            "PO SD 250 mg (perm)|Dapagliflozin|Specific intestinal permeability (transcellular)",
            "PO SD 5 mg (perm)|Dapagliflozin|Specific intestinal permeability (transcellular)",
            "PO SD 500 mg (perm)|Dapagliflozin|Specific intestinal permeability (transcellular)"
          ],
          "Parameters": [
            {
              "Name": "Start value",
              "Value": 4E-05,
              "Unit": "cm/min"
            },
            {
              "Name": "MinValue",
              "Value": 1E-06,
              "Unit": "cm/min"
            },
            {
              "Name": "MaxValue",
              "Value": 0.01,
              "Unit": "cm/min"
            }
          ]
        },
        {
          "Name": "UGT1A9",
          "Scaling": "Log",
          "LinkedParameters": [
            "IV 0.08 mg (perm)|Dapagliflozin-UGT1A9-Optimized|CLspec/[Enzyme]",
            "PO SD 10 mg (perm)|Dapagliflozin-UGT1A9-Optimized|CLspec/[Enzyme]",
            "PO SD 50 mg (perm)|Dapagliflozin-UGT1A9-Optimized|CLspec/[Enzyme]",
            "PO SD 100 mg (perm)|Dapagliflozin-UGT1A9-Optimized|CLspec/[Enzyme]",
            "PO SD 2.5 mg (perm)|Dapagliflozin-UGT1A9-Optimized|CLspec/[Enzyme]",
            "PO SD 20 mg (perm)|Dapagliflozin-UGT1A9-Optimized|CLspec/[Enzyme]",
            "PO SD 250 mg (perm)|Dapagliflozin-UGT1A9-Optimized|CLspec/[Enzyme]",
            "PO SD 5 mg (perm)|Dapagliflozin-UGT1A9-Optimized|CLspec/[Enzyme]",
            "PO SD 500 mg (perm)|Dapagliflozin-UGT1A9-Optimized|CLspec/[Enzyme]"
          ],
          "Parameters": [
            {
              "Name": "Start value",
              "Value": 0.4,
              "Unit": "l/µmol/min"
            },
            {
              "Name": "MinValue",
              "Value": 0.001,
              "Unit": "l/µmol/min"
            },
            {
              "Name": "MaxValue",
              "Value": 100.0,
              "Unit": "l/µmol/min"
            }
          ]
        },
        {
          "Name": "UGT2B7",
          "Scaling": "Log",
          "LinkedParameters": [
            "IV 0.08 mg (perm)|Dapagliflozin-UGT2B7-Optimized|CLspec/[Enzyme]",
            "PO SD 10 mg (perm)|Dapagliflozin-UGT2B7-Optimized|CLspec/[Enzyme]",
            "PO SD 50 mg (perm)|Dapagliflozin-UGT2B7-Optimized|CLspec/[Enzyme]",
            "PO SD 100 mg (perm)|Dapagliflozin-UGT2B7-Optimized|CLspec/[Enzyme]",
            "PO SD 2.5 mg (perm)|Dapagliflozin-UGT2B7-Optimized|CLspec/[Enzyme]",
            "PO SD 20 mg (perm)|Dapagliflozin-UGT2B7-Optimized|CLspec/[Enzyme]",
            "PO SD 250 mg (perm)|Dapagliflozin-UGT2B7-Optimized|CLspec/[Enzyme]",
            "PO SD 5 mg (perm)|Dapagliflozin-UGT2B7-Optimized|CLspec/[Enzyme]",
            "PO SD 500 mg (perm)|Dapagliflozin-UGT2B7-Optimized|CLspec/[Enzyme]"
          ],
          "Parameters": [
            {
              "Name": "Start value",
              "Value": 0.02,
              "Unit": "l/µmol/min"
            },
            {
              "Name": "MinValue",
              "Value": 0.001,
              "Unit": "l/µmol/min"
            },
            {
              "Name": "MaxValue",
              "Value": 100.0,
              "Unit": "l/µmol/min"
            }
          ]
        },
        {
          "Name": "Hep-CYP",
          "Scaling": "Log",
          "LinkedParameters": [
            "IV 0.08 mg (perm)|Dapagliflozin-Hepatic-CYP-Optimized|CLspec/[Enzyme]",
            "PO SD 10 mg (perm)|Dapagliflozin-Hepatic-CYP-Optimized|CLspec/[Enzyme]",
            "PO SD 50 mg (perm)|Dapagliflozin-Hepatic-CYP-Optimized|CLspec/[Enzyme]",
            "PO SD 100 mg (perm)|Dapagliflozin-Hepatic-CYP-Optimized|CLspec/[Enzyme]",
            "PO SD 2.5 mg (perm)|Dapagliflozin-Hepatic-CYP-Optimized|CLspec/[Enzyme]",
            "PO SD 20 mg (perm)|Dapagliflozin-Hepatic-CYP-Optimized|CLspec/[Enzyme]",
            "PO SD 250 mg (perm)|Dapagliflozin-Hepatic-CYP-Optimized|CLspec/[Enzyme]",
            "PO SD 5 mg (perm)|Dapagliflozin-Hepatic-CYP-Optimized|CLspec/[Enzyme]",
            "PO SD 500 mg (perm)|Dapagliflozin-Hepatic-CYP-Optimized|CLspec/[Enzyme]"
          ],
          "Parameters": [
            {
              "Name": "Start value",
              "Value": 0.15,
              "Unit": "l/µmol/min"
            },
            {
              "Name": "MinValue",
              "Value": 0.001,
              "Unit": "l/µmol/min"
            },
            {
              "Name": "MaxValue",
              "Value": 100.0,
              "Unit": "l/µmol/min"
            }
          ]
        },
        {
          "Name": "Solubility",
          "Scaling": "Log",
          "LinkedParameters": [
            "IV 0.08 mg (perm)|Dapagliflozin|Solubility at reference pH",
            "PO SD 10 mg (perm)|Dapagliflozin|Solubility at reference pH",
            "PO SD 50 mg (perm)|Dapagliflozin|Solubility at reference pH",
            "PO SD 100 mg (perm)|Dapagliflozin|Solubility at reference pH",
            "PO SD 2.5 mg (perm)|Dapagliflozin|Solubility at reference pH",
            "PO SD 20 mg (perm)|Dapagliflozin|Solubility at reference pH",
            "PO SD 250 mg (perm)|Dapagliflozin|Solubility at reference pH",
            "PO SD 5 mg (perm)|Dapagliflozin|Solubility at reference pH",
            "PO SD 500 mg (perm)|Dapagliflozin|Solubility at reference pH"
          ],
          "Parameters": [
            {
              "Name": "Start value",
              "Value": 0.173,
              "Unit": "mg/ml"
            },
            {
              "Name": "MinValue",
              "Value": 0.01,
              "Unit": "mg/ml"
            },
            {
              "Name": "MaxValue",
              "Value": 100.0,
              "Unit": "mg/ml"
            }
          ]
        },
        {
          "Name": "Permeability",
          "Scaling": "Log",
          "LinkedParameters": [
            "IV 0.08 mg (perm)|Dapagliflozin|Permeability",
            "PO SD 10 mg (perm)|Dapagliflozin|Permeability",
            "PO SD 50 mg (perm)|Dapagliflozin|Permeability",
            "PO SD 100 mg (perm)|Dapagliflozin|Permeability",
            "PO SD 2.5 mg (perm)|Dapagliflozin|Permeability",
            "PO SD 20 mg (perm)|Dapagliflozin|Permeability",
            "PO SD 250 mg (perm)|Dapagliflozin|Permeability",
            "PO SD 5 mg (perm)|Dapagliflozin|Permeability",
            "PO SD 500 mg (perm)|Dapagliflozin|Permeability"
          ],
          "Parameters": [
            {
              "Name": "Start value",
              "Value": 0.0004257,
              "Unit": "cm/min"
            },
            {
              "Name": "MinValue",
              "Value": 1E-06,
              "Unit": "cm/min"
            },
            {
              "Name": "MaxValue",
              "Value": 0.01,
              "Unit": "cm/min"
            }
          ]
        },
        {
          "Name": "logP (veg.oil/water)",
          "Scaling": "Linear",
          "LinkedParameters": [
            "IV 0.08 mg (perm)|Dapagliflozin|logP (veg.oil/water)",
            "PO SD 10 mg (perm)|Dapagliflozin|logP (veg.oil/water)",
            "PO SD 50 mg (perm)|Dapagliflozin|logP (veg.oil/water)",
            "PO SD 100 mg (perm)|Dapagliflozin|logP (veg.oil/water)",
            "PO SD 2.5 mg (perm)|Dapagliflozin|logP (veg.oil/water)",
            "PO SD 20 mg (perm)|Dapagliflozin|logP (veg.oil/water)",
            "PO SD 250 mg (perm)|Dapagliflozin|logP (veg.oil/water)",
            "PO SD 5 mg (perm)|Dapagliflozin|logP (veg.oil/water)",
            "PO SD 500 mg (perm)|Dapagliflozin|logP (veg.oil/water)"
          ],
          "Parameters": [
            {
              "Name": "Start value",
              "Value": 2.053,
              "Unit": "Log Units"
            },
            {
              "Name": "MinValue",
              "Value": 0.0,
              "Unit": "Log Units"
            },
            {
              "Name": "MaxValue",
              "Value": 4.0,
              "Unit": "Log Units"
            }
          ]
        },
        {
          "Name": "GFR fraction",
          "Scaling": "Linear",
          "LinkedParameters": [
            "IV 0.08 mg (perm)|Neighborhoods|Kidney_pls_Kidney_ur|Dapagliflozin|Glomerular Filtration-assumed|GFR fraction",
            "PO SD 10 mg (perm)|Neighborhoods|Kidney_pls_Kidney_ur|Dapagliflozin|Glomerular Filtration-assumed|GFR fraction",
            "PO SD 50 mg (perm)|Neighborhoods|Kidney_pls_Kidney_ur|Dapagliflozin|Glomerular Filtration-assumed|GFR fraction",
            "PO SD 100 mg (perm)|Neighborhoods|Kidney_pls_Kidney_ur|Dapagliflozin|Glomerular Filtration-assumed|GFR fraction",
            "PO SD 2.5 mg (perm)|Neighborhoods|Kidney_pls_Kidney_ur|Dapagliflozin|Glomerular Filtration-assumed|GFR fraction",
            "PO SD 20 mg (perm)|Neighborhoods|Kidney_pls_Kidney_ur|Dapagliflozin|Glomerular Filtration-assumed|GFR fraction",
            "PO SD 250 mg (perm)|Neighborhoods|Kidney_pls_Kidney_ur|Dapagliflozin|Glomerular Filtration-assumed|GFR fraction",
            "PO SD 5 mg (perm)|Neighborhoods|Kidney_pls_Kidney_ur|Dapagliflozin|Glomerular Filtration-assumed|GFR fraction",
            "PO SD 500 mg (perm)|Neighborhoods|Kidney_pls_Kidney_ur|Dapagliflozin|Glomerular Filtration-assumed|GFR fraction"
          ],
          "Parameters": [
            {
              "Name": "Start value",
              "Value": 1.0
            },
            {
              "Name": "MinValue",
              "Value": 0.1
            },
            {
              "Name": "MaxValue",
              "Value": 10.0
            }
          ]
        },
        {
          "Name": "Blood/Plasma concentration ratio",
          "Scaling": "Linear",
          "IsFixed": true,
          "LinkedParameters": [
            "IV 0.08 mg (perm)|Dapagliflozin|Blood/Plasma concentration ratio",
            "PO SD 10 mg (perm)|Dapagliflozin|Blood/Plasma concentration ratio",
            "PO SD 50 mg (perm)|Dapagliflozin|Blood/Plasma concentration ratio",
            "PO SD 100 mg (perm)|Dapagliflozin|Blood/Plasma concentration ratio",
            "PO SD 2.5 mg (perm)|Dapagliflozin|Blood/Plasma concentration ratio",
            "PO SD 20 mg (perm)|Dapagliflozin|Blood/Plasma concentration ratio",
            "PO SD 250 mg (perm)|Dapagliflozin|Blood/Plasma concentration ratio",
            "PO SD 5 mg (perm)|Dapagliflozin|Blood/Plasma concentration ratio",
            "PO SD 500 mg (perm)|Dapagliflozin|Blood/Plasma concentration ratio"
          ],
          "Parameters": [
            {
              "Name": "Start value",
              "Value": 0.88
            },
            {
              "Name": "MinValue",
              "Value": 0.0
            },
            {
              "Name": "MaxValue",
              "Value": 6.1244936725
            }
          ]
        }
      ],
      "Analyses": [
        {
          "Name": "Time Profile",
          "Type": "ParameterIdentificationTimeProfileChart",
          "Chart": {
            "Axes": [
              {
                "Unit": "h",
                "Dimension": "Time",
                "Type": "X",
                "GridLines": false,
                "Visible": true,
                "Min": 0.0,
                "Max": 24.0,
                "DefaultColor": "#FFFFFF",
                "DefaultLineStyle": "None",
                "Scaling": "Linear",
                "NumberMode": "Normal"
              },
              {
                "Unit": "mg/l",
                "Dimension": "Concentration (mass)",
                "Type": "Y",
                "GridLines": false,
                "Visible": true,
                "Min": 0.0001,
                "Max": 5.0,
                "DefaultColor": "#FFFFFF",
                "DefaultLineStyle": "Solid",
                "Scaling": "Log",
                "NumberMode": "Normal"
              },
              {
                "Unit": "%",
                "Dimension": "Fraction",
                "Type": "Y2",
                "GridLines": false,
                "Visible": true,
                "DefaultColor": "#FFFFFF",
                "DefaultLineStyle": "Dash",
                "Scaling": "Linear",
                "NumberMode": "Normal"
              }
            ],
            "Curves": [
              {
                "Name": "Kasichayanula 2013b - Healthy subjects with normal kidney function - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=8)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
                "X": "Kasichayanula 2013b - Healthy subjects with normal kidney function - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=8)|Time",
                "Y": "Kasichayanula 2013b - Healthy subjects with normal kidney function - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=8)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "VisibleInLegend": false,
                  "Color": "#FF0000",
                  "LegendIndex": 1,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Kasichayanula 2011b - Study 1: 50 mg Control (Perpetrator Placebo) - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=24)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
                "X": "Kasichayanula 2011b - Study 1: 50 mg Control (Perpetrator Placebo) - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=24)|Time",
                "Y": "Kasichayanula 2011b - Study 1: 50 mg Control (Perpetrator Placebo) - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=24)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "VisibleInLegend": false,
                  "Color": "#FF0000",
                  "LegendIndex": 2,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Komoroski 2009 - MAD 50 mg (day 1) - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=6)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
                "X": "Komoroski 2009 - MAD 50 mg (day 1) - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=6)|Time",
                "Y": "Komoroski 2009 - MAD 50 mg (day 1) - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "VisibleInLegend": false,
                  "Color": "#FF0000",
                  "LegendIndex": 3,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin Feces - Dapagliflozin - PO - 50 mg - Feces - agg. (n=6)-Dapagliflozin-Lumen-Feces-ArithmeticMean",
                "X": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin Feces - Dapagliflozin - PO - 50 mg - Feces - agg. (n=6)|Time",
                "Y": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin Feces - Dapagliflozin - PO - 50 mg - Feces - agg. (n=6)|ObservedData|Lumen|Feces|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "VisibleInLegend": false,
                  "Color": "#0000FF",
                  "LegendIndex": 4,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin Urine - Dapagliflozin - PO - 50 mg - Urine - agg. (n=6)-Dapagliflozin-Kidney-Urine-ArithmeticMean",
                "X": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin Urine - Dapagliflozin - PO - 50 mg - Urine - agg. (n=6)|Time",
                "Y": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin Urine - Dapagliflozin - PO - 50 mg - Urine - agg. (n=6)|ObservedData|Kidney|Urine|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "VisibleInLegend": false,
                  "Color": "#008000",
                  "LegendIndex": 5,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Komoroski 2009 - SAD 50 mg (Urine) - Dapagliflozin - PO - 50 mg - Urine - agg. (n=6)-Dapagliflozin-Kidney-Urine-ArithmeticMean",
                "X": "Komoroski 2009 - SAD 50 mg (Urine) - Dapagliflozin - PO - 50 mg - Urine - agg. (n=6)|Time",
                "Y": "Komoroski 2009 - SAD 50 mg (Urine) - Dapagliflozin - PO - 50 mg - Urine - agg. (n=6)|ObservedData|Kidney|Urine|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "VisibleInLegend": false,
                  "Color": "#008000",
                  "LegendIndex": 6,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Kasichayanula 2011c - Healthy Volunteers - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=6)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
                "X": "Kasichayanula 2011c - Healthy Volunteers - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=6)|Time",
                "Y": "Kasichayanula 2011c - Healthy Volunteers - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "VisibleInLegend": false,
                  "Color": "#FF00FF",
                  "LegendIndex": 7,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Vakkalagadda 2016 - Dapagliflozin - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=42)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
                "X": "Vakkalagadda 2016 - Dapagliflozin - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=42)|Time",
                "Y": "Vakkalagadda 2016 - Dapagliflozin - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=42)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "VisibleInLegend": false,
                  "Color": "#FF00FF",
                  "LegendIndex": 8,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Kasichayanula 2013a - Study 2: Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=16)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
                "X": "Kasichayanula 2013a - Study 2: Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=16)|Time",
                "Y": "Kasichayanula 2013a - Study 2: Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=16)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "VisibleInLegend": false,
                  "Color": "#FF00FF",
                  "LegendIndex": 9,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Kasichayanula 2013a - Study 1: Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=14)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
                "X": "Kasichayanula 2013a - Study 1: Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=14)|Time",
                "Y": "Kasichayanula 2013a - Study 1: Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=14)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "VisibleInLegend": false,
                  "Color": "#FF00FF",
                  "LegendIndex": 10,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Kasichayanula 2011a - fasted - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=14)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
                "X": "Kasichayanula 2011a - fasted - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=14)|Time",
                "Y": "Kasichayanula 2011a - fasted - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=14)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "VisibleInLegend": false,
                  "Color": "#FF00FF",
                  "LegendIndex": 11,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Imamura 2013 - Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=22)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
                "X": "Imamura 2013 - Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=22)|Time",
                "Y": "Imamura 2013 - Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=22)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "VisibleInLegend": false,
                  "Color": "#FF00FF",
                  "LegendIndex": 12,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Boulton 2013 - Dapagliflozin po - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=7)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
                "X": "Boulton 2013 - Dapagliflozin po - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=7)|Time",
                "Y": "Boulton 2013 - Dapagliflozin po - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=7)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "VisibleInLegend": false,
                  "Color": "#FF00FF",
                  "LegendIndex": 13,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Komoroski 2009 - MAD 10 mg (day 1) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=6)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
                "X": "Komoroski 2009 - MAD 10 mg (day 1) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=6)|Time",
                "Y": "Komoroski 2009 - MAD 10 mg (day 1) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "VisibleInLegend": false,
                  "Color": "#FF00FF",
                  "LegendIndex": 14,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Boulton 2013 - 14C-dapagliflozin iv - Dapagliflozin - IV - 0.08 mg - Plasma - agg. (n=7)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
                "X": "Boulton 2013 - 14C-dapagliflozin iv - Dapagliflozin - IV - 0.08 mg - Plasma - agg. (n=7)|Time",
                "Y": "Boulton 2013 - 14C-dapagliflozin iv - Dapagliflozin - IV - 0.08 mg - Plasma - agg. (n=7)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "VisibleInLegend": false,
                  "Color": "#FF8000",
                  "LegendIndex": 15,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin 3OG Gluc (incl. unchanged feces exret.) - Dapagliflozin-3-O-glucuronide - PO - 50 mg - Fraction - agg. (n=6)-Dapagliflozin-3-O-glucuronide-Undefined-Undefined-ArithmeticMean",
                "X": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin 3OG Gluc (incl. unchanged feces exret.) - Dapagliflozin-3-O-glucuronide - PO - 50 mg - Fraction - agg. (n=6)|Time",
                "Y": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin 3OG Gluc (incl. unchanged feces exret.) - Dapagliflozin-3-O-glucuronide - PO - 50 mg - Fraction - agg. (n=6)|ObservedData|Undefined|Undefined|Dapagliflozin-3-O-glucuronide|ArithmeticMean",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "VisibleInLegend": false,
                  "Color": "#00C0C0",
                  "LegendIndex": 16,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin 2OG Gluc (incl. unchanged feces exret.) - Dapagliflozin-2-O-glucuronide - PO - 50 mg - Fraction - agg. (n=6)-Dapagliflozin-2-O-glucuronide-Undefined-Undefined-ArithmeticMean",
                "X": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin 2OG Gluc (incl. unchanged feces exret.) - Dapagliflozin-2-O-glucuronide - PO - 50 mg - Fraction - agg. (n=6)|Time",
                "Y": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin 2OG Gluc (incl. unchanged feces exret.) - Dapagliflozin-2-O-glucuronide - PO - 50 mg - Fraction - agg. (n=6)|ObservedData|Undefined|Undefined|Dapagliflozin-2-O-glucuronide|ArithmeticMean",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "VisibleInLegend": false,
                  "Color": "#C000C0",
                  "LegendIndex": 17,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin oxid Metab - Dapagliflozin oxidative metabolites - PO - 50 mg - Fraction - agg. (n=6)-Dapagliflozin oxidative metabolites-Undefined-Undefined-ArithmeticMean",
                "X": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin oxid Metab - Dapagliflozin oxidative metabolites - PO - 50 mg - Fraction - agg. (n=6)|Time",
                "Y": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin oxid Metab - Dapagliflozin oxidative metabolites - PO - 50 mg - Fraction - agg. (n=6)|ObservedData|Undefined|Undefined|Dapagliflozin oxidative metabolites|ArithmeticMean",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "VisibleInLegend": false,
                  "Color": "#C04000",
                  "LegendIndex": 18,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Komoroski 2009 - SAD 100 mg - Dapagliflozin - PO - 100 mg - Plasma - agg. (n=6)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
                "X": "Komoroski 2009 - SAD 100 mg - Dapagliflozin - PO - 100 mg - Plasma - agg. (n=6)|Time",
                "Y": "Komoroski 2009 - SAD 100 mg - Dapagliflozin - PO - 100 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "VisibleInLegend": false,
                  "Color": "#00FF00",
                  "LegendIndex": 19,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Komoroski 2009 - MAD 100 mg (day 1) - Dapagliflozin - PO - 100 mg - Plasma - agg. (n=6)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
                "X": "Komoroski 2009 - MAD 100 mg (day 1) - Dapagliflozin - PO - 100 mg - Plasma - agg. (n=6)|Time",
                "Y": "Komoroski 2009 - MAD 100 mg (day 1) - Dapagliflozin - PO - 100 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "VisibleInLegend": false,
                  "Color": "#00FF00",
                  "LegendIndex": 20,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Komoroski 2009 - SAD 2.5 mg - Dapagliflozin - PO - 2.5 mg - Plasma - agg. (n=6)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
                "X": "Komoroski 2009 - SAD 2.5 mg - Dapagliflozin - PO - 2.5 mg - Plasma - agg. (n=6)|Time",
                "Y": "Komoroski 2009 - SAD 2.5 mg - Dapagliflozin - PO - 2.5 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "VisibleInLegend": false,
                  "Color": "#808080",
                  "LegendIndex": 21,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Komoroski 2009 - MAD 2.5 mg (day 1) - Dapagliflozin - PO - 2.5 mg - Plasma - agg. (n=6)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
                "X": "Komoroski 2009 - MAD 2.5 mg (day 1) - Dapagliflozin - PO - 2.5 mg - Plasma - agg. (n=6)|Time",
                "Y": "Komoroski 2009 - MAD 2.5 mg (day 1) - Dapagliflozin - PO - 2.5 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "VisibleInLegend": false,
                  "Color": "#808080",
                  "LegendIndex": 22,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Kasichayanula 2012 - Study 1: Control (Perpetrator Placebo) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=24)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
                "X": "Kasichayanula 2012 - Study 1: Control (Perpetrator Placebo) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=24)|Time",
                "Y": "Kasichayanula 2012 - Study 1: Control (Perpetrator Placebo) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=24)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "VisibleInLegend": false,
                  "Color": "#C0C000",
                  "LegendIndex": 23,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Komoroski 2009 - SAD 20 mg - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=6)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
                "X": "Komoroski 2009 - SAD 20 mg - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=6)|Time",
                "Y": "Komoroski 2009 - SAD 20 mg - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "VisibleInLegend": false,
                  "Color": "#C0C000",
                  "LegendIndex": 24,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Komoroski 2009 - MAD 20 mg (day 1) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=6)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
                "X": "Komoroski 2009 - MAD 20 mg (day 1) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=6)|Time",
                "Y": "Komoroski 2009 - MAD 20 mg (day 1) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "VisibleInLegend": false,
                  "Color": "#C0C000",
                  "LegendIndex": 25,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Komoroski 2009 - SAD 250 mg fasted - Dapagliflozin - PO - 250 mg - Plasma - agg. (n=6)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
                "X": "Komoroski 2009 - SAD 250 mg fasted - Dapagliflozin - PO - 250 mg - Plasma - agg. (n=6)|Time",
                "Y": "Komoroski 2009 - SAD 250 mg fasted - Dapagliflozin - PO - 250 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "VisibleInLegend": false,
                  "Color": "#8080FF",
                  "LegendIndex": 26,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Komoroski 2009 - SAD 5 mg - Dapagliflozin - PO - 5 mg - Plasma - agg. (n=6)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
                "X": "Komoroski 2009 - SAD 5 mg - Dapagliflozin - PO - 5 mg - Plasma - agg. (n=6)|Time",
                "Y": "Komoroski 2009 - SAD 5 mg - Dapagliflozin - PO - 5 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "VisibleInLegend": false,
                  "Color": "#0000C0",
                  "LegendIndex": 27,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Komoroski 2009 - SAD 500 mg - Dapagliflozin - PO - 500 mg - Plasma - agg. (n=6)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
                "X": "Komoroski 2009 - SAD 500 mg - Dapagliflozin - PO - 500 mg - Plasma - agg. (n=6)|Time",
                "Y": "Komoroski 2009 - SAD 500 mg - Dapagliflozin - PO - 500 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "VisibleInLegend": false,
                  "Color": "#00C000",
                  "LegendIndex": 28,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Komoroski 2009 - SAD 2.5 mg (Urine) - Dapagliflozin - PO - 2.5 mg - Urine - agg. (n=6)-Dapagliflozin-Kidney-Urine-ArithmeticMean",
                "X": "Komoroski 2009 - SAD 2.5 mg (Urine) - Dapagliflozin - PO - 2.5 mg - Urine - agg. (n=6)|Time",
                "Y": "Komoroski 2009 - SAD 2.5 mg (Urine) - Dapagliflozin - PO - 2.5 mg - Urine - agg. (n=6)|ObservedData|Kidney|Urine|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "VisibleInLegend": false,
                  "Color": "#C00000",
                  "LegendIndex": 29,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Komoroski 2009 - SAD 5 mg (Urine) - Dapagliflozin - PO - 5 mg - Urine - agg. (n=6)-Dapagliflozin-Kidney-Urine-ArithmeticMean",
                "X": "Komoroski 2009 - SAD 5 mg (Urine) - Dapagliflozin - PO - 5 mg - Urine - agg. (n=6)|Time",
                "Y": "Komoroski 2009 - SAD 5 mg (Urine) - Dapagliflozin - PO - 5 mg - Urine - agg. (n=6)|ObservedData|Kidney|Urine|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "VisibleInLegend": false,
                  "Color": "#FFFF00",
                  "LegendIndex": 30,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Komoroski 2009 - SAD 10 mg (Urine) - Dapagliflozin - PO - 10 mg - Urine - agg. (n=6)-Dapagliflozin-Kidney-Urine-ArithmeticMean",
                "X": "Komoroski 2009 - SAD 10 mg (Urine) - Dapagliflozin - PO - 10 mg - Urine - agg. (n=6)|Time",
                "Y": "Komoroski 2009 - SAD 10 mg (Urine) - Dapagliflozin - PO - 10 mg - Urine - agg. (n=6)|ObservedData|Kidney|Urine|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "VisibleInLegend": false,
                  "Color": "#008080",
                  "LegendIndex": 31,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Komoroski 2009 - SAD 20 mg (Urine) - Dapagliflozin - PO - 20 mg - Urine - agg. (n=6)-Dapagliflozin-Kidney-Urine-ArithmeticMean",
                "X": "Komoroski 2009 - SAD 20 mg (Urine) - Dapagliflozin - PO - 20 mg - Urine - agg. (n=6)|Time",
                "Y": "Komoroski 2009 - SAD 20 mg (Urine) - Dapagliflozin - PO - 20 mg - Urine - agg. (n=6)|ObservedData|Kidney|Urine|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "VisibleInLegend": false,
                  "Color": "#800080",
                  "LegendIndex": 32,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Komoroski 2009 - SAD 100 mg (Urine) - Dapagliflozin - PO - 100 mg - Urine - agg. (n=6)-Dapagliflozin-Kidney-Urine-ArithmeticMean",
                "X": "Komoroski 2009 - SAD 100 mg (Urine) - Dapagliflozin - PO - 100 mg - Urine - agg. (n=6)|Time",
                "Y": "Komoroski 2009 - SAD 100 mg (Urine) - Dapagliflozin - PO - 100 mg - Urine - agg. (n=6)|ObservedData|Kidney|Urine|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "VisibleInLegend": false,
                  "Color": "#804040",
                  "LegendIndex": 33,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Komoroski 2009 - SAD 250 mg fasted (Urine) - Dapagliflozin - PO - 250 mg - Urine - agg. (n=6)-Dapagliflozin-Kidney-Urine-ArithmeticMean",
                "X": "Komoroski 2009 - SAD 250 mg fasted (Urine) - Dapagliflozin - PO - 250 mg - Urine - agg. (n=6)|Time",
                "Y": "Komoroski 2009 - SAD 250 mg fasted (Urine) - Dapagliflozin - PO - 250 mg - Urine - agg. (n=6)|ObservedData|Kidney|Urine|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "VisibleInLegend": false,
                  "Color": "#80FF80",
                  "LegendIndex": 34,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Komoroski 2009 - SAD 500 mg (Urine) - Dapagliflozin - PO - 500 mg - Urine - agg. (n=6)-Dapagliflozin-Kidney-Urine-ArithmeticMean",
                "X": "Komoroski 2009 - SAD 500 mg (Urine) - Dapagliflozin - PO - 500 mg - Urine - agg. (n=6)|Time",
                "Y": "Komoroski 2009 - SAD 500 mg (Urine) - Dapagliflozin - PO - 500 mg - Urine - agg. (n=6)|ObservedData|Kidney|Urine|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "VisibleInLegend": false,
                  "Color": "#808000",
                  "LegendIndex": 35,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "PO SD 5 mg (perm)-Dapagliflozin-Peripheral Venous Blood-Plasma-Concentration",
                "X": "Time",
                "Y": "PO SD 5 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
                "CurveOptions": {
                  "Color": "#0000C0",
                  "LegendIndex": 36
                }
              },
              {
                "Name": "PO SD 5 mg (perm)-Dapagliflozin-Kidney-Urine-Fraction excreted to urine",
                "X": "Time",
                "Y": "PO SD 5 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "Color": "#FFFF00",
                  "LegendIndex": 37,
                  "LineStyle": "Dash"
                }
              },
              {
                "Name": "IV 0.08 mg (perm)-Dapagliflozin-Peripheral Venous Blood-Plasma-Concentration",
                "X": "Time",
                "Y": "IV 0.08 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
                "CurveOptions": {
                  "Color": "#FF8000",
                  "LegendIndex": 38
                }
              },
              {
                "Name": "PO SD 500 mg (perm)-Dapagliflozin-Peripheral Venous Blood-Plasma-Concentration",
                "X": "Time",
                "Y": "PO SD 500 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
                "CurveOptions": {
                  "Color": "#00C000",
                  "LegendIndex": 39
                }
              },
              {
                "Name": "PO SD 500 mg (perm)-Dapagliflozin-Kidney-Urine-Fraction excreted to urine",
                "X": "Time",
                "Y": "PO SD 500 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "Color": "#808000",
                  "LegendIndex": 40,
                  "LineStyle": "Dash"
                }
              },
              {
                "Name": "PO SD 20 mg (perm)-Dapagliflozin-Peripheral Venous Blood-Plasma-Concentration",
                "X": "Time",
                "Y": "PO SD 20 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
                "CurveOptions": {
                  "Color": "#C0C000",
                  "LegendIndex": 41
                }
              },
              {
                "Name": "PO SD 20 mg (perm)-Dapagliflozin-Kidney-Urine-Fraction excreted to urine",
                "X": "Time",
                "Y": "PO SD 20 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "Color": "#800080",
                  "LegendIndex": 42,
                  "LineStyle": "Dash"
                }
              },
              {
                "Name": "PO SD 100 mg (perm)-Dapagliflozin-Peripheral Venous Blood-Plasma-Concentration",
                "X": "Time",
                "Y": "PO SD 100 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
                "CurveOptions": {
                  "Color": "#00FF00",
                  "LegendIndex": 43
                }
              },
              {
                "Name": "PO SD 100 mg (perm)-Dapagliflozin-Kidney-Urine-Fraction excreted to urine",
                "X": "Time",
                "Y": "PO SD 100 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "Color": "#804040",
                  "LegendIndex": 44,
                  "LineStyle": "Dash"
                }
              },
              {
                "Name": "PO SD 10 mg (perm)-Dapagliflozin-Peripheral Venous Blood-Plasma-Concentration",
                "X": "Time",
                "Y": "PO SD 10 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
                "CurveOptions": {
                  "Color": "#FF00FF",
                  "LegendIndex": 45
                }
              },
              {
                "Name": "PO SD 10 mg (perm)-Dapagliflozin-Kidney-Urine-Fraction excreted to urine",
                "X": "Time",
                "Y": "PO SD 10 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "Color": "#008080",
                  "LegendIndex": 46,
                  "LineStyle": "Dash"
                }
              },
              {
                "Name": "PO SD 2.5 mg (perm)-Dapagliflozin-Peripheral Venous Blood-Plasma-Concentration",
                "X": "Time",
                "Y": "PO SD 2.5 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
                "CurveOptions": {
                  "Color": "#808080",
                  "LegendIndex": 47
                }
              },
              {
                "Name": "PO SD 2.5 mg (perm)-Dapagliflozin-Kidney-Urine-Fraction excreted to urine",
                "X": "Time",
                "Y": "PO SD 2.5 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "Color": "#C00000",
                  "LegendIndex": 48,
                  "LineStyle": "Dash"
                }
              },
              {
                "Name": "PO SD 50 mg (perm)-Dapagliflozin-Peripheral Venous Blood-Plasma-Concentration",
                "X": "Time",
                "Y": "PO SD 50 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
                "CurveOptions": {
                  "Color": "#FF0000",
                  "LegendIndex": 49
                }
              },
              {
                "Name": "PO SD 50 mg (perm)-Dapagliflozin-Kidney-Urine-Fraction excreted to urine",
                "X": "Time",
                "Y": "PO SD 50 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "Color": "#008000",
                  "LegendIndex": 50,
                  "LineStyle": "Dash"
                }
              },
              {
                "Name": "PO SD 50 mg (perm)-Dapagliflozin-Lumen-Feces-Fraction excreted to feces",
                "X": "Time",
                "Y": "PO SD 50 mg (perm)|Organism|Lumen|Feces|Dapagliflozin|Fraction excreted to feces",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "Color": "#0000FF",
                  "LegendIndex": 51,
                  "LineStyle": "Dash"
                }
              },
              {
                "Name": "PO SD 50 mg (perm)-Dapagliflozin-UGT1A9-Optimized Metabolite-Organism-Total fraction of dose-Dapagliflozin",
                "X": "Time",
                "Y": "PO SD 50 mg (perm)|Organism|Dapagliflozin-UGT1A9-Optimized Metabolite|Total fraction of dose-Dapagliflozin",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "Color": "#00C0C0",
                  "LegendIndex": 52,
                  "LineStyle": "Dash"
                }
              },
              {
                "Name": "PO SD 50 mg (perm)-Dapagliflozin-UGT2B7-Optimized Metabolite-Organism-Total fraction of dose-Dapagliflozin",
                "X": "Time",
                "Y": "PO SD 50 mg (perm)|Organism|Dapagliflozin-UGT2B7-Optimized Metabolite|Total fraction of dose-Dapagliflozin",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "Color": "#C000C0",
                  "LegendIndex": 53,
                  "LineStyle": "Dash"
                }
              },
              {
                "Name": "PO SD 50 mg (perm)-Dapagliflozin-Hepatic-CYP-Optimized Metabolite-Organism-Total fraction of dose-Dapagliflozin",
                "X": "Time",
                "Y": "PO SD 50 mg (perm)|Organism|Dapagliflozin-Hepatic-CYP-Optimized Metabolite|Total fraction of dose-Dapagliflozin",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "Color": "#C04000",
                  "LegendIndex": 54,
                  "LineStyle": "Dash"
                }
              },
              {
                "Name": "PO SD 250 mg (perm)-Dapagliflozin-Peripheral Venous Blood-Plasma-Concentration",
                "X": "Time",
                "Y": "PO SD 250 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
                "CurveOptions": {
                  "Color": "#8080FF",
                  "LegendIndex": 55
                }
              },
              {
                "Name": "PO SD 250 mg (perm)-Dapagliflozin-Kidney-Urine-Fraction excreted to urine",
                "X": "Time",
                "Y": "PO SD 250 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "Color": "#80FF80",
                  "LegendIndex": 56,
                  "LineStyle": "Dash"
                }
              }
            ],
            "Name": "Time Profile",
            "Settings": {
              "SideMarginsEnabled": true,
              "LegendPosition": "None",
              "BackColor": "#FFFFFF",
              "DiagramBackColor": "#FFFFFF"
            }
          }
        }
      ]
    },
    {
      "Name": "PI full  (perm) (fe unchanged)",
      "Simulations": [
        "IV 0.08 mg (perm)",
        "PO SD 10 mg (perm)",
        "PO SD 50 mg (perm)",
        "PO SD 100 mg (perm)",
        "PO SD 2.5 mg (perm)",
        "PO SD 20 mg (perm)",
        "PO SD 250 mg (perm)",
        "PO SD 5 mg (perm)",
        "PO SD 500 mg (perm)"
      ],
      "Configuration": {
        "LLOQMode": "OnlyObservedData",
        "RemoveLLOQMode": "Never",
        "CalculateJacobian": false,
        "Algorithm": {
          "Name": "Levenberg - Marquardt (MPFit)",
          "Properties": [
            {
              "Name": "ftol",
              "Value": 0.001
            },
            {
              "Name": "xtol",
              "Value": 1E-06
            },
            {
              "Name": "gtol",
              "Value": 1E-10
            },
            {
              "Name": "stepfactor",
              "Value": 100.0
            },
            {
              "Name": "maxiter",
              "Value": 200.0
            },
            {
              "Name": "maxfev",
              "Value": 0.0
            },
            {
              "Name": "epsfcn",
              "Value": 1E-09
            }
          ]
        }
      },
      "OutputMappings": [
        {
          "Scaling": "Log",
          "Path": "PO SD 50 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Kasichayanula 2013b - Healthy subjects with normal kidney function - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=8)"
        },
        {
          "Scaling": "Log",
          "Path": "PO SD 50 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Kasichayanula 2011b - Study 1: 50 mg Control (Perpetrator Placebo) - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=24)"
        },
        {
          "Scaling": "Linear",
          "Weight": 100.0,
          "Path": "PO SD 50 mg (perm)|Organism|Lumen|Feces|Dapagliflozin|Fraction excreted to feces",
          "ObservedData": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin Feces - Dapagliflozin - PO - 50 mg - Feces - agg. (n=6)"
        },
        {
          "Scaling": "Linear",
          "Weight": 10.0,
          "Path": "PO SD 50 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
          "ObservedData": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin Urine - Dapagliflozin - PO - 50 mg - Urine - agg. (n=6)"
        },
        {
          "Scaling": "Log",
          "Path": "PO SD 10 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Kasichayanula 2011c - Healthy Volunteers - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=6)"
        },
        {
          "Scaling": "Log",
          "Path": "PO SD 10 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Vakkalagadda 2016 - Dapagliflozin - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=42)"
        },
        {
          "Scaling": "Log",
          "Path": "PO SD 10 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Kasichayanula 2013a - Study 2: Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=16)"
        },
        {
          "Scaling": "Log",
          "Path": "PO SD 10 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Kasichayanula 2013a - Study 1: Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=14)"
        },
        {
          "Scaling": "Log",
          "Path": "PO SD 10 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Kasichayanula 2011a - fasted - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=14)"
        },
        {
          "Scaling": "Log",
          "Path": "PO SD 10 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Imamura 2013 - Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=22)"
        },
        {
          "Scaling": "Log",
          "Path": "PO SD 10 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Boulton 2013 - Dapagliflozin po - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=7)"
        },
        {
          "Scaling": "Log",
          "Path": "IV 0.08 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Boulton 2013 - 14C-dapagliflozin iv - Dapagliflozin - IV - 0.08 mg - Plasma - agg. (n=7)"
        },
        {
          "Scaling": "Linear",
          "Weight": 10.0,
          "Path": "PO SD 50 mg (perm)|Organism|Dapagliflozin-UGT1A9-Optimized Metabolite|Total fraction of dose-Dapagliflozin",
          "ObservedData": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin 3OG Gluc - Dapagliflozin-3-O-glucuronide - PO - 50 mg - Fraction - agg. (n=6)"
        },
        {
          "Scaling": "Linear",
          "Weight": 10.0,
          "Path": "PO SD 50 mg (perm)|Organism|Dapagliflozin-UGT2B7-Optimized Metabolite|Total fraction of dose-Dapagliflozin",
          "ObservedData": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin 2OG Gluc - Dapagliflozin-2-O-glucuronide - PO - 50 mg - Fraction - agg. (n=6)"
        },
        {
          "Scaling": "Linear",
          "Weight": 10.0,
          "Path": "PO SD 50 mg (perm)|Organism|Dapagliflozin-Hepatic-CYP-Optimized Metabolite|Total fraction of dose-Dapagliflozin",
          "ObservedData": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin oxid Metab - Dapagliflozin oxidative metabolites - PO - 50 mg - Fraction - agg. (n=6)"
        },
        {
          "Scaling": "Log",
          "Path": "PO SD 100 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Komoroski 2009 - SAD 100 mg - Dapagliflozin - PO - 100 mg - Plasma - agg. (n=6)"
        },
        {
          "Scaling": "Log",
          "Path": "PO SD 2.5 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Komoroski 2009 - SAD 2.5 mg - Dapagliflozin - PO - 2.5 mg - Plasma - agg. (n=6)"
        },
        {
          "Scaling": "Log",
          "Path": "PO SD 20 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Kasichayanula 2012 - Study 1: Control (Perpetrator Placebo) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=24)"
        },
        {
          "Scaling": "Log",
          "Path": "PO SD 20 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Komoroski 2009 - SAD 20 mg - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=6)"
        },
        {
          "Scaling": "Log",
          "Path": "PO SD 250 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Komoroski 2009 - SAD 250 mg fasted - Dapagliflozin - PO - 250 mg - Plasma - agg. (n=6)"
        },
        {
          "Scaling": "Log",
          "Path": "PO SD 5 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Komoroski 2009 - SAD 5 mg - Dapagliflozin - PO - 5 mg - Plasma - agg. (n=6)"
        },
        {
          "Scaling": "Log",
          "Path": "PO SD 500 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Komoroski 2009 - SAD 500 mg - Dapagliflozin - PO - 500 mg - Plasma - agg. (n=6)"
        },
        {
          "Scaling": "Linear",
          "Path": "PO SD 2.5 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
          "ObservedData": "Komoroski 2009 - SAD 2.5 mg (Urine) - Dapagliflozin - PO - 2.5 mg - Urine - agg. (n=6)"
        },
        {
          "Scaling": "Linear",
          "Path": "PO SD 5 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
          "ObservedData": "Komoroski 2009 - SAD 5 mg (Urine) - Dapagliflozin - PO - 5 mg - Urine - agg. (n=6)"
        },
        {
          "Scaling": "Linear",
          "Path": "PO SD 10 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
          "ObservedData": "Komoroski 2009 - SAD 10 mg (Urine) - Dapagliflozin - PO - 10 mg - Urine - agg. (n=6)"
        },
        {
          "Scaling": "Linear",
          "Path": "PO SD 20 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
          "ObservedData": "Komoroski 2009 - SAD 20 mg (Urine) - Dapagliflozin - PO - 20 mg - Urine - agg. (n=6)"
        },
        {
          "Scaling": "Linear",
          "Path": "PO SD 50 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
          "ObservedData": "Komoroski 2009 - SAD 50 mg (Urine) - Dapagliflozin - PO - 50 mg - Urine - agg. (n=6)"
        },
        {
          "Scaling": "Linear",
          "Path": "PO SD 100 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
          "ObservedData": "Komoroski 2009 - SAD 100 mg (Urine) - Dapagliflozin - PO - 100 mg - Urine - agg. (n=6)"
        },
        {
          "Scaling": "Linear",
          "Path": "PO SD 250 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
          "ObservedData": "Komoroski 2009 - SAD 250 mg fasted (Urine) - Dapagliflozin - PO - 250 mg - Urine - agg. (n=6)"
        },
        {
          "Scaling": "Linear",
          "Path": "PO SD 500 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
          "ObservedData": "Komoroski 2009 - SAD 500 mg (Urine) - Dapagliflozin - PO - 500 mg - Urine - agg. (n=6)"
        }
      ],
      "IdentificationParameters": [
        {
          "Name": "Lipophilicity",
          "Scaling": "Linear",
          "LinkedParameters": [
            "IV 0.08 mg (perm)|Dapagliflozin|Lipophilicity",
            "PO SD 10 mg (perm)|Dapagliflozin|Lipophilicity",
            "PO SD 50 mg (perm)|Dapagliflozin|Lipophilicity",
            "PO SD 100 mg (perm)|Dapagliflozin|Lipophilicity",
            "PO SD 2.5 mg (perm)|Dapagliflozin|Lipophilicity",
            "PO SD 20 mg (perm)|Dapagliflozin|Lipophilicity",
            "PO SD 250 mg (perm)|Dapagliflozin|Lipophilicity",
            "PO SD 5 mg (perm)|Dapagliflozin|Lipophilicity",
            "PO SD 500 mg (perm)|Dapagliflozin|Lipophilicity"
          ],
          "Parameters": [
            {
              "Name": "Start value",
              "Value": 2.546,
              "Unit": "Log Units"
            },
            {
              "Name": "MinValue",
              "Value": 1.0,
              "Unit": "Log Units"
            },
            {
              "Name": "MaxValue",
              "Value": 4.0,
              "Unit": "Log Units"
            }
          ]
        },
        {
          "Name": "P int",
          "Scaling": "Log",
          "LinkedParameters": [
            "IV 0.08 mg (perm)|Dapagliflozin|Specific intestinal permeability (transcellular)",
            "PO SD 10 mg (perm)|Dapagliflozin|Specific intestinal permeability (transcellular)",
            "PO SD 50 mg (perm)|Dapagliflozin|Specific intestinal permeability (transcellular)",
            "PO SD 100 mg (perm)|Dapagliflozin|Specific intestinal permeability (transcellular)",
            "PO SD 2.5 mg (perm)|Dapagliflozin|Specific intestinal permeability (transcellular)",
            "PO SD 20 mg (perm)|Dapagliflozin|Specific intestinal permeability (transcellular)",
            "PO SD 250 mg (perm)|Dapagliflozin|Specific intestinal permeability (transcellular)",
            "PO SD 5 mg (perm)|Dapagliflozin|Specific intestinal permeability (transcellular)",
            "PO SD 500 mg (perm)|Dapagliflozin|Specific intestinal permeability (transcellular)"
          ],
          "Parameters": [
            {
              "Name": "Start value",
              "Value": 4E-05,
              "Unit": "cm/min"
            },
            {
              "Name": "MinValue",
              "Value": 1E-06,
              "Unit": "cm/min"
            },
            {
              "Name": "MaxValue",
              "Value": 0.01,
              "Unit": "cm/min"
            }
          ]
        },
        {
          "Name": "UGT1A9",
          "Scaling": "Log",
          "LinkedParameters": [
            "IV 0.08 mg (perm)|Dapagliflozin-UGT1A9-Optimized|CLspec/[Enzyme]",
            "PO SD 10 mg (perm)|Dapagliflozin-UGT1A9-Optimized|CLspec/[Enzyme]",
            "PO SD 50 mg (perm)|Dapagliflozin-UGT1A9-Optimized|CLspec/[Enzyme]",
            "PO SD 100 mg (perm)|Dapagliflozin-UGT1A9-Optimized|CLspec/[Enzyme]",
            "PO SD 2.5 mg (perm)|Dapagliflozin-UGT1A9-Optimized|CLspec/[Enzyme]",
            "PO SD 20 mg (perm)|Dapagliflozin-UGT1A9-Optimized|CLspec/[Enzyme]",
            "PO SD 250 mg (perm)|Dapagliflozin-UGT1A9-Optimized|CLspec/[Enzyme]",
            "PO SD 5 mg (perm)|Dapagliflozin-UGT1A9-Optimized|CLspec/[Enzyme]",
            "PO SD 500 mg (perm)|Dapagliflozin-UGT1A9-Optimized|CLspec/[Enzyme]"
          ],
          "Parameters": [
            {
              "Name": "Start value",
              "Value": 0.4,
              "Unit": "l/µmol/min"
            },
            {
              "Name": "MinValue",
              "Value": 0.001,
              "Unit": "l/µmol/min"
            },
            {
              "Name": "MaxValue",
              "Value": 100.0,
              "Unit": "l/µmol/min"
            }
          ]
        },
        {
          "Name": "UGT2B7",
          "Scaling": "Log",
          "LinkedParameters": [
            "IV 0.08 mg (perm)|Dapagliflozin-UGT2B7-Optimized|CLspec/[Enzyme]",
            "PO SD 10 mg (perm)|Dapagliflozin-UGT2B7-Optimized|CLspec/[Enzyme]",
            "PO SD 50 mg (perm)|Dapagliflozin-UGT2B7-Optimized|CLspec/[Enzyme]",
            "PO SD 100 mg (perm)|Dapagliflozin-UGT2B7-Optimized|CLspec/[Enzyme]",
            "PO SD 2.5 mg (perm)|Dapagliflozin-UGT2B7-Optimized|CLspec/[Enzyme]",
            "PO SD 20 mg (perm)|Dapagliflozin-UGT2B7-Optimized|CLspec/[Enzyme]",
            "PO SD 250 mg (perm)|Dapagliflozin-UGT2B7-Optimized|CLspec/[Enzyme]",
            "PO SD 5 mg (perm)|Dapagliflozin-UGT2B7-Optimized|CLspec/[Enzyme]",
            "PO SD 500 mg (perm)|Dapagliflozin-UGT2B7-Optimized|CLspec/[Enzyme]"
          ],
          "Parameters": [
            {
              "Name": "Start value",
              "Value": 0.02,
              "Unit": "l/µmol/min"
            },
            {
              "Name": "MinValue",
              "Value": 0.001,
              "Unit": "l/µmol/min"
            },
            {
              "Name": "MaxValue",
              "Value": 100.0,
              "Unit": "l/µmol/min"
            }
          ]
        },
        {
          "Name": "Hep-CYP",
          "Scaling": "Log",
          "LinkedParameters": [
            "IV 0.08 mg (perm)|Dapagliflozin-Hepatic-CYP-Optimized|CLspec/[Enzyme]",
            "PO SD 10 mg (perm)|Dapagliflozin-Hepatic-CYP-Optimized|CLspec/[Enzyme]",
            "PO SD 50 mg (perm)|Dapagliflozin-Hepatic-CYP-Optimized|CLspec/[Enzyme]",
            "PO SD 100 mg (perm)|Dapagliflozin-Hepatic-CYP-Optimized|CLspec/[Enzyme]",
            "PO SD 2.5 mg (perm)|Dapagliflozin-Hepatic-CYP-Optimized|CLspec/[Enzyme]",
            "PO SD 20 mg (perm)|Dapagliflozin-Hepatic-CYP-Optimized|CLspec/[Enzyme]",
            "PO SD 250 mg (perm)|Dapagliflozin-Hepatic-CYP-Optimized|CLspec/[Enzyme]",
            "PO SD 5 mg (perm)|Dapagliflozin-Hepatic-CYP-Optimized|CLspec/[Enzyme]",
            "PO SD 500 mg (perm)|Dapagliflozin-Hepatic-CYP-Optimized|CLspec/[Enzyme]"
          ],
          "Parameters": [
            {
              "Name": "Start value",
              "Value": 0.15,
              "Unit": "l/µmol/min"
            },
            {
              "Name": "MinValue",
              "Value": 0.001,
              "Unit": "l/µmol/min"
            },
            {
              "Name": "MaxValue",
              "Value": 100.0,
              "Unit": "l/µmol/min"
            }
          ]
        },
        {
          "Name": "Solubility",
          "Scaling": "Log",
          "LinkedParameters": [
            "IV 0.08 mg (perm)|Dapagliflozin|Solubility at reference pH",
            "PO SD 10 mg (perm)|Dapagliflozin|Solubility at reference pH",
            "PO SD 50 mg (perm)|Dapagliflozin|Solubility at reference pH",
            "PO SD 100 mg (perm)|Dapagliflozin|Solubility at reference pH",
            "PO SD 2.5 mg (perm)|Dapagliflozin|Solubility at reference pH",
            "PO SD 20 mg (perm)|Dapagliflozin|Solubility at reference pH",
            "PO SD 250 mg (perm)|Dapagliflozin|Solubility at reference pH",
            "PO SD 5 mg (perm)|Dapagliflozin|Solubility at reference pH",
            "PO SD 500 mg (perm)|Dapagliflozin|Solubility at reference pH"
          ],
          "Parameters": [
            {
              "Name": "Start value",
              "Value": 0.173,
              "Unit": "mg/ml"
            },
            {
              "Name": "MinValue",
              "Value": 0.01,
              "Unit": "mg/ml"
            },
            {
              "Name": "MaxValue",
              "Value": 100.0,
              "Unit": "mg/ml"
            }
          ]
        },
        {
          "Name": "Permeability",
          "Scaling": "Log",
          "LinkedParameters": [
            "IV 0.08 mg (perm)|Dapagliflozin|Permeability",
            "PO SD 10 mg (perm)|Dapagliflozin|Permeability",
            "PO SD 50 mg (perm)|Dapagliflozin|Permeability",
            "PO SD 100 mg (perm)|Dapagliflozin|Permeability",
            "PO SD 2.5 mg (perm)|Dapagliflozin|Permeability",
            "PO SD 20 mg (perm)|Dapagliflozin|Permeability",
            "PO SD 250 mg (perm)|Dapagliflozin|Permeability",
            "PO SD 5 mg (perm)|Dapagliflozin|Permeability",
            "PO SD 500 mg (perm)|Dapagliflozin|Permeability"
          ],
          "Parameters": [
            {
              "Name": "Start value",
              "Value": 0.0004257,
              "Unit": "cm/min"
            },
            {
              "Name": "MinValue",
              "Value": 1E-06,
              "Unit": "cm/min"
            },
            {
              "Name": "MaxValue",
              "Value": 0.01,
              "Unit": "cm/min"
            }
          ]
        },
        {
          "Name": "logP (veg.oil/water)",
          "Scaling": "Linear",
          "LinkedParameters": [
            "IV 0.08 mg (perm)|Dapagliflozin|logP (veg.oil/water)",
            "PO SD 10 mg (perm)|Dapagliflozin|logP (veg.oil/water)",
            "PO SD 50 mg (perm)|Dapagliflozin|logP (veg.oil/water)",
            "PO SD 100 mg (perm)|Dapagliflozin|logP (veg.oil/water)",
            "PO SD 2.5 mg (perm)|Dapagliflozin|logP (veg.oil/water)",
            "PO SD 20 mg (perm)|Dapagliflozin|logP (veg.oil/water)",
            "PO SD 250 mg (perm)|Dapagliflozin|logP (veg.oil/water)",
            "PO SD 5 mg (perm)|Dapagliflozin|logP (veg.oil/water)",
            "PO SD 500 mg (perm)|Dapagliflozin|logP (veg.oil/water)"
          ],
          "Parameters": [
            {
              "Name": "Start value",
              "Value": 2.053,
              "Unit": "Log Units"
            },
            {
              "Name": "MinValue",
              "Value": 0.0,
              "Unit": "Log Units"
            },
            {
              "Name": "MaxValue",
              "Value": 4.0,
              "Unit": "Log Units"
            }
          ]
        },
        {
          "Name": "GFR fraction",
          "Scaling": "Linear",
          "LinkedParameters": [
            "IV 0.08 mg (perm)|Neighborhoods|Kidney_pls_Kidney_ur|Dapagliflozin|Glomerular Filtration-assumed|GFR fraction",
            "PO SD 10 mg (perm)|Neighborhoods|Kidney_pls_Kidney_ur|Dapagliflozin|Glomerular Filtration-assumed|GFR fraction",
            "PO SD 50 mg (perm)|Neighborhoods|Kidney_pls_Kidney_ur|Dapagliflozin|Glomerular Filtration-assumed|GFR fraction",
            "PO SD 100 mg (perm)|Neighborhoods|Kidney_pls_Kidney_ur|Dapagliflozin|Glomerular Filtration-assumed|GFR fraction",
            "PO SD 2.5 mg (perm)|Neighborhoods|Kidney_pls_Kidney_ur|Dapagliflozin|Glomerular Filtration-assumed|GFR fraction",
            "PO SD 20 mg (perm)|Neighborhoods|Kidney_pls_Kidney_ur|Dapagliflozin|Glomerular Filtration-assumed|GFR fraction",
            "PO SD 250 mg (perm)|Neighborhoods|Kidney_pls_Kidney_ur|Dapagliflozin|Glomerular Filtration-assumed|GFR fraction",
            "PO SD 5 mg (perm)|Neighborhoods|Kidney_pls_Kidney_ur|Dapagliflozin|Glomerular Filtration-assumed|GFR fraction",
            "PO SD 500 mg (perm)|Neighborhoods|Kidney_pls_Kidney_ur|Dapagliflozin|Glomerular Filtration-assumed|GFR fraction"
          ],
          "Parameters": [
            {
              "Name": "Start value",
              "Value": 1.0
            },
            {
              "Name": "MinValue",
              "Value": 0.1
            },
            {
              "Name": "MaxValue",
              "Value": 10.0
            }
          ]
        },
        {
          "Name": "Blood/Plasma concentration ratio",
          "Scaling": "Linear",
          "IsFixed": true,
          "LinkedParameters": [
            "IV 0.08 mg (perm)|Dapagliflozin|Blood/Plasma concentration ratio",
            "PO SD 10 mg (perm)|Dapagliflozin|Blood/Plasma concentration ratio",
            "PO SD 50 mg (perm)|Dapagliflozin|Blood/Plasma concentration ratio",
            "PO SD 100 mg (perm)|Dapagliflozin|Blood/Plasma concentration ratio",
            "PO SD 2.5 mg (perm)|Dapagliflozin|Blood/Plasma concentration ratio",
            "PO SD 20 mg (perm)|Dapagliflozin|Blood/Plasma concentration ratio",
            "PO SD 250 mg (perm)|Dapagliflozin|Blood/Plasma concentration ratio",
            "PO SD 5 mg (perm)|Dapagliflozin|Blood/Plasma concentration ratio",
            "PO SD 500 mg (perm)|Dapagliflozin|Blood/Plasma concentration ratio"
          ],
          "Parameters": [
            {
              "Name": "Start value",
              "Value": 0.88
            },
            {
              "Name": "MinValue",
              "Value": 0.0
            },
            {
              "Name": "MaxValue",
              "Value": 6.1244936725
            }
          ]
        }
      ],
      "Analyses": [
        {
          "Name": "Time Profile",
          "Type": "ParameterIdentificationTimeProfileChart",
          "Chart": {
            "Axes": [
              {
                "Unit": "h",
                "Dimension": "Time",
                "Type": "X",
                "GridLines": false,
                "Visible": true,
                "Min": 0.0,
                "Max": 24.0,
                "DefaultColor": "#FFFFFF",
                "DefaultLineStyle": "None",
                "Scaling": "Linear",
                "NumberMode": "Normal"
              },
              {
                "Unit": "mg/l",
                "Dimension": "Concentration (mass)",
                "Type": "Y",
                "GridLines": false,
                "Visible": true,
                "Min": 0.0001,
                "Max": 5.0,
                "DefaultColor": "#FFFFFF",
                "DefaultLineStyle": "Solid",
                "Scaling": "Log",
                "NumberMode": "Normal"
              },
              {
                "Unit": "%",
                "Dimension": "Fraction",
                "Type": "Y2",
                "GridLines": false,
                "Visible": true,
                "DefaultColor": "#FFFFFF",
                "DefaultLineStyle": "Dash",
                "Scaling": "Linear",
                "NumberMode": "Normal"
              }
            ],
            "Curves": [
              {
                "Name": "Kasichayanula 2013b - Healthy subjects with normal kidney function - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=8)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
                "X": "Kasichayanula 2013b - Healthy subjects with normal kidney function - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=8)|Time",
                "Y": "Kasichayanula 2013b - Healthy subjects with normal kidney function - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=8)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "VisibleInLegend": false,
                  "Color": "#FF0000",
                  "LegendIndex": 1,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Kasichayanula 2011b - Study 1: 50 mg Control (Perpetrator Placebo) - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=24)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
                "X": "Kasichayanula 2011b - Study 1: 50 mg Control (Perpetrator Placebo) - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=24)|Time",
                "Y": "Kasichayanula 2011b - Study 1: 50 mg Control (Perpetrator Placebo) - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=24)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "VisibleInLegend": false,
                  "Color": "#FF0000",
                  "LegendIndex": 2,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin Feces - Dapagliflozin - PO - 50 mg - Feces - agg. (n=6)-Dapagliflozin-Lumen-Feces-ArithmeticMean",
                "X": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin Feces - Dapagliflozin - PO - 50 mg - Feces - agg. (n=6)|Time",
                "Y": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin Feces - Dapagliflozin - PO - 50 mg - Feces - agg. (n=6)|ObservedData|Lumen|Feces|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "VisibleInLegend": false,
                  "Color": "#0000FF",
                  "LegendIndex": 3,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin Urine - Dapagliflozin - PO - 50 mg - Urine - agg. (n=6)-Dapagliflozin-Kidney-Urine-ArithmeticMean",
                "X": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin Urine - Dapagliflozin - PO - 50 mg - Urine - agg. (n=6)|Time",
                "Y": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin Urine - Dapagliflozin - PO - 50 mg - Urine - agg. (n=6)|ObservedData|Kidney|Urine|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "VisibleInLegend": false,
                  "Color": "#008000",
                  "LegendIndex": 4,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Komoroski 2009 - SAD 50 mg (Urine) - Dapagliflozin - PO - 50 mg - Urine - agg. (n=6)-Dapagliflozin-Kidney-Urine-ArithmeticMean",
                "X": "Komoroski 2009 - SAD 50 mg (Urine) - Dapagliflozin - PO - 50 mg - Urine - agg. (n=6)|Time",
                "Y": "Komoroski 2009 - SAD 50 mg (Urine) - Dapagliflozin - PO - 50 mg - Urine - agg. (n=6)|ObservedData|Kidney|Urine|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "VisibleInLegend": false,
                  "Color": "#008000",
                  "LegendIndex": 5,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Kasichayanula 2011c - Healthy Volunteers - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=6)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
                "X": "Kasichayanula 2011c - Healthy Volunteers - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=6)|Time",
                "Y": "Kasichayanula 2011c - Healthy Volunteers - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "VisibleInLegend": false,
                  "Color": "#FF00FF",
                  "LegendIndex": 6,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Vakkalagadda 2016 - Dapagliflozin - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=42)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
                "X": "Vakkalagadda 2016 - Dapagliflozin - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=42)|Time",
                "Y": "Vakkalagadda 2016 - Dapagliflozin - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=42)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "VisibleInLegend": false,
                  "Color": "#FF00FF",
                  "LegendIndex": 7,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Kasichayanula 2013a - Study 2: Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=16)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
                "X": "Kasichayanula 2013a - Study 2: Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=16)|Time",
                "Y": "Kasichayanula 2013a - Study 2: Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=16)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "VisibleInLegend": false,
                  "Color": "#FF00FF",
                  "LegendIndex": 8,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Kasichayanula 2013a - Study 1: Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=14)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
                "X": "Kasichayanula 2013a - Study 1: Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=14)|Time",
                "Y": "Kasichayanula 2013a - Study 1: Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=14)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "VisibleInLegend": false,
                  "Color": "#FF00FF",
                  "LegendIndex": 9,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Kasichayanula 2011a - fasted - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=14)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
                "X": "Kasichayanula 2011a - fasted - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=14)|Time",
                "Y": "Kasichayanula 2011a - fasted - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=14)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "VisibleInLegend": false,
                  "Color": "#FF00FF",
                  "LegendIndex": 10,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Imamura 2013 - Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=22)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
                "X": "Imamura 2013 - Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=22)|Time",
                "Y": "Imamura 2013 - Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=22)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "VisibleInLegend": false,
                  "Color": "#FF00FF",
                  "LegendIndex": 11,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Boulton 2013 - Dapagliflozin po - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=7)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
                "X": "Boulton 2013 - Dapagliflozin po - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=7)|Time",
                "Y": "Boulton 2013 - Dapagliflozin po - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=7)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "VisibleInLegend": false,
                  "Color": "#FF00FF",
                  "LegendIndex": 12,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Boulton 2013 - 14C-dapagliflozin iv - Dapagliflozin - IV - 0.08 mg - Plasma - agg. (n=7)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
                "X": "Boulton 2013 - 14C-dapagliflozin iv - Dapagliflozin - IV - 0.08 mg - Plasma - agg. (n=7)|Time",
                "Y": "Boulton 2013 - 14C-dapagliflozin iv - Dapagliflozin - IV - 0.08 mg - Plasma - agg. (n=7)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "VisibleInLegend": false,
                  "Color": "#FF8000",
                  "LegendIndex": 13,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin 3OG Gluc - Dapagliflozin-3-O-glucuronide - PO - 50 mg - Fraction - agg. (n=6)-Dapagliflozin-3-O-glucuronide-Undefined-Undefined-ArithmeticMean",
                "X": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin 3OG Gluc - Dapagliflozin-3-O-glucuronide - PO - 50 mg - Fraction - agg. (n=6)|Time",
                "Y": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin 3OG Gluc - Dapagliflozin-3-O-glucuronide - PO - 50 mg - Fraction - agg. (n=6)|ObservedData|Undefined|Undefined|Dapagliflozin-3-O-glucuronide|ArithmeticMean",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "VisibleInLegend": false,
                  "Color": "#00C0C0",
                  "LegendIndex": 14,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin 2OG Gluc - Dapagliflozin-2-O-glucuronide - PO - 50 mg - Fraction - agg. (n=6)-Dapagliflozin-2-O-glucuronide-Undefined-Undefined-ArithmeticMean",
                "X": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin 2OG Gluc - Dapagliflozin-2-O-glucuronide - PO - 50 mg - Fraction - agg. (n=6)|Time",
                "Y": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin 2OG Gluc - Dapagliflozin-2-O-glucuronide - PO - 50 mg - Fraction - agg. (n=6)|ObservedData|Undefined|Undefined|Dapagliflozin-2-O-glucuronide|ArithmeticMean",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "VisibleInLegend": false,
                  "Color": "#C000C0",
                  "LegendIndex": 15,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin oxid Metab - Dapagliflozin oxidative metabolites - PO - 50 mg - Fraction - agg. (n=6)-Dapagliflozin oxidative metabolites-Undefined-Undefined-ArithmeticMean",
                "X": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin oxid Metab - Dapagliflozin oxidative metabolites - PO - 50 mg - Fraction - agg. (n=6)|Time",
                "Y": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin oxid Metab - Dapagliflozin oxidative metabolites - PO - 50 mg - Fraction - agg. (n=6)|ObservedData|Undefined|Undefined|Dapagliflozin oxidative metabolites|ArithmeticMean",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "VisibleInLegend": false,
                  "Color": "#C04000",
                  "LegendIndex": 16,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Komoroski 2009 - SAD 100 mg - Dapagliflozin - PO - 100 mg - Plasma - agg. (n=6)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
                "X": "Komoroski 2009 - SAD 100 mg - Dapagliflozin - PO - 100 mg - Plasma - agg. (n=6)|Time",
                "Y": "Komoroski 2009 - SAD 100 mg - Dapagliflozin - PO - 100 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "VisibleInLegend": false,
                  "Color": "#00FF00",
                  "LegendIndex": 17,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Komoroski 2009 - SAD 2.5 mg - Dapagliflozin - PO - 2.5 mg - Plasma - agg. (n=6)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
                "X": "Komoroski 2009 - SAD 2.5 mg - Dapagliflozin - PO - 2.5 mg - Plasma - agg. (n=6)|Time",
                "Y": "Komoroski 2009 - SAD 2.5 mg - Dapagliflozin - PO - 2.5 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "VisibleInLegend": false,
                  "Color": "#808080",
                  "LegendIndex": 18,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Kasichayanula 2012 - Study 1: Control (Perpetrator Placebo) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=24)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
                "X": "Kasichayanula 2012 - Study 1: Control (Perpetrator Placebo) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=24)|Time",
                "Y": "Kasichayanula 2012 - Study 1: Control (Perpetrator Placebo) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=24)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "VisibleInLegend": false,
                  "Color": "#C0C000",
                  "LegendIndex": 19,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Komoroski 2009 - SAD 20 mg - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=6)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
                "X": "Komoroski 2009 - SAD 20 mg - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=6)|Time",
                "Y": "Komoroski 2009 - SAD 20 mg - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "VisibleInLegend": false,
                  "Color": "#C0C000",
                  "LegendIndex": 20,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Komoroski 2009 - SAD 250 mg fasted - Dapagliflozin - PO - 250 mg - Plasma - agg. (n=6)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
                "X": "Komoroski 2009 - SAD 250 mg fasted - Dapagliflozin - PO - 250 mg - Plasma - agg. (n=6)|Time",
                "Y": "Komoroski 2009 - SAD 250 mg fasted - Dapagliflozin - PO - 250 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "VisibleInLegend": false,
                  "Color": "#8080FF",
                  "LegendIndex": 21,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Komoroski 2009 - SAD 5 mg - Dapagliflozin - PO - 5 mg - Plasma - agg. (n=6)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
                "X": "Komoroski 2009 - SAD 5 mg - Dapagliflozin - PO - 5 mg - Plasma - agg. (n=6)|Time",
                "Y": "Komoroski 2009 - SAD 5 mg - Dapagliflozin - PO - 5 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "VisibleInLegend": false,
                  "Color": "#0000C0",
                  "LegendIndex": 22,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Komoroski 2009 - SAD 500 mg - Dapagliflozin - PO - 500 mg - Plasma - agg. (n=6)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
                "X": "Komoroski 2009 - SAD 500 mg - Dapagliflozin - PO - 500 mg - Plasma - agg. (n=6)|Time",
                "Y": "Komoroski 2009 - SAD 500 mg - Dapagliflozin - PO - 500 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "VisibleInLegend": false,
                  "Color": "#00C000",
                  "LegendIndex": 23,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Komoroski 2009 - SAD 2.5 mg (Urine) - Dapagliflozin - PO - 2.5 mg - Urine - agg. (n=6)-Dapagliflozin-Kidney-Urine-ArithmeticMean",
                "X": "Komoroski 2009 - SAD 2.5 mg (Urine) - Dapagliflozin - PO - 2.5 mg - Urine - agg. (n=6)|Time",
                "Y": "Komoroski 2009 - SAD 2.5 mg (Urine) - Dapagliflozin - PO - 2.5 mg - Urine - agg. (n=6)|ObservedData|Kidney|Urine|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "VisibleInLegend": false,
                  "Color": "#C00000",
                  "LegendIndex": 24,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Komoroski 2009 - SAD 5 mg (Urine) - Dapagliflozin - PO - 5 mg - Urine - agg. (n=6)-Dapagliflozin-Kidney-Urine-ArithmeticMean",
                "X": "Komoroski 2009 - SAD 5 mg (Urine) - Dapagliflozin - PO - 5 mg - Urine - agg. (n=6)|Time",
                "Y": "Komoroski 2009 - SAD 5 mg (Urine) - Dapagliflozin - PO - 5 mg - Urine - agg. (n=6)|ObservedData|Kidney|Urine|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "VisibleInLegend": false,
                  "Color": "#FFFF00",
                  "LegendIndex": 25,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Komoroski 2009 - SAD 10 mg (Urine) - Dapagliflozin - PO - 10 mg - Urine - agg. (n=6)-Dapagliflozin-Kidney-Urine-ArithmeticMean",
                "X": "Komoroski 2009 - SAD 10 mg (Urine) - Dapagliflozin - PO - 10 mg - Urine - agg. (n=6)|Time",
                "Y": "Komoroski 2009 - SAD 10 mg (Urine) - Dapagliflozin - PO - 10 mg - Urine - agg. (n=6)|ObservedData|Kidney|Urine|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "VisibleInLegend": false,
                  "Color": "#008080",
                  "LegendIndex": 26,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Komoroski 2009 - SAD 20 mg (Urine) - Dapagliflozin - PO - 20 mg - Urine - agg. (n=6)-Dapagliflozin-Kidney-Urine-ArithmeticMean",
                "X": "Komoroski 2009 - SAD 20 mg (Urine) - Dapagliflozin - PO - 20 mg - Urine - agg. (n=6)|Time",
                "Y": "Komoroski 2009 - SAD 20 mg (Urine) - Dapagliflozin - PO - 20 mg - Urine - agg. (n=6)|ObservedData|Kidney|Urine|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "VisibleInLegend": false,
                  "Color": "#800080",
                  "LegendIndex": 27,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Komoroski 2009 - SAD 100 mg (Urine) - Dapagliflozin - PO - 100 mg - Urine - agg. (n=6)-Dapagliflozin-Kidney-Urine-ArithmeticMean",
                "X": "Komoroski 2009 - SAD 100 mg (Urine) - Dapagliflozin - PO - 100 mg - Urine - agg. (n=6)|Time",
                "Y": "Komoroski 2009 - SAD 100 mg (Urine) - Dapagliflozin - PO - 100 mg - Urine - agg. (n=6)|ObservedData|Kidney|Urine|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "VisibleInLegend": false,
                  "Color": "#804040",
                  "LegendIndex": 28,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Komoroski 2009 - SAD 250 mg fasted (Urine) - Dapagliflozin - PO - 250 mg - Urine - agg. (n=6)-Dapagliflozin-Kidney-Urine-ArithmeticMean",
                "X": "Komoroski 2009 - SAD 250 mg fasted (Urine) - Dapagliflozin - PO - 250 mg - Urine - agg. (n=6)|Time",
                "Y": "Komoroski 2009 - SAD 250 mg fasted (Urine) - Dapagliflozin - PO - 250 mg - Urine - agg. (n=6)|ObservedData|Kidney|Urine|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "VisibleInLegend": false,
                  "Color": "#80FF80",
                  "LegendIndex": 29,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Komoroski 2009 - SAD 500 mg (Urine) - Dapagliflozin - PO - 500 mg - Urine - agg. (n=6)-Dapagliflozin-Kidney-Urine-ArithmeticMean",
                "X": "Komoroski 2009 - SAD 500 mg (Urine) - Dapagliflozin - PO - 500 mg - Urine - agg. (n=6)|Time",
                "Y": "Komoroski 2009 - SAD 500 mg (Urine) - Dapagliflozin - PO - 500 mg - Urine - agg. (n=6)|ObservedData|Kidney|Urine|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "VisibleInLegend": false,
                  "Color": "#808000",
                  "LegendIndex": 30,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "PO SD 5 mg (perm)-Dapagliflozin-Peripheral Venous Blood-Plasma-Concentration",
                "X": "Time",
                "Y": "PO SD 5 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
                "CurveOptions": {
                  "Color": "#0000C0",
                  "LegendIndex": 31
                }
              },
              {
                "Name": "PO SD 5 mg (perm)-Dapagliflozin-Kidney-Urine-Fraction excreted to urine",
                "X": "Time",
                "Y": "PO SD 5 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "Color": "#FFFF00",
                  "LegendIndex": 32,
                  "LineStyle": "Dash"
                }
              },
              {
                "Name": "PO SD 2.5 mg (perm)-Dapagliflozin-Peripheral Venous Blood-Plasma-Concentration",
                "X": "Time",
                "Y": "PO SD 2.5 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
                "CurveOptions": {
                  "Color": "#808080",
                  "LegendIndex": 33
                }
              },
              {
                "Name": "PO SD 2.5 mg (perm)-Dapagliflozin-Kidney-Urine-Fraction excreted to urine",
                "X": "Time",
                "Y": "PO SD 2.5 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "Color": "#C00000",
                  "LegendIndex": 34,
                  "LineStyle": "Dash"
                }
              },
              {
                "Name": "PO SD 500 mg (perm)-Dapagliflozin-Peripheral Venous Blood-Plasma-Concentration",
                "X": "Time",
                "Y": "PO SD 500 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
                "CurveOptions": {
                  "Color": "#00C000",
                  "LegendIndex": 35
                }
              },
              {
                "Name": "PO SD 500 mg (perm)-Dapagliflozin-Kidney-Urine-Fraction excreted to urine",
                "X": "Time",
                "Y": "PO SD 500 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "Color": "#808000",
                  "LegendIndex": 36,
                  "LineStyle": "Dash"
                }
              },
              {
                "Name": "IV 0.08 mg (perm)-Dapagliflozin-Peripheral Venous Blood-Plasma-Concentration",
                "X": "Time",
                "Y": "IV 0.08 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
                "CurveOptions": {
                  "Color": "#FF8000",
                  "LegendIndex": 37
                }
              },
              {
                "Name": "PO SD 10 mg (perm)-Dapagliflozin-Peripheral Venous Blood-Plasma-Concentration",
                "X": "Time",
                "Y": "PO SD 10 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
                "CurveOptions": {
                  "Color": "#FF00FF",
                  "LegendIndex": 38
                }
              },
              {
                "Name": "PO SD 10 mg (perm)-Dapagliflozin-Kidney-Urine-Fraction excreted to urine",
                "X": "Time",
                "Y": "PO SD 10 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "Color": "#008080",
                  "LegendIndex": 39,
                  "LineStyle": "Dash"
                }
              },
              {
                "Name": "PO SD 20 mg (perm)-Dapagliflozin-Peripheral Venous Blood-Plasma-Concentration",
                "X": "Time",
                "Y": "PO SD 20 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
                "CurveOptions": {
                  "Color": "#C0C000",
                  "LegendIndex": 40
                }
              },
              {
                "Name": "PO SD 20 mg (perm)-Dapagliflozin-Kidney-Urine-Fraction excreted to urine",
                "X": "Time",
                "Y": "PO SD 20 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "Color": "#800080",
                  "LegendIndex": 41,
                  "LineStyle": "Dash"
                }
              },
              {
                "Name": "PO SD 100 mg (perm)-Dapagliflozin-Peripheral Venous Blood-Plasma-Concentration",
                "X": "Time",
                "Y": "PO SD 100 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
                "CurveOptions": {
                  "Color": "#00FF00",
                  "LegendIndex": 42
                }
              },
              {
                "Name": "PO SD 100 mg (perm)-Dapagliflozin-Kidney-Urine-Fraction excreted to urine",
                "X": "Time",
                "Y": "PO SD 100 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "Color": "#804040",
                  "LegendIndex": 43,
                  "LineStyle": "Dash"
                }
              },
              {
                "Name": "PO SD 250 mg (perm)-Dapagliflozin-Peripheral Venous Blood-Plasma-Concentration",
                "X": "Time",
                "Y": "PO SD 250 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
                "CurveOptions": {
                  "Color": "#8080FF",
                  "LegendIndex": 44
                }
              },
              {
                "Name": "PO SD 250 mg (perm)-Dapagliflozin-Kidney-Urine-Fraction excreted to urine",
                "X": "Time",
                "Y": "PO SD 250 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "Color": "#80FF80",
                  "LegendIndex": 45,
                  "LineStyle": "Dash"
                }
              },
              {
                "Name": "PO SD 50 mg (perm)-Dapagliflozin-Peripheral Venous Blood-Plasma-Concentration",
                "X": "Time",
                "Y": "PO SD 50 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
                "CurveOptions": {
                  "Color": "#FF0000",
                  "LegendIndex": 46
                }
              },
              {
                "Name": "PO SD 50 mg (perm)-Dapagliflozin-Kidney-Urine-Fraction excreted to urine",
                "X": "Time",
                "Y": "PO SD 50 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "Color": "#008000",
                  "LegendIndex": 47,
                  "LineStyle": "Dash"
                }
              },
              {
                "Name": "PO SD 50 mg (perm)-Dapagliflozin-Lumen-Feces-Fraction excreted to feces",
                "X": "Time",
                "Y": "PO SD 50 mg (perm)|Organism|Lumen|Feces|Dapagliflozin|Fraction excreted to feces",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "Color": "#0000FF",
                  "LegendIndex": 48,
                  "LineStyle": "Dash"
                }
              },
              {
                "Name": "PO SD 50 mg (perm)-Dapagliflozin-UGT1A9-Optimized Metabolite-Organism-Total fraction of dose-Dapagliflozin",
                "X": "Time",
                "Y": "PO SD 50 mg (perm)|Organism|Dapagliflozin-UGT1A9-Optimized Metabolite|Total fraction of dose-Dapagliflozin",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "Color": "#00C0C0",
                  "LegendIndex": 49,
                  "LineStyle": "Dash"
                }
              },
              {
                "Name": "PO SD 50 mg (perm)-Dapagliflozin-UGT2B7-Optimized Metabolite-Organism-Total fraction of dose-Dapagliflozin",
                "X": "Time",
                "Y": "PO SD 50 mg (perm)|Organism|Dapagliflozin-UGT2B7-Optimized Metabolite|Total fraction of dose-Dapagliflozin",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "Color": "#C000C0",
                  "LegendIndex": 50,
                  "LineStyle": "Dash"
                }
              },
              {
                "Name": "PO SD 50 mg (perm)-Dapagliflozin-Hepatic-CYP-Optimized Metabolite-Organism-Total fraction of dose-Dapagliflozin",
                "X": "Time",
                "Y": "PO SD 50 mg (perm)|Organism|Dapagliflozin-Hepatic-CYP-Optimized Metabolite|Total fraction of dose-Dapagliflozin",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "Color": "#C04000",
                  "LegendIndex": 51,
                  "LineStyle": "Dash"
                }
              }
            ],
            "Name": "Time Profile",
            "Settings": {
              "SideMarginsEnabled": true,
              "LegendPosition": "None",
              "BackColor": "#FFFFFF",
              "DiagramBackColor": "#FFFFFF"
            }
          }
        }
      ]
    },
    {
      "Name": "PI [-logP]  (perm)",
      "Simulations": [
        "IV 0.08 mg (perm)",
        "PO SD 10 mg (perm)",
        "PO SD 50 mg (perm)",
        "PO SD 100 mg (perm)",
        "PO SD 2.5 mg (perm)",
        "PO SD 20 mg (perm)",
        "PO SD 250 mg (perm)",
        "PO SD 5 mg (perm)",
        "PO SD 500 mg (perm)"
      ],
      "Configuration": {
        "LLOQMode": "OnlyObservedData",
        "RemoveLLOQMode": "Never",
        "CalculateJacobian": true,
        "Algorithm": {
          "Name": "Levenberg - Marquardt (MPFit)",
          "Properties": [
            {
              "Name": "ftol",
              "Value": 0.001
            },
            {
              "Name": "xtol",
              "Value": 1E-06
            },
            {
              "Name": "gtol",
              "Value": 1E-10
            },
            {
              "Name": "stepfactor",
              "Value": 100.0
            },
            {
              "Name": "maxiter",
              "Value": 200.0
            },
            {
              "Name": "maxfev",
              "Value": 0.0
            },
            {
              "Name": "epsfcn",
              "Value": 1E-09
            }
          ]
        }
      },
      "OutputMappings": [
        {
          "Scaling": "Log",
          "Path": "PO SD 50 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Kasichayanula 2013b - Healthy subjects with normal kidney function - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=8)"
        },
        {
          "Scaling": "Log",
          "Path": "PO SD 50 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Kasichayanula 2011b - Study 1: 50 mg Control (Perpetrator Placebo) - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=24)"
        },
        {
          "Scaling": "Linear",
          "Weight": 0.0,
          "Path": "PO SD 50 mg (perm)|Organism|Lumen|Feces|Dapagliflozin|Fraction excreted to feces",
          "ObservedData": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin Feces - Dapagliflozin - PO - 50 mg - Feces - agg. (n=6)"
        },
        {
          "Scaling": "Linear",
          "Weight": 10.0,
          "Path": "PO SD 50 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
          "ObservedData": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin Urine - Dapagliflozin - PO - 50 mg - Urine - agg. (n=6)"
        },
        {
          "Scaling": "Log",
          "Path": "PO SD 10 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Kasichayanula 2011c - Healthy Volunteers - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=6)"
        },
        {
          "Scaling": "Log",
          "Path": "PO SD 10 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Vakkalagadda 2016 - Dapagliflozin - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=42)"
        },
        {
          "Scaling": "Log",
          "Path": "PO SD 10 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Kasichayanula 2013a - Study 2: Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=16)"
        },
        {
          "Scaling": "Log",
          "Path": "PO SD 10 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Kasichayanula 2013a - Study 1: Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=14)"
        },
        {
          "Scaling": "Log",
          "Path": "PO SD 10 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Kasichayanula 2011a - fasted - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=14)"
        },
        {
          "Scaling": "Log",
          "Path": "PO SD 10 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Imamura 2013 - Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=22)"
        },
        {
          "Scaling": "Log",
          "Path": "PO SD 10 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Boulton 2013 - Dapagliflozin po - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=7)"
        },
        {
          "Scaling": "Log",
          "Path": "IV 0.08 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Boulton 2013 - 14C-dapagliflozin iv - Dapagliflozin - IV - 0.08 mg - Plasma - agg. (n=7)"
        },
        {
          "Scaling": "Linear",
          "Weight": 10.0,
          "Path": "PO SD 50 mg (perm)|Organism|Dapagliflozin-UGT1A9-Optimized Metabolite|Total fraction of dose-Dapagliflozin",
          "ObservedData": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin 3OG Gluc (incl. unchanged feces exret.) - Dapagliflozin-3-O-glucuronide - PO - 50 mg - Fraction - agg. (n=6)"
        },
        {
          "Scaling": "Linear",
          "Weight": 10.0,
          "Path": "PO SD 50 mg (perm)|Organism|Dapagliflozin-UGT2B7-Optimized Metabolite|Total fraction of dose-Dapagliflozin",
          "ObservedData": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin 2OG Gluc (incl. unchanged feces exret.) - Dapagliflozin-2-O-glucuronide - PO - 50 mg - Fraction - agg. (n=6)"
        },
        {
          "Scaling": "Linear",
          "Weight": 10.0,
          "Path": "PO SD 50 mg (perm)|Organism|Dapagliflozin-Hepatic-CYP-Optimized Metabolite|Total fraction of dose-Dapagliflozin",
          "ObservedData": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin oxid Metab - Dapagliflozin oxidative metabolites - PO - 50 mg - Fraction - agg. (n=6)"
        },
        {
          "Scaling": "Log",
          "Path": "PO SD 100 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Komoroski 2009 - SAD 100 mg - Dapagliflozin - PO - 100 mg - Plasma - agg. (n=6)"
        },
        {
          "Scaling": "Log",
          "Path": "PO SD 2.5 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Komoroski 2009 - SAD 2.5 mg - Dapagliflozin - PO - 2.5 mg - Plasma - agg. (n=6)"
        },
        {
          "Scaling": "Log",
          "Path": "PO SD 20 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Kasichayanula 2012 - Study 1: Control (Perpetrator Placebo) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=24)"
        },
        {
          "Scaling": "Log",
          "Path": "PO SD 20 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Komoroski 2009 - SAD 20 mg - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=6)"
        },
        {
          "Scaling": "Log",
          "Path": "PO SD 250 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Komoroski 2009 - SAD 250 mg fasted - Dapagliflozin - PO - 250 mg - Plasma - agg. (n=6)"
        },
        {
          "Scaling": "Log",
          "Path": "PO SD 5 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Komoroski 2009 - SAD 5 mg - Dapagliflozin - PO - 5 mg - Plasma - agg. (n=6)"
        },
        {
          "Scaling": "Log",
          "Path": "PO SD 500 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Komoroski 2009 - SAD 500 mg - Dapagliflozin - PO - 500 mg - Plasma - agg. (n=6)"
        },
        {
          "Scaling": "Linear",
          "Path": "PO SD 2.5 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
          "ObservedData": "Komoroski 2009 - SAD 2.5 mg (Urine) - Dapagliflozin - PO - 2.5 mg - Urine - agg. (n=6)"
        },
        {
          "Scaling": "Linear",
          "Path": "PO SD 5 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
          "ObservedData": "Komoroski 2009 - SAD 5 mg (Urine) - Dapagliflozin - PO - 5 mg - Urine - agg. (n=6)"
        },
        {
          "Scaling": "Linear",
          "Path": "PO SD 10 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
          "ObservedData": "Komoroski 2009 - SAD 10 mg (Urine) - Dapagliflozin - PO - 10 mg - Urine - agg. (n=6)"
        },
        {
          "Scaling": "Linear",
          "Path": "PO SD 20 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
          "ObservedData": "Komoroski 2009 - SAD 20 mg (Urine) - Dapagliflozin - PO - 20 mg - Urine - agg. (n=6)"
        },
        {
          "Scaling": "Linear",
          "Path": "PO SD 50 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
          "ObservedData": "Komoroski 2009 - SAD 50 mg (Urine) - Dapagliflozin - PO - 50 mg - Urine - agg. (n=6)"
        },
        {
          "Scaling": "Linear",
          "Path": "PO SD 100 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
          "ObservedData": "Komoroski 2009 - SAD 100 mg (Urine) - Dapagliflozin - PO - 100 mg - Urine - agg. (n=6)"
        },
        {
          "Scaling": "Linear",
          "Path": "PO SD 250 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
          "ObservedData": "Komoroski 2009 - SAD 250 mg fasted (Urine) - Dapagliflozin - PO - 250 mg - Urine - agg. (n=6)"
        },
        {
          "Scaling": "Linear",
          "Path": "PO SD 500 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
          "ObservedData": "Komoroski 2009 - SAD 500 mg (Urine) - Dapagliflozin - PO - 500 mg - Urine - agg. (n=6)"
        }
      ],
      "IdentificationParameters": [
        {
          "Name": "Lipophilicity",
          "Scaling": "Linear",
          "LinkedParameters": [
            "IV 0.08 mg (perm)|Dapagliflozin|Lipophilicity",
            "PO SD 10 mg (perm)|Dapagliflozin|Lipophilicity",
            "PO SD 50 mg (perm)|Dapagliflozin|Lipophilicity",
            "PO SD 100 mg (perm)|Dapagliflozin|Lipophilicity",
            "PO SD 2.5 mg (perm)|Dapagliflozin|Lipophilicity",
            "PO SD 20 mg (perm)|Dapagliflozin|Lipophilicity",
            "PO SD 250 mg (perm)|Dapagliflozin|Lipophilicity",
            "PO SD 5 mg (perm)|Dapagliflozin|Lipophilicity",
            "PO SD 500 mg (perm)|Dapagliflozin|Lipophilicity"
          ],
          "Parameters": [
            {
              "Name": "Start value",
              "Value": 2.546,
              "Unit": "Log Units"
            },
            {
              "Name": "MinValue",
              "Value": 1.0,
              "Unit": "Log Units"
            },
            {
              "Name": "MaxValue",
              "Value": 4.0,
              "Unit": "Log Units"
            }
          ]
        },
        {
          "Name": "P int",
          "Scaling": "Log",
          "LinkedParameters": [
            "IV 0.08 mg (perm)|Dapagliflozin|Specific intestinal permeability (transcellular)",
            "PO SD 10 mg (perm)|Dapagliflozin|Specific intestinal permeability (transcellular)",
            "PO SD 50 mg (perm)|Dapagliflozin|Specific intestinal permeability (transcellular)",
            "PO SD 100 mg (perm)|Dapagliflozin|Specific intestinal permeability (transcellular)",
            "PO SD 2.5 mg (perm)|Dapagliflozin|Specific intestinal permeability (transcellular)",
            "PO SD 20 mg (perm)|Dapagliflozin|Specific intestinal permeability (transcellular)",
            "PO SD 250 mg (perm)|Dapagliflozin|Specific intestinal permeability (transcellular)",
            "PO SD 5 mg (perm)|Dapagliflozin|Specific intestinal permeability (transcellular)",
            "PO SD 500 mg (perm)|Dapagliflozin|Specific intestinal permeability (transcellular)"
          ],
          "Parameters": [
            {
              "Name": "Start value",
              "Value": 4E-05,
              "Unit": "cm/min"
            },
            {
              "Name": "MinValue",
              "Value": 1E-06,
              "Unit": "cm/min"
            },
            {
              "Name": "MaxValue",
              "Value": 0.01,
              "Unit": "cm/min"
            }
          ]
        },
        {
          "Name": "UGT1A9",
          "Scaling": "Log",
          "LinkedParameters": [
            "IV 0.08 mg (perm)|Dapagliflozin-UGT1A9-Optimized|CLspec/[Enzyme]",
            "PO SD 10 mg (perm)|Dapagliflozin-UGT1A9-Optimized|CLspec/[Enzyme]",
            "PO SD 50 mg (perm)|Dapagliflozin-UGT1A9-Optimized|CLspec/[Enzyme]",
            "PO SD 100 mg (perm)|Dapagliflozin-UGT1A9-Optimized|CLspec/[Enzyme]",
            "PO SD 2.5 mg (perm)|Dapagliflozin-UGT1A9-Optimized|CLspec/[Enzyme]",
            "PO SD 20 mg (perm)|Dapagliflozin-UGT1A9-Optimized|CLspec/[Enzyme]",
            "PO SD 250 mg (perm)|Dapagliflozin-UGT1A9-Optimized|CLspec/[Enzyme]",
            "PO SD 5 mg (perm)|Dapagliflozin-UGT1A9-Optimized|CLspec/[Enzyme]",
            "PO SD 500 mg (perm)|Dapagliflozin-UGT1A9-Optimized|CLspec/[Enzyme]"
          ],
          "Parameters": [
            {
              "Name": "Start value",
              "Value": 0.4,
              "Unit": "l/µmol/min"
            },
            {
              "Name": "MinValue",
              "Value": 0.001,
              "Unit": "l/µmol/min"
            },
            {
              "Name": "MaxValue",
              "Value": 100.0,
              "Unit": "l/µmol/min"
            }
          ]
        },
        {
          "Name": "UGT2B7",
          "Scaling": "Log",
          "LinkedParameters": [
            "IV 0.08 mg (perm)|Dapagliflozin-UGT2B7-Optimized|CLspec/[Enzyme]",
            "PO SD 10 mg (perm)|Dapagliflozin-UGT2B7-Optimized|CLspec/[Enzyme]",
            "PO SD 50 mg (perm)|Dapagliflozin-UGT2B7-Optimized|CLspec/[Enzyme]",
            "PO SD 100 mg (perm)|Dapagliflozin-UGT2B7-Optimized|CLspec/[Enzyme]",
            "PO SD 2.5 mg (perm)|Dapagliflozin-UGT2B7-Optimized|CLspec/[Enzyme]",
            "PO SD 20 mg (perm)|Dapagliflozin-UGT2B7-Optimized|CLspec/[Enzyme]",
            "PO SD 250 mg (perm)|Dapagliflozin-UGT2B7-Optimized|CLspec/[Enzyme]",
            "PO SD 5 mg (perm)|Dapagliflozin-UGT2B7-Optimized|CLspec/[Enzyme]",
            "PO SD 500 mg (perm)|Dapagliflozin-UGT2B7-Optimized|CLspec/[Enzyme]"
          ],
          "Parameters": [
            {
              "Name": "Start value",
              "Value": 0.02,
              "Unit": "l/µmol/min"
            },
            {
              "Name": "MinValue",
              "Value": 0.001,
              "Unit": "l/µmol/min"
            },
            {
              "Name": "MaxValue",
              "Value": 100.0,
              "Unit": "l/µmol/min"
            }
          ]
        },
        {
          "Name": "Hep-CYP",
          "Scaling": "Log",
          "LinkedParameters": [
            "IV 0.08 mg (perm)|Dapagliflozin-Hepatic-CYP-Optimized|CLspec/[Enzyme]",
            "PO SD 10 mg (perm)|Dapagliflozin-Hepatic-CYP-Optimized|CLspec/[Enzyme]",
            "PO SD 50 mg (perm)|Dapagliflozin-Hepatic-CYP-Optimized|CLspec/[Enzyme]",
            "PO SD 100 mg (perm)|Dapagliflozin-Hepatic-CYP-Optimized|CLspec/[Enzyme]",
            "PO SD 2.5 mg (perm)|Dapagliflozin-Hepatic-CYP-Optimized|CLspec/[Enzyme]",
            "PO SD 20 mg (perm)|Dapagliflozin-Hepatic-CYP-Optimized|CLspec/[Enzyme]",
            "PO SD 250 mg (perm)|Dapagliflozin-Hepatic-CYP-Optimized|CLspec/[Enzyme]",
            "PO SD 5 mg (perm)|Dapagliflozin-Hepatic-CYP-Optimized|CLspec/[Enzyme]",
            "PO SD 500 mg (perm)|Dapagliflozin-Hepatic-CYP-Optimized|CLspec/[Enzyme]"
          ],
          "Parameters": [
            {
              "Name": "Start value",
              "Value": 0.15,
              "Unit": "l/µmol/min"
            },
            {
              "Name": "MinValue",
              "Value": 0.001,
              "Unit": "l/µmol/min"
            },
            {
              "Name": "MaxValue",
              "Value": 100.0,
              "Unit": "l/µmol/min"
            }
          ]
        },
        {
          "Name": "Solubility",
          "Scaling": "Log",
          "LinkedParameters": [
            "IV 0.08 mg (perm)|Dapagliflozin|Solubility at reference pH",
            "PO SD 10 mg (perm)|Dapagliflozin|Solubility at reference pH",
            "PO SD 50 mg (perm)|Dapagliflozin|Solubility at reference pH",
            "PO SD 100 mg (perm)|Dapagliflozin|Solubility at reference pH",
            "PO SD 2.5 mg (perm)|Dapagliflozin|Solubility at reference pH",
            "PO SD 20 mg (perm)|Dapagliflozin|Solubility at reference pH",
            "PO SD 250 mg (perm)|Dapagliflozin|Solubility at reference pH",
            "PO SD 5 mg (perm)|Dapagliflozin|Solubility at reference pH",
            "PO SD 500 mg (perm)|Dapagliflozin|Solubility at reference pH"
          ],
          "Parameters": [
            {
              "Name": "Start value",
              "Value": 0.173,
              "Unit": "mg/ml"
            },
            {
              "Name": "MinValue",
              "Value": 0.01,
              "Unit": "mg/ml"
            },
            {
              "Name": "MaxValue",
              "Value": 100.0,
              "Unit": "mg/ml"
            }
          ]
        },
        {
          "Name": "Permeability",
          "Scaling": "Log",
          "LinkedParameters": [
            "IV 0.08 mg (perm)|Dapagliflozin|Permeability",
            "PO SD 10 mg (perm)|Dapagliflozin|Permeability",
            "PO SD 50 mg (perm)|Dapagliflozin|Permeability",
            "PO SD 100 mg (perm)|Dapagliflozin|Permeability",
            "PO SD 2.5 mg (perm)|Dapagliflozin|Permeability",
            "PO SD 20 mg (perm)|Dapagliflozin|Permeability",
            "PO SD 250 mg (perm)|Dapagliflozin|Permeability",
            "PO SD 5 mg (perm)|Dapagliflozin|Permeability",
            "PO SD 500 mg (perm)|Dapagliflozin|Permeability"
          ],
          "Parameters": [
            {
              "Name": "Start value",
              "Value": 0.0004257,
              "Unit": "cm/min"
            },
            {
              "Name": "MinValue",
              "Value": 1E-06,
              "Unit": "cm/min"
            },
            {
              "Name": "MaxValue",
              "Value": 0.01,
              "Unit": "cm/min"
            }
          ]
        },
        {
          "Name": "GFR fraction",
          "Scaling": "Linear",
          "LinkedParameters": [
            "IV 0.08 mg (perm)|Neighborhoods|Kidney_pls_Kidney_ur|Dapagliflozin|Glomerular Filtration-assumed|GFR fraction",
            "PO SD 10 mg (perm)|Neighborhoods|Kidney_pls_Kidney_ur|Dapagliflozin|Glomerular Filtration-assumed|GFR fraction",
            "PO SD 50 mg (perm)|Neighborhoods|Kidney_pls_Kidney_ur|Dapagliflozin|Glomerular Filtration-assumed|GFR fraction",
            "PO SD 100 mg (perm)|Neighborhoods|Kidney_pls_Kidney_ur|Dapagliflozin|Glomerular Filtration-assumed|GFR fraction",
            "PO SD 2.5 mg (perm)|Neighborhoods|Kidney_pls_Kidney_ur|Dapagliflozin|Glomerular Filtration-assumed|GFR fraction",
            "PO SD 20 mg (perm)|Neighborhoods|Kidney_pls_Kidney_ur|Dapagliflozin|Glomerular Filtration-assumed|GFR fraction",
            "PO SD 250 mg (perm)|Neighborhoods|Kidney_pls_Kidney_ur|Dapagliflozin|Glomerular Filtration-assumed|GFR fraction",
            "PO SD 5 mg (perm)|Neighborhoods|Kidney_pls_Kidney_ur|Dapagliflozin|Glomerular Filtration-assumed|GFR fraction",
            "PO SD 500 mg (perm)|Neighborhoods|Kidney_pls_Kidney_ur|Dapagliflozin|Glomerular Filtration-assumed|GFR fraction"
          ],
          "Parameters": [
            {
              "Name": "Start value",
              "Value": 1.0
            },
            {
              "Name": "MinValue",
              "Value": 0.1
            },
            {
              "Name": "MaxValue",
              "Value": 10.0
            }
          ]
        },
        {
          "Name": "Blood/Plasma concentration ratio",
          "Scaling": "Linear",
          "IsFixed": true,
          "LinkedParameters": [
            "IV 0.08 mg (perm)|Dapagliflozin|Blood/Plasma concentration ratio",
            "PO SD 10 mg (perm)|Dapagliflozin|Blood/Plasma concentration ratio",
            "PO SD 50 mg (perm)|Dapagliflozin|Blood/Plasma concentration ratio",
            "PO SD 100 mg (perm)|Dapagliflozin|Blood/Plasma concentration ratio",
            "PO SD 2.5 mg (perm)|Dapagliflozin|Blood/Plasma concentration ratio",
            "PO SD 20 mg (perm)|Dapagliflozin|Blood/Plasma concentration ratio",
            "PO SD 250 mg (perm)|Dapagliflozin|Blood/Plasma concentration ratio",
            "PO SD 5 mg (perm)|Dapagliflozin|Blood/Plasma concentration ratio",
            "PO SD 500 mg (perm)|Dapagliflozin|Blood/Plasma concentration ratio"
          ],
          "Parameters": [
            {
              "Name": "Start value",
              "Value": 0.88
            },
            {
              "Name": "MinValue",
              "Value": 0.0
            },
            {
              "Name": "MaxValue",
              "Value": 6.1244936725
            }
          ]
        }
      ],
      "Analyses": [
        {
          "Name": "Time Profile",
          "Type": "ParameterIdentificationTimeProfileChart",
          "Chart": {
            "Axes": [
              {
                "Unit": "h",
                "Dimension": "Time",
                "Type": "X",
                "GridLines": false,
                "Visible": true,
                "Min": 0.05,
                "Max": 24.0,
                "DefaultColor": "#FFFFFF",
                "DefaultLineStyle": "None",
                "Scaling": "Linear",
                "NumberMode": "Normal"
              },
              {
                "Unit": "mg/l",
                "Dimension": "Concentration (mass)",
                "Type": "Y",
                "GridLines": false,
                "Visible": true,
                "Min": 0.0001,
                "Max": 5.0,
                "DefaultColor": "#FFFFFF",
                "DefaultLineStyle": "Solid",
                "Scaling": "Log",
                "NumberMode": "Normal"
              },
              {
                "Unit": "%",
                "Dimension": "Fraction",
                "Type": "Y2",
                "GridLines": false,
                "Visible": true,
                "DefaultColor": "#FFFFFF",
                "DefaultLineStyle": "Dash",
                "Scaling": "Linear",
                "NumberMode": "Normal"
              }
            ],
            "Curves": [
              {
                "Name": "Kasichayanula 2013b - Healthy subjects with normal kidney function - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=8)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
                "X": "Kasichayanula 2013b - Healthy subjects with normal kidney function - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=8)|Time",
                "Y": "Kasichayanula 2013b - Healthy subjects with normal kidney function - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=8)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "VisibleInLegend": false,
                  "Color": "#FF0000",
                  "LegendIndex": 1,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Kasichayanula 2011b - Study 1: 50 mg Control (Perpetrator Placebo) - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=24)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
                "X": "Kasichayanula 2011b - Study 1: 50 mg Control (Perpetrator Placebo) - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=24)|Time",
                "Y": "Kasichayanula 2011b - Study 1: 50 mg Control (Perpetrator Placebo) - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=24)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "VisibleInLegend": false,
                  "Color": "#FF0000",
                  "LegendIndex": 2,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin Feces - Dapagliflozin - PO - 50 mg - Feces - agg. (n=6)-Dapagliflozin-Lumen-Feces-ArithmeticMean",
                "X": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin Feces - Dapagliflozin - PO - 50 mg - Feces - agg. (n=6)|Time",
                "Y": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin Feces - Dapagliflozin - PO - 50 mg - Feces - agg. (n=6)|ObservedData|Lumen|Feces|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "VisibleInLegend": false,
                  "Color": "#0000FF",
                  "LegendIndex": 3,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin Urine - Dapagliflozin - PO - 50 mg - Urine - agg. (n=6)-Dapagliflozin-Kidney-Urine-ArithmeticMean",
                "X": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin Urine - Dapagliflozin - PO - 50 mg - Urine - agg. (n=6)|Time",
                "Y": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin Urine - Dapagliflozin - PO - 50 mg - Urine - agg. (n=6)|ObservedData|Kidney|Urine|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "VisibleInLegend": false,
                  "Color": "#008000",
                  "LegendIndex": 4,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Komoroski 2009 - SAD 50 mg (Urine) - Dapagliflozin - PO - 50 mg - Urine - agg. (n=6)-Dapagliflozin-Kidney-Urine-ArithmeticMean",
                "X": "Komoroski 2009 - SAD 50 mg (Urine) - Dapagliflozin - PO - 50 mg - Urine - agg. (n=6)|Time",
                "Y": "Komoroski 2009 - SAD 50 mg (Urine) - Dapagliflozin - PO - 50 mg - Urine - agg. (n=6)|ObservedData|Kidney|Urine|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "VisibleInLegend": false,
                  "Color": "#008000",
                  "LegendIndex": 5,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Kasichayanula 2011c - Healthy Volunteers - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=6)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
                "X": "Kasichayanula 2011c - Healthy Volunteers - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=6)|Time",
                "Y": "Kasichayanula 2011c - Healthy Volunteers - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "VisibleInLegend": false,
                  "Color": "#FF00FF",
                  "LegendIndex": 6,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Vakkalagadda 2016 - Dapagliflozin - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=42)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
                "X": "Vakkalagadda 2016 - Dapagliflozin - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=42)|Time",
                "Y": "Vakkalagadda 2016 - Dapagliflozin - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=42)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "VisibleInLegend": false,
                  "Color": "#FF00FF",
                  "LegendIndex": 7,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Kasichayanula 2013a - Study 2: Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=16)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
                "X": "Kasichayanula 2013a - Study 2: Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=16)|Time",
                "Y": "Kasichayanula 2013a - Study 2: Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=16)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "VisibleInLegend": false,
                  "Color": "#FF00FF",
                  "LegendIndex": 8,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Kasichayanula 2013a - Study 1: Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=14)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
                "X": "Kasichayanula 2013a - Study 1: Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=14)|Time",
                "Y": "Kasichayanula 2013a - Study 1: Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=14)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "VisibleInLegend": false,
                  "Color": "#FF00FF",
                  "LegendIndex": 9,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Kasichayanula 2011a - fasted - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=14)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
                "X": "Kasichayanula 2011a - fasted - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=14)|Time",
                "Y": "Kasichayanula 2011a - fasted - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=14)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "VisibleInLegend": false,
                  "Color": "#FF00FF",
                  "LegendIndex": 10,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Imamura 2013 - Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=22)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
                "X": "Imamura 2013 - Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=22)|Time",
                "Y": "Imamura 2013 - Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=22)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "VisibleInLegend": false,
                  "Color": "#FF00FF",
                  "LegendIndex": 11,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Boulton 2013 - Dapagliflozin po - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=7)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
                "X": "Boulton 2013 - Dapagliflozin po - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=7)|Time",
                "Y": "Boulton 2013 - Dapagliflozin po - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=7)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "VisibleInLegend": false,
                  "Color": "#FF00FF",
                  "LegendIndex": 12,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Boulton 2013 - 14C-dapagliflozin iv - Dapagliflozin - IV - 0.08 mg - Plasma - agg. (n=7)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
                "X": "Boulton 2013 - 14C-dapagliflozin iv - Dapagliflozin - IV - 0.08 mg - Plasma - agg. (n=7)|Time",
                "Y": "Boulton 2013 - 14C-dapagliflozin iv - Dapagliflozin - IV - 0.08 mg - Plasma - agg. (n=7)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "VisibleInLegend": false,
                  "Color": "#FF8000",
                  "LegendIndex": 13,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin 3OG Gluc (incl. unchanged feces exret.) - Dapagliflozin-3-O-glucuronide - PO - 50 mg - Fraction - agg. (n=6)-Dapagliflozin-3-O-glucuronide-Undefined-Undefined-ArithmeticMean",
                "X": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin 3OG Gluc (incl. unchanged feces exret.) - Dapagliflozin-3-O-glucuronide - PO - 50 mg - Fraction - agg. (n=6)|Time",
                "Y": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin 3OG Gluc (incl. unchanged feces exret.) - Dapagliflozin-3-O-glucuronide - PO - 50 mg - Fraction - agg. (n=6)|ObservedData|Undefined|Undefined|Dapagliflozin-3-O-glucuronide|ArithmeticMean",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "VisibleInLegend": false,
                  "Color": "#00C0C0",
                  "LegendIndex": 14,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin 2OG Gluc (incl. unchanged feces exret.) - Dapagliflozin-2-O-glucuronide - PO - 50 mg - Fraction - agg. (n=6)-Dapagliflozin-2-O-glucuronide-Undefined-Undefined-ArithmeticMean",
                "X": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin 2OG Gluc (incl. unchanged feces exret.) - Dapagliflozin-2-O-glucuronide - PO - 50 mg - Fraction - agg. (n=6)|Time",
                "Y": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin 2OG Gluc (incl. unchanged feces exret.) - Dapagliflozin-2-O-glucuronide - PO - 50 mg - Fraction - agg. (n=6)|ObservedData|Undefined|Undefined|Dapagliflozin-2-O-glucuronide|ArithmeticMean",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "VisibleInLegend": false,
                  "Color": "#C000C0",
                  "LegendIndex": 15,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin oxid Metab - Dapagliflozin oxidative metabolites - PO - 50 mg - Fraction - agg. (n=6)-Dapagliflozin oxidative metabolites-Undefined-Undefined-ArithmeticMean",
                "X": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin oxid Metab - Dapagliflozin oxidative metabolites - PO - 50 mg - Fraction - agg. (n=6)|Time",
                "Y": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin oxid Metab - Dapagliflozin oxidative metabolites - PO - 50 mg - Fraction - agg. (n=6)|ObservedData|Undefined|Undefined|Dapagliflozin oxidative metabolites|ArithmeticMean",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "VisibleInLegend": false,
                  "Color": "#C04000",
                  "LegendIndex": 16,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Komoroski 2009 - SAD 100 mg - Dapagliflozin - PO - 100 mg - Plasma - agg. (n=6)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
                "X": "Komoroski 2009 - SAD 100 mg - Dapagliflozin - PO - 100 mg - Plasma - agg. (n=6)|Time",
                "Y": "Komoroski 2009 - SAD 100 mg - Dapagliflozin - PO - 100 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "VisibleInLegend": false,
                  "Color": "#00FF00",
                  "LegendIndex": 17,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Komoroski 2009 - SAD 2.5 mg - Dapagliflozin - PO - 2.5 mg - Plasma - agg. (n=6)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
                "X": "Komoroski 2009 - SAD 2.5 mg - Dapagliflozin - PO - 2.5 mg - Plasma - agg. (n=6)|Time",
                "Y": "Komoroski 2009 - SAD 2.5 mg - Dapagliflozin - PO - 2.5 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "VisibleInLegend": false,
                  "Color": "#808080",
                  "LegendIndex": 18,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Kasichayanula 2012 - Study 1: Control (Perpetrator Placebo) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=24)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
                "X": "Kasichayanula 2012 - Study 1: Control (Perpetrator Placebo) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=24)|Time",
                "Y": "Kasichayanula 2012 - Study 1: Control (Perpetrator Placebo) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=24)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "VisibleInLegend": false,
                  "Color": "#C0C000",
                  "LegendIndex": 19,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Komoroski 2009 - SAD 20 mg - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=6)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
                "X": "Komoroski 2009 - SAD 20 mg - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=6)|Time",
                "Y": "Komoroski 2009 - SAD 20 mg - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "VisibleInLegend": false,
                  "Color": "#C0C000",
                  "LegendIndex": 20,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Komoroski 2009 - SAD 250 mg fasted - Dapagliflozin - PO - 250 mg - Plasma - agg. (n=6)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
                "X": "Komoroski 2009 - SAD 250 mg fasted - Dapagliflozin - PO - 250 mg - Plasma - agg. (n=6)|Time",
                "Y": "Komoroski 2009 - SAD 250 mg fasted - Dapagliflozin - PO - 250 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "VisibleInLegend": false,
                  "Color": "#8080FF",
                  "LegendIndex": 21,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Komoroski 2009 - SAD 5 mg - Dapagliflozin - PO - 5 mg - Plasma - agg. (n=6)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
                "X": "Komoroski 2009 - SAD 5 mg - Dapagliflozin - PO - 5 mg - Plasma - agg. (n=6)|Time",
                "Y": "Komoroski 2009 - SAD 5 mg - Dapagliflozin - PO - 5 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "VisibleInLegend": false,
                  "Color": "#0000C0",
                  "LegendIndex": 22,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Komoroski 2009 - SAD 500 mg - Dapagliflozin - PO - 500 mg - Plasma - agg. (n=6)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
                "X": "Komoroski 2009 - SAD 500 mg - Dapagliflozin - PO - 500 mg - Plasma - agg. (n=6)|Time",
                "Y": "Komoroski 2009 - SAD 500 mg - Dapagliflozin - PO - 500 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "VisibleInLegend": false,
                  "Color": "#00C000",
                  "LegendIndex": 23,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Komoroski 2009 - SAD 2.5 mg (Urine) - Dapagliflozin - PO - 2.5 mg - Urine - agg. (n=6)-Dapagliflozin-Kidney-Urine-ArithmeticMean",
                "X": "Komoroski 2009 - SAD 2.5 mg (Urine) - Dapagliflozin - PO - 2.5 mg - Urine - agg. (n=6)|Time",
                "Y": "Komoroski 2009 - SAD 2.5 mg (Urine) - Dapagliflozin - PO - 2.5 mg - Urine - agg. (n=6)|ObservedData|Kidney|Urine|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "VisibleInLegend": false,
                  "Color": "#C00000",
                  "LegendIndex": 24,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Komoroski 2009 - SAD 5 mg (Urine) - Dapagliflozin - PO - 5 mg - Urine - agg. (n=6)-Dapagliflozin-Kidney-Urine-ArithmeticMean",
                "X": "Komoroski 2009 - SAD 5 mg (Urine) - Dapagliflozin - PO - 5 mg - Urine - agg. (n=6)|Time",
                "Y": "Komoroski 2009 - SAD 5 mg (Urine) - Dapagliflozin - PO - 5 mg - Urine - agg. (n=6)|ObservedData|Kidney|Urine|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "VisibleInLegend": false,
                  "Color": "#FFFF00",
                  "LegendIndex": 25,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Komoroski 2009 - SAD 10 mg (Urine) - Dapagliflozin - PO - 10 mg - Urine - agg. (n=6)-Dapagliflozin-Kidney-Urine-ArithmeticMean",
                "X": "Komoroski 2009 - SAD 10 mg (Urine) - Dapagliflozin - PO - 10 mg - Urine - agg. (n=6)|Time",
                "Y": "Komoroski 2009 - SAD 10 mg (Urine) - Dapagliflozin - PO - 10 mg - Urine - agg. (n=6)|ObservedData|Kidney|Urine|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "VisibleInLegend": false,
                  "Color": "#008080",
                  "LegendIndex": 26,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Komoroski 2009 - SAD 20 mg (Urine) - Dapagliflozin - PO - 20 mg - Urine - agg. (n=6)-Dapagliflozin-Kidney-Urine-ArithmeticMean",
                "X": "Komoroski 2009 - SAD 20 mg (Urine) - Dapagliflozin - PO - 20 mg - Urine - agg. (n=6)|Time",
                "Y": "Komoroski 2009 - SAD 20 mg (Urine) - Dapagliflozin - PO - 20 mg - Urine - agg. (n=6)|ObservedData|Kidney|Urine|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "VisibleInLegend": false,
                  "Color": "#800080",
                  "LegendIndex": 27,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Komoroski 2009 - SAD 100 mg (Urine) - Dapagliflozin - PO - 100 mg - Urine - agg. (n=6)-Dapagliflozin-Kidney-Urine-ArithmeticMean",
                "X": "Komoroski 2009 - SAD 100 mg (Urine) - Dapagliflozin - PO - 100 mg - Urine - agg. (n=6)|Time",
                "Y": "Komoroski 2009 - SAD 100 mg (Urine) - Dapagliflozin - PO - 100 mg - Urine - agg. (n=6)|ObservedData|Kidney|Urine|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "VisibleInLegend": false,
                  "Color": "#804040",
                  "LegendIndex": 28,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Komoroski 2009 - SAD 250 mg fasted (Urine) - Dapagliflozin - PO - 250 mg - Urine - agg. (n=6)-Dapagliflozin-Kidney-Urine-ArithmeticMean",
                "X": "Komoroski 2009 - SAD 250 mg fasted (Urine) - Dapagliflozin - PO - 250 mg - Urine - agg. (n=6)|Time",
                "Y": "Komoroski 2009 - SAD 250 mg fasted (Urine) - Dapagliflozin - PO - 250 mg - Urine - agg. (n=6)|ObservedData|Kidney|Urine|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "VisibleInLegend": false,
                  "Color": "#80FF80",
                  "LegendIndex": 29,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Komoroski 2009 - SAD 500 mg (Urine) - Dapagliflozin - PO - 500 mg - Urine - agg. (n=6)-Dapagliflozin-Kidney-Urine-ArithmeticMean",
                "X": "Komoroski 2009 - SAD 500 mg (Urine) - Dapagliflozin - PO - 500 mg - Urine - agg. (n=6)|Time",
                "Y": "Komoroski 2009 - SAD 500 mg (Urine) - Dapagliflozin - PO - 500 mg - Urine - agg. (n=6)|ObservedData|Kidney|Urine|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "VisibleInLegend": false,
                  "Color": "#808000",
                  "LegendIndex": 30,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "PO SD 5 mg (perm)-Dapagliflozin-Peripheral Venous Blood-Plasma-Concentration",
                "X": "Time",
                "Y": "PO SD 5 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
                "CurveOptions": {
                  "Color": "#0000C0",
                  "LegendIndex": 31
                }
              },
              {
                "Name": "PO SD 5 mg (perm)-Dapagliflozin-Kidney-Urine-Fraction excreted to urine",
                "X": "Time",
                "Y": "PO SD 5 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "Color": "#FFFF00",
                  "LegendIndex": 32,
                  "LineStyle": "Dash"
                }
              },
              {
                "Name": "PO SD 100 mg (perm)-Dapagliflozin-Peripheral Venous Blood-Plasma-Concentration",
                "X": "Time",
                "Y": "PO SD 100 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
                "CurveOptions": {
                  "Color": "#00FF00",
                  "LegendIndex": 33
                }
              },
              {
                "Name": "PO SD 100 mg (perm)-Dapagliflozin-Kidney-Urine-Fraction excreted to urine",
                "X": "Time",
                "Y": "PO SD 100 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "Color": "#804040",
                  "LegendIndex": 34,
                  "LineStyle": "Dash"
                }
              },
              {
                "Name": "PO SD 500 mg (perm)-Dapagliflozin-Peripheral Venous Blood-Plasma-Concentration",
                "X": "Time",
                "Y": "PO SD 500 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
                "CurveOptions": {
                  "Color": "#00C000",
                  "LegendIndex": 35
                }
              },
              {
                "Name": "PO SD 500 mg (perm)-Dapagliflozin-Kidney-Urine-Fraction excreted to urine",
                "X": "Time",
                "Y": "PO SD 500 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "Color": "#808000",
                  "LegendIndex": 36,
                  "LineStyle": "Dash"
                }
              },
              {
                "Name": "IV 0.08 mg (perm)-Dapagliflozin-Peripheral Venous Blood-Plasma-Concentration",
                "X": "Time",
                "Y": "IV 0.08 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
                "CurveOptions": {
                  "Color": "#FF8000",
                  "LegendIndex": 37
                }
              },
              {
                "Name": "PO SD 2.5 mg (perm)-Dapagliflozin-Peripheral Venous Blood-Plasma-Concentration",
                "X": "Time",
                "Y": "PO SD 2.5 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
                "CurveOptions": {
                  "Color": "#808080",
                  "LegendIndex": 38
                }
              },
              {
                "Name": "PO SD 2.5 mg (perm)-Dapagliflozin-Kidney-Urine-Fraction excreted to urine",
                "X": "Time",
                "Y": "PO SD 2.5 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "Color": "#C00000",
                  "LegendIndex": 39,
                  "LineStyle": "Dash"
                }
              },
              {
                "Name": "PO SD 20 mg (perm)-Dapagliflozin-Peripheral Venous Blood-Plasma-Concentration",
                "X": "Time",
                "Y": "PO SD 20 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
                "CurveOptions": {
                  "Color": "#C0C000",
                  "LegendIndex": 40
                }
              },
              {
                "Name": "PO SD 20 mg (perm)-Dapagliflozin-Kidney-Urine-Fraction excreted to urine",
                "X": "Time",
                "Y": "PO SD 20 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "Color": "#800080",
                  "LegendIndex": 41,
                  "LineStyle": "Dash"
                }
              },
              {
                "Name": "PO SD 10 mg (perm)-Dapagliflozin-Peripheral Venous Blood-Plasma-Concentration",
                "X": "Time",
                "Y": "PO SD 10 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
                "CurveOptions": {
                  "Color": "#FF00FF",
                  "LegendIndex": 42
                }
              },
              {
                "Name": "PO SD 10 mg (perm)-Dapagliflozin-Kidney-Urine-Fraction excreted to urine",
                "X": "Time",
                "Y": "PO SD 10 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "Color": "#008080",
                  "LegendIndex": 43,
                  "LineStyle": "Dash"
                }
              },
              {
                "Name": "PO SD 50 mg (perm)-Dapagliflozin-Peripheral Venous Blood-Plasma-Concentration",
                "X": "Time",
                "Y": "PO SD 50 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
                "CurveOptions": {
                  "Color": "#FF0000",
                  "LegendIndex": 44
                }
              },
              {
                "Name": "PO SD 50 mg (perm)-Dapagliflozin-Kidney-Urine-Fraction excreted to urine",
                "X": "Time",
                "Y": "PO SD 50 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "Color": "#008000",
                  "LegendIndex": 45,
                  "LineStyle": "Dash"
                }
              },
              {
                "Name": "PO SD 50 mg (perm)-Dapagliflozin-Lumen-Feces-Fraction excreted to feces",
                "X": "Time",
                "Y": "PO SD 50 mg (perm)|Organism|Lumen|Feces|Dapagliflozin|Fraction excreted to feces",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "Color": "#0000FF",
                  "LegendIndex": 46,
                  "LineStyle": "Dash"
                }
              },
              {
                "Name": "PO SD 50 mg (perm)-Dapagliflozin-UGT1A9-Optimized Metabolite-Organism-Total fraction of dose-Dapagliflozin",
                "X": "Time",
                "Y": "PO SD 50 mg (perm)|Organism|Dapagliflozin-UGT1A9-Optimized Metabolite|Total fraction of dose-Dapagliflozin",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "Color": "#00C0C0",
                  "LegendIndex": 47,
                  "LineStyle": "Dash"
                }
              },
              {
                "Name": "PO SD 50 mg (perm)-Dapagliflozin-UGT2B7-Optimized Metabolite-Organism-Total fraction of dose-Dapagliflozin",
                "X": "Time",
                "Y": "PO SD 50 mg (perm)|Organism|Dapagliflozin-UGT2B7-Optimized Metabolite|Total fraction of dose-Dapagliflozin",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "Color": "#C000C0",
                  "LegendIndex": 48,
                  "LineStyle": "Dash"
                }
              },
              {
                "Name": "PO SD 50 mg (perm)-Dapagliflozin-Hepatic-CYP-Optimized Metabolite-Organism-Total fraction of dose-Dapagliflozin",
                "X": "Time",
                "Y": "PO SD 50 mg (perm)|Organism|Dapagliflozin-Hepatic-CYP-Optimized Metabolite|Total fraction of dose-Dapagliflozin",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "Color": "#C04000",
                  "LegendIndex": 49,
                  "LineStyle": "Dash"
                }
              },
              {
                "Name": "PO SD 250 mg (perm)-Dapagliflozin-Peripheral Venous Blood-Plasma-Concentration",
                "X": "Time",
                "Y": "PO SD 250 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
                "CurveOptions": {
                  "Color": "#8080FF",
                  "LegendIndex": 50
                }
              },
              {
                "Name": "PO SD 250 mg (perm)-Dapagliflozin-Kidney-Urine-Fraction excreted to urine",
                "X": "Time",
                "Y": "PO SD 250 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "Color": "#80FF80",
                  "LegendIndex": 51,
                  "LineStyle": "Dash"
                }
              }
            ],
            "Name": "Time Profile",
            "Settings": {
              "SideMarginsEnabled": true,
              "LegendPosition": "None",
              "BackColor": "#FFFFFF",
              "DiagramBackColor": "#FFFFFF"
            }
          }
        }
      ]
    },
    {
      "Name": "PI [-Solub]  (perm)",
      "Simulations": [
        "IV 0.08 mg (perm)",
        "PO SD 10 mg (perm)",
        "PO SD 50 mg (perm)",
        "PO SD 100 mg (perm)",
        "PO SD 2.5 mg (perm)",
        "PO SD 20 mg (perm)",
        "PO SD 250 mg (perm)",
        "PO SD 5 mg (perm)",
        "PO SD 500 mg (perm)"
      ],
      "Configuration": {
        "LLOQMode": "OnlyObservedData",
        "RemoveLLOQMode": "Never",
        "CalculateJacobian": true,
        "Algorithm": {
          "Name": "Levenberg - Marquardt (MPFit)",
          "Properties": [
            {
              "Name": "ftol",
              "Value": 0.001
            },
            {
              "Name": "xtol",
              "Value": 1E-06
            },
            {
              "Name": "gtol",
              "Value": 1E-10
            },
            {
              "Name": "stepfactor",
              "Value": 100.0
            },
            {
              "Name": "maxiter",
              "Value": 200.0
            },
            {
              "Name": "maxfev",
              "Value": 0.0
            },
            {
              "Name": "epsfcn",
              "Value": 1E-09
            }
          ]
        }
      },
      "OutputMappings": [
        {
          "Scaling": "Log",
          "Path": "PO SD 50 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Kasichayanula 2013b - Healthy subjects with normal kidney function - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=8)"
        },
        {
          "Scaling": "Log",
          "Path": "PO SD 50 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Kasichayanula 2011b - Study 1: 50 mg Control (Perpetrator Placebo) - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=24)"
        },
        {
          "Scaling": "Linear",
          "Weight": 0.0,
          "Path": "PO SD 50 mg (perm)|Organism|Lumen|Feces|Dapagliflozin|Fraction excreted to feces",
          "ObservedData": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin Feces - Dapagliflozin - PO - 50 mg - Feces - agg. (n=6)"
        },
        {
          "Scaling": "Linear",
          "Weight": 10.0,
          "Path": "PO SD 50 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
          "ObservedData": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin Urine - Dapagliflozin - PO - 50 mg - Urine - agg. (n=6)"
        },
        {
          "Scaling": "Log",
          "Path": "PO SD 10 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Kasichayanula 2011c - Healthy Volunteers - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=6)"
        },
        {
          "Scaling": "Log",
          "Path": "PO SD 10 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Vakkalagadda 2016 - Dapagliflozin - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=42)"
        },
        {
          "Scaling": "Log",
          "Path": "PO SD 10 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Kasichayanula 2013a - Study 2: Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=16)"
        },
        {
          "Scaling": "Log",
          "Path": "PO SD 10 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Kasichayanula 2013a - Study 1: Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=14)"
        },
        {
          "Scaling": "Log",
          "Path": "PO SD 10 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Kasichayanula 2011a - fasted - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=14)"
        },
        {
          "Scaling": "Log",
          "Path": "PO SD 10 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Imamura 2013 - Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=22)"
        },
        {
          "Scaling": "Log",
          "Path": "PO SD 10 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Boulton 2013 - Dapagliflozin po - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=7)"
        },
        {
          "Scaling": "Log",
          "Path": "IV 0.08 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Boulton 2013 - 14C-dapagliflozin iv - Dapagliflozin - IV - 0.08 mg - Plasma - agg. (n=7)"
        },
        {
          "Scaling": "Linear",
          "Weight": 10.0,
          "Path": "PO SD 50 mg (perm)|Organism|Dapagliflozin-UGT1A9-Optimized Metabolite|Total fraction of dose-Dapagliflozin",
          "ObservedData": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin 3OG Gluc (incl. unchanged feces exret.) - Dapagliflozin-3-O-glucuronide - PO - 50 mg - Fraction - agg. (n=6)"
        },
        {
          "Scaling": "Linear",
          "Weight": 10.0,
          "Path": "PO SD 50 mg (perm)|Organism|Dapagliflozin-UGT2B7-Optimized Metabolite|Total fraction of dose-Dapagliflozin",
          "ObservedData": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin 2OG Gluc (incl. unchanged feces exret.) - Dapagliflozin-2-O-glucuronide - PO - 50 mg - Fraction - agg. (n=6)"
        },
        {
          "Scaling": "Linear",
          "Weight": 10.0,
          "Path": "PO SD 50 mg (perm)|Organism|Dapagliflozin-Hepatic-CYP-Optimized Metabolite|Total fraction of dose-Dapagliflozin",
          "ObservedData": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin oxid Metab - Dapagliflozin oxidative metabolites - PO - 50 mg - Fraction - agg. (n=6)"
        },
        {
          "Scaling": "Log",
          "Path": "PO SD 100 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Komoroski 2009 - SAD 100 mg - Dapagliflozin - PO - 100 mg - Plasma - agg. (n=6)"
        },
        {
          "Scaling": "Log",
          "Path": "PO SD 2.5 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Komoroski 2009 - SAD 2.5 mg - Dapagliflozin - PO - 2.5 mg - Plasma - agg. (n=6)"
        },
        {
          "Scaling": "Log",
          "Path": "PO SD 20 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Kasichayanula 2012 - Study 1: Control (Perpetrator Placebo) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=24)"
        },
        {
          "Scaling": "Log",
          "Path": "PO SD 20 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Komoroski 2009 - SAD 20 mg - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=6)"
        },
        {
          "Scaling": "Log",
          "Path": "PO SD 250 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Komoroski 2009 - SAD 250 mg fasted - Dapagliflozin - PO - 250 mg - Plasma - agg. (n=6)"
        },
        {
          "Scaling": "Log",
          "Path": "PO SD 5 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Komoroski 2009 - SAD 5 mg - Dapagliflozin - PO - 5 mg - Plasma - agg. (n=6)"
        },
        {
          "Scaling": "Log",
          "Path": "PO SD 500 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Komoroski 2009 - SAD 500 mg - Dapagliflozin - PO - 500 mg - Plasma - agg. (n=6)"
        },
        {
          "Scaling": "Linear",
          "Path": "PO SD 2.5 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
          "ObservedData": "Komoroski 2009 - SAD 2.5 mg (Urine) - Dapagliflozin - PO - 2.5 mg - Urine - agg. (n=6)"
        },
        {
          "Scaling": "Linear",
          "Path": "PO SD 5 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
          "ObservedData": "Komoroski 2009 - SAD 5 mg (Urine) - Dapagliflozin - PO - 5 mg - Urine - agg. (n=6)"
        },
        {
          "Scaling": "Linear",
          "Path": "PO SD 10 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
          "ObservedData": "Komoroski 2009 - SAD 10 mg (Urine) - Dapagliflozin - PO - 10 mg - Urine - agg. (n=6)"
        },
        {
          "Scaling": "Linear",
          "Path": "PO SD 20 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
          "ObservedData": "Komoroski 2009 - SAD 20 mg (Urine) - Dapagliflozin - PO - 20 mg - Urine - agg. (n=6)"
        },
        {
          "Scaling": "Linear",
          "Path": "PO SD 50 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
          "ObservedData": "Komoroski 2009 - SAD 50 mg (Urine) - Dapagliflozin - PO - 50 mg - Urine - agg. (n=6)"
        },
        {
          "Scaling": "Linear",
          "Path": "PO SD 100 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
          "ObservedData": "Komoroski 2009 - SAD 100 mg (Urine) - Dapagliflozin - PO - 100 mg - Urine - agg. (n=6)"
        },
        {
          "Scaling": "Linear",
          "Path": "PO SD 250 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
          "ObservedData": "Komoroski 2009 - SAD 250 mg fasted (Urine) - Dapagliflozin - PO - 250 mg - Urine - agg. (n=6)"
        },
        {
          "Scaling": "Linear",
          "Path": "PO SD 500 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
          "ObservedData": "Komoroski 2009 - SAD 500 mg (Urine) - Dapagliflozin - PO - 500 mg - Urine - agg. (n=6)"
        }
      ],
      "IdentificationParameters": [
        {
          "Name": "Lipophilicity",
          "Scaling": "Linear",
          "LinkedParameters": [
            "IV 0.08 mg (perm)|Dapagliflozin|Lipophilicity",
            "PO SD 10 mg (perm)|Dapagliflozin|Lipophilicity",
            "PO SD 50 mg (perm)|Dapagliflozin|Lipophilicity",
            "PO SD 100 mg (perm)|Dapagliflozin|Lipophilicity",
            "PO SD 2.5 mg (perm)|Dapagliflozin|Lipophilicity",
            "PO SD 20 mg (perm)|Dapagliflozin|Lipophilicity",
            "PO SD 250 mg (perm)|Dapagliflozin|Lipophilicity",
            "PO SD 5 mg (perm)|Dapagliflozin|Lipophilicity",
            "PO SD 500 mg (perm)|Dapagliflozin|Lipophilicity"
          ],
          "Parameters": [
            {
              "Name": "Start value",
              "Value": 2.546,
              "Unit": "Log Units"
            },
            {
              "Name": "MinValue",
              "Value": 1.0,
              "Unit": "Log Units"
            },
            {
              "Name": "MaxValue",
              "Value": 4.0,
              "Unit": "Log Units"
            }
          ]
        },
        {
          "Name": "P int",
          "Scaling": "Log",
          "LinkedParameters": [
            "IV 0.08 mg (perm)|Dapagliflozin|Specific intestinal permeability (transcellular)",
            "PO SD 10 mg (perm)|Dapagliflozin|Specific intestinal permeability (transcellular)",
            "PO SD 50 mg (perm)|Dapagliflozin|Specific intestinal permeability (transcellular)",
            "PO SD 100 mg (perm)|Dapagliflozin|Specific intestinal permeability (transcellular)",
            "PO SD 2.5 mg (perm)|Dapagliflozin|Specific intestinal permeability (transcellular)",
            "PO SD 20 mg (perm)|Dapagliflozin|Specific intestinal permeability (transcellular)",
            "PO SD 250 mg (perm)|Dapagliflozin|Specific intestinal permeability (transcellular)",
            "PO SD 5 mg (perm)|Dapagliflozin|Specific intestinal permeability (transcellular)",
            "PO SD 500 mg (perm)|Dapagliflozin|Specific intestinal permeability (transcellular)"
          ],
          "Parameters": [
            {
              "Name": "Start value",
              "Value": 4E-05,
              "Unit": "cm/min"
            },
            {
              "Name": "MinValue",
              "Value": 1E-06,
              "Unit": "cm/min"
            },
            {
              "Name": "MaxValue",
              "Value": 0.01,
              "Unit": "cm/min"
            }
          ]
        },
        {
          "Name": "UGT1A9",
          "Scaling": "Log",
          "LinkedParameters": [
            "IV 0.08 mg (perm)|Dapagliflozin-UGT1A9-Optimized|CLspec/[Enzyme]",
            "PO SD 10 mg (perm)|Dapagliflozin-UGT1A9-Optimized|CLspec/[Enzyme]",
            "PO SD 50 mg (perm)|Dapagliflozin-UGT1A9-Optimized|CLspec/[Enzyme]",
            "PO SD 100 mg (perm)|Dapagliflozin-UGT1A9-Optimized|CLspec/[Enzyme]",
            "PO SD 2.5 mg (perm)|Dapagliflozin-UGT1A9-Optimized|CLspec/[Enzyme]",
            "PO SD 20 mg (perm)|Dapagliflozin-UGT1A9-Optimized|CLspec/[Enzyme]",
            "PO SD 250 mg (perm)|Dapagliflozin-UGT1A9-Optimized|CLspec/[Enzyme]",
            "PO SD 5 mg (perm)|Dapagliflozin-UGT1A9-Optimized|CLspec/[Enzyme]",
            "PO SD 500 mg (perm)|Dapagliflozin-UGT1A9-Optimized|CLspec/[Enzyme]"
          ],
          "Parameters": [
            {
              "Name": "Start value",
              "Value": 0.4,
              "Unit": "l/µmol/min"
            },
            {
              "Name": "MinValue",
              "Value": 0.001,
              "Unit": "l/µmol/min"
            },
            {
              "Name": "MaxValue",
              "Value": 100.0,
              "Unit": "l/µmol/min"
            }
          ]
        },
        {
          "Name": "UGT2B7",
          "Scaling": "Log",
          "LinkedParameters": [
            "IV 0.08 mg (perm)|Dapagliflozin-UGT2B7-Optimized|CLspec/[Enzyme]",
            "PO SD 10 mg (perm)|Dapagliflozin-UGT2B7-Optimized|CLspec/[Enzyme]",
            "PO SD 50 mg (perm)|Dapagliflozin-UGT2B7-Optimized|CLspec/[Enzyme]",
            "PO SD 100 mg (perm)|Dapagliflozin-UGT2B7-Optimized|CLspec/[Enzyme]",
            "PO SD 2.5 mg (perm)|Dapagliflozin-UGT2B7-Optimized|CLspec/[Enzyme]",
            "PO SD 20 mg (perm)|Dapagliflozin-UGT2B7-Optimized|CLspec/[Enzyme]",
            "PO SD 250 mg (perm)|Dapagliflozin-UGT2B7-Optimized|CLspec/[Enzyme]",
            "PO SD 5 mg (perm)|Dapagliflozin-UGT2B7-Optimized|CLspec/[Enzyme]",
            "PO SD 500 mg (perm)|Dapagliflozin-UGT2B7-Optimized|CLspec/[Enzyme]"
          ],
          "Parameters": [
            {
              "Name": "Start value",
              "Value": 0.02,
              "Unit": "l/µmol/min"
            },
            {
              "Name": "MinValue",
              "Value": 0.001,
              "Unit": "l/µmol/min"
            },
            {
              "Name": "MaxValue",
              "Value": 100.0,
              "Unit": "l/µmol/min"
            }
          ]
        },
        {
          "Name": "Hep-CYP",
          "Scaling": "Log",
          "LinkedParameters": [
            "IV 0.08 mg (perm)|Dapagliflozin-Hepatic-CYP-Optimized|CLspec/[Enzyme]",
            "PO SD 10 mg (perm)|Dapagliflozin-Hepatic-CYP-Optimized|CLspec/[Enzyme]",
            "PO SD 50 mg (perm)|Dapagliflozin-Hepatic-CYP-Optimized|CLspec/[Enzyme]",
            "PO SD 100 mg (perm)|Dapagliflozin-Hepatic-CYP-Optimized|CLspec/[Enzyme]",
            "PO SD 2.5 mg (perm)|Dapagliflozin-Hepatic-CYP-Optimized|CLspec/[Enzyme]",
            "PO SD 20 mg (perm)|Dapagliflozin-Hepatic-CYP-Optimized|CLspec/[Enzyme]",
            "PO SD 250 mg (perm)|Dapagliflozin-Hepatic-CYP-Optimized|CLspec/[Enzyme]",
            "PO SD 5 mg (perm)|Dapagliflozin-Hepatic-CYP-Optimized|CLspec/[Enzyme]",
            "PO SD 500 mg (perm)|Dapagliflozin-Hepatic-CYP-Optimized|CLspec/[Enzyme]"
          ],
          "Parameters": [
            {
              "Name": "Start value",
              "Value": 0.15,
              "Unit": "l/µmol/min"
            },
            {
              "Name": "MinValue",
              "Value": 0.001,
              "Unit": "l/µmol/min"
            },
            {
              "Name": "MaxValue",
              "Value": 100.0,
              "Unit": "l/µmol/min"
            }
          ]
        },
        {
          "Name": "Solubility",
          "Scaling": "Log",
          "IsFixed": true,
          "LinkedParameters": [
            "IV 0.08 mg (perm)|Dapagliflozin|Solubility at reference pH",
            "PO SD 10 mg (perm)|Dapagliflozin|Solubility at reference pH",
            "PO SD 50 mg (perm)|Dapagliflozin|Solubility at reference pH",
            "PO SD 100 mg (perm)|Dapagliflozin|Solubility at reference pH",
            "PO SD 2.5 mg (perm)|Dapagliflozin|Solubility at reference pH",
            "PO SD 20 mg (perm)|Dapagliflozin|Solubility at reference pH",
            "PO SD 250 mg (perm)|Dapagliflozin|Solubility at reference pH",
            "PO SD 5 mg (perm)|Dapagliflozin|Solubility at reference pH",
            "PO SD 500 mg (perm)|Dapagliflozin|Solubility at reference pH"
          ],
          "Parameters": [
            {
              "Name": "Start value",
              "Value": 100.0,
              "Unit": "mg/ml"
            },
            {
              "Name": "MinValue",
              "Value": 0.01,
              "Unit": "mg/ml"
            },
            {
              "Name": "MaxValue",
              "Value": 100.0,
              "Unit": "mg/ml"
            }
          ]
        },
        {
          "Name": "Permeability",
          "Scaling": "Log",
          "LinkedParameters": [
            "IV 0.08 mg (perm)|Dapagliflozin|Permeability",
            "PO SD 10 mg (perm)|Dapagliflozin|Permeability",
            "PO SD 50 mg (perm)|Dapagliflozin|Permeability",
            "PO SD 100 mg (perm)|Dapagliflozin|Permeability",
            "PO SD 2.5 mg (perm)|Dapagliflozin|Permeability",
            "PO SD 20 mg (perm)|Dapagliflozin|Permeability",
            "PO SD 250 mg (perm)|Dapagliflozin|Permeability",
            "PO SD 5 mg (perm)|Dapagliflozin|Permeability",
            "PO SD 500 mg (perm)|Dapagliflozin|Permeability"
          ],
          "Parameters": [
            {
              "Name": "Start value",
              "Value": 0.0004257,
              "Unit": "cm/min"
            },
            {
              "Name": "MinValue",
              "Value": 1E-06,
              "Unit": "cm/min"
            },
            {
              "Name": "MaxValue",
              "Value": 0.01,
              "Unit": "cm/min"
            }
          ]
        },
        {
          "Name": "logP (veg.oil/water)",
          "Scaling": "Linear",
          "LinkedParameters": [
            "IV 0.08 mg (perm)|Dapagliflozin|logP (veg.oil/water)",
            "PO SD 10 mg (perm)|Dapagliflozin|logP (veg.oil/water)",
            "PO SD 50 mg (perm)|Dapagliflozin|logP (veg.oil/water)",
            "PO SD 100 mg (perm)|Dapagliflozin|logP (veg.oil/water)",
            "PO SD 2.5 mg (perm)|Dapagliflozin|logP (veg.oil/water)",
            "PO SD 20 mg (perm)|Dapagliflozin|logP (veg.oil/water)",
            "PO SD 250 mg (perm)|Dapagliflozin|logP (veg.oil/water)",
            "PO SD 5 mg (perm)|Dapagliflozin|logP (veg.oil/water)",
            "PO SD 500 mg (perm)|Dapagliflozin|logP (veg.oil/water)"
          ],
          "Parameters": [
            {
              "Name": "Start value",
              "Value": 2.053,
              "Unit": "Log Units"
            },
            {
              "Name": "MinValue",
              "Value": 0.0,
              "Unit": "Log Units"
            },
            {
              "Name": "MaxValue",
              "Value": 4.0,
              "Unit": "Log Units"
            }
          ]
        },
        {
          "Name": "GFR fraction",
          "Scaling": "Linear",
          "LinkedParameters": [
            "IV 0.08 mg (perm)|Neighborhoods|Kidney_pls_Kidney_ur|Dapagliflozin|Glomerular Filtration-assumed|GFR fraction",
            "PO SD 10 mg (perm)|Neighborhoods|Kidney_pls_Kidney_ur|Dapagliflozin|Glomerular Filtration-assumed|GFR fraction",
            "PO SD 50 mg (perm)|Neighborhoods|Kidney_pls_Kidney_ur|Dapagliflozin|Glomerular Filtration-assumed|GFR fraction",
            "PO SD 100 mg (perm)|Neighborhoods|Kidney_pls_Kidney_ur|Dapagliflozin|Glomerular Filtration-assumed|GFR fraction",
            "PO SD 2.5 mg (perm)|Neighborhoods|Kidney_pls_Kidney_ur|Dapagliflozin|Glomerular Filtration-assumed|GFR fraction",
            "PO SD 20 mg (perm)|Neighborhoods|Kidney_pls_Kidney_ur|Dapagliflozin|Glomerular Filtration-assumed|GFR fraction",
            "PO SD 250 mg (perm)|Neighborhoods|Kidney_pls_Kidney_ur|Dapagliflozin|Glomerular Filtration-assumed|GFR fraction",
            "PO SD 5 mg (perm)|Neighborhoods|Kidney_pls_Kidney_ur|Dapagliflozin|Glomerular Filtration-assumed|GFR fraction",
            "PO SD 500 mg (perm)|Neighborhoods|Kidney_pls_Kidney_ur|Dapagliflozin|Glomerular Filtration-assumed|GFR fraction"
          ],
          "Parameters": [
            {
              "Name": "Start value",
              "Value": 1.0
            },
            {
              "Name": "MinValue",
              "Value": 0.1
            },
            {
              "Name": "MaxValue",
              "Value": 10.0
            }
          ]
        },
        {
          "Name": "Blood/Plasma concentration ratio",
          "Scaling": "Linear",
          "IsFixed": true,
          "LinkedParameters": [
            "IV 0.08 mg (perm)|Dapagliflozin|Blood/Plasma concentration ratio",
            "PO SD 10 mg (perm)|Dapagliflozin|Blood/Plasma concentration ratio",
            "PO SD 50 mg (perm)|Dapagliflozin|Blood/Plasma concentration ratio",
            "PO SD 100 mg (perm)|Dapagliflozin|Blood/Plasma concentration ratio",
            "PO SD 2.5 mg (perm)|Dapagliflozin|Blood/Plasma concentration ratio",
            "PO SD 20 mg (perm)|Dapagliflozin|Blood/Plasma concentration ratio",
            "PO SD 250 mg (perm)|Dapagliflozin|Blood/Plasma concentration ratio",
            "PO SD 5 mg (perm)|Dapagliflozin|Blood/Plasma concentration ratio",
            "PO SD 500 mg (perm)|Dapagliflozin|Blood/Plasma concentration ratio"
          ],
          "Parameters": [
            {
              "Name": "Start value",
              "Value": 0.88
            },
            {
              "Name": "MinValue",
              "Value": 0.0
            },
            {
              "Name": "MaxValue",
              "Value": 6.1244936725
            }
          ]
        }
      ],
      "Analyses": [
        {
          "Name": "Time Profile",
          "Type": "ParameterIdentificationTimeProfileChart",
          "Chart": {
            "Axes": [
              {
                "Unit": "h",
                "Dimension": "Time",
                "Type": "X",
                "GridLines": false,
                "Visible": true,
                "Min": 0.0,
                "Max": 24.0,
                "DefaultColor": "#FFFFFF",
                "DefaultLineStyle": "None",
                "Scaling": "Linear",
                "NumberMode": "Normal"
              },
              {
                "Unit": "mg/l",
                "Dimension": "Concentration (mass)",
                "Type": "Y",
                "GridLines": false,
                "Visible": true,
                "Min": 0.0001,
                "Max": 5.0,
                "DefaultColor": "#FFFFFF",
                "DefaultLineStyle": "Solid",
                "Scaling": "Log",
                "NumberMode": "Normal"
              },
              {
                "Unit": "%",
                "Dimension": "Fraction",
                "Type": "Y2",
                "GridLines": false,
                "Visible": true,
                "Min": 0.0,
                "Max": 79.72589,
                "DefaultColor": "#FFFFFF",
                "DefaultLineStyle": "Dash",
                "Scaling": "Linear",
                "NumberMode": "Normal"
              }
            ],
            "Curves": [
              {
                "Name": "Kasichayanula 2013b - Healthy subjects with normal kidney function - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=8)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
                "X": "Kasichayanula 2013b - Healthy subjects with normal kidney function - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=8)|Time",
                "Y": "Kasichayanula 2013b - Healthy subjects with normal kidney function - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=8)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "VisibleInLegend": false,
                  "Color": "#FF0000",
                  "LegendIndex": 1,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Kasichayanula 2011b - Study 1: 50 mg Control (Perpetrator Placebo) - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=24)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
                "X": "Kasichayanula 2011b - Study 1: 50 mg Control (Perpetrator Placebo) - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=24)|Time",
                "Y": "Kasichayanula 2011b - Study 1: 50 mg Control (Perpetrator Placebo) - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=24)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "VisibleInLegend": false,
                  "Color": "#FF0000",
                  "LegendIndex": 2,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin Feces - Dapagliflozin - PO - 50 mg - Feces - agg. (n=6)-Dapagliflozin-Lumen-Feces-ArithmeticMean",
                "X": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin Feces - Dapagliflozin - PO - 50 mg - Feces - agg. (n=6)|Time",
                "Y": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin Feces - Dapagliflozin - PO - 50 mg - Feces - agg. (n=6)|ObservedData|Lumen|Feces|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "VisibleInLegend": false,
                  "Color": "#0000FF",
                  "LegendIndex": 3,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin Urine - Dapagliflozin - PO - 50 mg - Urine - agg. (n=6)-Dapagliflozin-Kidney-Urine-ArithmeticMean",
                "X": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin Urine - Dapagliflozin - PO - 50 mg - Urine - agg. (n=6)|Time",
                "Y": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin Urine - Dapagliflozin - PO - 50 mg - Urine - agg. (n=6)|ObservedData|Kidney|Urine|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "VisibleInLegend": false,
                  "Color": "#008000",
                  "LegendIndex": 4,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Komoroski 2009 - SAD 50 mg (Urine) - Dapagliflozin - PO - 50 mg - Urine - agg. (n=6)-Dapagliflozin-Kidney-Urine-ArithmeticMean",
                "X": "Komoroski 2009 - SAD 50 mg (Urine) - Dapagliflozin - PO - 50 mg - Urine - agg. (n=6)|Time",
                "Y": "Komoroski 2009 - SAD 50 mg (Urine) - Dapagliflozin - PO - 50 mg - Urine - agg. (n=6)|ObservedData|Kidney|Urine|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "VisibleInLegend": false,
                  "Color": "#008000",
                  "LegendIndex": 5,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Kasichayanula 2011c - Healthy Volunteers - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=6)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
                "X": "Kasichayanula 2011c - Healthy Volunteers - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=6)|Time",
                "Y": "Kasichayanula 2011c - Healthy Volunteers - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "VisibleInLegend": false,
                  "Color": "#FF00FF",
                  "LegendIndex": 6,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Vakkalagadda 2016 - Dapagliflozin - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=42)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
                "X": "Vakkalagadda 2016 - Dapagliflozin - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=42)|Time",
                "Y": "Vakkalagadda 2016 - Dapagliflozin - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=42)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "VisibleInLegend": false,
                  "Color": "#FF00FF",
                  "LegendIndex": 7,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Kasichayanula 2013a - Study 2: Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=16)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
                "X": "Kasichayanula 2013a - Study 2: Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=16)|Time",
                "Y": "Kasichayanula 2013a - Study 2: Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=16)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "VisibleInLegend": false,
                  "Color": "#FF00FF",
                  "LegendIndex": 8,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Kasichayanula 2013a - Study 1: Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=14)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
                "X": "Kasichayanula 2013a - Study 1: Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=14)|Time",
                "Y": "Kasichayanula 2013a - Study 1: Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=14)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "VisibleInLegend": false,
                  "Color": "#FF00FF",
                  "LegendIndex": 9,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Kasichayanula 2011a - fasted - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=14)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
                "X": "Kasichayanula 2011a - fasted - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=14)|Time",
                "Y": "Kasichayanula 2011a - fasted - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=14)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "VisibleInLegend": false,
                  "Color": "#FF00FF",
                  "LegendIndex": 10,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Imamura 2013 - Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=22)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
                "X": "Imamura 2013 - Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=22)|Time",
                "Y": "Imamura 2013 - Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=22)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "VisibleInLegend": false,
                  "Color": "#FF00FF",
                  "LegendIndex": 11,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Boulton 2013 - Dapagliflozin po - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=7)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
                "X": "Boulton 2013 - Dapagliflozin po - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=7)|Time",
                "Y": "Boulton 2013 - Dapagliflozin po - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=7)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "VisibleInLegend": false,
                  "Color": "#FF00FF",
                  "LegendIndex": 12,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Boulton 2013 - 14C-dapagliflozin iv - Dapagliflozin - IV - 0.08 mg - Plasma - agg. (n=7)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
                "X": "Boulton 2013 - 14C-dapagliflozin iv - Dapagliflozin - IV - 0.08 mg - Plasma - agg. (n=7)|Time",
                "Y": "Boulton 2013 - 14C-dapagliflozin iv - Dapagliflozin - IV - 0.08 mg - Plasma - agg. (n=7)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "VisibleInLegend": false,
                  "Color": "#FF8000",
                  "LegendIndex": 13,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin 3OG Gluc (incl. unchanged feces exret.) - Dapagliflozin-3-O-glucuronide - PO - 50 mg - Fraction - agg. (n=6)-Dapagliflozin-3-O-glucuronide-Undefined-Undefined-ArithmeticMean",
                "X": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin 3OG Gluc (incl. unchanged feces exret.) - Dapagliflozin-3-O-glucuronide - PO - 50 mg - Fraction - agg. (n=6)|Time",
                "Y": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin 3OG Gluc (incl. unchanged feces exret.) - Dapagliflozin-3-O-glucuronide - PO - 50 mg - Fraction - agg. (n=6)|ObservedData|Undefined|Undefined|Dapagliflozin-3-O-glucuronide|ArithmeticMean",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "VisibleInLegend": false,
                  "Color": "#00C0C0",
                  "LegendIndex": 14,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin 2OG Gluc (incl. unchanged feces exret.) - Dapagliflozin-2-O-glucuronide - PO - 50 mg - Fraction - agg. (n=6)-Dapagliflozin-2-O-glucuronide-Undefined-Undefined-ArithmeticMean",
                "X": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin 2OG Gluc (incl. unchanged feces exret.) - Dapagliflozin-2-O-glucuronide - PO - 50 mg - Fraction - agg. (n=6)|Time",
                "Y": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin 2OG Gluc (incl. unchanged feces exret.) - Dapagliflozin-2-O-glucuronide - PO - 50 mg - Fraction - agg. (n=6)|ObservedData|Undefined|Undefined|Dapagliflozin-2-O-glucuronide|ArithmeticMean",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "VisibleInLegend": false,
                  "Color": "#C000C0",
                  "LegendIndex": 15,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin oxid Metab - Dapagliflozin oxidative metabolites - PO - 50 mg - Fraction - agg. (n=6)-Dapagliflozin oxidative metabolites-Undefined-Undefined-ArithmeticMean",
                "X": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin oxid Metab - Dapagliflozin oxidative metabolites - PO - 50 mg - Fraction - agg. (n=6)|Time",
                "Y": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin oxid Metab - Dapagliflozin oxidative metabolites - PO - 50 mg - Fraction - agg. (n=6)|ObservedData|Undefined|Undefined|Dapagliflozin oxidative metabolites|ArithmeticMean",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "VisibleInLegend": false,
                  "Color": "#C04000",
                  "LegendIndex": 16,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Komoroski 2009 - SAD 100 mg - Dapagliflozin - PO - 100 mg - Plasma - agg. (n=6)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
                "X": "Komoroski 2009 - SAD 100 mg - Dapagliflozin - PO - 100 mg - Plasma - agg. (n=6)|Time",
                "Y": "Komoroski 2009 - SAD 100 mg - Dapagliflozin - PO - 100 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "VisibleInLegend": false,
                  "Color": "#00FF00",
                  "LegendIndex": 17,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Komoroski 2009 - SAD 2.5 mg - Dapagliflozin - PO - 2.5 mg - Plasma - agg. (n=6)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
                "X": "Komoroski 2009 - SAD 2.5 mg - Dapagliflozin - PO - 2.5 mg - Plasma - agg. (n=6)|Time",
                "Y": "Komoroski 2009 - SAD 2.5 mg - Dapagliflozin - PO - 2.5 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "VisibleInLegend": false,
                  "Color": "#808080",
                  "LegendIndex": 18,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Kasichayanula 2012 - Study 1: Control (Perpetrator Placebo) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=24)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
                "X": "Kasichayanula 2012 - Study 1: Control (Perpetrator Placebo) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=24)|Time",
                "Y": "Kasichayanula 2012 - Study 1: Control (Perpetrator Placebo) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=24)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "VisibleInLegend": false,
                  "Color": "#C0C000",
                  "LegendIndex": 19,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Komoroski 2009 - SAD 20 mg - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=6)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
                "X": "Komoroski 2009 - SAD 20 mg - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=6)|Time",
                "Y": "Komoroski 2009 - SAD 20 mg - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "VisibleInLegend": false,
                  "Color": "#C0C000",
                  "LegendIndex": 20,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Komoroski 2009 - SAD 250 mg fasted - Dapagliflozin - PO - 250 mg - Plasma - agg. (n=6)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
                "X": "Komoroski 2009 - SAD 250 mg fasted - Dapagliflozin - PO - 250 mg - Plasma - agg. (n=6)|Time",
                "Y": "Komoroski 2009 - SAD 250 mg fasted - Dapagliflozin - PO - 250 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "VisibleInLegend": false,
                  "Color": "#8080FF",
                  "LegendIndex": 21,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Komoroski 2009 - SAD 5 mg - Dapagliflozin - PO - 5 mg - Plasma - agg. (n=6)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
                "X": "Komoroski 2009 - SAD 5 mg - Dapagliflozin - PO - 5 mg - Plasma - agg. (n=6)|Time",
                "Y": "Komoroski 2009 - SAD 5 mg - Dapagliflozin - PO - 5 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "VisibleInLegend": false,
                  "Color": "#0000C0",
                  "LegendIndex": 22,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Komoroski 2009 - SAD 500 mg - Dapagliflozin - PO - 500 mg - Plasma - agg. (n=6)-Dapagliflozin-Peripheral Venous Blood-Plasma-ArithmeticMean",
                "X": "Komoroski 2009 - SAD 500 mg - Dapagliflozin - PO - 500 mg - Plasma - agg. (n=6)|Time",
                "Y": "Komoroski 2009 - SAD 500 mg - Dapagliflozin - PO - 500 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "VisibleInLegend": false,
                  "Color": "#00C000",
                  "LegendIndex": 23,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Komoroski 2009 - SAD 2.5 mg (Urine) - Dapagliflozin - PO - 2.5 mg - Urine - agg. (n=6)-Dapagliflozin-Kidney-Urine-ArithmeticMean",
                "X": "Komoroski 2009 - SAD 2.5 mg (Urine) - Dapagliflozin - PO - 2.5 mg - Urine - agg. (n=6)|Time",
                "Y": "Komoroski 2009 - SAD 2.5 mg (Urine) - Dapagliflozin - PO - 2.5 mg - Urine - agg. (n=6)|ObservedData|Kidney|Urine|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "VisibleInLegend": false,
                  "Color": "#C00000",
                  "LegendIndex": 24,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Komoroski 2009 - SAD 5 mg (Urine) - Dapagliflozin - PO - 5 mg - Urine - agg. (n=6)-Dapagliflozin-Kidney-Urine-ArithmeticMean",
                "X": "Komoroski 2009 - SAD 5 mg (Urine) - Dapagliflozin - PO - 5 mg - Urine - agg. (n=6)|Time",
                "Y": "Komoroski 2009 - SAD 5 mg (Urine) - Dapagliflozin - PO - 5 mg - Urine - agg. (n=6)|ObservedData|Kidney|Urine|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "VisibleInLegend": false,
                  "Color": "#FFFF00",
                  "LegendIndex": 25,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Komoroski 2009 - SAD 10 mg (Urine) - Dapagliflozin - PO - 10 mg - Urine - agg. (n=6)-Dapagliflozin-Kidney-Urine-ArithmeticMean",
                "X": "Komoroski 2009 - SAD 10 mg (Urine) - Dapagliflozin - PO - 10 mg - Urine - agg. (n=6)|Time",
                "Y": "Komoroski 2009 - SAD 10 mg (Urine) - Dapagliflozin - PO - 10 mg - Urine - agg. (n=6)|ObservedData|Kidney|Urine|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "VisibleInLegend": false,
                  "Color": "#008080",
                  "LegendIndex": 26,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Komoroski 2009 - SAD 20 mg (Urine) - Dapagliflozin - PO - 20 mg - Urine - agg. (n=6)-Dapagliflozin-Kidney-Urine-ArithmeticMean",
                "X": "Komoroski 2009 - SAD 20 mg (Urine) - Dapagliflozin - PO - 20 mg - Urine - agg. (n=6)|Time",
                "Y": "Komoroski 2009 - SAD 20 mg (Urine) - Dapagliflozin - PO - 20 mg - Urine - agg. (n=6)|ObservedData|Kidney|Urine|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "VisibleInLegend": false,
                  "Color": "#800080",
                  "LegendIndex": 27,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Komoroski 2009 - SAD 100 mg (Urine) - Dapagliflozin - PO - 100 mg - Urine - agg. (n=6)-Dapagliflozin-Kidney-Urine-ArithmeticMean",
                "X": "Komoroski 2009 - SAD 100 mg (Urine) - Dapagliflozin - PO - 100 mg - Urine - agg. (n=6)|Time",
                "Y": "Komoroski 2009 - SAD 100 mg (Urine) - Dapagliflozin - PO - 100 mg - Urine - agg. (n=6)|ObservedData|Kidney|Urine|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "VisibleInLegend": false,
                  "Color": "#804040",
                  "LegendIndex": 28,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Komoroski 2009 - SAD 250 mg fasted (Urine) - Dapagliflozin - PO - 250 mg - Urine - agg. (n=6)-Dapagliflozin-Kidney-Urine-ArithmeticMean",
                "X": "Komoroski 2009 - SAD 250 mg fasted (Urine) - Dapagliflozin - PO - 250 mg - Urine - agg. (n=6)|Time",
                "Y": "Komoroski 2009 - SAD 250 mg fasted (Urine) - Dapagliflozin - PO - 250 mg - Urine - agg. (n=6)|ObservedData|Kidney|Urine|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "VisibleInLegend": false,
                  "Color": "#80FF80",
                  "LegendIndex": 29,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "Komoroski 2009 - SAD 500 mg (Urine) - Dapagliflozin - PO - 500 mg - Urine - agg. (n=6)-Dapagliflozin-Kidney-Urine-ArithmeticMean",
                "X": "Komoroski 2009 - SAD 500 mg (Urine) - Dapagliflozin - PO - 500 mg - Urine - agg. (n=6)|Time",
                "Y": "Komoroski 2009 - SAD 500 mg (Urine) - Dapagliflozin - PO - 500 mg - Urine - agg. (n=6)|ObservedData|Kidney|Urine|Dapagliflozin|ArithmeticMean",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "VisibleInLegend": false,
                  "Color": "#808000",
                  "LegendIndex": 30,
                  "LineStyle": "None",
                  "Symbol": "Circle"
                }
              },
              {
                "Name": "PO SD 5 mg (perm)-Dapagliflozin-Peripheral Venous Blood-Plasma-Concentration",
                "X": "Time",
                "Y": "PO SD 5 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
                "CurveOptions": {
                  "Color": "#0000C0",
                  "LegendIndex": 31
                }
              },
              {
                "Name": "PO SD 5 mg (perm)-Dapagliflozin-Kidney-Urine-Fraction excreted to urine",
                "X": "Time",
                "Y": "PO SD 5 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "Color": "#FFFF00",
                  "LegendIndex": 32,
                  "LineStyle": "Dash"
                }
              },
              {
                "Name": "IV 0.08 mg (perm)-Dapagliflozin-Peripheral Venous Blood-Plasma-Concentration",
                "X": "Time",
                "Y": "IV 0.08 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
                "CurveOptions": {
                  "Color": "#FF8000",
                  "LegendIndex": 33
                }
              },
              {
                "Name": "PO SD 500 mg (perm)-Dapagliflozin-Peripheral Venous Blood-Plasma-Concentration",
                "X": "Time",
                "Y": "PO SD 500 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
                "CurveOptions": {
                  "Color": "#00C000",
                  "LegendIndex": 34
                }
              },
              {
                "Name": "PO SD 500 mg (perm)-Dapagliflozin-Kidney-Urine-Fraction excreted to urine",
                "X": "Time",
                "Y": "PO SD 500 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "Color": "#808000",
                  "LegendIndex": 35,
                  "LineStyle": "Dash"
                }
              },
              {
                "Name": "PO SD 250 mg (perm)-Dapagliflozin-Peripheral Venous Blood-Plasma-Concentration",
                "X": "Time",
                "Y": "PO SD 250 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
                "CurveOptions": {
                  "Color": "#8080FF",
                  "LegendIndex": 36
                }
              },
              {
                "Name": "PO SD 250 mg (perm)-Dapagliflozin-Kidney-Urine-Fraction excreted to urine",
                "X": "Time",
                "Y": "PO SD 250 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "Color": "#80FF80",
                  "LegendIndex": 37,
                  "LineStyle": "Dash"
                }
              },
              {
                "Name": "PO SD 10 mg (perm)-Dapagliflozin-Peripheral Venous Blood-Plasma-Concentration",
                "X": "Time",
                "Y": "PO SD 10 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
                "CurveOptions": {
                  "Color": "#FF00FF",
                  "LegendIndex": 38
                }
              },
              {
                "Name": "PO SD 10 mg (perm)-Dapagliflozin-Kidney-Urine-Fraction excreted to urine",
                "X": "Time",
                "Y": "PO SD 10 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "Color": "#008080",
                  "LegendIndex": 39,
                  "LineStyle": "Dash"
                }
              },
              {
                "Name": "PO SD 2.5 mg (perm)-Dapagliflozin-Peripheral Venous Blood-Plasma-Concentration",
                "X": "Time",
                "Y": "PO SD 2.5 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
                "CurveOptions": {
                  "Color": "#808080",
                  "LegendIndex": 40
                }
              },
              {
                "Name": "PO SD 2.5 mg (perm)-Dapagliflozin-Kidney-Urine-Fraction excreted to urine",
                "X": "Time",
                "Y": "PO SD 2.5 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "Color": "#C00000",
                  "LegendIndex": 41,
                  "LineStyle": "Dash"
                }
              },
              {
                "Name": "PO SD 100 mg (perm)-Dapagliflozin-Peripheral Venous Blood-Plasma-Concentration",
                "X": "Time",
                "Y": "PO SD 100 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
                "CurveOptions": {
                  "Color": "#00FF00",
                  "LegendIndex": 42
                }
              },
              {
                "Name": "PO SD 100 mg (perm)-Dapagliflozin-Kidney-Urine-Fraction excreted to urine",
                "X": "Time",
                "Y": "PO SD 100 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "Color": "#804040",
                  "LegendIndex": 43,
                  "LineStyle": "Dash"
                }
              },
              {
                "Name": "PO SD 20 mg (perm)-Dapagliflozin-Peripheral Venous Blood-Plasma-Concentration",
                "X": "Time",
                "Y": "PO SD 20 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
                "CurveOptions": {
                  "Color": "#C0C000",
                  "LegendIndex": 44
                }
              },
              {
                "Name": "PO SD 20 mg (perm)-Dapagliflozin-Kidney-Urine-Fraction excreted to urine",
                "X": "Time",
                "Y": "PO SD 20 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "Color": "#800080",
                  "LegendIndex": 45,
                  "LineStyle": "Dash"
                }
              },
              {
                "Name": "PO SD 50 mg (perm)-Dapagliflozin-Peripheral Venous Blood-Plasma-Concentration",
                "X": "Time",
                "Y": "PO SD 50 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
                "CurveOptions": {
                  "Color": "#FF0000",
                  "LegendIndex": 46
                }
              },
              {
                "Name": "PO SD 50 mg (perm)-Dapagliflozin-Kidney-Urine-Fraction excreted to urine",
                "X": "Time",
                "Y": "PO SD 50 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "Color": "#008000",
                  "LegendIndex": 47,
                  "LineStyle": "Dash"
                }
              },
              {
                "Name": "PO SD 50 mg (perm)-Dapagliflozin-Lumen-Feces-Fraction excreted to feces",
                "X": "Time",
                "Y": "PO SD 50 mg (perm)|Organism|Lumen|Feces|Dapagliflozin|Fraction excreted to feces",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "Color": "#0000FF",
                  "LegendIndex": 48,
                  "LineStyle": "Dash"
                }
              },
              {
                "Name": "PO SD 50 mg (perm)-Dapagliflozin-UGT1A9-Optimized Metabolite-Organism-Total fraction of dose-Dapagliflozin",
                "X": "Time",
                "Y": "PO SD 50 mg (perm)|Organism|Dapagliflozin-UGT1A9-Optimized Metabolite|Total fraction of dose-Dapagliflozin",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "Color": "#00C0C0",
                  "LegendIndex": 49,
                  "LineStyle": "Dash"
                }
              },
              {
                "Name": "PO SD 50 mg (perm)-Dapagliflozin-UGT2B7-Optimized Metabolite-Organism-Total fraction of dose-Dapagliflozin",
                "X": "Time",
                "Y": "PO SD 50 mg (perm)|Organism|Dapagliflozin-UGT2B7-Optimized Metabolite|Total fraction of dose-Dapagliflozin",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "Color": "#C000C0",
                  "LegendIndex": 50,
                  "LineStyle": "Dash"
                }
              },
              {
                "Name": "PO SD 50 mg (perm)-Dapagliflozin-Hepatic-CYP-Optimized Metabolite-Organism-Total fraction of dose-Dapagliflozin",
                "X": "Time",
                "Y": "PO SD 50 mg (perm)|Organism|Dapagliflozin-Hepatic-CYP-Optimized Metabolite|Total fraction of dose-Dapagliflozin",
                "CurveOptions": {
                  "yAxisType": "Y2",
                  "Color": "#C04000",
                  "LegendIndex": 51,
                  "LineStyle": "Dash"
                }
              }
            ],
            "Name": "Time Profile",
            "Settings": {
              "SideMarginsEnabled": true,
              "LegendPosition": "None",
              "BackColor": "#FFFFFF",
              "DiagramBackColor": "#FFFFFF"
            }
          }
        }
      ]
    },
    {
      "Name": "PI full  (perm) MSV",
      "Simulations": [
        "IV 0.08 mg (perm)",
        "PO SD 10 mg (perm)",
        "PO SD 50 mg (perm)",
        "PO SD 100 mg (perm)",
        "PO SD 2.5 mg (perm)",
        "PO SD 20 mg (perm)",
        "PO SD 250 mg (perm)",
        "PO SD 5 mg (perm)",
        "PO SD 500 mg (perm)"
      ],
      "Configuration": {
        "LLOQMode": "OnlyObservedData",
        "RemoveLLOQMode": "Never",
        "CalculateJacobian": false,
        "Algorithm": {
          "Name": "Levenberg - Marquardt (MPFit)",
          "Properties": [
            {
              "Name": "ftol",
              "Value": 0.001
            },
            {
              "Name": "xtol",
              "Value": 1E-06
            },
            {
              "Name": "gtol",
              "Value": 1E-10
            },
            {
              "Name": "stepfactor",
              "Value": 100.0
            },
            {
              "Name": "maxiter",
              "Value": 200.0
            },
            {
              "Name": "maxfev",
              "Value": 0.0
            },
            {
              "Name": "epsfcn",
              "Value": 1E-09
            }
          ]
        },
        "RunMode": {
          "NumberOfRuns": 50
        }
      },
      "OutputMappings": [
        {
          "Scaling": "Log",
          "Path": "PO SD 50 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Kasichayanula 2013b - Healthy subjects with normal kidney function - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=8)"
        },
        {
          "Scaling": "Log",
          "Path": "PO SD 50 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Kasichayanula 2011b - Study 1: 50 mg Control (Perpetrator Placebo) - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=24)"
        },
        {
          "Scaling": "Linear",
          "Weight": 0.0,
          "Path": "PO SD 50 mg (perm)|Organism|Lumen|Feces|Dapagliflozin|Fraction excreted to feces",
          "ObservedData": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin Feces - Dapagliflozin - PO - 50 mg - Feces - agg. (n=6)"
        },
        {
          "Scaling": "Linear",
          "Weight": 10.0,
          "Path": "PO SD 50 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
          "ObservedData": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin Urine - Dapagliflozin - PO - 50 mg - Urine - agg. (n=6)"
        },
        {
          "Scaling": "Log",
          "Path": "PO SD 10 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Kasichayanula 2011c - Healthy Volunteers - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=6)"
        },
        {
          "Scaling": "Log",
          "Path": "PO SD 10 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Vakkalagadda 2016 - Dapagliflozin - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=42)"
        },
        {
          "Scaling": "Log",
          "Path": "PO SD 10 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Kasichayanula 2013a - Study 2: Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=16)"
        },
        {
          "Scaling": "Log",
          "Path": "PO SD 10 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Kasichayanula 2013a - Study 1: Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=14)"
        },
        {
          "Scaling": "Log",
          "Path": "PO SD 10 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Kasichayanula 2011a - fasted - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=14)"
        },
        {
          "Scaling": "Log",
          "Path": "PO SD 10 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Imamura 2013 - Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=22)"
        },
        {
          "Scaling": "Log",
          "Path": "PO SD 10 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Boulton 2013 - Dapagliflozin po - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=7)"
        },
        {
          "Scaling": "Log",
          "Path": "IV 0.08 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Boulton 2013 - 14C-dapagliflozin iv - Dapagliflozin - IV - 0.08 mg - Plasma - agg. (n=7)"
        },
        {
          "Scaling": "Linear",
          "Weight": 10.0,
          "Path": "PO SD 50 mg (perm)|Organism|Dapagliflozin-UGT1A9-Optimized Metabolite|Total fraction of dose-Dapagliflozin",
          "ObservedData": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin 3OG Gluc (incl. unchanged feces exret.) - Dapagliflozin-3-O-glucuronide - PO - 50 mg - Fraction - agg. (n=6)"
        },
        {
          "Scaling": "Linear",
          "Weight": 10.0,
          "Path": "PO SD 50 mg (perm)|Organism|Dapagliflozin-UGT2B7-Optimized Metabolite|Total fraction of dose-Dapagliflozin",
          "ObservedData": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin 2OG Gluc (incl. unchanged feces exret.) - Dapagliflozin-2-O-glucuronide - PO - 50 mg - Fraction - agg. (n=6)"
        },
        {
          "Scaling": "Linear",
          "Weight": 10.0,
          "Path": "PO SD 50 mg (perm)|Organism|Dapagliflozin-Hepatic-CYP-Optimized Metabolite|Total fraction of dose-Dapagliflozin",
          "ObservedData": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin oxid Metab - Dapagliflozin oxidative metabolites - PO - 50 mg - Fraction - agg. (n=6)"
        },
        {
          "Scaling": "Log",
          "Path": "PO SD 100 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Komoroski 2009 - SAD 100 mg - Dapagliflozin - PO - 100 mg - Plasma - agg. (n=6)"
        },
        {
          "Scaling": "Log",
          "Path": "PO SD 2.5 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Komoroski 2009 - SAD 2.5 mg - Dapagliflozin - PO - 2.5 mg - Plasma - agg. (n=6)"
        },
        {
          "Scaling": "Log",
          "Path": "PO SD 20 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Kasichayanula 2012 - Study 1: Control (Perpetrator Placebo) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=24)"
        },
        {
          "Scaling": "Log",
          "Path": "PO SD 20 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Komoroski 2009 - SAD 20 mg - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=6)"
        },
        {
          "Scaling": "Log",
          "Path": "PO SD 250 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Komoroski 2009 - SAD 250 mg fasted - Dapagliflozin - PO - 250 mg - Plasma - agg. (n=6)"
        },
        {
          "Scaling": "Log",
          "Path": "PO SD 5 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Komoroski 2009 - SAD 5 mg - Dapagliflozin - PO - 5 mg - Plasma - agg. (n=6)"
        },
        {
          "Scaling": "Log",
          "Path": "PO SD 500 mg (perm)|Organism|PeripheralVenousBlood|Dapagliflozin|Plasma (Peripheral Venous Blood)",
          "ObservedData": "Komoroski 2009 - SAD 500 mg - Dapagliflozin - PO - 500 mg - Plasma - agg. (n=6)"
        },
        {
          "Scaling": "Linear",
          "Path": "PO SD 2.5 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
          "ObservedData": "Komoroski 2009 - SAD 2.5 mg (Urine) - Dapagliflozin - PO - 2.5 mg - Urine - agg. (n=6)"
        },
        {
          "Scaling": "Linear",
          "Path": "PO SD 5 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
          "ObservedData": "Komoroski 2009 - SAD 5 mg (Urine) - Dapagliflozin - PO - 5 mg - Urine - agg. (n=6)"
        },
        {
          "Scaling": "Linear",
          "Path": "PO SD 10 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
          "ObservedData": "Komoroski 2009 - SAD 10 mg (Urine) - Dapagliflozin - PO - 10 mg - Urine - agg. (n=6)"
        },
        {
          "Scaling": "Linear",
          "Path": "PO SD 20 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
          "ObservedData": "Komoroski 2009 - SAD 20 mg (Urine) - Dapagliflozin - PO - 20 mg - Urine - agg. (n=6)"
        },
        {
          "Scaling": "Linear",
          "Path": "PO SD 50 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
          "ObservedData": "Komoroski 2009 - SAD 50 mg (Urine) - Dapagliflozin - PO - 50 mg - Urine - agg. (n=6)"
        },
        {
          "Scaling": "Linear",
          "Path": "PO SD 100 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
          "ObservedData": "Komoroski 2009 - SAD 100 mg (Urine) - Dapagliflozin - PO - 100 mg - Urine - agg. (n=6)"
        },
        {
          "Scaling": "Linear",
          "Path": "PO SD 250 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
          "ObservedData": "Komoroski 2009 - SAD 250 mg fasted (Urine) - Dapagliflozin - PO - 250 mg - Urine - agg. (n=6)"
        },
        {
          "Scaling": "Linear",
          "Path": "PO SD 500 mg (perm)|Organism|Kidney|Urine|Dapagliflozin|Fraction excreted to urine",
          "ObservedData": "Komoroski 2009 - SAD 500 mg (Urine) - Dapagliflozin - PO - 500 mg - Urine - agg. (n=6)"
        }
      ],
      "IdentificationParameters": [
        {
          "Name": "Lipophilicity",
          "Scaling": "Linear",
          "LinkedParameters": [
            "IV 0.08 mg (perm)|Dapagliflozin|Lipophilicity",
            "PO SD 10 mg (perm)|Dapagliflozin|Lipophilicity",
            "PO SD 50 mg (perm)|Dapagliflozin|Lipophilicity",
            "PO SD 100 mg (perm)|Dapagliflozin|Lipophilicity",
            "PO SD 2.5 mg (perm)|Dapagliflozin|Lipophilicity",
            "PO SD 20 mg (perm)|Dapagliflozin|Lipophilicity",
            "PO SD 250 mg (perm)|Dapagliflozin|Lipophilicity",
            "PO SD 5 mg (perm)|Dapagliflozin|Lipophilicity",
            "PO SD 500 mg (perm)|Dapagliflozin|Lipophilicity"
          ],
          "Parameters": [
            {
              "Name": "Start value",
              "Value": 2.546,
              "Unit": "Log Units"
            },
            {
              "Name": "MinValue",
              "Value": 1.0,
              "Unit": "Log Units"
            },
            {
              "Name": "MaxValue",
              "Value": 4.0,
              "Unit": "Log Units"
            }
          ]
        },
        {
          "Name": "P int",
          "Scaling": "Log",
          "LinkedParameters": [
            "IV 0.08 mg (perm)|Dapagliflozin|Specific intestinal permeability (transcellular)",
            "PO SD 10 mg (perm)|Dapagliflozin|Specific intestinal permeability (transcellular)",
            "PO SD 50 mg (perm)|Dapagliflozin|Specific intestinal permeability (transcellular)",
            "PO SD 100 mg (perm)|Dapagliflozin|Specific intestinal permeability (transcellular)",
            "PO SD 2.5 mg (perm)|Dapagliflozin|Specific intestinal permeability (transcellular)",
            "PO SD 20 mg (perm)|Dapagliflozin|Specific intestinal permeability (transcellular)",
            "PO SD 250 mg (perm)|Dapagliflozin|Specific intestinal permeability (transcellular)",
            "PO SD 5 mg (perm)|Dapagliflozin|Specific intestinal permeability (transcellular)",
            "PO SD 500 mg (perm)|Dapagliflozin|Specific intestinal permeability (transcellular)"
          ],
          "Parameters": [
            {
              "Name": "Start value",
              "Value": 4E-05,
              "Unit": "cm/min"
            },
            {
              "Name": "MinValue",
              "Value": 1E-06,
              "Unit": "cm/min"
            },
            {
              "Name": "MaxValue",
              "Value": 0.01,
              "Unit": "cm/min"
            }
          ]
        },
        {
          "Name": "UGT1A9",
          "Scaling": "Log",
          "LinkedParameters": [
            "IV 0.08 mg (perm)|Dapagliflozin-UGT1A9-Optimized|CLspec/[Enzyme]",
            "PO SD 10 mg (perm)|Dapagliflozin-UGT1A9-Optimized|CLspec/[Enzyme]",
            "PO SD 50 mg (perm)|Dapagliflozin-UGT1A9-Optimized|CLspec/[Enzyme]",
            "PO SD 100 mg (perm)|Dapagliflozin-UGT1A9-Optimized|CLspec/[Enzyme]",
            "PO SD 2.5 mg (perm)|Dapagliflozin-UGT1A9-Optimized|CLspec/[Enzyme]",
            "PO SD 20 mg (perm)|Dapagliflozin-UGT1A9-Optimized|CLspec/[Enzyme]",
            "PO SD 250 mg (perm)|Dapagliflozin-UGT1A9-Optimized|CLspec/[Enzyme]",
            "PO SD 5 mg (perm)|Dapagliflozin-UGT1A9-Optimized|CLspec/[Enzyme]",
            "PO SD 500 mg (perm)|Dapagliflozin-UGT1A9-Optimized|CLspec/[Enzyme]"
          ],
          "Parameters": [
            {
              "Name": "Start value",
              "Value": 0.4,
              "Unit": "l/µmol/min"
            },
            {
              "Name": "MinValue",
              "Value": 0.001,
              "Unit": "l/µmol/min"
            },
            {
              "Name": "MaxValue",
              "Value": 100.0,
              "Unit": "l/µmol/min"
            }
          ]
        },
        {
          "Name": "UGT2B7",
          "Scaling": "Log",
          "LinkedParameters": [
            "IV 0.08 mg (perm)|Dapagliflozin-UGT2B7-Optimized|CLspec/[Enzyme]",
            "PO SD 10 mg (perm)|Dapagliflozin-UGT2B7-Optimized|CLspec/[Enzyme]",
            "PO SD 50 mg (perm)|Dapagliflozin-UGT2B7-Optimized|CLspec/[Enzyme]",
            "PO SD 100 mg (perm)|Dapagliflozin-UGT2B7-Optimized|CLspec/[Enzyme]",
            "PO SD 2.5 mg (perm)|Dapagliflozin-UGT2B7-Optimized|CLspec/[Enzyme]",
            "PO SD 20 mg (perm)|Dapagliflozin-UGT2B7-Optimized|CLspec/[Enzyme]",
            "PO SD 250 mg (perm)|Dapagliflozin-UGT2B7-Optimized|CLspec/[Enzyme]",
            "PO SD 5 mg (perm)|Dapagliflozin-UGT2B7-Optimized|CLspec/[Enzyme]",
            "PO SD 500 mg (perm)|Dapagliflozin-UGT2B7-Optimized|CLspec/[Enzyme]"
          ],
          "Parameters": [
            {
              "Name": "Start value",
              "Value": 0.02,
              "Unit": "l/µmol/min"
            },
            {
              "Name": "MinValue",
              "Value": 0.001,
              "Unit": "l/µmol/min"
            },
            {
              "Name": "MaxValue",
              "Value": 100.0,
              "Unit": "l/µmol/min"
            }
          ]
        },
        {
          "Name": "Hep-CYP",
          "Scaling": "Log",
          "LinkedParameters": [
            "IV 0.08 mg (perm)|Dapagliflozin-Hepatic-CYP-Optimized|CLspec/[Enzyme]",
            "PO SD 10 mg (perm)|Dapagliflozin-Hepatic-CYP-Optimized|CLspec/[Enzyme]",
            "PO SD 50 mg (perm)|Dapagliflozin-Hepatic-CYP-Optimized|CLspec/[Enzyme]",
            "PO SD 100 mg (perm)|Dapagliflozin-Hepatic-CYP-Optimized|CLspec/[Enzyme]",
            "PO SD 2.5 mg (perm)|Dapagliflozin-Hepatic-CYP-Optimized|CLspec/[Enzyme]",
            "PO SD 20 mg (perm)|Dapagliflozin-Hepatic-CYP-Optimized|CLspec/[Enzyme]",
            "PO SD 250 mg (perm)|Dapagliflozin-Hepatic-CYP-Optimized|CLspec/[Enzyme]",
            "PO SD 5 mg (perm)|Dapagliflozin-Hepatic-CYP-Optimized|CLspec/[Enzyme]",
            "PO SD 500 mg (perm)|Dapagliflozin-Hepatic-CYP-Optimized|CLspec/[Enzyme]"
          ],
          "Parameters": [
            {
              "Name": "Start value",
              "Value": 0.15,
              "Unit": "l/µmol/min"
            },
            {
              "Name": "MinValue",
              "Value": 0.001,
              "Unit": "l/µmol/min"
            },
            {
              "Name": "MaxValue",
              "Value": 100.0,
              "Unit": "l/µmol/min"
            }
          ]
        },
        {
          "Name": "Solubility",
          "Scaling": "Log",
          "LinkedParameters": [
            "IV 0.08 mg (perm)|Dapagliflozin|Solubility at reference pH",
            "PO SD 10 mg (perm)|Dapagliflozin|Solubility at reference pH",
            "PO SD 50 mg (perm)|Dapagliflozin|Solubility at reference pH",
            "PO SD 100 mg (perm)|Dapagliflozin|Solubility at reference pH",
            "PO SD 2.5 mg (perm)|Dapagliflozin|Solubility at reference pH",
            "PO SD 20 mg (perm)|Dapagliflozin|Solubility at reference pH",
            "PO SD 250 mg (perm)|Dapagliflozin|Solubility at reference pH",
            "PO SD 5 mg (perm)|Dapagliflozin|Solubility at reference pH",
            "PO SD 500 mg (perm)|Dapagliflozin|Solubility at reference pH"
          ],
          "Parameters": [
            {
              "Name": "Start value",
              "Value": 0.173,
              "Unit": "mg/ml"
            },
            {
              "Name": "MinValue",
              "Value": 0.01,
              "Unit": "mg/ml"
            },
            {
              "Name": "MaxValue",
              "Value": 100.0,
              "Unit": "mg/ml"
            }
          ]
        },
        {
          "Name": "Permeability",
          "Scaling": "Log",
          "LinkedParameters": [
            "IV 0.08 mg (perm)|Dapagliflozin|Permeability",
            "PO SD 10 mg (perm)|Dapagliflozin|Permeability",
            "PO SD 50 mg (perm)|Dapagliflozin|Permeability",
            "PO SD 100 mg (perm)|Dapagliflozin|Permeability",
            "PO SD 2.5 mg (perm)|Dapagliflozin|Permeability",
            "PO SD 20 mg (perm)|Dapagliflozin|Permeability",
            "PO SD 250 mg (perm)|Dapagliflozin|Permeability",
            "PO SD 5 mg (perm)|Dapagliflozin|Permeability",
            "PO SD 500 mg (perm)|Dapagliflozin|Permeability"
          ],
          "Parameters": [
            {
              "Name": "Start value",
              "Value": 0.0004257,
              "Unit": "cm/min"
            },
            {
              "Name": "MinValue",
              "Value": 1E-06,
              "Unit": "cm/min"
            },
            {
              "Name": "MaxValue",
              "Value": 0.01,
              "Unit": "cm/min"
            }
          ]
        },
        {
          "Name": "logP (veg.oil/water)",
          "Scaling": "Linear",
          "LinkedParameters": [
            "IV 0.08 mg (perm)|Dapagliflozin|logP (veg.oil/water)",
            "PO SD 10 mg (perm)|Dapagliflozin|logP (veg.oil/water)",
            "PO SD 50 mg (perm)|Dapagliflozin|logP (veg.oil/water)",
            "PO SD 100 mg (perm)|Dapagliflozin|logP (veg.oil/water)",
            "PO SD 2.5 mg (perm)|Dapagliflozin|logP (veg.oil/water)",
            "PO SD 20 mg (perm)|Dapagliflozin|logP (veg.oil/water)",
            "PO SD 250 mg (perm)|Dapagliflozin|logP (veg.oil/water)",
            "PO SD 5 mg (perm)|Dapagliflozin|logP (veg.oil/water)",
            "PO SD 500 mg (perm)|Dapagliflozin|logP (veg.oil/water)"
          ],
          "Parameters": [
            {
              "Name": "Start value",
              "Value": 2.053,
              "Unit": "Log Units"
            },
            {
              "Name": "MinValue",
              "Value": 0.0,
              "Unit": "Log Units"
            },
            {
              "Name": "MaxValue",
              "Value": 4.0,
              "Unit": "Log Units"
            }
          ]
        },
        {
          "Name": "GFR fraction",
          "Scaling": "Linear",
          "LinkedParameters": [
            "IV 0.08 mg (perm)|Neighborhoods|Kidney_pls_Kidney_ur|Dapagliflozin|Glomerular Filtration-assumed|GFR fraction",
            "PO SD 10 mg (perm)|Neighborhoods|Kidney_pls_Kidney_ur|Dapagliflozin|Glomerular Filtration-assumed|GFR fraction",
            "PO SD 50 mg (perm)|Neighborhoods|Kidney_pls_Kidney_ur|Dapagliflozin|Glomerular Filtration-assumed|GFR fraction",
            "PO SD 100 mg (perm)|Neighborhoods|Kidney_pls_Kidney_ur|Dapagliflozin|Glomerular Filtration-assumed|GFR fraction",
            "PO SD 2.5 mg (perm)|Neighborhoods|Kidney_pls_Kidney_ur|Dapagliflozin|Glomerular Filtration-assumed|GFR fraction",
            "PO SD 20 mg (perm)|Neighborhoods|Kidney_pls_Kidney_ur|Dapagliflozin|Glomerular Filtration-assumed|GFR fraction",
            "PO SD 250 mg (perm)|Neighborhoods|Kidney_pls_Kidney_ur|Dapagliflozin|Glomerular Filtration-assumed|GFR fraction",
            "PO SD 5 mg (perm)|Neighborhoods|Kidney_pls_Kidney_ur|Dapagliflozin|Glomerular Filtration-assumed|GFR fraction",
            "PO SD 500 mg (perm)|Neighborhoods|Kidney_pls_Kidney_ur|Dapagliflozin|Glomerular Filtration-assumed|GFR fraction"
          ],
          "Parameters": [
            {
              "Name": "Start value",
              "Value": 1.0
            },
            {
              "Name": "MinValue",
              "Value": 0.1
            },
            {
              "Name": "MaxValue",
              "Value": 10.0
            }
          ]
        },
        {
          "Name": "Blood/Plasma concentration ratio",
          "Scaling": "Linear",
          "IsFixed": true,
          "LinkedParameters": [
            "IV 0.08 mg (perm)|Dapagliflozin|Blood/Plasma concentration ratio",
            "PO SD 10 mg (perm)|Dapagliflozin|Blood/Plasma concentration ratio",
            "PO SD 50 mg (perm)|Dapagliflozin|Blood/Plasma concentration ratio",
            "PO SD 100 mg (perm)|Dapagliflozin|Blood/Plasma concentration ratio",
            "PO SD 2.5 mg (perm)|Dapagliflozin|Blood/Plasma concentration ratio",
            "PO SD 20 mg (perm)|Dapagliflozin|Blood/Plasma concentration ratio",
            "PO SD 250 mg (perm)|Dapagliflozin|Blood/Plasma concentration ratio",
            "PO SD 5 mg (perm)|Dapagliflozin|Blood/Plasma concentration ratio",
            "PO SD 500 mg (perm)|Dapagliflozin|Blood/Plasma concentration ratio"
          ],
          "Parameters": [
            {
              "Name": "Start value",
              "Value": 0.88
            },
            {
              "Name": "MinValue",
              "Value": 0.0
            },
            {
              "Name": "MaxValue",
              "Value": 6.1244936725
            }
          ]
        }
      ]
    }
  ],
  "ObservedData": [
    {
      "Name": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin Feces - Dapagliflozin - PO - 50 mg - Feces - agg. (n=6)",
      "ExtendedProperties": [
        {
          "Name": "DB Version",
          "Value": "OSP DATABASE"
        },
        {
          "Name": "ID",
          "Value": 674.0
        },
        {
          "Name": "Study Id",
          "Value": "Kasichayanula 2008"
        },
        {
          "Name": "Reference",
          "Value": "https://scholar.google.com/scholar?q=Kasichayanula+S.+Disposition+and+mass+balance+of+14C-dapagliflozin+after+single+oral+doses+in+healthy+male+volunteers.+American+Association+of+Pharmaceutical+Scientists,+Atlanta,+GA+2008+"
        },
        {
          "Name": "Source",
          "Value": "209803,209805,209806Orig1s000ClinPharmR.pdf, 202293Orig1s000ClinPharmR.pdf"
        },
        {
          "Name": "Grouping",
          "Value": "Mass Balance of 14C-dapagliflozin Feces"
        },
        {
          "Name": "Data type",
          "Value": "aggregated"
        },
        {
          "Name": "N",
          "Value": 6.0
        },
        {
          "Name": "Molecule",
          "Value": "Dapagliflozin"
        },
        {
          "Name": "Species",
          "Value": "Human"
        },
        {
          "Name": "Organ",
          "Value": "Lumen"
        },
        {
          "Name": "Compartment",
          "Value": "Feces"
        },
        {
          "Name": "Route",
          "Value": "PO"
        },
        {
          "Name": "Dose",
          "Value": "50 mg"
        },
        {
          "Name": "Times of Administration [h]",
          "Value": 0.0
        },
        {
          "Name": "Formulation",
          "Value": "Solution"
        },
        {
          "Name": "Food state",
          "Value": "."
        },
        {
          "Name": "Comment",
          "Value": "."
        }
      ],
      "Columns": [
        {
          "Name": "Avg",
          "QuantityInfo": {
            "Name": "Avg",
            "Path": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin Feces - Dapagliflozin - PO - 50 mg - Feces - agg. (n=6)|ObservedData|Lumen|Feces|Dapagliflozin|ArithmeticMean"
          },
          "DataInfo": {
            "Origin": "Observation",
            "AuxiliaryType": "Undefined",
            "Date": "0001-01-01T00:00:00",
            "MolWeight": 408.87
          },
          "Values": [
            18.9
          ],
          "Dimension": "Fraction",
          "Unit": "%"
        }
      ],
      "BaseGrid": {
        "Name": "Time",
        "QuantityInfo": {
          "Name": "Time",
          "Path": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin Feces - Dapagliflozin - PO - 50 mg - Feces - agg. (n=6)|Time",
          "Type": "Time"
        },
        "DataInfo": {
          "Origin": "BaseGrid",
          "AuxiliaryType": "Undefined",
          "Date": "0001-01-01T00:00:00"
        },
        "Values": [
          312.0
        ],
        "Dimension": "Time",
        "Unit": "h"
      }
    },
    {
      "Name": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin Urine - Dapagliflozin - PO - 50 mg - Urine - agg. (n=6)",
      "ExtendedProperties": [
        {
          "Name": "DB Version",
          "Value": "OSP DATABASE"
        },
        {
          "Name": "ID",
          "Value": 673.0
        },
        {
          "Name": "Study Id",
          "Value": "Kasichayanula 2008"
        },
        {
          "Name": "Reference",
          "Value": "https://scholar.google.com/scholar?q=Kasichayanula+S.+Disposition+and+mass+balance+of+14C-dapagliflozin+after+single+oral+doses+in+healthy+male+volunteers.+American+Association+of+Pharmaceutical+Scientists,+Atlanta,+GA+2008+"
        },
        {
          "Name": "Source",
          "Value": "209803,209805,209806Orig1s000ClinPharmR.pdf, 202293Orig1s000ClinPharmR.pdf"
        },
        {
          "Name": "Grouping",
          "Value": "Mass Balance of 14C-dapagliflozin Urine"
        },
        {
          "Name": "Data type",
          "Value": "aggregated"
        },
        {
          "Name": "N",
          "Value": 6.0
        },
        {
          "Name": "Molecule",
          "Value": "Dapagliflozin"
        },
        {
          "Name": "Species",
          "Value": "Human"
        },
        {
          "Name": "Organ",
          "Value": "Kidney"
        },
        {
          "Name": "Compartment",
          "Value": "Urine"
        },
        {
          "Name": "Route",
          "Value": "PO"
        },
        {
          "Name": "Dose",
          "Value": "50 mg"
        },
        {
          "Name": "Times of Administration [h]",
          "Value": 0.0
        },
        {
          "Name": "Formulation",
          "Value": "Solution"
        },
        {
          "Name": "Food state",
          "Value": "."
        },
        {
          "Name": "Comment",
          "Value": "."
        }
      ],
      "Columns": [
        {
          "Name": "Avg",
          "QuantityInfo": {
            "Name": "Avg",
            "Path": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin Urine - Dapagliflozin - PO - 50 mg - Urine - agg. (n=6)|ObservedData|Kidney|Urine|Dapagliflozin|ArithmeticMean"
          },
          "DataInfo": {
            "Origin": "Observation",
            "AuxiliaryType": "Undefined",
            "Date": "0001-01-01T00:00:00",
            "MolWeight": 408.87
          },
          "Values": [
            1.23
          ],
          "Dimension": "Fraction",
          "Unit": "%"
        }
      ],
      "BaseGrid": {
        "Name": "Time",
        "QuantityInfo": {
          "Name": "Time",
          "Path": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin Urine - Dapagliflozin - PO - 50 mg - Urine - agg. (n=6)|Time",
          "Type": "Time"
        },
        "DataInfo": {
          "Origin": "BaseGrid",
          "AuxiliaryType": "Undefined",
          "Date": "0001-01-01T00:00:00"
        },
        "Values": [
          312.0
        ],
        "Dimension": "Time",
        "Unit": "h"
      }
    },
    {
      "Name": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin oxid Metab - Dapagliflozin oxidative metabolites - PO - 50 mg - Fraction - agg. (n=6)",
      "ExtendedProperties": [
        {
          "Name": "DB Version",
          "Value": "OSP DATABASE"
        },
        {
          "Name": "ID",
          "Value": 672.0
        },
        {
          "Name": "Study Id",
          "Value": "Kasichayanula 2008"
        },
        {
          "Name": "Reference",
          "Value": "https://scholar.google.com/scholar?q=Kasichayanula+S.+Disposition+and+mass+balance+of+14C-dapagliflozin+after+single+oral+doses+in+healthy+male+volunteers.+American+Association+of+Pharmaceutical+Scientists,+Atlanta,+GA+2008+"
        },
        {
          "Name": "Source",
          "Value": "209803,209805,209806Orig1s000ClinPharmR.pdf, 202293Orig1s000ClinPharmR.pdf"
        },
        {
          "Name": "Grouping",
          "Value": "Mass Balance of 14C-dapagliflozin oxid Metab"
        },
        {
          "Name": "Data type",
          "Value": "aggregated"
        },
        {
          "Name": "N",
          "Value": 6.0
        },
        {
          "Name": "Molecule",
          "Value": "Dapagliflozin oxidative metabolites"
        },
        {
          "Name": "Species",
          "Value": "Human"
        },
        {
          "Name": "Organ",
          "Value": "Undefined"
        },
        {
          "Name": "Compartment",
          "Value": "Undefined"
        },
        {
          "Name": "Route",
          "Value": "PO"
        },
        {
          "Name": "Dose",
          "Value": "50 mg"
        },
        {
          "Name": "Times of Administration [h]",
          "Value": 0.0
        },
        {
          "Name": "Formulation",
          "Value": "Solution"
        },
        {
          "Name": "Food state",
          "Value": "."
        },
        {
          "Name": "Comment",
          "Value": "."
        }
      ],
      "Columns": [
        {
          "Name": "Avg",
          "QuantityInfo": {
            "Name": "Avg",
            "Path": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin oxid Metab - Dapagliflozin oxidative metabolites - PO - 50 mg - Fraction - agg. (n=6)|ObservedData|Undefined|Undefined|Dapagliflozin oxidative metabolites|ArithmeticMean"
          },
          "DataInfo": {
            "Origin": "Observation",
            "AuxiliaryType": "Undefined",
            "Date": "0001-01-01T00:00:00",
            "MolWeight": 0.0
          },
          "Values": [
            9.1
          ],
          "Dimension": "Fraction",
          "Unit": "%"
        }
      ],
      "BaseGrid": {
        "Name": "Time",
        "QuantityInfo": {
          "Name": "Time",
          "Path": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin oxid Metab - Dapagliflozin oxidative metabolites - PO - 50 mg - Fraction - agg. (n=6)|Time",
          "Type": "Time"
        },
        "DataInfo": {
          "Origin": "BaseGrid",
          "AuxiliaryType": "Undefined",
          "Date": "0001-01-01T00:00:00"
        },
        "Values": [
          312.0
        ],
        "Dimension": "Time",
        "Unit": "h"
      }
    },
    {
      "Name": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin 2OG Gluc - Dapagliflozin-2-O-glucuronide - PO - 50 mg - Fraction - agg. (n=6)",
      "ExtendedProperties": [
        {
          "Name": "DB Version",
          "Value": "OSP DATABASE"
        },
        {
          "Name": "ID",
          "Value": 671.0
        },
        {
          "Name": "Study Id",
          "Value": "Kasichayanula 2008"
        },
        {
          "Name": "Reference",
          "Value": "https://scholar.google.com/scholar?q=Kasichayanula+S.+Disposition+and+mass+balance+of+14C-dapagliflozin+after+single+oral+doses+in+healthy+male+volunteers.+American+Association+of+Pharmaceutical+Scientists,+Atlanta,+GA+2008+"
        },
        {
          "Name": "Source",
          "Value": "209803,209805,209806Orig1s000ClinPharmR.pdf, 202293Orig1s000ClinPharmR.pdf"
        },
        {
          "Name": "Grouping",
          "Value": "Mass Balance of 14C-dapagliflozin 2OG Gluc"
        },
        {
          "Name": "Data type",
          "Value": "aggregated"
        },
        {
          "Name": "N",
          "Value": 6.0
        },
        {
          "Name": "Molecule",
          "Value": "Dapagliflozin-2-O-glucuronide"
        },
        {
          "Name": "Species",
          "Value": "Human"
        },
        {
          "Name": "Organ",
          "Value": "Undefined"
        },
        {
          "Name": "Compartment",
          "Value": "Undefined"
        },
        {
          "Name": "Route",
          "Value": "PO"
        },
        {
          "Name": "Dose",
          "Value": "50 mg"
        },
        {
          "Name": "Times of Administration [h]",
          "Value": 0.0
        },
        {
          "Name": "Formulation",
          "Value": "Solution"
        },
        {
          "Name": "Food state",
          "Value": "."
        },
        {
          "Name": "Comment",
          "Value": "."
        }
      ],
      "Columns": [
        {
          "Name": "Avg",
          "QuantityInfo": {
            "Name": "Avg",
            "Path": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin 2OG Gluc - Dapagliflozin-2-O-glucuronide - PO - 50 mg - Fraction - agg. (n=6)|ObservedData|Undefined|Undefined|Dapagliflozin-2-O-glucuronide|ArithmeticMean"
          },
          "DataInfo": {
            "Origin": "Observation",
            "AuxiliaryType": "Undefined",
            "Date": "0001-01-01T00:00:00",
            "MolWeight": 585.0
          },
          "Values": [
            0.055
          ],
          "Dimension": "Fraction"
        }
      ],
      "BaseGrid": {
        "Name": "Time",
        "QuantityInfo": {
          "Name": "Time",
          "Path": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin 2OG Gluc - Dapagliflozin-2-O-glucuronide - PO - 50 mg - Fraction - agg. (n=6)|Time",
          "Type": "Time"
        },
        "DataInfo": {
          "Origin": "BaseGrid",
          "AuxiliaryType": "Undefined",
          "Date": "0001-01-01T00:00:00"
        },
        "Values": [
          312.0
        ],
        "Dimension": "Time",
        "Unit": "h"
      }
    },
    {
      "Name": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin 3OG Gluc - Dapagliflozin-3-O-glucuronide - PO - 50 mg - Fraction - agg. (n=6)",
      "ExtendedProperties": [
        {
          "Name": "DB Version",
          "Value": "OSP DATABASE"
        },
        {
          "Name": "ID",
          "Value": 670.0
        },
        {
          "Name": "Study Id",
          "Value": "Kasichayanula 2008"
        },
        {
          "Name": "Reference",
          "Value": "https://scholar.google.com/scholar?q=Kasichayanula+S.+Disposition+and+mass+balance+of+14C-dapagliflozin+after+single+oral+doses+in+healthy+male+volunteers.+American+Association+of+Pharmaceutical+Scientists,+Atlanta,+GA+2008+"
        },
        {
          "Name": "Source",
          "Value": "209803,209805,209806Orig1s000ClinPharmR.pdf, 202293Orig1s000ClinPharmR.pdf"
        },
        {
          "Name": "Grouping",
          "Value": "Mass Balance of 14C-dapagliflozin 3OG Gluc"
        },
        {
          "Name": "Data type",
          "Value": "aggregated"
        },
        {
          "Name": "N",
          "Value": 6.0
        },
        {
          "Name": "Molecule",
          "Value": "Dapagliflozin-3-O-glucuronide"
        },
        {
          "Name": "Species",
          "Value": "Human"
        },
        {
          "Name": "Organ",
          "Value": "Undefined"
        },
        {
          "Name": "Compartment",
          "Value": "Undefined"
        },
        {
          "Name": "Route",
          "Value": "PO"
        },
        {
          "Name": "Dose",
          "Value": "50 mg"
        },
        {
          "Name": "Times of Administration [h]",
          "Value": 0.0
        },
        {
          "Name": "Formulation",
          "Value": "Solution"
        },
        {
          "Name": "Food state",
          "Value": "."
        },
        {
          "Name": "Comment",
          "Value": "."
        }
      ],
      "Columns": [
        {
          "Name": "Avg",
          "QuantityInfo": {
            "Name": "Avg",
            "Path": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin 3OG Gluc - Dapagliflozin-3-O-glucuronide - PO - 50 mg - Fraction - agg. (n=6)|ObservedData|Undefined|Undefined|Dapagliflozin-3-O-glucuronide|ArithmeticMean"
          },
          "DataInfo": {
            "Origin": "Observation",
            "AuxiliaryType": "Undefined",
            "Date": "0001-01-01T00:00:00",
            "MolWeight": 585.0
          },
          "Values": [
            0.614
          ],
          "Dimension": "Fraction"
        }
      ],
      "BaseGrid": {
        "Name": "Time",
        "QuantityInfo": {
          "Name": "Time",
          "Path": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin 3OG Gluc - Dapagliflozin-3-O-glucuronide - PO - 50 mg - Fraction - agg. (n=6)|Time",
          "Type": "Time"
        },
        "DataInfo": {
          "Origin": "BaseGrid",
          "AuxiliaryType": "Undefined",
          "Date": "0001-01-01T00:00:00"
        },
        "Values": [
          312.0
        ],
        "Dimension": "Time",
        "Unit": "h"
      }
    },
    {
      "Name": "Kasichayanula 2011c - Healthy Volunteers - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=6)",
      "ExtendedProperties": [
        {
          "Name": "DB Version",
          "Value": "OSP DATABASE"
        },
        {
          "Name": "ID",
          "Value": 651.0
        },
        {
          "Name": "Study Id",
          "Value": "Kasichayanula 2011c"
        },
        {
          "Name": "Reference",
          "Value": "https://www.ncbi.nlm.nih.gov/pubmed/22030444"
        },
        {
          "Name": "Source",
          "Value": "Fig. 1A"
        },
        {
          "Name": "Grouping",
          "Value": "Healthy Volunteers"
        },
        {
          "Name": "Data type",
          "Value": "aggregated"
        },
        {
          "Name": "N",
          "Value": 6.0
        },
        {
          "Name": "Molecule",
          "Value": "Dapagliflozin"
        },
        {
          "Name": "Species",
          "Value": "Human"
        },
        {
          "Name": "Organ",
          "Value": "Peripheral Venous Blood"
        },
        {
          "Name": "Compartment",
          "Value": "Plasma"
        },
        {
          "Name": "Route",
          "Value": "PO"
        },
        {
          "Name": "Dose",
          "Value": "10 mg"
        },
        {
          "Name": "Times of Administration [h]",
          "Value": 0.0
        },
        {
          "Name": "Formulation",
          "Value": "."
        },
        {
          "Name": "Food state",
          "Value": "Fasted"
        },
        {
          "Name": "Comment",
          "Value": "."
        }
      ],
      "Columns": [
        {
          "Name": "Avg",
          "RelatedColumns": [
            {
              "Name": "Var",
              "QuantityInfo": {
                "Name": "Var",
                "Path": "Kasichayanula 2011c - Healthy Volunteers - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticStdDev"
              },
              "DataInfo": {
                "Origin": "ObservationAuxiliary",
                "AuxiliaryType": "ArithmeticStdDev",
                "Date": "0001-01-01T00:00:00",
                "MolWeight": 408.87
              },
              "Values": [
                0.0650289,
                0.0346820764,
                0.02601156,
                0.0294797681,
                0.0147398841,
                "NaN",
                "NaN",
                0.00353494124,
                0.00140821643,
                0.000105760293,
                0.000592953467,
                0.000594688638,
                3.38492573E-05
              ],
              "Dimension": "Concentration (mass)",
              "Unit": "mg/l"
            }
          ],
          "QuantityInfo": {
            "Name": "Avg",
            "Path": "Kasichayanula 2011c - Healthy Volunteers - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean"
          },
          "DataInfo": {
            "Origin": "Observation",
            "AuxiliaryType": "Undefined",
            "Date": "0001-01-01T00:00:00",
            "MolWeight": 408.87
          },
          "Values": [
            92.77457,
            118.786125,
            84.10405,
            69.36416,
            46.82081,
            32.9479752,
            19.0751438,
            12.51875,
            7.673923,
            4.34140873,
            2.792499,
            1.96192729,
            1.38949549
          ],
          "Dimension": "Concentration (mass)",
          "Unit": "µg/l"
        }
      ],
      "BaseGrid": {
        "Name": "Time",
        "QuantityInfo": {
          "Name": "Time",
          "Path": "Kasichayanula 2011c - Healthy Volunteers - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=6)|Time",
          "Type": "Time"
        },
        "DataInfo": {
          "Origin": "BaseGrid",
          "AuxiliaryType": "Undefined",
          "Date": "0001-01-01T00:00:00"
        },
        "Values": [
          0.5,
          1.0,
          1.5,
          2.0,
          3.0,
          4.0,
          6.0,
          8.0,
          12.0,
          16.0,
          24.0,
          36.0,
          48.0
        ],
        "Dimension": "Time",
        "Unit": "h"
      }
    },
    {
      "Name": "DeFronzo 2013 - Healthy Subjects - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=12)",
      "ExtendedProperties": [
        {
          "Name": "DB Version",
          "Value": "OSP DATABASE"
        },
        {
          "Name": "ID",
          "Value": 650.0
        },
        {
          "Name": "Study Id",
          "Value": "DeFronzo 2013"
        },
        {
          "Name": "Reference",
          "Value": "https://www.ncbi.nlm.nih.gov/pubmed/23735727"
        },
        {
          "Name": "Source",
          "Value": "Supplementary Figure 2"
        },
        {
          "Name": "Grouping",
          "Value": "Healthy Subjects"
        },
        {
          "Name": "Data type",
          "Value": "aggregated"
        },
        {
          "Name": "N",
          "Value": 12.0
        },
        {
          "Name": "Molecule",
          "Value": "Dapagliflozin"
        },
        {
          "Name": "Species",
          "Value": "Human"
        },
        {
          "Name": "Organ",
          "Value": "Peripheral Venous Blood"
        },
        {
          "Name": "Compartment",
          "Value": "Plasma"
        },
        {
          "Name": "Route",
          "Value": "PO"
        },
        {
          "Name": "Dose",
          "Value": "10 mg"
        },
        {
          "Name": "Times of Administration [h]",
          "Value": "(S0-T24-R7)"
        },
        {
          "Name": "Formulation",
          "Value": "."
        },
        {
          "Name": "Food state",
          "Value": "."
        },
        {
          "Name": "Comment",
          "Value": "."
        }
      ],
      "Columns": [
        {
          "Name": "Avg",
          "RelatedColumns": [
            {
              "Name": "Var",
              "QuantityInfo": {
                "Name": "Var",
                "Path": "DeFronzo 2013 - Healthy Subjects - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=12)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticStdDev"
              },
              "DataInfo": {
                "Origin": "ObservationAuxiliary",
                "AuxiliaryType": "ArithmeticStdDev",
                "Date": "0001-01-01T00:00:00",
                "MolWeight": 408.87
              },
              "Values": [
                0.00192307681,
                0.0233333334,
                0.03448706,
                0.0273075756,
                0.0225642212,
                0.01602576,
                0.011025642,
                0.0101282047,
                0.008333099,
                0.0075641023,
                0.005897671,
                0.00435920944
              ],
              "Dimension": "Concentration (mass)",
              "Unit": "mg/l"
            }
          ],
          "QuantityInfo": {
            "Name": "Avg",
            "Path": "DeFronzo 2013 - Healthy Subjects - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=12)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean"
          },
          "DataInfo": {
            "Origin": "Observation",
            "AuxiliaryType": "Undefined",
            "Date": "0001-01-01T00:00:00",
            "MolWeight": 408.87
          },
          "Values": [
            0.00474758539,
            0.0212894548,
            0.0378316753,
            0.0528352,
            0.053479638,
            0.0470730178,
            0.0389996246,
            0.0337468572,
            0.0282376781,
            0.02336941,
            0.0205523055,
            0.00218348275
          ],
          "Dimension": "Concentration (mass)",
          "Unit": "mg/l"
        }
      ],
      "BaseGrid": {
        "Name": "Time",
        "QuantityInfo": {
          "Name": "Time",
          "Path": "DeFronzo 2013 - Healthy Subjects - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=12)|Time",
          "Type": "Time"
        },
        "DataInfo": {
          "Origin": "BaseGrid",
          "AuxiliaryType": "Undefined",
          "Date": "0001-01-01T00:00:00"
        },
        "Values": [
          144.0,
          144.666672,
          145.333328,
          146.0,
          146.666672,
          147.333328,
          148.0,
          148.666,
          149.333328,
          150.0,
          150.666672,
          168.0
        ],
        "Dimension": "Time",
        "Unit": "h"
      }
    },
    {
      "Name": "Vakkalagadda 2016 - Dapagliflozin - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=42)",
      "ExtendedProperties": [
        {
          "Name": "DB Version",
          "Value": "OSP DATABASE"
        },
        {
          "Name": "ID",
          "Value": 649.0
        },
        {
          "Name": "Study Id",
          "Value": "Vakkalagadda 2016"
        },
        {
          "Name": "Reference",
          "Value": "https://www.ncbi.nlm.nih.gov/pubmed/27491280"
        },
        {
          "Name": "Source",
          "Value": "Fig. 2 (inset)"
        },
        {
          "Name": "Grouping",
          "Value": "Dapagliflozin"
        },
        {
          "Name": "Data type",
          "Value": "aggregated"
        },
        {
          "Name": "N",
          "Value": 42.0
        },
        {
          "Name": "Molecule",
          "Value": "Dapagliflozin"
        },
        {
          "Name": "Species",
          "Value": "Human"
        },
        {
          "Name": "Organ",
          "Value": "Peripheral Venous Blood"
        },
        {
          "Name": "Compartment",
          "Value": "Plasma"
        },
        {
          "Name": "Route",
          "Value": "PO"
        },
        {
          "Name": "Dose",
          "Value": "10 mg"
        },
        {
          "Name": "Times of Administration [h]",
          "Value": 0.0
        },
        {
          "Name": "Formulation",
          "Value": "."
        },
        {
          "Name": "Food state",
          "Value": "Fasted"
        },
        {
          "Name": "Comment",
          "Value": "."
        }
      ],
      "Columns": [
        {
          "Name": "Avg",
          "QuantityInfo": {
            "Name": "Avg",
            "Path": "Vakkalagadda 2016 - Dapagliflozin - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=42)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean"
          },
          "DataInfo": {
            "Origin": "Observation",
            "AuxiliaryType": "Undefined",
            "Date": "0001-01-01T00:00:00",
            "MolWeight": 408.87
          },
          "Values": [
            103.5613,
            115.8323,
            85.13168,
            66.17115,
            44.71528,
            24.15343,
            13.79805,
            9.066649,
            3.701596,
            1.554137,
            1.11069,
            0.6900901
          ],
          "Dimension": "Concentration (mass)",
          "Unit": "µg/l"
        }
      ],
      "BaseGrid": {
        "Name": "Time",
        "QuantityInfo": {
          "Name": "Time",
          "Path": "Vakkalagadda 2016 - Dapagliflozin - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=42)|Time",
          "Type": "Time"
        },
        "DataInfo": {
          "Origin": "BaseGrid",
          "AuxiliaryType": "Undefined",
          "Date": "0001-01-01T00:00:00"
        },
        "Values": [
          0.5,
          1.0,
          1.5,
          2.0,
          3.0,
          5.0,
          8.0,
          12.0,
          24.0,
          36.0,
          48.0,
          60.0
        ],
        "Dimension": "Time",
        "Unit": "h"
      }
    },
    {
      "Name": "Kasichayanula 2013b - T2DM with severe renal impairment - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=4)",
      "ExtendedProperties": [
        {
          "Name": "DB Version",
          "Value": "OSP DATABASE"
        },
        {
          "Name": "ID",
          "Value": 648.0
        },
        {
          "Name": "Study Id",
          "Value": "Kasichayanula 2013b"
        },
        {
          "Name": "Reference",
          "Value": "https://www.ncbi.nlm.nih.gov/pubmed/23210765"
        },
        {
          "Name": "Source",
          "Value": "Fig. S2A"
        },
        {
          "Name": "Grouping",
          "Value": "T2DM with severe renal impairment"
        },
        {
          "Name": "Data type",
          "Value": "aggregated"
        },
        {
          "Name": "N",
          "Value": 4.0
        },
        {
          "Name": "Molecule",
          "Value": "Dapagliflozin"
        },
        {
          "Name": "Species",
          "Value": "Human"
        },
        {
          "Name": "Organ",
          "Value": "Peripheral Venous Blood"
        },
        {
          "Name": "Compartment",
          "Value": "Plasma"
        },
        {
          "Name": "Route",
          "Value": "PO"
        },
        {
          "Name": "Dose",
          "Value": "50 mg"
        },
        {
          "Name": "Times of Administration [h]",
          "Value": 0.0
        },
        {
          "Name": "Formulation",
          "Value": "."
        },
        {
          "Name": "Food state",
          "Value": "Fasted"
        },
        {
          "Name": "Comment",
          "Value": "."
        }
      ],
      "Columns": [
        {
          "Name": "Avg",
          "QuantityInfo": {
            "Name": "Avg",
            "Path": "Kasichayanula 2013b - T2DM with severe renal impairment - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=4)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean"
          },
          "DataInfo": {
            "Origin": "Observation",
            "AuxiliaryType": "Undefined",
            "Date": "0001-01-01T00:00:00",
            "MolWeight": 408.87
          },
          "Values": [
            0.07210761,
            0.314893275,
            0.332690269,
            0.2816559,
            0.143209949,
            0.07867486,
            0.0395406038,
            0.0386436358,
            0.0216801651,
            0.0173430666,
            0.0146628534
          ],
          "Dimension": "Concentration (mass)",
          "Unit": "mg/l"
        }
      ],
      "BaseGrid": {
        "Name": "Time",
        "QuantityInfo": {
          "Name": "Time",
          "Path": "Kasichayanula 2013b - T2DM with severe renal impairment - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=4)|Time",
          "Type": "Time"
        },
        "DataInfo": {
          "Origin": "BaseGrid",
          "AuxiliaryType": "Undefined",
          "Date": "0001-01-01T00:00:00"
        },
        "Values": [
          0.25,
          0.5,
          4.0,
          6.0,
          8.0,
          12.0,
          18.0,
          24.0,
          36.0,
          48.0,
          60.0
        ],
        "Dimension": "Time",
        "Unit": "h"
      }
    },
    {
      "Name": "Kasichayanula 2013b - T2DM with moderate renal impairment - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=8)",
      "ExtendedProperties": [
        {
          "Name": "DB Version",
          "Value": "OSP DATABASE"
        },
        {
          "Name": "ID",
          "Value": 647.0
        },
        {
          "Name": "Study Id",
          "Value": "Kasichayanula 2013b"
        },
        {
          "Name": "Reference",
          "Value": "https://www.ncbi.nlm.nih.gov/pubmed/23210765"
        },
        {
          "Name": "Source",
          "Value": "Fig. S2A"
        },
        {
          "Name": "Grouping",
          "Value": "T2DM with moderate renal impairment"
        },
        {
          "Name": "Data type",
          "Value": "aggregated"
        },
        {
          "Name": "N",
          "Value": 8.0
        },
        {
          "Name": "Molecule",
          "Value": "Dapagliflozin"
        },
        {
          "Name": "Species",
          "Value": "Human"
        },
        {
          "Name": "Organ",
          "Value": "Peripheral Venous Blood"
        },
        {
          "Name": "Compartment",
          "Value": "Plasma"
        },
        {
          "Name": "Route",
          "Value": "PO"
        },
        {
          "Name": "Dose",
          "Value": "50 mg"
        },
        {
          "Name": "Times of Administration [h]",
          "Value": 0.0
        },
        {
          "Name": "Formulation",
          "Value": "."
        },
        {
          "Name": "Food state",
          "Value": "Fasted"
        },
        {
          "Name": "Comment",
          "Value": "."
        }
      ],
      "Columns": [
        {
          "Name": "Avg",
          "QuantityInfo": {
            "Name": "Avg",
            "Path": "Kasichayanula 2013b - T2DM with moderate renal impairment - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=8)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean"
          },
          "DataInfo": {
            "Origin": "Observation",
            "AuxiliaryType": "Undefined",
            "Date": "0001-01-01T00:00:00",
            "MolWeight": 408.87
          },
          "Values": [
            0.332858235,
            0.8633453,
            0.2912488,
            0.218279928,
            0.132517755,
            0.09188278,
            0.05893019,
            0.06020084,
            0.03023431,
            0.0239178073,
            0.0143417139,
            0.006664917
          ],
          "Dimension": "Concentration (mass)",
          "Unit": "mg/l"
        }
      ],
      "BaseGrid": {
        "Name": "Time",
        "QuantityInfo": {
          "Name": "Time",
          "Path": "Kasichayanula 2013b - T2DM with moderate renal impairment - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=8)|Time",
          "Type": "Time"
        },
        "DataInfo": {
          "Origin": "BaseGrid",
          "AuxiliaryType": "Undefined",
          "Date": "0001-01-01T00:00:00"
        },
        "Values": [
          0.25,
          0.5,
          4.0,
          6.0,
          8.0,
          12.0,
          18.0,
          24.0,
          36.0,
          48.0,
          60.0,
          72.0
        ],
        "Dimension": "Time",
        "Unit": "h"
      }
    },
    {
      "Name": "Kasichayanula 2013b - T2DM with mild renal impairment - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=8)",
      "ExtendedProperties": [
        {
          "Name": "DB Version",
          "Value": "OSP DATABASE"
        },
        {
          "Name": "ID",
          "Value": 646.0
        },
        {
          "Name": "Study Id",
          "Value": "Kasichayanula 2013b"
        },
        {
          "Name": "Reference",
          "Value": "https://www.ncbi.nlm.nih.gov/pubmed/23210765"
        },
        {
          "Name": "Source",
          "Value": "Fig. S2A"
        },
        {
          "Name": "Grouping",
          "Value": "T2DM with mild renal impairment"
        },
        {
          "Name": "Data type",
          "Value": "aggregated"
        },
        {
          "Name": "N",
          "Value": 8.0
        },
        {
          "Name": "Molecule",
          "Value": "Dapagliflozin"
        },
        {
          "Name": "Species",
          "Value": "Human"
        },
        {
          "Name": "Organ",
          "Value": "Peripheral Venous Blood"
        },
        {
          "Name": "Compartment",
          "Value": "Plasma"
        },
        {
          "Name": "Route",
          "Value": "PO"
        },
        {
          "Name": "Dose",
          "Value": "50 mg"
        },
        {
          "Name": "Times of Administration [h]",
          "Value": 0.0
        },
        {
          "Name": "Formulation",
          "Value": "."
        },
        {
          "Name": "Food state",
          "Value": "Fasted"
        },
        {
          "Name": "Comment",
          "Value": "."
        }
      ],
      "Columns": [
        {
          "Name": "Avg",
          "QuantityInfo": {
            "Name": "Avg",
            "Path": "Kasichayanula 2013b - T2DM with mild renal impairment - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=8)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean"
          },
          "DataInfo": {
            "Origin": "Observation",
            "AuxiliaryType": "Undefined",
            "Date": "0001-01-01T00:00:00",
            "MolWeight": 408.87
          },
          "Values": [
            0.19123888,
            0.524326861,
            0.772752345,
            0.5359441,
            0.380057633,
            0.257822454,
            0.213513315,
            0.16545026,
            0.108556405,
            0.0609720647,
            0.0361855775,
            0.02710395,
            0.0179579742,
            0.0101876613,
            0.008905044,
            0.008989975
          ],
          "Dimension": "Concentration (mass)",
          "Unit": "mg/l"
        }
      ],
      "BaseGrid": {
        "Name": "Time",
        "QuantityInfo": {
          "Name": "Time",
          "Path": "Kasichayanula 2013b - T2DM with mild renal impairment - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=8)|Time",
          "Type": "Time"
        },
        "DataInfo": {
          "Origin": "BaseGrid",
          "AuxiliaryType": "Undefined",
          "Date": "0001-01-01T00:00:00"
        },
        "Values": [
          0.25,
          0.5,
          1.0,
          2.0,
          3.0,
          4.0,
          5.0,
          6.0,
          8.0,
          12.0,
          18.0,
          24.0,
          36.0,
          48.0,
          60.0,
          72.0
        ],
        "Dimension": "Time",
        "Unit": "h"
      }
    },
    {
      "Name": "Kasichayanula 2013b - T2DM with normal kidney function - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=12)",
      "ExtendedProperties": [
        {
          "Name": "DB Version",
          "Value": "OSP DATABASE"
        },
        {
          "Name": "ID",
          "Value": 645.0
        },
        {
          "Name": "Study Id",
          "Value": "Kasichayanula 2013b"
        },
        {
          "Name": "Reference",
          "Value": "https://www.ncbi.nlm.nih.gov/pubmed/23210765"
        },
        {
          "Name": "Source",
          "Value": "Fig. S2A"
        },
        {
          "Name": "Grouping",
          "Value": "T2DM with normal kidney function"
        },
        {
          "Name": "Data type",
          "Value": "aggregated"
        },
        {
          "Name": "N",
          "Value": 12.0
        },
        {
          "Name": "Molecule",
          "Value": "Dapagliflozin"
        },
        {
          "Name": "Species",
          "Value": "Human"
        },
        {
          "Name": "Organ",
          "Value": "Peripheral Venous Blood"
        },
        {
          "Name": "Compartment",
          "Value": "Plasma"
        },
        {
          "Name": "Route",
          "Value": "PO"
        },
        {
          "Name": "Dose",
          "Value": "50 mg"
        },
        {
          "Name": "Times of Administration [h]",
          "Value": 0.0
        },
        {
          "Name": "Formulation",
          "Value": "."
        },
        {
          "Name": "Food state",
          "Value": "Fasted"
        },
        {
          "Name": "Comment",
          "Value": "."
        }
      ],
      "Columns": [
        {
          "Name": "Avg",
          "QuantityInfo": {
            "Name": "Avg",
            "Path": "Kasichayanula 2013b - T2DM with normal kidney function - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=12)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean"
          },
          "DataInfo": {
            "Origin": "Observation",
            "AuxiliaryType": "Undefined",
            "Date": "0001-01-01T00:00:00",
            "MolWeight": 408.87
          },
          "Values": [
            0.340307862,
            0.5071295,
            0.235979825,
            0.154851452,
            0.129669473,
            0.102726713,
            0.06740252,
            0.03661859,
            0.0232274439,
            0.0172067676,
            0.008545652,
            0.00458684424,
            0.0026020573
          ],
          "Dimension": "Concentration (mass)",
          "Unit": "mg/l"
        }
      ],
      "BaseGrid": {
        "Name": "Time",
        "QuantityInfo": {
          "Name": "Time",
          "Path": "Kasichayanula 2013b - T2DM with normal kidney function - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=12)|Time",
          "Type": "Time"
        },
        "DataInfo": {
          "Origin": "BaseGrid",
          "AuxiliaryType": "Undefined",
          "Date": "0001-01-01T00:00:00"
        },
        "Values": [
          0.5,
          1.0,
          3.0,
          4.0,
          5.0,
          6.0,
          8.0,
          12.0,
          18.0,
          24.0,
          36.0,
          48.0,
          60.0
        ],
        "Dimension": "Time",
        "Unit": "h"
      }
    },
    {
      "Name": "Kasichayanula 2013b - Healthy subjects with normal kidney function - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=8)",
      "ExtendedProperties": [
        {
          "Name": "DB Version",
          "Value": "OSP DATABASE"
        },
        {
          "Name": "ID",
          "Value": 644.0
        },
        {
          "Name": "Study Id",
          "Value": "Kasichayanula 2013b"
        },
        {
          "Name": "Reference",
          "Value": "https://www.ncbi.nlm.nih.gov/pubmed/23210765"
        },
        {
          "Name": "Source",
          "Value": "Fig. S2A"
        },
        {
          "Name": "Grouping",
          "Value": "Healthy subjects with normal kidney function"
        },
        {
          "Name": "Data type",
          "Value": "aggregated"
        },
        {
          "Name": "N",
          "Value": 8.0
        },
        {
          "Name": "Molecule",
          "Value": "Dapagliflozin"
        },
        {
          "Name": "Species",
          "Value": "Human"
        },
        {
          "Name": "Organ",
          "Value": "Peripheral Venous Blood"
        },
        {
          "Name": "Compartment",
          "Value": "Plasma"
        },
        {
          "Name": "Route",
          "Value": "PO"
        },
        {
          "Name": "Dose",
          "Value": "50 mg"
        },
        {
          "Name": "Times of Administration [h]",
          "Value": 0.0
        },
        {
          "Name": "Formulation",
          "Value": "."
        },
        {
          "Name": "Food state",
          "Value": "Fasted"
        },
        {
          "Name": "Comment",
          "Value": "."
        }
      ],
      "Columns": [
        {
          "Name": "Avg",
          "QuantityInfo": {
            "Name": "Avg",
            "Path": "Kasichayanula 2013b - Healthy subjects with normal kidney function - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=8)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean"
          },
          "DataInfo": {
            "Origin": "Observation",
            "AuxiliaryType": "Undefined",
            "Date": "0001-01-01T00:00:00",
            "MolWeight": 408.87
          },
          "Values": [
            91.88711,
            382.540283,
            563.1916,
            421.378052,
            279.379272,
            194.4079,
            160.222839,
            132.048935,
            81.42564,
            46.6972542,
            24.9072323,
            19.5586357,
            12.967638,
            8.392368,
            4.36938143,
            3.43109751
          ],
          "Dimension": "Concentration (mass)",
          "Unit": "µg/l"
        }
      ],
      "BaseGrid": {
        "Name": "Time",
        "QuantityInfo": {
          "Name": "Time",
          "Path": "Kasichayanula 2013b - Healthy subjects with normal kidney function - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=8)|Time",
          "Type": "Time"
        },
        "DataInfo": {
          "Origin": "BaseGrid",
          "AuxiliaryType": "Undefined",
          "Date": "0001-01-01T00:00:00"
        },
        "Values": [
          0.25,
          0.5,
          1.0,
          2.0,
          3.0,
          4.0,
          5.0,
          6.0,
          8.0,
          12.0,
          18.0,
          23.0,
          36.0,
          48.0,
          60.0,
          72.0
        ],
        "Dimension": "Time",
        "Unit": "h"
      }
    },
    {
      "Name": "Kasichayanula 2013a - Study 2: Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=16)",
      "ExtendedProperties": [
        {
          "Name": "DB Version",
          "Value": "OSP DATABASE"
        },
        {
          "Name": "ID",
          "Value": 641.0
        },
        {
          "Name": "Study Id",
          "Value": "Kasichayanula 2013a"
        },
        {
          "Name": "Reference",
          "Value": "https://www.ncbi.nlm.nih.gov/pubmed/23061428"
        },
        {
          "Name": "Source",
          "Value": "Fig. 1B"
        },
        {
          "Name": "Grouping",
          "Value": "Study 2: Control (Perpetrator Placebo)"
        },
        {
          "Name": "Data type",
          "Value": "aggregated"
        },
        {
          "Name": "N",
          "Value": 16.0
        },
        {
          "Name": "Molecule",
          "Value": "Dapagliflozin"
        },
        {
          "Name": "Species",
          "Value": "Human"
        },
        {
          "Name": "Organ",
          "Value": "Peripheral Venous Blood"
        },
        {
          "Name": "Compartment",
          "Value": "Plasma"
        },
        {
          "Name": "Route",
          "Value": "PO"
        },
        {
          "Name": "Dose",
          "Value": "10 mg"
        },
        {
          "Name": "Times of Administration [h]",
          "Value": 0.0
        },
        {
          "Name": "Formulation",
          "Value": "."
        },
        {
          "Name": "Food state",
          "Value": "."
        },
        {
          "Name": "Comment",
          "Value": "."
        }
      ],
      "Columns": [
        {
          "Name": "Avg",
          "RelatedColumns": [
            {
              "Name": "Var",
              "QuantityInfo": {
                "Name": "Var",
                "Path": "Kasichayanula 2013a - Study 2: Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=16)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticStdDev"
              },
              "DataInfo": {
                "Origin": "ObservationAuxiliary",
                "AuxiliaryType": "ArithmeticStdDev",
                "Date": "0001-01-01T00:00:00",
                "MolWeight": 408.87
              },
              "Values": [
                0.06428597,
                0.05097495,
                0.0285730883,
                0.0194805916,
                0.02045463,
                0.009741821,
                0.00681858463,
                0.003895738
              ],
              "Dimension": "Concentration (mass)",
              "Unit": "mg/l"
            }
          ],
          "QuantityInfo": {
            "Name": "Avg",
            "Path": "Kasichayanula 2013a - Study 2: Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=16)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean"
          },
          "DataInfo": {
            "Origin": "Observation",
            "AuxiliaryType": "Undefined",
            "Date": "0001-01-01T00:00:00",
            "MolWeight": 408.87
          },
          "Values": [
            107.4542,
            137.6423,
            120.751808,
            90.21964,
            69.75128,
            32.03501,
            12.76998,
            7.467561
          ],
          "Dimension": "Concentration (mass)",
          "Unit": "µg/l"
        }
      ],
      "BaseGrid": {
        "Name": "Time",
        "QuantityInfo": {
          "Name": "Time",
          "Path": "Kasichayanula 2013a - Study 2: Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=16)|Time",
          "Type": "Time"
        },
        "DataInfo": {
          "Origin": "BaseGrid",
          "AuxiliaryType": "Undefined",
          "Date": "0001-01-01T00:00:00"
        },
        "Values": [
          0.5,
          0.75,
          1.0,
          1.5,
          2.0,
          4.0,
          8.0,
          12.0
        ],
        "Dimension": "Time",
        "Unit": "h"
      }
    },
    {
      "Name": "Kasichayanula 2013a - Study 1: Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=14)",
      "ExtendedProperties": [
        {
          "Name": "DB Version",
          "Value": "OSP DATABASE"
        },
        {
          "Name": "ID",
          "Value": 640.0
        },
        {
          "Name": "Study Id",
          "Value": "Kasichayanula 2013a"
        },
        {
          "Name": "Reference",
          "Value": "https://www.ncbi.nlm.nih.gov/pubmed/23061428"
        },
        {
          "Name": "Source",
          "Value": "Fig. 1A"
        },
        {
          "Name": "Grouping",
          "Value": "Study 1: Control (Perpetrator Placebo)"
        },
        {
          "Name": "Data type",
          "Value": "aggregated"
        },
        {
          "Name": "N",
          "Value": 14.0
        },
        {
          "Name": "Molecule",
          "Value": "Dapagliflozin"
        },
        {
          "Name": "Species",
          "Value": "Human"
        },
        {
          "Name": "Organ",
          "Value": "Peripheral Venous Blood"
        },
        {
          "Name": "Compartment",
          "Value": "Plasma"
        },
        {
          "Name": "Route",
          "Value": "PO"
        },
        {
          "Name": "Dose",
          "Value": "10 mg"
        },
        {
          "Name": "Times of Administration [h]",
          "Value": 0.0
        },
        {
          "Name": "Formulation",
          "Value": "."
        },
        {
          "Name": "Food state",
          "Value": "."
        },
        {
          "Name": "Comment",
          "Value": "."
        }
      ],
      "Columns": [
        {
          "Name": "Avg",
          "RelatedColumns": [
            {
              "Name": "Var",
              "QuantityInfo": {
                "Name": "Var",
                "Path": "Kasichayanula 2013a - Study 1: Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=14)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticStdDev"
              },
              "DataInfo": {
                "Origin": "ObservationAuxiliary",
                "AuxiliaryType": "ArithmeticStdDev",
                "Date": "0001-01-01T00:00:00",
                "MolWeight": 408.87
              },
              "Values": [
                0.07916476,
                0.05509261,
                0.04259254,
                0.02638889,
                0.01851852,
                0.01342592,
                0.006018515,
                0.004627728
              ],
              "Dimension": "Concentration (mass)",
              "Unit": "mg/l"
            }
          ],
          "QuantityInfo": {
            "Name": "Avg",
            "Path": "Kasichayanula 2013a - Study 1: Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=14)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean"
          },
          "DataInfo": {
            "Origin": "Observation",
            "AuxiliaryType": "Undefined",
            "Date": "0001-01-01T00:00:00",
            "MolWeight": 408.87
          },
          "Values": [
            90.77876,
            126.4459,
            123.685295,
            89.93079,
            71.91326,
            36.41722,
            16.35486,
            8.794395
          ],
          "Dimension": "Concentration (mass)",
          "Unit": "µg/l"
        }
      ],
      "BaseGrid": {
        "Name": "Time",
        "QuantityInfo": {
          "Name": "Time",
          "Path": "Kasichayanula 2013a - Study 1: Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=14)|Time",
          "Type": "Time"
        },
        "DataInfo": {
          "Origin": "BaseGrid",
          "AuxiliaryType": "Undefined",
          "Date": "0001-01-01T00:00:00"
        },
        "Values": [
          0.5,
          0.75,
          1.0,
          1.5,
          2.0,
          4.0,
          8.0,
          12.0
        ],
        "Dimension": "Time",
        "Unit": "h"
      }
    },
    {
      "Name": "Kasichayanula 2012 - Study 1: Control (Perpetrator Placebo) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=24)",
      "ExtendedProperties": [
        {
          "Name": "DB Version",
          "Value": "OSP DATABASE"
        },
        {
          "Name": "ID",
          "Value": 639.0
        },
        {
          "Name": "Study Id",
          "Value": "Kasichayanula 2012"
        },
        {
          "Name": "Reference",
          "Value": "https://www.ncbi.nlm.nih.gov/pubmed/22271159"
        },
        {
          "Name": "Source",
          "Value": "Fig. 2"
        },
        {
          "Name": "Grouping",
          "Value": "Study 1: Control (Perpetrator Placebo)"
        },
        {
          "Name": "Data type",
          "Value": "aggregated"
        },
        {
          "Name": "N",
          "Value": 24.0
        },
        {
          "Name": "Molecule",
          "Value": "Dapagliflozin"
        },
        {
          "Name": "Species",
          "Value": "Human"
        },
        {
          "Name": "Organ",
          "Value": "Peripheral Venous Blood"
        },
        {
          "Name": "Compartment",
          "Value": "Plasma"
        },
        {
          "Name": "Route",
          "Value": "PO"
        },
        {
          "Name": "Dose",
          "Value": "20 mg"
        },
        {
          "Name": "Times of Administration [h]",
          "Value": 0.0
        },
        {
          "Name": "Formulation",
          "Value": "."
        },
        {
          "Name": "Food state",
          "Value": "Fasted"
        },
        {
          "Name": "Comment",
          "Value": "."
        }
      ],
      "Columns": [
        {
          "Name": "Avg",
          "QuantityInfo": {
            "Name": "Avg",
            "Path": "Kasichayanula 2012 - Study 1: Control (Perpetrator Placebo) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=24)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean"
          },
          "DataInfo": {
            "Origin": "Observation",
            "AuxiliaryType": "Undefined",
            "Date": "0001-01-01T00:00:00",
            "MolWeight": 408.87
          },
          "Values": [
            184.7854,
            222.7338,
            154.3538,
            117.6191,
            80.85839,
            61.8167343,
            38.92559,
            26.16097,
            13.29698,
            8.018408,
            5.065627
          ],
          "Dimension": "Concentration (mass)",
          "Unit": "µg/l"
        }
      ],
      "BaseGrid": {
        "Name": "Time",
        "QuantityInfo": {
          "Name": "Time",
          "Path": "Kasichayanula 2012 - Study 1: Control (Perpetrator Placebo) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=24)|Time",
          "Type": "Time"
        },
        "DataInfo": {
          "Origin": "BaseGrid",
          "AuxiliaryType": "Undefined",
          "Date": "0001-01-01T00:00:00"
        },
        "Values": [
          0.5,
          1.0,
          1.5,
          2.0,
          3.0,
          4.0,
          6.0,
          8.0,
          12.0,
          16.0,
          24.0
        ],
        "Dimension": "Time",
        "Unit": "h"
      }
    },
    {
      "Name": "Kasichayanula 2011b - Study 3: 20 mg Control (Perpetrator Placebo) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=18)",
      "ExtendedProperties": [
        {
          "Name": "DB Version",
          "Value": "OSP DATABASE"
        },
        {
          "Name": "ID",
          "Value": 638.0
        },
        {
          "Name": "Study Id",
          "Value": "Kasichayanula 2011b"
        },
        {
          "Name": "Reference",
          "Value": "https://www.ncbi.nlm.nih.gov/pubmed/21114603"
        },
        {
          "Name": "Source",
          "Value": "Fig. 3c"
        },
        {
          "Name": "Grouping",
          "Value": "Study 3: 20 mg Control (Perpetrator Placebo)"
        },
        {
          "Name": "Data type",
          "Value": "aggregated"
        },
        {
          "Name": "N",
          "Value": 18.0
        },
        {
          "Name": "Molecule",
          "Value": "Dapagliflozin"
        },
        {
          "Name": "Species",
          "Value": "Human"
        },
        {
          "Name": "Organ",
          "Value": "Peripheral Venous Blood"
        },
        {
          "Name": "Compartment",
          "Value": "Plasma"
        },
        {
          "Name": "Route",
          "Value": "PO"
        },
        {
          "Name": "Dose",
          "Value": "20 mg"
        },
        {
          "Name": "Times of Administration [h]",
          "Value": 0.0
        },
        {
          "Name": "Formulation",
          "Value": "."
        },
        {
          "Name": "Food state",
          "Value": "Fasted"
        },
        {
          "Name": "Comment",
          "Value": "."
        }
      ],
      "Columns": [
        {
          "Name": "Avg",
          "QuantityInfo": {
            "Name": "Avg",
            "Path": "Kasichayanula 2011b - Study 3: 20 mg Control (Perpetrator Placebo) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=18)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean"
          },
          "DataInfo": {
            "Origin": "Observation",
            "AuxiliaryType": "Undefined",
            "Date": "0001-01-01T00:00:00",
            "MolWeight": 408.87
          },
          "Values": [
            52.07948,
            123.4999,
            152.5223,
            152.5223,
            116.5914,
            98.09947,
            66.83439,
            46.41589,
            25.11886,
            15.25223,
            8.576959,
            3.758374,
            2.196174,
            1.467799
          ],
          "Dimension": "Concentration (mass)",
          "Unit": "µg/l"
        }
      ],
      "BaseGrid": {
        "Name": "Time",
        "QuantityInfo": {
          "Name": "Time",
          "Path": "Kasichayanula 2011b - Study 3: 20 mg Control (Perpetrator Placebo) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=18)|Time",
          "Type": "Time"
        },
        "DataInfo": {
          "Origin": "BaseGrid",
          "AuxiliaryType": "Undefined",
          "Date": "0001-01-01T00:00:00"
        },
        "Values": [
          0.5,
          1.0,
          1.5,
          2.0,
          3.0,
          4.0,
          6.0,
          8.0,
          12.0,
          16.0,
          24.0,
          36.0,
          48.0,
          72.0
        ],
        "Dimension": "Time",
        "Unit": "h"
      }
    },
    {
      "Name": "Kasichayanula 2011b - Study 2: 20 mg Control (Perpetrator Placebo) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=18)",
      "ExtendedProperties": [
        {
          "Name": "DB Version",
          "Value": "OSP DATABASE"
        },
        {
          "Name": "ID",
          "Value": 637.0
        },
        {
          "Name": "Study Id",
          "Value": "Kasichayanula 2011b"
        },
        {
          "Name": "Reference",
          "Value": "https://www.ncbi.nlm.nih.gov/pubmed/21114603"
        },
        {
          "Name": "Source",
          "Value": "Fig. 3b"
        },
        {
          "Name": "Grouping",
          "Value": "Study 2: 20 mg Control (Perpetrator Placebo)"
        },
        {
          "Name": "Data type",
          "Value": "aggregated"
        },
        {
          "Name": "N",
          "Value": 18.0
        },
        {
          "Name": "Molecule",
          "Value": "Dapagliflozin"
        },
        {
          "Name": "Species",
          "Value": "Human"
        },
        {
          "Name": "Organ",
          "Value": "Peripheral Venous Blood"
        },
        {
          "Name": "Compartment",
          "Value": "Plasma"
        },
        {
          "Name": "Route",
          "Value": "PO"
        },
        {
          "Name": "Dose",
          "Value": "20 mg"
        },
        {
          "Name": "Times of Administration [h]",
          "Value": 0.0
        },
        {
          "Name": "Formulation",
          "Value": "."
        },
        {
          "Name": "Food state",
          "Value": "Fasted"
        },
        {
          "Name": "Comment",
          "Value": "."
        }
      ],
      "Columns": [
        {
          "Name": "Avg",
          "QuantityInfo": {
            "Name": "Avg",
            "Path": "Kasichayanula 2011b - Study 2: 20 mg Control (Perpetrator Placebo) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=18)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean"
          },
          "DataInfo": {
            "Origin": "Observation",
            "AuxiliaryType": "Undefined",
            "Date": "0001-01-01T00:00:00",
            "MolWeight": 408.87
          },
          "Values": [
            39.35875,
            112.0951,
            125.6532,
            116.4436,
            98.115036,
            79.58412,
            50.40566,
            36.47401,
            20.60865,
            10.7909,
            7.099695,
            3.253844,
            2.689999,
            1.640122
          ],
          "Dimension": "Concentration (mass)",
          "Unit": "µg/l"
        }
      ],
      "BaseGrid": {
        "Name": "Time",
        "QuantityInfo": {
          "Name": "Time",
          "Path": "Kasichayanula 2011b - Study 2: 20 mg Control (Perpetrator Placebo) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=18)|Time",
          "Type": "Time"
        },
        "DataInfo": {
          "Origin": "BaseGrid",
          "AuxiliaryType": "Undefined",
          "Date": "0001-01-01T00:00:00"
        },
        "Values": [
          0.5,
          1.0,
          1.5,
          2.0,
          3.0,
          4.0,
          6.0,
          8.0,
          12.0,
          16.0,
          24.0,
          36.0,
          48.0,
          72.0
        ],
        "Dimension": "Time",
        "Unit": "h"
      }
    },
    {
      "Name": "Kasichayanula 2011b - Study 1: 50 mg Control (Perpetrator Placebo) - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=24)",
      "ExtendedProperties": [
        {
          "Name": "DB Version",
          "Value": "OSP DATABASE"
        },
        {
          "Name": "ID",
          "Value": 636.0
        },
        {
          "Name": "Study Id",
          "Value": "Kasichayanula 2011b"
        },
        {
          "Name": "Reference",
          "Value": "https://www.ncbi.nlm.nih.gov/pubmed/21114603"
        },
        {
          "Name": "Source",
          "Value": "Fig. 3a"
        },
        {
          "Name": "Grouping",
          "Value": "Study 1: 50 mg Control (Perpetrator Placebo)"
        },
        {
          "Name": "Data type",
          "Value": "aggregated"
        },
        {
          "Name": "N",
          "Value": 24.0
        },
        {
          "Name": "Molecule",
          "Value": "Dapagliflozin"
        },
        {
          "Name": "Species",
          "Value": "Human"
        },
        {
          "Name": "Organ",
          "Value": "Peripheral Venous Blood"
        },
        {
          "Name": "Compartment",
          "Value": "Plasma"
        },
        {
          "Name": "Route",
          "Value": "PO"
        },
        {
          "Name": "Dose",
          "Value": "50 mg"
        },
        {
          "Name": "Times of Administration [h]",
          "Value": 0.0
        },
        {
          "Name": "Formulation",
          "Value": "."
        },
        {
          "Name": "Food state",
          "Value": "Fasted"
        },
        {
          "Name": "Comment",
          "Value": "."
        }
      ],
      "Columns": [
        {
          "Name": "Avg",
          "QuantityInfo": {
            "Name": "Avg",
            "Path": "Kasichayanula 2011b - Study 1: 50 mg Control (Perpetrator Placebo) - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=24)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean"
          },
          "DataInfo": {
            "Origin": "Observation",
            "AuxiliaryType": "Undefined",
            "Date": "0001-01-01T00:00:00",
            "MolWeight": 408.87
          },
          "Values": [
            331.5725,
            503.8911,
            408.6677,
            319.0514,
            213.898,
            114.0904,
            66.91098,
            37.76467,
            23.0002,
            15.09974,
            9.54318,
            5.589135,
            4.523667,
            2.80191684,
            2.4446
          ],
          "Dimension": "Concentration (mass)",
          "Unit": "µg/l"
        }
      ],
      "BaseGrid": {
        "Name": "Time",
        "QuantityInfo": {
          "Name": "Time",
          "Path": "Kasichayanula 2011b - Study 1: 50 mg Control (Perpetrator Placebo) - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=24)|Time",
          "Type": "Time"
        },
        "DataInfo": {
          "Origin": "BaseGrid",
          "AuxiliaryType": "Undefined",
          "Date": "0001-01-01T00:00:00"
        },
        "Values": [
          0.5,
          1.0,
          1.5,
          2.0,
          3.0,
          5.0,
          8.0,
          12.0,
          16.0,
          24.0,
          32.0,
          40.0,
          48.0,
          60.0,
          72.0
        ],
        "Dimension": "Time",
        "Unit": "h"
      }
    },
    {
      "Name": "Kasichayanula 2011a - fed - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=14)",
      "ExtendedProperties": [
        {
          "Name": "DB Version",
          "Value": "OSP DATABASE"
        },
        {
          "Name": "ID",
          "Value": 635.0
        },
        {
          "Name": "Study Id",
          "Value": "Kasichayanula 2011a"
        },
        {
          "Name": "Reference",
          "Value": "https://www.ncbi.nlm.nih.gov/pubmed/21435141"
        },
        {
          "Name": "Source",
          "Value": "Fig. 1A"
        },
        {
          "Name": "Grouping",
          "Value": "fed"
        },
        {
          "Name": "Data type",
          "Value": "aggregated"
        },
        {
          "Name": "N",
          "Value": 14.0
        },
        {
          "Name": "Molecule",
          "Value": "Dapagliflozin"
        },
        {
          "Name": "Species",
          "Value": "Human"
        },
        {
          "Name": "Organ",
          "Value": "Peripheral Venous Blood"
        },
        {
          "Name": "Compartment",
          "Value": "Plasma"
        },
        {
          "Name": "Route",
          "Value": "PO"
        },
        {
          "Name": "Dose",
          "Value": "10 mg"
        },
        {
          "Name": "Times of Administration [h]",
          "Value": 0.0
        },
        {
          "Name": "Formulation",
          "Value": "."
        },
        {
          "Name": "Food state",
          "Value": "Fed"
        },
        {
          "Name": "Comment",
          "Value": "."
        }
      ],
      "Columns": [
        {
          "Name": "Avg",
          "RelatedColumns": [
            {
              "Name": "Var",
              "QuantityInfo": {
                "Name": "Var",
                "Path": "Kasichayanula 2011a - fed - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=14)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticStdDev"
              },
              "DataInfo": {
                "Origin": "ObservationAuxiliary",
                "AuxiliaryType": "ArithmeticStdDev",
                "Date": "0001-01-01T00:00:00",
                "MolWeight": 408.87
              },
              "Values": [
                0.01125628,
                0.04502512,
                0.0430150777,
                0.0285427086,
                0.02251257,
                0.01366834,
                0.009246227,
                0.00964823551,
                0.01125628,
                0.006834173,
                0.007638193,
                0.002412062,
                0.00160804,
                "NaN",
                "NaN",
                "NaN",
                "NaN"
              ],
              "Dimension": "Concentration (mass)",
              "Unit": "mg/l"
            }
          ],
          "QuantityInfo": {
            "Name": "Avg",
            "Path": "Kasichayanula 2011a - fed - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=14)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean"
          },
          "DataInfo": {
            "Origin": "Observation",
            "AuxiliaryType": "Undefined",
            "Date": "0001-01-01T00:00:00",
            "MolWeight": 408.87
          },
          "Values": [
            0.01125628,
            0.03738694,
            0.07075377,
            0.07678392,
            0.0691457242,
            0.06030151,
            0.0530653335,
            0.0466331728,
            0.0357789,
            0.02572864,
            0.01849246,
            0.01005025,
            0.006030151,
            0.004020101,
            0.00241206,
            0.00160804,
            0.00160804
          ],
          "Dimension": "Concentration (mass)",
          "Unit": "mg/l"
        }
      ],
      "BaseGrid": {
        "Name": "Time",
        "QuantityInfo": {
          "Name": "Time",
          "Path": "Kasichayanula 2011a - fed - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=14)|Time",
          "Type": "Time"
        },
        "DataInfo": {
          "Origin": "BaseGrid",
          "AuxiliaryType": "Undefined",
          "Date": "0001-01-01T00:00:00"
        },
        "Values": [
          0.5,
          1.0,
          1.5,
          2.0,
          2.5,
          3.0,
          3.5,
          4.0,
          5.0,
          6.0,
          8.0,
          12.0,
          16.0,
          24.0,
          36.0,
          48.0,
          72.0
        ],
        "Dimension": "Time",
        "Unit": "h"
      }
    },
    {
      "Name": "Kasichayanula 2011a - fasted - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=14)",
      "ExtendedProperties": [
        {
          "Name": "DB Version",
          "Value": "OSP DATABASE"
        },
        {
          "Name": "ID",
          "Value": 634.0
        },
        {
          "Name": "Study Id",
          "Value": "Kasichayanula 2011a"
        },
        {
          "Name": "Reference",
          "Value": "https://www.ncbi.nlm.nih.gov/pubmed/21435141"
        },
        {
          "Name": "Source",
          "Value": "Fig. 1A"
        },
        {
          "Name": "Grouping",
          "Value": "fasted"
        },
        {
          "Name": "Data type",
          "Value": "aggregated"
        },
        {
          "Name": "N",
          "Value": 14.0
        },
        {
          "Name": "Molecule",
          "Value": "Dapagliflozin"
        },
        {
          "Name": "Species",
          "Value": "Human"
        },
        {
          "Name": "Organ",
          "Value": "Peripheral Venous Blood"
        },
        {
          "Name": "Compartment",
          "Value": "Plasma"
        },
        {
          "Name": "Route",
          "Value": "PO"
        },
        {
          "Name": "Dose",
          "Value": "10 mg"
        },
        {
          "Name": "Times of Administration [h]",
          "Value": 0.0
        },
        {
          "Name": "Formulation",
          "Value": "."
        },
        {
          "Name": "Food state",
          "Value": "Fasted"
        },
        {
          "Name": "Comment",
          "Value": "."
        }
      ],
      "Columns": [
        {
          "Name": "Avg",
          "RelatedColumns": [
            {
              "Name": "Var",
              "QuantityInfo": {
                "Name": "Var",
                "Path": "Kasichayanula 2011a - fasted - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=14)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticStdDev"
              },
              "DataInfo": {
                "Origin": "ObservationAuxiliary",
                "AuxiliaryType": "ArithmeticStdDev",
                "Date": "0001-01-01T00:00:00",
                "MolWeight": 408.87
              },
              "Values": [
                0.04462316,
                0.03015079,
                0.01969849,
                0.01728643,
                0.01246231,
                0.00804020651,
                0.008844227,
                0.007638187,
                0.005628138,
                0.005628139,
                0.003618089,
                0.00281407,
                0.00241206,
                "NaN",
                "NaN",
                "NaN",
                "NaN"
              ],
              "Dimension": "Concentration (mass)",
              "Unit": "mg/l"
            }
          ],
          "QuantityInfo": {
            "Name": "Avg",
            "Path": "Kasichayanula 2011a - fasted - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=14)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean"
          },
          "DataInfo": {
            "Origin": "Observation",
            "AuxiliaryType": "Undefined",
            "Date": "0001-01-01T00:00:00",
            "MolWeight": 408.87
          },
          "Values": [
            105.7286,
            121.809,
            87.63819,
            66.73367,
            52.26131,
            42.61306,
            37.38694,
            32.96482,
            23.71859,
            19.29648,
            14.4723587,
            8.442211,
            5.628141,
            3.21608,
            2.41206,
            1.60804,
            0.8040201
          ],
          "Dimension": "Concentration (mass)",
          "Unit": "µg/l"
        }
      ],
      "BaseGrid": {
        "Name": "Time",
        "QuantityInfo": {
          "Name": "Time",
          "Path": "Kasichayanula 2011a - fasted - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=14)|Time",
          "Type": "Time"
        },
        "DataInfo": {
          "Origin": "BaseGrid",
          "AuxiliaryType": "Undefined",
          "Date": "0001-01-01T00:00:00"
        },
        "Values": [
          0.5,
          1.0,
          1.5,
          2.0,
          2.5,
          3.0,
          3.5,
          4.0,
          5.0,
          6.0,
          8.0,
          12.0,
          16.0,
          24.0,
          36.0,
          48.0,
          72.0
        ],
        "Dimension": "Time",
        "Unit": "h"
      }
    },
    {
      "Name": "Imamura 2013 - Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=22)",
      "ExtendedProperties": [
        {
          "Name": "DB Version",
          "Value": "OSP DATABASE"
        },
        {
          "Name": "ID",
          "Value": 633.0
        },
        {
          "Name": "Study Id",
          "Value": "Imamura 2013"
        },
        {
          "Name": "Reference",
          "Value": "https://www.ncbi.nlm.nih.gov/pubmed/23307267"
        },
        {
          "Name": "Source",
          "Value": "Fig. 2"
        },
        {
          "Name": "Grouping",
          "Value": "Control (Perpetrator Placebo)"
        },
        {
          "Name": "Data type",
          "Value": "aggregated"
        },
        {
          "Name": "N",
          "Value": 22.0
        },
        {
          "Name": "Molecule",
          "Value": "Dapagliflozin"
        },
        {
          "Name": "Species",
          "Value": "Human"
        },
        {
          "Name": "Organ",
          "Value": "Peripheral Venous Blood"
        },
        {
          "Name": "Compartment",
          "Value": "Plasma"
        },
        {
          "Name": "Route",
          "Value": "PO"
        },
        {
          "Name": "Dose",
          "Value": "10 mg"
        },
        {
          "Name": "Times of Administration [h]",
          "Value": 0.0
        },
        {
          "Name": "Formulation",
          "Value": "."
        },
        {
          "Name": "Food state",
          "Value": "Fasted"
        },
        {
          "Name": "Comment",
          "Value": "."
        }
      ],
      "Columns": [
        {
          "Name": "Avg",
          "QuantityInfo": {
            "Name": "Avg",
            "Path": "Imamura 2013 - Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=22)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean"
          },
          "DataInfo": {
            "Origin": "Observation",
            "AuxiliaryType": "Undefined",
            "Date": "0001-01-01T00:00:00",
            "MolWeight": 408.87
          },
          "Values": [
            44.84305,
            167.6009,
            137.3318,
            85.76233,
            63.90134,
            33.07175,
            19.0583,
            11.7713,
            9.529148,
            7.847534,
            5.605381,
            3.923767
          ],
          "Dimension": "Concentration (mass)",
          "Unit": "µg/l"
        }
      ],
      "BaseGrid": {
        "Name": "Time",
        "QuantityInfo": {
          "Name": "Time",
          "Path": "Imamura 2013 - Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=22)|Time",
          "Type": "Time"
        },
        "DataInfo": {
          "Origin": "BaseGrid",
          "AuxiliaryType": "Undefined",
          "Date": "0001-01-01T00:00:00"
        },
        "Values": [
          0.25,
          0.5,
          1.0,
          1.5,
          2.0,
          4.0,
          6.0,
          8.0,
          10.0,
          12.0,
          14.0,
          24.0
        ],
        "Dimension": "Time",
        "Unit": "h"
      }
    },
    {
      "Name": "Chang 2015 - Study 1 Treatment A (single oral doses) - Dapagliflozin - PO - 5 mg - Plasma - agg. (n=36)",
      "ExtendedProperties": [
        {
          "Name": "DB Version",
          "Value": "OSP DATABASE"
        },
        {
          "Name": "ID",
          "Value": 631.0
        },
        {
          "Name": "Study Id",
          "Value": "Chang 2015"
        },
        {
          "Name": "Reference",
          "Value": "https://www.ncbi.nlm.nih.gov/pubmed/26048185"
        },
        {
          "Name": "Source",
          "Value": "Fig. 2A"
        },
        {
          "Name": "Grouping",
          "Value": "Study 1 Treatment A (single oral doses)"
        },
        {
          "Name": "Data type",
          "Value": "aggregated"
        },
        {
          "Name": "N",
          "Value": 36.0
        },
        {
          "Name": "Molecule",
          "Value": "Dapagliflozin"
        },
        {
          "Name": "Species",
          "Value": "Human"
        },
        {
          "Name": "Organ",
          "Value": "Peripheral Venous Blood"
        },
        {
          "Name": "Compartment",
          "Value": "Plasma"
        },
        {
          "Name": "Route",
          "Value": "PO"
        },
        {
          "Name": "Dose",
          "Value": "5 mg"
        },
        {
          "Name": "Times of Administration [h]",
          "Value": 0.0
        },
        {
          "Name": "Formulation",
          "Value": "."
        },
        {
          "Name": "Food state",
          "Value": "Fed"
        },
        {
          "Name": "Comment",
          "Value": "."
        }
      ],
      "Columns": [
        {
          "Name": "Avg",
          "QuantityInfo": {
            "Name": "Avg",
            "Path": "Chang 2015 - Study 1 Treatment A (single oral doses) - Dapagliflozin - PO - 5 mg - Plasma - agg. (n=36)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean"
          },
          "DataInfo": {
            "Origin": "Observation",
            "AuxiliaryType": "Undefined",
            "Date": "0001-01-01T00:00:00",
            "MolWeight": 408.87
          },
          "Values": [
            30.7500019,
            37.875,
            21.3750019,
            13.5,
            9.75,
            6.0,
            4.5,
            3.375
          ],
          "Dimension": "Concentration (mass)",
          "Unit": "µg/l"
        }
      ],
      "BaseGrid": {
        "Name": "Time",
        "QuantityInfo": {
          "Name": "Time",
          "Path": "Chang 2015 - Study 1 Treatment A (single oral doses) - Dapagliflozin - PO - 5 mg - Plasma - agg. (n=36)|Time",
          "Type": "Time"
        },
        "DataInfo": {
          "Origin": "BaseGrid",
          "AuxiliaryType": "Undefined",
          "Date": "0001-01-01T00:00:00"
        },
        "Values": [
          1.0,
          2.0,
          4.0,
          6.0,
          8.0,
          12.0,
          16.0,
          24.0
        ],
        "Dimension": "Time",
        "Unit": "h"
      }
    },
    {
      "Name": "Boulton 2013 - Dapagliflozin po - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=7)",
      "ExtendedProperties": [
        {
          "Name": "DB Version",
          "Value": "OSP DATABASE"
        },
        {
          "Name": "ID",
          "Value": 630.0
        },
        {
          "Name": "Study Id",
          "Value": "Boulton 2013"
        },
        {
          "Name": "Reference",
          "Value": "https://www.ncbi.nlm.nih.gov/pubmed/22823746"
        },
        {
          "Name": "Source",
          "Value": "Fig. 1"
        },
        {
          "Name": "Grouping",
          "Value": "Dapagliflozin po"
        },
        {
          "Name": "Data type",
          "Value": "aggregated"
        },
        {
          "Name": "N",
          "Value": 7.0
        },
        {
          "Name": "Molecule",
          "Value": "Dapagliflozin"
        },
        {
          "Name": "Species",
          "Value": "Human"
        },
        {
          "Name": "Organ",
          "Value": "Peripheral Venous Blood"
        },
        {
          "Name": "Compartment",
          "Value": "Plasma"
        },
        {
          "Name": "Route",
          "Value": "PO"
        },
        {
          "Name": "Dose",
          "Value": "10 mg"
        },
        {
          "Name": "Times of Administration [h]",
          "Value": 0.0
        },
        {
          "Name": "Formulation",
          "Value": "."
        },
        {
          "Name": "Food state",
          "Value": "Fasted"
        },
        {
          "Name": "Comment",
          "Value": "."
        }
      ],
      "Columns": [
        {
          "Name": "Avg",
          "RelatedColumns": [
            {
              "Name": "Var",
              "QuantityInfo": {
                "Name": "Var",
                "Path": "Boulton 2013 - Dapagliflozin po - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=7)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticStdDev"
              },
              "DataInfo": {
                "Origin": "ObservationAuxiliary",
                "AuxiliaryType": "ArithmeticStdDev",
                "Date": "0001-01-01T00:00:00",
                "MolWeight": 408.87
              },
              "Values": [
                0.06889832,
                0.0445817,
                0.00847678352,
                0.008923919,
                0.004601345,
                0.005103712,
                0.002741817,
                0.002177832,
                0.001576359,
                0.000922100269,
                0.0003313069,
                0.0002363651
              ],
              "Dimension": "Concentration (mass)",
              "Unit": "mg/l"
            }
          ],
          "QuantityInfo": {
            "Name": "Avg",
            "Path": "Boulton 2013 - Dapagliflozin po - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=7)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean"
          },
          "DataInfo": {
            "Origin": "Observation",
            "AuxiliaryType": "Undefined",
            "Date": "0001-01-01T00:00:00",
            "MolWeight": 408.87
          },
          "Values": [
            106.5117,
            141.4767,
            93.88641,
            75.28566,
            38.81871,
            25.76077,
            18.79198,
            10.99249,
            7.068302,
            4.134646,
            2.270724,
            1.370839
          ],
          "Dimension": "Concentration (mass)",
          "Unit": "µg/l"
        }
      ],
      "BaseGrid": {
        "Name": "Time",
        "QuantityInfo": {
          "Name": "Time",
          "Path": "Boulton 2013 - Dapagliflozin po - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=7)|Time",
          "Type": "Time"
        },
        "DataInfo": {
          "Origin": "BaseGrid",
          "AuxiliaryType": "Undefined",
          "Date": "0001-01-01T00:00:00"
        },
        "Values": [
          0.5,
          1.0,
          1.5,
          2.0,
          4.0,
          6.0,
          8.0,
          12.0,
          16.0,
          24.0,
          36.0,
          48.0
        ],
        "Dimension": "Time",
        "Unit": "h"
      }
    },
    {
      "Name": "Boulton 2013 - 14C-dapagliflozin iv - Dapagliflozin - IV - 0.08 mg - Plasma - agg. (n=7)",
      "ExtendedProperties": [
        {
          "Name": "DB Version",
          "Value": "OSP DATABASE"
        },
        {
          "Name": "ID",
          "Value": 629.0
        },
        {
          "Name": "Study Id",
          "Value": "Boulton 2013"
        },
        {
          "Name": "Reference",
          "Value": "https://www.ncbi.nlm.nih.gov/pubmed/22823746"
        },
        {
          "Name": "Source",
          "Value": "Fig. 1"
        },
        {
          "Name": "Grouping",
          "Value": "14C-dapagliflozin iv"
        },
        {
          "Name": "Data type",
          "Value": "aggregated"
        },
        {
          "Name": "N",
          "Value": 7.0
        },
        {
          "Name": "Molecule",
          "Value": "Dapagliflozin"
        },
        {
          "Name": "Species",
          "Value": "Human"
        },
        {
          "Name": "Organ",
          "Value": "Peripheral Venous Blood"
        },
        {
          "Name": "Compartment",
          "Value": "Plasma"
        },
        {
          "Name": "Route",
          "Value": "IV"
        },
        {
          "Name": "Dose",
          "Value": "0.08 mg"
        },
        {
          "Name": "Times of Administration [h]",
          "Value": 1.0
        },
        {
          "Name": "Formulation",
          "Value": "Solution"
        },
        {
          "Name": "Food state",
          "Value": "Fasted"
        },
        {
          "Name": "Comment",
          "Value": "."
        }
      ],
      "Columns": [
        {
          "Name": "Avg",
          "QuantityInfo": {
            "Name": "Avg",
            "Path": "Boulton 2013 - 14C-dapagliflozin iv - Dapagliflozin - IV - 0.08 mg - Plasma - agg. (n=7)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean"
          },
          "DataInfo": {
            "Origin": "Observation",
            "AuxiliaryType": "Undefined",
            "Date": "0001-01-01T00:00:00",
            "MolWeight": 408.87
          },
          "Values": [
            10.2129993,
            6.56045,
            2.622795,
            1.973306,
            1.189912,
            1.015933,
            0.8673914,
            0.4192042,
            0.2779303,
            0.2227543,
            0.1183659,
            0.06491678,
            0.0379269,
            0.01891855,
            0.01832981,
            0.01832981
          ],
          "Dimension": "Concentration (mass)",
          "Unit": "µg/l"
        }
      ],
      "BaseGrid": {
        "Name": "Time",
        "QuantityInfo": {
          "Name": "Time",
          "Path": "Boulton 2013 - 14C-dapagliflozin iv - Dapagliflozin - IV - 0.08 mg - Plasma - agg. (n=7)|Time",
          "Type": "Time"
        },
        "DataInfo": {
          "Origin": "BaseGrid",
          "AuxiliaryType": "Undefined",
          "Date": "0001-01-01T00:00:00"
        },
        "Values": [
          1.08333337,
          1.16666663,
          1.33333337,
          1.5,
          1.66666663,
          1.83333337,
          2.0,
          4.0,
          6.0,
          8.0,
          12.0,
          16.0,
          24.0,
          36.0,
          48.0,
          49.0
        ],
        "Dimension": "Time",
        "Unit": "h"
      }
    },
    {
      "Name": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin 3OG Gluc (incl. unchanged feces exret.) - Dapagliflozin-3-O-glucuronide - PO - 50 mg - Fraction - agg. (n=6)",
      "ExtendedProperties": [
        {
          "Name": "DB Version",
          "Value": "OSP DATABASE"
        },
        {
          "Name": "ID",
          "Value": 675.0
        },
        {
          "Name": "Study Id",
          "Value": "Kasichayanula 2008"
        },
        {
          "Name": "Reference",
          "Value": "https://scholar.google.com/scholar?q=Kasichayanula+S.+Disposition+and+mass+balance+of+14C-dapagliflozin+after+single+oral+doses+in+healthy+male+volunteers.+American+Association+of+Pharmaceutical+Scientists,+Atlanta,+GA+2008+"
        },
        {
          "Name": "Source",
          "Value": "209803,209805,209806Orig1s000ClinPharmR.pdf, 202293Orig1s000ClinPharmR.pdf"
        },
        {
          "Name": "Grouping",
          "Value": "Mass Balance of 14C-dapagliflozin 3OG Gluc (incl. unchanged feces exret.)"
        },
        {
          "Name": "Data type",
          "Value": "aggregated"
        },
        {
          "Name": "N",
          "Value": 6.0
        },
        {
          "Name": "Molecule",
          "Value": "Dapagliflozin-3-O-glucuronide"
        },
        {
          "Name": "Species",
          "Value": "Human"
        },
        {
          "Name": "Organ",
          "Value": "Undefined"
        },
        {
          "Name": "Compartment",
          "Value": "Undefined"
        },
        {
          "Name": "Route",
          "Value": "PO"
        },
        {
          "Name": "Dose",
          "Value": "50 mg"
        },
        {
          "Name": "Times of Administration [h]",
          "Value": 0.0
        },
        {
          "Name": "Formulation",
          "Value": "Solution"
        },
        {
          "Name": "Food state",
          "Value": "."
        },
        {
          "Name": "Comment",
          "Value": "."
        }
      ],
      "Columns": [
        {
          "Name": "Avg",
          "QuantityInfo": {
            "Name": "Avg",
            "Path": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin 3OG Gluc (incl. unchanged feces exret.) - Dapagliflozin-3-O-glucuronide - PO - 50 mg - Fraction - agg. (n=6)|ObservedData|Undefined|Undefined|Dapagliflozin-3-O-glucuronide|ArithmeticMean"
          },
          "DataInfo": {
            "Origin": "Observation",
            "AuxiliaryType": "Undefined",
            "Date": "0001-01-01T00:00:00",
            "MolWeight": 585.0
          },
          "Values": [
            78.8
          ],
          "Dimension": "Fraction",
          "Unit": "%"
        }
      ],
      "BaseGrid": {
        "Name": "Time",
        "QuantityInfo": {
          "Name": "Time",
          "Path": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin 3OG Gluc (incl. unchanged feces exret.) - Dapagliflozin-3-O-glucuronide - PO - 50 mg - Fraction - agg. (n=6)|Time",
          "Type": "Time"
        },
        "DataInfo": {
          "Origin": "BaseGrid",
          "AuxiliaryType": "Undefined",
          "Date": "0001-01-01T00:00:00"
        },
        "Values": [
          312.0
        ],
        "Dimension": "Time",
        "Unit": "h"
      }
    },
    {
      "Name": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin 2OG Gluc (incl. unchanged feces exret.) - Dapagliflozin-2-O-glucuronide - PO - 50 mg - Fraction - agg. (n=6)",
      "ExtendedProperties": [
        {
          "Name": "DB Version",
          "Value": "OSP DATABASE"
        },
        {
          "Name": "ID",
          "Value": 676.0
        },
        {
          "Name": "Study Id",
          "Value": "Kasichayanula 2008"
        },
        {
          "Name": "Reference",
          "Value": "https://scholar.google.com/scholar?q=Kasichayanula+S.+Disposition+and+mass+balance+of+14C-dapagliflozin+after+single+oral+doses+in+healthy+male+volunteers.+American+Association+of+Pharmaceutical+Scientists,+Atlanta,+GA+2008+"
        },
        {
          "Name": "Source",
          "Value": "209803,209805,209806Orig1s000ClinPharmR.pdf, 202293Orig1s000ClinPharmR.pdf"
        },
        {
          "Name": "Grouping",
          "Value": "Mass Balance of 14C-dapagliflozin 2OG Gluc (incl. unchanged feces exret.)"
        },
        {
          "Name": "Data type",
          "Value": "aggregated"
        },
        {
          "Name": "N",
          "Value": 6.0
        },
        {
          "Name": "Molecule",
          "Value": "Dapagliflozin-2-O-glucuronide"
        },
        {
          "Name": "Species",
          "Value": "Human"
        },
        {
          "Name": "Organ",
          "Value": "Undefined"
        },
        {
          "Name": "Compartment",
          "Value": "Undefined"
        },
        {
          "Name": "Route",
          "Value": "PO"
        },
        {
          "Name": "Dose",
          "Value": "50 mg"
        },
        {
          "Name": "Times of Administration [h]",
          "Value": 0.0
        },
        {
          "Name": "Formulation",
          "Value": "Solution"
        },
        {
          "Name": "Food state",
          "Value": "."
        },
        {
          "Name": "Comment",
          "Value": "."
        }
      ],
      "Columns": [
        {
          "Name": "Avg",
          "QuantityInfo": {
            "Name": "Avg",
            "Path": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin 2OG Gluc (incl. unchanged feces exret.) - Dapagliflozin-2-O-glucuronide - PO - 50 mg - Fraction - agg. (n=6)|ObservedData|Undefined|Undefined|Dapagliflozin-2-O-glucuronide|ArithmeticMean"
          },
          "DataInfo": {
            "Origin": "Observation",
            "AuxiliaryType": "Undefined",
            "Date": "0001-01-01T00:00:00",
            "MolWeight": 585.0
          },
          "Values": [
            7.0
          ],
          "Dimension": "Fraction",
          "Unit": "%"
        }
      ],
      "BaseGrid": {
        "Name": "Time",
        "QuantityInfo": {
          "Name": "Time",
          "Path": "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin 2OG Gluc (incl. unchanged feces exret.) - Dapagliflozin-2-O-glucuronide - PO - 50 mg - Fraction - agg. (n=6)|Time",
          "Type": "Time"
        },
        "DataInfo": {
          "Origin": "BaseGrid",
          "AuxiliaryType": "Undefined",
          "Date": "0001-01-01T00:00:00"
        },
        "Values": [
          312.0
        ],
        "Dimension": "Time",
        "Unit": "h"
      }
    },
    {
      "Name": "Komoroski 2009 - SAD 2.5 mg - Dapagliflozin - PO - 2.5 mg - Plasma - agg. (n=6)",
      "ExtendedProperties": [
        {
          "Name": "DB Version",
          "Value": "OSP DATABASE"
        },
        {
          "Name": "ID",
          "Value": 655.0
        },
        {
          "Name": "Study Id",
          "Value": "Komoroski 2009"
        },
        {
          "Name": "Reference",
          "Value": "https://www.ncbi.nlm.nih.gov/pubmed/19129748"
        },
        {
          "Name": "Source",
          "Value": "Fig. 11 (202293Orig1s000ClinPharmR.pdf)"
        },
        {
          "Name": "Grouping",
          "Value": "SAD 2.5 mg"
        },
        {
          "Name": "Data type",
          "Value": "aggregated"
        },
        {
          "Name": "N",
          "Value": 6.0
        },
        {
          "Name": "Molecule",
          "Value": "Dapagliflozin"
        },
        {
          "Name": "Species",
          "Value": "Human"
        },
        {
          "Name": "Organ",
          "Value": "Peripheral Venous Blood"
        },
        {
          "Name": "Compartment",
          "Value": "Plasma"
        },
        {
          "Name": "Route",
          "Value": "PO"
        },
        {
          "Name": "Dose",
          "Value": "2.5 mg"
        },
        {
          "Name": "Times of Administration [h]",
          "Value": 0.0
        },
        {
          "Name": "Formulation",
          "Value": "Solution"
        },
        {
          "Name": "Food state",
          "Value": "Fasted"
        },
        {
          "Name": "Comment",
          "Value": "."
        }
      ],
      "Columns": [
        {
          "Name": "Avg",
          "QuantityInfo": {
            "Name": "Avg",
            "Path": "Komoroski 2009 - SAD 2.5 mg - Dapagliflozin - PO - 2.5 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean"
          },
          "DataInfo": {
            "Origin": "Observation",
            "AuxiliaryType": "Undefined",
            "Date": "0001-01-01T00:00:00",
            "MolWeight": 408.87
          },
          "Values": [
            31.7,
            28.3,
            21.3,
            17.31236,
            12.54961
          ],
          "Dimension": "Concentration (mass)",
          "Unit": "µg/l"
        }
      ],
      "BaseGrid": {
        "Name": "Time",
        "QuantityInfo": {
          "Name": "Time",
          "Path": "Komoroski 2009 - SAD 2.5 mg - Dapagliflozin - PO - 2.5 mg - Plasma - agg. (n=6)|Time",
          "Type": "Time"
        },
        "DataInfo": {
          "Origin": "BaseGrid",
          "AuxiliaryType": "Undefined",
          "Date": "0001-01-01T00:00:00"
        },
        "Values": [
          0.5,
          1.0,
          1.5,
          2.0,
          4.0
        ],
        "Dimension": "Time",
        "Unit": "h"
      }
    },
    {
      "Name": "Komoroski 2009 - SAD 5 mg - Dapagliflozin - PO - 5 mg - Plasma - agg. (n=6)",
      "ExtendedProperties": [
        {
          "Name": "DB Version",
          "Value": "OSP DATABASE"
        },
        {
          "Name": "ID",
          "Value": 656.0
        },
        {
          "Name": "Study Id",
          "Value": "Komoroski 2009"
        },
        {
          "Name": "Reference",
          "Value": "https://www.ncbi.nlm.nih.gov/pubmed/19129748"
        },
        {
          "Name": "Source",
          "Value": "Fig. 11 (202293Orig1s000ClinPharmR.pdf)"
        },
        {
          "Name": "Grouping",
          "Value": "SAD 5 mg"
        },
        {
          "Name": "Data type",
          "Value": "aggregated"
        },
        {
          "Name": "N",
          "Value": 6.0
        },
        {
          "Name": "Molecule",
          "Value": "Dapagliflozin"
        },
        {
          "Name": "Species",
          "Value": "Human"
        },
        {
          "Name": "Organ",
          "Value": "Peripheral Venous Blood"
        },
        {
          "Name": "Compartment",
          "Value": "Plasma"
        },
        {
          "Name": "Route",
          "Value": "PO"
        },
        {
          "Name": "Dose",
          "Value": "5 mg"
        },
        {
          "Name": "Times of Administration [h]",
          "Value": 0.0
        },
        {
          "Name": "Formulation",
          "Value": "Solution"
        },
        {
          "Name": "Food state",
          "Value": "Fasted"
        },
        {
          "Name": "Comment",
          "Value": "."
        }
      ],
      "Columns": [
        {
          "Name": "Avg",
          "QuantityInfo": {
            "Name": "Avg",
            "Path": "Komoroski 2009 - SAD 5 mg - Dapagliflozin - PO - 5 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean"
          },
          "DataInfo": {
            "Origin": "Observation",
            "AuxiliaryType": "Undefined",
            "Date": "0001-01-01T00:00:00",
            "MolWeight": 408.87
          },
          "Values": [
            65.11764,
            53.88983,
            36.90823,
            29.97177,
            16.66932,
            11.2025,
            12.31433
          ],
          "Dimension": "Concentration (mass)",
          "Unit": "µg/l"
        }
      ],
      "BaseGrid": {
        "Name": "Time",
        "QuantityInfo": {
          "Name": "Time",
          "Path": "Komoroski 2009 - SAD 5 mg - Dapagliflozin - PO - 5 mg - Plasma - agg. (n=6)|Time",
          "Type": "Time"
        },
        "DataInfo": {
          "Origin": "BaseGrid",
          "AuxiliaryType": "Undefined",
          "Date": "0001-01-01T00:00:00"
        },
        "Values": [
          0.5,
          1.0,
          1.5,
          2.0,
          4.0,
          6.0,
          8.0
        ],
        "Dimension": "Time",
        "Unit": "h"
      }
    },
    {
      "Name": "Komoroski 2009 - SAD 10 mg - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=6)",
      "ExtendedProperties": [
        {
          "Name": "DB Version",
          "Value": "OSP DATABASE"
        },
        {
          "Name": "ID",
          "Value": 657.0
        },
        {
          "Name": "Study Id",
          "Value": "Komoroski 2009"
        },
        {
          "Name": "Reference",
          "Value": "https://www.ncbi.nlm.nih.gov/pubmed/19129748"
        },
        {
          "Name": "Source",
          "Value": "Fig. 11 (202293Orig1s000ClinPharmR.pdf)"
        },
        {
          "Name": "Grouping",
          "Value": "SAD 10 mg"
        },
        {
          "Name": "Data type",
          "Value": "aggregated"
        },
        {
          "Name": "N",
          "Value": 6.0
        },
        {
          "Name": "Molecule",
          "Value": "Dapagliflozin"
        },
        {
          "Name": "Species",
          "Value": "Human"
        },
        {
          "Name": "Organ",
          "Value": "Peripheral Venous Blood"
        },
        {
          "Name": "Compartment",
          "Value": "Plasma"
        },
        {
          "Name": "Route",
          "Value": "PO"
        },
        {
          "Name": "Dose",
          "Value": "10 mg"
        },
        {
          "Name": "Times of Administration [h]",
          "Value": 0.0
        },
        {
          "Name": "Formulation",
          "Value": "Capsule"
        },
        {
          "Name": "Food state",
          "Value": "Fasted"
        },
        {
          "Name": "Comment",
          "Value": "."
        }
      ],
      "Columns": [
        {
          "Name": "Avg",
          "QuantityInfo": {
            "Name": "Avg",
            "Path": "Komoroski 2009 - SAD 10 mg - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean"
          },
          "DataInfo": {
            "Origin": "Observation",
            "AuxiliaryType": "Undefined",
            "Date": "0001-01-01T00:00:00",
            "MolWeight": 408.87
          },
          "Values": [
            61.5235062,
            110.6205,
            86.49405,
            59.23832,
            32.32876,
            18.32372,
            14.3272991,
            13.79514,
            10.19106
          ],
          "Dimension": "Concentration (mass)",
          "Unit": "µg/l"
        }
      ],
      "BaseGrid": {
        "Name": "Time",
        "QuantityInfo": {
          "Name": "Time",
          "Path": "Komoroski 2009 - SAD 10 mg - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=6)|Time",
          "Type": "Time"
        },
        "DataInfo": {
          "Origin": "BaseGrid",
          "AuxiliaryType": "Undefined",
          "Date": "0001-01-01T00:00:00"
        },
        "Values": [
          0.5,
          1.0,
          1.5,
          2.0,
          4.0,
          6.0,
          8.0,
          10.0,
          12.0
        ],
        "Dimension": "Time",
        "Unit": "h"
      }
    },
    {
      "Name": "Komoroski 2009 - SAD 20 mg - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=6)",
      "ExtendedProperties": [
        {
          "Name": "DB Version",
          "Value": "OSP DATABASE"
        },
        {
          "Name": "ID",
          "Value": 658.0
        },
        {
          "Name": "Study Id",
          "Value": "Komoroski 2009"
        },
        {
          "Name": "Reference",
          "Value": "https://www.ncbi.nlm.nih.gov/pubmed/19129748"
        },
        {
          "Name": "Source",
          "Value": "Fig. 11 (202293Orig1s000ClinPharmR.pdf)"
        },
        {
          "Name": "Grouping",
          "Value": "SAD 20 mg"
        },
        {
          "Name": "Data type",
          "Value": "aggregated"
        },
        {
          "Name": "N",
          "Value": 6.0
        },
        {
          "Name": "Molecule",
          "Value": "Dapagliflozin"
        },
        {
          "Name": "Species",
          "Value": "Human"
        },
        {
          "Name": "Organ",
          "Value": "Peripheral Venous Blood"
        },
        {
          "Name": "Compartment",
          "Value": "Plasma"
        },
        {
          "Name": "Route",
          "Value": "PO"
        },
        {
          "Name": "Dose",
          "Value": "20 mg"
        },
        {
          "Name": "Times of Administration [h]",
          "Value": 0.0
        },
        {
          "Name": "Formulation",
          "Value": "Capsule"
        },
        {
          "Name": "Food state",
          "Value": "Fasted"
        },
        {
          "Name": "Comment",
          "Value": "."
        }
      ],
      "Columns": [
        {
          "Name": "Avg",
          "QuantityInfo": {
            "Name": "Avg",
            "Path": "Komoroski 2009 - SAD 20 mg - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean"
          },
          "DataInfo": {
            "Origin": "Observation",
            "AuxiliaryType": "Undefined",
            "Date": "0001-01-01T00:00:00",
            "MolWeight": 408.87
          },
          "Values": [
            80.18803,
            254.377914,
            195.1691,
            164.6032,
            81.72008,
            40.57132,
            31.12796,
            22.56445,
            17.31236,
            12.31433,
            11.41653,
            10.38576
          ],
          "Dimension": "Concentration (mass)",
          "Unit": "µg/l"
        }
      ],
      "BaseGrid": {
        "Name": "Time",
        "QuantityInfo": {
          "Name": "Time",
          "Path": "Komoroski 2009 - SAD 20 mg - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=6)|Time",
          "Type": "Time"
        },
        "DataInfo": {
          "Origin": "BaseGrid",
          "AuxiliaryType": "Undefined",
          "Date": "0001-01-01T00:00:00"
        },
        "Values": [
          0.5,
          1.0,
          1.5,
          2.0,
          4.0,
          6.0,
          8.0,
          10.0,
          12.0,
          14.0,
          18.0,
          22.0
        ],
        "Dimension": "Time",
        "Unit": "h"
      }
    },
    {
      "Name": "Komoroski 2009 - SAD 50 mg - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=6)",
      "ExtendedProperties": [
        {
          "Name": "DB Version",
          "Value": "OSP DATABASE"
        },
        {
          "Name": "ID",
          "Value": 659.0
        },
        {
          "Name": "Study Id",
          "Value": "Komoroski 2009"
        },
        {
          "Name": "Reference",
          "Value": "https://www.ncbi.nlm.nih.gov/pubmed/19129748"
        },
        {
          "Name": "Source",
          "Value": "Fig. 11 (202293Orig1s000ClinPharmR.pdf)"
        },
        {
          "Name": "Grouping",
          "Value": "SAD 50 mg"
        },
        {
          "Name": "Data type",
          "Value": "aggregated"
        },
        {
          "Name": "N",
          "Value": 6.0
        },
        {
          "Name": "Molecule",
          "Value": "Dapagliflozin"
        },
        {
          "Name": "Species",
          "Value": "Human"
        },
        {
          "Name": "Organ",
          "Value": "Peripheral Venous Blood"
        },
        {
          "Name": "Compartment",
          "Value": "Plasma"
        },
        {
          "Name": "Route",
          "Value": "PO"
        },
        {
          "Name": "Dose",
          "Value": "50 mg"
        },
        {
          "Name": "Times of Administration [h]",
          "Value": 0.0
        },
        {
          "Name": "Formulation",
          "Value": "Capsule"
        },
        {
          "Name": "Food state",
          "Value": "Fasted"
        },
        {
          "Name": "Comment",
          "Value": "."
        }
      ],
      "Columns": [
        {
          "Name": "Avg",
          "QuantityInfo": {
            "Name": "Avg",
            "Path": "Komoroski 2009 - SAD 50 mg - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean"
          },
          "DataInfo": {
            "Origin": "Observation",
            "AuxiliaryType": "Undefined",
            "Date": "0001-01-01T00:00:00",
            "MolWeight": 408.87
          },
          "Values": [
            279.6246,
            607.5215,
            466.1151,
            290.4114,
            144.1797,
            78.68472,
            54.91943,
            43.76187,
            32.32876,
            23.4348888,
            17.31236,
            14.87999,
            11.85694
          ],
          "Dimension": "Concentration (mass)",
          "Unit": "µg/l"
        }
      ],
      "BaseGrid": {
        "Name": "Time",
        "QuantityInfo": {
          "Name": "Time",
          "Path": "Komoroski 2009 - SAD 50 mg - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=6)|Time",
          "Type": "Time"
        },
        "DataInfo": {
          "Origin": "BaseGrid",
          "AuxiliaryType": "Undefined",
          "Date": "0001-01-01T00:00:00"
        },
        "Values": [
          0.5,
          1.0,
          1.5,
          2.0,
          4.0,
          6.0,
          8.0,
          10.0,
          12.0,
          14.0,
          18.0,
          22.0,
          24.0
        ],
        "Dimension": "Time",
        "Unit": "h"
      }
    },
    {
      "Name": "Komoroski 2009 - SAD 100 mg - Dapagliflozin - PO - 100 mg - Plasma - agg. (n=6)",
      "ExtendedProperties": [
        {
          "Name": "DB Version",
          "Value": "OSP DATABASE"
        },
        {
          "Name": "ID",
          "Value": 660.0
        },
        {
          "Name": "Study Id",
          "Value": "Komoroski 2009"
        },
        {
          "Name": "Reference",
          "Value": "https://www.ncbi.nlm.nih.gov/pubmed/19129748"
        },
        {
          "Name": "Source",
          "Value": "Fig. 11 (202293Orig1s000ClinPharmR.pdf)"
        },
        {
          "Name": "Grouping",
          "Value": "SAD 100 mg"
        },
        {
          "Name": "Data type",
          "Value": "aggregated"
        },
        {
          "Name": "N",
          "Value": 6.0
        },
        {
          "Name": "Molecule",
          "Value": "Dapagliflozin"
        },
        {
          "Name": "Species",
          "Value": "Human"
        },
        {
          "Name": "Organ",
          "Value": "Peripheral Venous Blood"
        },
        {
          "Name": "Compartment",
          "Value": "Plasma"
        },
        {
          "Name": "Route",
          "Value": "PO"
        },
        {
          "Name": "Dose",
          "Value": "100 mg"
        },
        {
          "Name": "Times of Administration [h]",
          "Value": 0.0
        },
        {
          "Name": "Formulation",
          "Value": "Capsule"
        },
        {
          "Name": "Food state",
          "Value": "Fasted"
        },
        {
          "Name": "Comment",
          "Value": "."
        }
      ],
      "Columns": [
        {
          "Name": "Avg",
          "QuantityInfo": {
            "Name": "Avg",
            "Path": "Komoroski 2009 - SAD 100 mg - Dapagliflozin - PO - 100 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean"
          },
          "DataInfo": {
            "Origin": "Observation",
            "AuxiliaryType": "Undefined",
            "Date": "0001-01-01T00:00:00",
            "MolWeight": 408.87
          },
          "Values": [
            393.1158,
            887.0441,
            975.0818,
            693.5789,
            313.2495,
            158.4893,
            123.922607,
            91.54694,
            68.92173,
            58.12775,
            45.45004,
            36.90823,
            36.2163
          ],
          "Dimension": "Concentration (mass)",
          "Unit": "µg/l"
        }
      ],
      "BaseGrid": {
        "Name": "Time",
        "QuantityInfo": {
          "Name": "Time",
          "Path": "Komoroski 2009 - SAD 100 mg - Dapagliflozin - PO - 100 mg - Plasma - agg. (n=6)|Time",
          "Type": "Time"
        },
        "DataInfo": {
          "Origin": "BaseGrid",
          "AuxiliaryType": "Undefined",
          "Date": "0001-01-01T00:00:00"
        },
        "Values": [
          0.5,
          1.0,
          1.5,
          2.0,
          4.0,
          6.0,
          8.0,
          10.0,
          12.0,
          14.0,
          18.0,
          22.0,
          24.0
        ],
        "Dimension": "Time",
        "Unit": "h"
      }
    },
    {
      "Name": "Komoroski 2009 - SAD 250 mg fasted - Dapagliflozin - PO - 250 mg - Plasma - agg. (n=6)",
      "ExtendedProperties": [
        {
          "Name": "DB Version",
          "Value": "OSP DATABASE"
        },
        {
          "Name": "ID",
          "Value": 661.0
        },
        {
          "Name": "Study Id",
          "Value": "Komoroski 2009"
        },
        {
          "Name": "Reference",
          "Value": "https://www.ncbi.nlm.nih.gov/pubmed/19129748"
        },
        {
          "Name": "Source",
          "Value": "Fig. 3 / Fig. 11 (202293Orig1s000ClinPharmR.pdf)"
        },
        {
          "Name": "Grouping",
          "Value": "SAD 250 mg fasted"
        },
        {
          "Name": "Data type",
          "Value": "aggregated"
        },
        {
          "Name": "N",
          "Value": 6.0
        },
        {
          "Name": "Molecule",
          "Value": "Dapagliflozin"
        },
        {
          "Name": "Species",
          "Value": "Human"
        },
        {
          "Name": "Organ",
          "Value": "Peripheral Venous Blood"
        },
        {
          "Name": "Compartment",
          "Value": "Plasma"
        },
        {
          "Name": "Route",
          "Value": "PO"
        },
        {
          "Name": "Dose",
          "Value": "250 mg"
        },
        {
          "Name": "Times of Administration [h]",
          "Value": 0.0
        },
        {
          "Name": "Formulation",
          "Value": "Capsule"
        },
        {
          "Name": "Food state",
          "Value": "Fasted"
        },
        {
          "Name": "Comment",
          "Value": "."
        }
      ],
      "Columns": [
        {
          "Name": "Avg",
          "QuantityInfo": {
            "Name": "Avg",
            "Path": "Komoroski 2009 - SAD 250 mg fasted - Dapagliflozin - PO - 250 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean"
          },
          "DataInfo": {
            "Origin": "Observation",
            "AuxiliaryType": "Undefined",
            "Date": "0001-01-01T00:00:00",
            "MolWeight": 408.87
          },
          "Values": [
            563.2289,
            2559.877,
            2118.49487,
            2078.779,
            1113.205,
            542.3087,
            371.418,
            295.9599,
            244.9295,
            191.5101,
            141.4767,
            100.6328,
            93.296
          ],
          "Dimension": "Concentration (mass)",
          "Unit": "µg/l"
        }
      ],
      "BaseGrid": {
        "Name": "Time",
        "QuantityInfo": {
          "Name": "Time",
          "Path": "Komoroski 2009 - SAD 250 mg fasted - Dapagliflozin - PO - 250 mg - Plasma - agg. (n=6)|Time",
          "Type": "Time"
        },
        "DataInfo": {
          "Origin": "BaseGrid",
          "AuxiliaryType": "Undefined",
          "Date": "0001-01-01T00:00:00"
        },
        "Values": [
          0.5,
          1.0,
          1.5,
          2.0,
          4.0,
          6.0,
          8.0,
          10.0,
          12.0,
          14.0,
          18.0,
          22.0,
          24.0
        ],
        "Dimension": "Time",
        "Unit": "h"
      }
    },
    {
      "Name": "Komoroski 2009 - SAD 500 mg - Dapagliflozin - PO - 500 mg - Plasma - agg. (n=6)",
      "ExtendedProperties": [
        {
          "Name": "DB Version",
          "Value": "OSP DATABASE"
        },
        {
          "Name": "ID",
          "Value": 662.0
        },
        {
          "Name": "Study Id",
          "Value": "Komoroski 2009"
        },
        {
          "Name": "Reference",
          "Value": "https://www.ncbi.nlm.nih.gov/pubmed/19129748"
        },
        {
          "Name": "Source",
          "Value": "Fig. 11 (202293Orig1s000ClinPharmR.pdf)"
        },
        {
          "Name": "Grouping",
          "Value": "SAD 500 mg"
        },
        {
          "Name": "Data type",
          "Value": "aggregated"
        },
        {
          "Name": "N",
          "Value": 6.0
        },
        {
          "Name": "Molecule",
          "Value": "Dapagliflozin"
        },
        {
          "Name": "Species",
          "Value": "Human"
        },
        {
          "Name": "Organ",
          "Value": "Peripheral Venous Blood"
        },
        {
          "Name": "Compartment",
          "Value": "Plasma"
        },
        {
          "Name": "Route",
          "Value": "PO"
        },
        {
          "Name": "Dose",
          "Value": "500 mg"
        },
        {
          "Name": "Times of Administration [h]",
          "Value": 0.0
        },
        {
          "Name": "Formulation",
          "Value": "Capsule"
        },
        {
          "Name": "Food state",
          "Value": "Fasted"
        },
        {
          "Name": "Comment",
          "Value": "."
        }
      ],
      "Columns": [
        {
          "Name": "Avg",
          "QuantityInfo": {
            "Name": "Avg",
            "Path": "Komoroski 2009 - SAD 500 mg - Dapagliflozin - PO - 500 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean"
          },
          "DataInfo": {
            "Origin": "Observation",
            "AuxiliaryType": "Undefined",
            "Date": "0001-01-01T00:00:00",
            "MolWeight": 408.87
          },
          "Values": [
            720.3345,
            4431.751,
            4780.266,
            4031.61914,
            1927.22083,
            1051.763,
            734.0969,
            563.2289,
            466.1151,
            371.418,
            259.238,
            191.5101,
            195.1691
          ],
          "Dimension": "Concentration (mass)",
          "Unit": "µg/l"
        }
      ],
      "BaseGrid": {
        "Name": "Time",
        "QuantityInfo": {
          "Name": "Time",
          "Path": "Komoroski 2009 - SAD 500 mg - Dapagliflozin - PO - 500 mg - Plasma - agg. (n=6)|Time",
          "Type": "Time"
        },
        "DataInfo": {
          "Origin": "BaseGrid",
          "AuxiliaryType": "Undefined",
          "Date": "0001-01-01T00:00:00"
        },
        "Values": [
          0.5,
          1.0,
          1.5,
          2.0,
          4.0,
          6.0,
          8.0,
          10.0,
          12.0,
          14.0,
          18.0,
          22.0,
          24.0
        ],
        "Dimension": "Time",
        "Unit": "h"
      }
    },
    {
      "Name": "Komoroski 2009 - SAD 2.5 mg (Urine) - Dapagliflozin - PO - 2.5 mg - Urine - agg. (n=6)",
      "ExtendedProperties": [
        {
          "Name": "DB Version",
          "Value": "OSP DATABASE"
        },
        {
          "Name": "ID",
          "Value": 677.0
        },
        {
          "Name": "Study Id",
          "Value": "Komoroski 2009"
        },
        {
          "Name": "Reference",
          "Value": "https://www.ncbi.nlm.nih.gov/pubmed/19129748"
        },
        {
          "Name": "Source",
          "Value": "Tab. 6 (202293Orig1s000ClinPharmR.pdf)"
        },
        {
          "Name": "Grouping",
          "Value": "SAD 2.5 mg (Urine)"
        },
        {
          "Name": "Data type",
          "Value": "aggregated"
        },
        {
          "Name": "N",
          "Value": 6.0
        },
        {
          "Name": "Molecule",
          "Value": "Dapagliflozin"
        },
        {
          "Name": "Species",
          "Value": "Human"
        },
        {
          "Name": "Organ",
          "Value": "Kidney"
        },
        {
          "Name": "Compartment",
          "Value": "Urine"
        },
        {
          "Name": "Route",
          "Value": "PO"
        },
        {
          "Name": "Dose",
          "Value": "2.5 mg"
        },
        {
          "Name": "Times of Administration [h]",
          "Value": 0.0
        },
        {
          "Name": "Formulation",
          "Value": "Solution"
        },
        {
          "Name": "Food state",
          "Value": "Fasted"
        },
        {
          "Name": "Comment",
          "Value": "."
        }
      ],
      "Columns": [
        {
          "Name": "Avg",
          "RelatedColumns": [
            {
              "Name": "Var",
              "QuantityInfo": {
                "Name": "Var",
                "Path": "Komoroski 2009 - SAD 2.5 mg (Urine) - Dapagliflozin - PO - 2.5 mg - Urine - agg. (n=6)|ObservedData|Kidney|Urine|Dapagliflozin|ArithmeticStdDev"
              },
              "DataInfo": {
                "Origin": "ObservationAuxiliary",
                "AuxiliaryType": "ArithmeticStdDev",
                "Date": "0001-01-01T00:00:00",
                "MolWeight": 408.87
              },
              "Values": [
                0.0089
              ],
              "Dimension": "Fraction"
            }
          ],
          "QuantityInfo": {
            "Name": "Avg",
            "Path": "Komoroski 2009 - SAD 2.5 mg (Urine) - Dapagliflozin - PO - 2.5 mg - Urine - agg. (n=6)|ObservedData|Kidney|Urine|Dapagliflozin|ArithmeticMean"
          },
          "DataInfo": {
            "Origin": "Observation",
            "AuxiliaryType": "Undefined",
            "Date": "0001-01-01T00:00:00",
            "MolWeight": 408.87
          },
          "Values": [
            0.0154
          ],
          "Dimension": "Fraction"
        }
      ],
      "BaseGrid": {
        "Name": "Time",
        "QuantityInfo": {
          "Name": "Time",
          "Path": "Komoroski 2009 - SAD 2.5 mg (Urine) - Dapagliflozin - PO - 2.5 mg - Urine - agg. (n=6)|Time",
          "Type": "Time"
        },
        "DataInfo": {
          "Origin": "BaseGrid",
          "AuxiliaryType": "Undefined",
          "Date": "0001-01-01T00:00:00"
        },
        "Values": [
          120.0
        ],
        "Dimension": "Time",
        "Unit": "h"
      }
    },
    {
      "Name": "Komoroski 2009 - SAD 5 mg (Urine) - Dapagliflozin - PO - 5 mg - Urine - agg. (n=6)",
      "ExtendedProperties": [
        {
          "Name": "DB Version",
          "Value": "OSP DATABASE"
        },
        {
          "Name": "ID",
          "Value": 678.0
        },
        {
          "Name": "Study Id",
          "Value": "Komoroski 2009"
        },
        {
          "Name": "Reference",
          "Value": "https://www.ncbi.nlm.nih.gov/pubmed/19129748"
        },
        {
          "Name": "Source",
          "Value": "Tab. 6 (202293Orig1s000ClinPharmR.pdf)"
        },
        {
          "Name": "Grouping",
          "Value": "SAD 5 mg (Urine)"
        },
        {
          "Name": "Data type",
          "Value": "aggregated"
        },
        {
          "Name": "N",
          "Value": 6.0
        },
        {
          "Name": "Molecule",
          "Value": "Dapagliflozin"
        },
        {
          "Name": "Species",
          "Value": "Human"
        },
        {
          "Name": "Organ",
          "Value": "Kidney"
        },
        {
          "Name": "Compartment",
          "Value": "Urine"
        },
        {
          "Name": "Route",
          "Value": "PO"
        },
        {
          "Name": "Dose",
          "Value": "5 mg"
        },
        {
          "Name": "Times of Administration [h]",
          "Value": 0.0
        },
        {
          "Name": "Formulation",
          "Value": "Solution"
        },
        {
          "Name": "Food state",
          "Value": "Fasted"
        },
        {
          "Name": "Comment",
          "Value": "."
        }
      ],
      "Columns": [
        {
          "Name": "Avg",
          "RelatedColumns": [
            {
              "Name": "Var",
              "QuantityInfo": {
                "Name": "Var",
                "Path": "Komoroski 2009 - SAD 5 mg (Urine) - Dapagliflozin - PO - 5 mg - Urine - agg. (n=6)|ObservedData|Kidney|Urine|Dapagliflozin|ArithmeticStdDev"
              },
              "DataInfo": {
                "Origin": "ObservationAuxiliary",
                "AuxiliaryType": "ArithmeticStdDev",
                "Date": "0001-01-01T00:00:00",
                "MolWeight": 408.87
              },
              "Values": [
                0.0019
              ],
              "Dimension": "Fraction"
            }
          ],
          "QuantityInfo": {
            "Name": "Avg",
            "Path": "Komoroski 2009 - SAD 5 mg (Urine) - Dapagliflozin - PO - 5 mg - Urine - agg. (n=6)|ObservedData|Kidney|Urine|Dapagliflozin|ArithmeticMean"
          },
          "DataInfo": {
            "Origin": "Observation",
            "AuxiliaryType": "Undefined",
            "Date": "0001-01-01T00:00:00",
            "MolWeight": 408.87
          },
          "Values": [
            0.0046
          ],
          "Dimension": "Fraction"
        }
      ],
      "BaseGrid": {
        "Name": "Time",
        "QuantityInfo": {
          "Name": "Time",
          "Path": "Komoroski 2009 - SAD 5 mg (Urine) - Dapagliflozin - PO - 5 mg - Urine - agg. (n=6)|Time",
          "Type": "Time"
        },
        "DataInfo": {
          "Origin": "BaseGrid",
          "AuxiliaryType": "Undefined",
          "Date": "0001-01-01T00:00:00"
        },
        "Values": [
          120.0
        ],
        "Dimension": "Time",
        "Unit": "h"
      }
    },
    {
      "Name": "Komoroski 2009 - SAD 10 mg (Urine) - Dapagliflozin - PO - 10 mg - Urine - agg. (n=6)",
      "ExtendedProperties": [
        {
          "Name": "DB Version",
          "Value": "OSP DATABASE"
        },
        {
          "Name": "ID",
          "Value": 679.0
        },
        {
          "Name": "Study Id",
          "Value": "Komoroski 2009"
        },
        {
          "Name": "Reference",
          "Value": "https://www.ncbi.nlm.nih.gov/pubmed/19129748"
        },
        {
          "Name": "Source",
          "Value": "Tab. 6 (202293Orig1s000ClinPharmR.pdf)"
        },
        {
          "Name": "Grouping",
          "Value": "SAD 10 mg (Urine)"
        },
        {
          "Name": "Data type",
          "Value": "aggregated"
        },
        {
          "Name": "N",
          "Value": 6.0
        },
        {
          "Name": "Molecule",
          "Value": "Dapagliflozin"
        },
        {
          "Name": "Species",
          "Value": "Human"
        },
        {
          "Name": "Organ",
          "Value": "Kidney"
        },
        {
          "Name": "Compartment",
          "Value": "Urine"
        },
        {
          "Name": "Route",
          "Value": "PO"
        },
        {
          "Name": "Dose",
          "Value": "10 mg"
        },
        {
          "Name": "Times of Administration [h]",
          "Value": 0.0
        },
        {
          "Name": "Formulation",
          "Value": "Capsule"
        },
        {
          "Name": "Food state",
          "Value": "Fasted"
        },
        {
          "Name": "Comment",
          "Value": "."
        }
      ],
      "Columns": [
        {
          "Name": "Avg",
          "RelatedColumns": [
            {
              "Name": "Var",
              "QuantityInfo": {
                "Name": "Var",
                "Path": "Komoroski 2009 - SAD 10 mg (Urine) - Dapagliflozin - PO - 10 mg - Urine - agg. (n=6)|ObservedData|Kidney|Urine|Dapagliflozin|ArithmeticStdDev"
              },
              "DataInfo": {
                "Origin": "ObservationAuxiliary",
                "AuxiliaryType": "ArithmeticStdDev",
                "Date": "0001-01-01T00:00:00",
                "MolWeight": 408.87
              },
              "Values": [
                0.0139
              ],
              "Dimension": "Fraction"
            }
          ],
          "QuantityInfo": {
            "Name": "Avg",
            "Path": "Komoroski 2009 - SAD 10 mg (Urine) - Dapagliflozin - PO - 10 mg - Urine - agg. (n=6)|ObservedData|Kidney|Urine|Dapagliflozin|ArithmeticMean"
          },
          "DataInfo": {
            "Origin": "Observation",
            "AuxiliaryType": "Undefined",
            "Date": "0001-01-01T00:00:00",
            "MolWeight": 408.87
          },
          "Values": [
            0.032
          ],
          "Dimension": "Fraction"
        }
      ],
      "BaseGrid": {
        "Name": "Time",
        "QuantityInfo": {
          "Name": "Time",
          "Path": "Komoroski 2009 - SAD 10 mg (Urine) - Dapagliflozin - PO - 10 mg - Urine - agg. (n=6)|Time",
          "Type": "Time"
        },
        "DataInfo": {
          "Origin": "BaseGrid",
          "AuxiliaryType": "Undefined",
          "Date": "0001-01-01T00:00:00"
        },
        "Values": [
          120.0
        ],
        "Dimension": "Time",
        "Unit": "h"
      }
    },
    {
      "Name": "Komoroski 2009 - SAD 20 mg (Urine) - Dapagliflozin - PO - 20 mg - Urine - agg. (n=6)",
      "ExtendedProperties": [
        {
          "Name": "DB Version",
          "Value": "OSP DATABASE"
        },
        {
          "Name": "ID",
          "Value": 680.0
        },
        {
          "Name": "Study Id",
          "Value": "Komoroski 2009"
        },
        {
          "Name": "Reference",
          "Value": "https://www.ncbi.nlm.nih.gov/pubmed/19129748"
        },
        {
          "Name": "Source",
          "Value": "Tab. 6 (202293Orig1s000ClinPharmR.pdf)"
        },
        {
          "Name": "Grouping",
          "Value": "SAD 20 mg (Urine)"
        },
        {
          "Name": "Data type",
          "Value": "aggregated"
        },
        {
          "Name": "N",
          "Value": 6.0
        },
        {
          "Name": "Molecule",
          "Value": "Dapagliflozin"
        },
        {
          "Name": "Species",
          "Value": "Human"
        },
        {
          "Name": "Organ",
          "Value": "Kidney"
        },
        {
          "Name": "Compartment",
          "Value": "Urine"
        },
        {
          "Name": "Route",
          "Value": "PO"
        },
        {
          "Name": "Dose",
          "Value": "20 mg"
        },
        {
          "Name": "Times of Administration [h]",
          "Value": 0.0
        },
        {
          "Name": "Formulation",
          "Value": "Capsule"
        },
        {
          "Name": "Food state",
          "Value": "Fasted"
        },
        {
          "Name": "Comment",
          "Value": "."
        }
      ],
      "Columns": [
        {
          "Name": "Avg",
          "RelatedColumns": [
            {
              "Name": "Var",
              "QuantityInfo": {
                "Name": "Var",
                "Path": "Komoroski 2009 - SAD 20 mg (Urine) - Dapagliflozin - PO - 20 mg - Urine - agg. (n=6)|ObservedData|Kidney|Urine|Dapagliflozin|ArithmeticStdDev"
              },
              "DataInfo": {
                "Origin": "ObservationAuxiliary",
                "AuxiliaryType": "ArithmeticStdDev",
                "Date": "0001-01-01T00:00:00",
                "MolWeight": 408.87
              },
              "Values": [
                0.0016
              ],
              "Dimension": "Fraction"
            }
          ],
          "QuantityInfo": {
            "Name": "Avg",
            "Path": "Komoroski 2009 - SAD 20 mg (Urine) - Dapagliflozin - PO - 20 mg - Urine - agg. (n=6)|ObservedData|Kidney|Urine|Dapagliflozin|ArithmeticMean"
          },
          "DataInfo": {
            "Origin": "Observation",
            "AuxiliaryType": "Undefined",
            "Date": "0001-01-01T00:00:00",
            "MolWeight": 408.87
          },
          "Values": [
            0.00610000035
          ],
          "Dimension": "Fraction"
        }
      ],
      "BaseGrid": {
        "Name": "Time",
        "QuantityInfo": {
          "Name": "Time",
          "Path": "Komoroski 2009 - SAD 20 mg (Urine) - Dapagliflozin - PO - 20 mg - Urine - agg. (n=6)|Time",
          "Type": "Time"
        },
        "DataInfo": {
          "Origin": "BaseGrid",
          "AuxiliaryType": "Undefined",
          "Date": "0001-01-01T00:00:00"
        },
        "Values": [
          120.0
        ],
        "Dimension": "Time",
        "Unit": "h"
      }
    },
    {
      "Name": "Komoroski 2009 - SAD 50 mg (Urine) - Dapagliflozin - PO - 50 mg - Urine - agg. (n=6)",
      "ExtendedProperties": [
        {
          "Name": "DB Version",
          "Value": "OSP DATABASE"
        },
        {
          "Name": "ID",
          "Value": 681.0
        },
        {
          "Name": "Study Id",
          "Value": "Komoroski 2009"
        },
        {
          "Name": "Reference",
          "Value": "https://www.ncbi.nlm.nih.gov/pubmed/19129748"
        },
        {
          "Name": "Source",
          "Value": "Tab. 6 (202293Orig1s000ClinPharmR.pdf)"
        },
        {
          "Name": "Grouping",
          "Value": "SAD 50 mg (Urine)"
        },
        {
          "Name": "Data type",
          "Value": "aggregated"
        },
        {
          "Name": "N",
          "Value": 6.0
        },
        {
          "Name": "Molecule",
          "Value": "Dapagliflozin"
        },
        {
          "Name": "Species",
          "Value": "Human"
        },
        {
          "Name": "Organ",
          "Value": "Kidney"
        },
        {
          "Name": "Compartment",
          "Value": "Urine"
        },
        {
          "Name": "Route",
          "Value": "PO"
        },
        {
          "Name": "Dose",
          "Value": "50 mg"
        },
        {
          "Name": "Times of Administration [h]",
          "Value": 0.0
        },
        {
          "Name": "Formulation",
          "Value": "Capsule"
        },
        {
          "Name": "Food state",
          "Value": "Fasted"
        },
        {
          "Name": "Comment",
          "Value": "."
        }
      ],
      "Columns": [
        {
          "Name": "Avg",
          "RelatedColumns": [
            {
              "Name": "Var",
              "QuantityInfo": {
                "Name": "Var",
                "Path": "Komoroski 2009 - SAD 50 mg (Urine) - Dapagliflozin - PO - 50 mg - Urine - agg. (n=6)|ObservedData|Kidney|Urine|Dapagliflozin|ArithmeticStdDev"
              },
              "DataInfo": {
                "Origin": "ObservationAuxiliary",
                "AuxiliaryType": "ArithmeticStdDev",
                "Date": "0001-01-01T00:00:00",
                "MolWeight": 408.87
              },
              "Values": [
                0.0017
              ],
              "Dimension": "Fraction"
            }
          ],
          "QuantityInfo": {
            "Name": "Avg",
            "Path": "Komoroski 2009 - SAD 50 mg (Urine) - Dapagliflozin - PO - 50 mg - Urine - agg. (n=6)|ObservedData|Kidney|Urine|Dapagliflozin|ArithmeticMean"
          },
          "DataInfo": {
            "Origin": "Observation",
            "AuxiliaryType": "Undefined",
            "Date": "0001-01-01T00:00:00",
            "MolWeight": 408.87
          },
          "Values": [
            0.72
          ],
          "Dimension": "Fraction",
          "Unit": "%"
        }
      ],
      "BaseGrid": {
        "Name": "Time",
        "QuantityInfo": {
          "Name": "Time",
          "Path": "Komoroski 2009 - SAD 50 mg (Urine) - Dapagliflozin - PO - 50 mg - Urine - agg. (n=6)|Time",
          "Type": "Time"
        },
        "DataInfo": {
          "Origin": "BaseGrid",
          "AuxiliaryType": "Undefined",
          "Date": "0001-01-01T00:00:00"
        },
        "Values": [
          120.0
        ],
        "Dimension": "Time",
        "Unit": "h"
      }
    },
    {
      "Name": "Komoroski 2009 - SAD 100 mg (Urine) - Dapagliflozin - PO - 100 mg - Urine - agg. (n=6)",
      "ExtendedProperties": [
        {
          "Name": "DB Version",
          "Value": "OSP DATABASE"
        },
        {
          "Name": "ID",
          "Value": 682.0
        },
        {
          "Name": "Study Id",
          "Value": "Komoroski 2009"
        },
        {
          "Name": "Reference",
          "Value": "https://www.ncbi.nlm.nih.gov/pubmed/19129748"
        },
        {
          "Name": "Source",
          "Value": "Tab. 6 (202293Orig1s000ClinPharmR.pdf)"
        },
        {
          "Name": "Grouping",
          "Value": "SAD 100 mg (Urine)"
        },
        {
          "Name": "Data type",
          "Value": "aggregated"
        },
        {
          "Name": "N",
          "Value": 6.0
        },
        {
          "Name": "Molecule",
          "Value": "Dapagliflozin"
        },
        {
          "Name": "Species",
          "Value": "Human"
        },
        {
          "Name": "Organ",
          "Value": "Kidney"
        },
        {
          "Name": "Compartment",
          "Value": "Urine"
        },
        {
          "Name": "Route",
          "Value": "PO"
        },
        {
          "Name": "Dose",
          "Value": "100 mg"
        },
        {
          "Name": "Times of Administration [h]",
          "Value": 0.0
        },
        {
          "Name": "Formulation",
          "Value": "Capsule"
        },
        {
          "Name": "Food state",
          "Value": "Fasted"
        },
        {
          "Name": "Comment",
          "Value": "."
        }
      ],
      "Columns": [
        {
          "Name": "Avg",
          "RelatedColumns": [
            {
              "Name": "Var",
              "QuantityInfo": {
                "Name": "Var",
                "Path": "Komoroski 2009 - SAD 100 mg (Urine) - Dapagliflozin - PO - 100 mg - Urine - agg. (n=6)|ObservedData|Kidney|Urine|Dapagliflozin|ArithmeticStdDev"
              },
              "DataInfo": {
                "Origin": "ObservationAuxiliary",
                "AuxiliaryType": "ArithmeticStdDev",
                "Date": "0001-01-01T00:00:00",
                "MolWeight": 408.87
              },
              "Values": [
                0.0021
              ],
              "Dimension": "Fraction"
            }
          ],
          "QuantityInfo": {
            "Name": "Avg",
            "Path": "Komoroski 2009 - SAD 100 mg (Urine) - Dapagliflozin - PO - 100 mg - Urine - agg. (n=6)|ObservedData|Kidney|Urine|Dapagliflozin|ArithmeticMean"
          },
          "DataInfo": {
            "Origin": "Observation",
            "AuxiliaryType": "Undefined",
            "Date": "0001-01-01T00:00:00",
            "MolWeight": 408.87
          },
          "Values": [
            0.0104
          ],
          "Dimension": "Fraction"
        }
      ],
      "BaseGrid": {
        "Name": "Time",
        "QuantityInfo": {
          "Name": "Time",
          "Path": "Komoroski 2009 - SAD 100 mg (Urine) - Dapagliflozin - PO - 100 mg - Urine - agg. (n=6)|Time",
          "Type": "Time"
        },
        "DataInfo": {
          "Origin": "BaseGrid",
          "AuxiliaryType": "Undefined",
          "Date": "0001-01-01T00:00:00"
        },
        "Values": [
          120.0
        ],
        "Dimension": "Time",
        "Unit": "h"
      }
    },
    {
      "Name": "Komoroski 2009 - SAD 250 mg fasted (Urine) - Dapagliflozin - PO - 250 mg - Urine - agg. (n=6)",
      "ExtendedProperties": [
        {
          "Name": "DB Version",
          "Value": "OSP DATABASE"
        },
        {
          "Name": "ID",
          "Value": 683.0
        },
        {
          "Name": "Study Id",
          "Value": "Komoroski 2009"
        },
        {
          "Name": "Reference",
          "Value": "https://www.ncbi.nlm.nih.gov/pubmed/19129748"
        },
        {
          "Name": "Source",
          "Value": "Tab. 6 (202293Orig1s000ClinPharmR.pdf)"
        },
        {
          "Name": "Grouping",
          "Value": "SAD 250 mg fasted (Urine)"
        },
        {
          "Name": "Data type",
          "Value": "aggregated"
        },
        {
          "Name": "N",
          "Value": 6.0
        },
        {
          "Name": "Molecule",
          "Value": "Dapagliflozin"
        },
        {
          "Name": "Species",
          "Value": "Human"
        },
        {
          "Name": "Organ",
          "Value": "Kidney"
        },
        {
          "Name": "Compartment",
          "Value": "Urine"
        },
        {
          "Name": "Route",
          "Value": "PO"
        },
        {
          "Name": "Dose",
          "Value": "250 mg"
        },
        {
          "Name": "Times of Administration [h]",
          "Value": 0.0
        },
        {
          "Name": "Formulation",
          "Value": "Capsule"
        },
        {
          "Name": "Food state",
          "Value": "Fasted"
        },
        {
          "Name": "Comment",
          "Value": "."
        }
      ],
      "Columns": [
        {
          "Name": "Avg",
          "RelatedColumns": [
            {
              "Name": "Var",
              "QuantityInfo": {
                "Name": "Var",
                "Path": "Komoroski 2009 - SAD 250 mg fasted (Urine) - Dapagliflozin - PO - 250 mg - Urine - agg. (n=6)|ObservedData|Kidney|Urine|Dapagliflozin|ArithmeticStdDev"
              },
              "DataInfo": {
                "Origin": "ObservationAuxiliary",
                "AuxiliaryType": "ArithmeticStdDev",
                "Date": "0001-01-01T00:00:00",
                "MolWeight": 408.87
              },
              "Values": [
                0.004
              ],
              "Dimension": "Fraction"
            }
          ],
          "QuantityInfo": {
            "Name": "Avg",
            "Path": "Komoroski 2009 - SAD 250 mg fasted (Urine) - Dapagliflozin - PO - 250 mg - Urine - agg. (n=6)|ObservedData|Kidney|Urine|Dapagliflozin|ArithmeticMean"
          },
          "DataInfo": {
            "Origin": "Observation",
            "AuxiliaryType": "Undefined",
            "Date": "0001-01-01T00:00:00",
            "MolWeight": 408.87
          },
          "Values": [
            0.0154
          ],
          "Dimension": "Fraction"
        }
      ],
      "BaseGrid": {
        "Name": "Time",
        "QuantityInfo": {
          "Name": "Time",
          "Path": "Komoroski 2009 - SAD 250 mg fasted (Urine) - Dapagliflozin - PO - 250 mg - Urine - agg. (n=6)|Time",
          "Type": "Time"
        },
        "DataInfo": {
          "Origin": "BaseGrid",
          "AuxiliaryType": "Undefined",
          "Date": "0001-01-01T00:00:00"
        },
        "Values": [
          120.0
        ],
        "Dimension": "Time",
        "Unit": "h"
      }
    },
    {
      "Name": "Komoroski 2009 - SAD 500 mg (Urine) - Dapagliflozin - PO - 500 mg - Urine - agg. (n=6)",
      "ExtendedProperties": [
        {
          "Name": "DB Version",
          "Value": "OSP DATABASE"
        },
        {
          "Name": "ID",
          "Value": 684.0
        },
        {
          "Name": "Study Id",
          "Value": "Komoroski 2009"
        },
        {
          "Name": "Reference",
          "Value": "https://www.ncbi.nlm.nih.gov/pubmed/19129748"
        },
        {
          "Name": "Source",
          "Value": "Tab. 6 (202293Orig1s000ClinPharmR.pdf)"
        },
        {
          "Name": "Grouping",
          "Value": "SAD 500 mg (Urine)"
        },
        {
          "Name": "Data type",
          "Value": "aggregated"
        },
        {
          "Name": "N",
          "Value": 6.0
        },
        {
          "Name": "Molecule",
          "Value": "Dapagliflozin"
        },
        {
          "Name": "Species",
          "Value": "Human"
        },
        {
          "Name": "Organ",
          "Value": "Kidney"
        },
        {
          "Name": "Compartment",
          "Value": "Urine"
        },
        {
          "Name": "Route",
          "Value": "PO"
        },
        {
          "Name": "Dose",
          "Value": "500 mg"
        },
        {
          "Name": "Times of Administration [h]",
          "Value": 0.0
        },
        {
          "Name": "Formulation",
          "Value": "Capsule"
        },
        {
          "Name": "Food state",
          "Value": "Fasted"
        },
        {
          "Name": "Comment",
          "Value": "."
        }
      ],
      "Columns": [
        {
          "Name": "Avg",
          "RelatedColumns": [
            {
              "Name": "Var",
              "QuantityInfo": {
                "Name": "Var",
                "Path": "Komoroski 2009 - SAD 500 mg (Urine) - Dapagliflozin - PO - 500 mg - Urine - agg. (n=6)|ObservedData|Kidney|Urine|Dapagliflozin|ArithmeticStdDev"
              },
              "DataInfo": {
                "Origin": "ObservationAuxiliary",
                "AuxiliaryType": "ArithmeticStdDev",
                "Date": "0001-01-01T00:00:00",
                "MolWeight": 408.87
              },
              "Values": [
                0.0054
              ],
              "Dimension": "Fraction"
            }
          ],
          "QuantityInfo": {
            "Name": "Avg",
            "Path": "Komoroski 2009 - SAD 500 mg (Urine) - Dapagliflozin - PO - 500 mg - Urine - agg. (n=6)|ObservedData|Kidney|Urine|Dapagliflozin|ArithmeticMean"
          },
          "DataInfo": {
            "Origin": "Observation",
            "AuxiliaryType": "Undefined",
            "Date": "0001-01-01T00:00:00",
            "MolWeight": 408.87
          },
          "Values": [
            0.0117
          ],
          "Dimension": "Fraction"
        }
      ],
      "BaseGrid": {
        "Name": "Time",
        "QuantityInfo": {
          "Name": "Time",
          "Path": "Komoroski 2009 - SAD 500 mg (Urine) - Dapagliflozin - PO - 500 mg - Urine - agg. (n=6)|Time",
          "Type": "Time"
        },
        "DataInfo": {
          "Origin": "BaseGrid",
          "AuxiliaryType": "Undefined",
          "Date": "0001-01-01T00:00:00"
        },
        "Values": [
          120.0
        ],
        "Dimension": "Time",
        "Unit": "h"
      }
    },
    {
      "Name": "Komoroski 2009 - SAD 250 mg fed - Dapagliflozin - PO - 250 mg - Plasma - agg. (n=6)",
      "ExtendedProperties": [
        {
          "Name": "DB Version",
          "Value": "OSP DATABASE"
        },
        {
          "Name": "ID",
          "Value": 663.0
        },
        {
          "Name": "Study Id",
          "Value": "Komoroski 2009"
        },
        {
          "Name": "Reference",
          "Value": "https://www.ncbi.nlm.nih.gov/pubmed/19129748"
        },
        {
          "Name": "Source",
          "Value": "Fig. 3"
        },
        {
          "Name": "Grouping",
          "Value": "SAD 250 mg fed"
        },
        {
          "Name": "Data type",
          "Value": "aggregated"
        },
        {
          "Name": "N",
          "Value": 6.0
        },
        {
          "Name": "Molecule",
          "Value": "Dapagliflozin"
        },
        {
          "Name": "Species",
          "Value": "Human"
        },
        {
          "Name": "Organ",
          "Value": "Peripheral Venous Blood"
        },
        {
          "Name": "Compartment",
          "Value": "Plasma"
        },
        {
          "Name": "Route",
          "Value": "PO"
        },
        {
          "Name": "Dose",
          "Value": "250 mg"
        },
        {
          "Name": "Times of Administration [h]",
          "Value": 0.0
        },
        {
          "Name": "Formulation",
          "Value": "Capsule"
        },
        {
          "Name": "Food state",
          "Value": "Fed"
        },
        {
          "Name": "Comment",
          "Value": "."
        }
      ],
      "Columns": [
        {
          "Name": "Avg",
          "RelatedColumns": [
            {
              "Name": "Var",
              "QuantityInfo": {
                "Name": "Var",
                "Path": "Komoroski 2009 - SAD 250 mg fed - Dapagliflozin - PO - 250 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticStdDev"
              },
              "DataInfo": {
                "Origin": "ObservationAuxiliary",
                "AuxiliaryType": "ArithmeticStdDev",
                "Date": "0001-01-01T00:00:00",
                "MolWeight": 408.87
              },
              "Values": [
                0.02284221,
                0.08125716,
                0.39447552,
                0.155647516,
                0.3783071,
                0.1943467,
                0.132401,
                0.0916664451,
                0.06012634,
                0.0407123,
                "NaN",
                "NaN",
                "NaN"
              ],
              "Dimension": "Concentration (mass)",
              "Unit": "mg/l"
            }
          ],
          "QuantityInfo": {
            "Name": "Avg",
            "Path": "Komoroski 2009 - SAD 250 mg fed - Dapagliflozin - PO - 250 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean"
          },
          "DataInfo": {
            "Origin": "Observation",
            "AuxiliaryType": "Undefined",
            "Date": "0001-01-01T00:00:00",
            "MolWeight": 408.87
          },
          "Values": [
            26.14091,
            125.688995,
            582.413,
            977.2166,
            1524.698,
            716.1255,
            533.7182,
            369.4447,
            296.4653,
            225.0702,
            153.1845,
            116.4725,
            116.6552
          ],
          "Dimension": "Concentration (mass)",
          "Unit": "µg/l"
        }
      ],
      "BaseGrid": {
        "Name": "Time",
        "QuantityInfo": {
          "Name": "Time",
          "Path": "Komoroski 2009 - SAD 250 mg fed - Dapagliflozin - PO - 250 mg - Plasma - agg. (n=6)|Time",
          "Type": "Time"
        },
        "DataInfo": {
          "Origin": "BaseGrid",
          "AuxiliaryType": "Undefined",
          "Date": "0001-01-01T00:00:00"
        },
        "Values": [
          0.5,
          1.0,
          1.5,
          2.0,
          4.0,
          6.0,
          8.0,
          10.0,
          12.0,
          14.0,
          18.0,
          22.0,
          24.0
        ],
        "Dimension": "Time",
        "Unit": "h"
      }
    },
    {
      "Name": "Komoroski 2009 - MAD 2.5 mg (day 1) - Dapagliflozin - PO - 2.5 mg - Plasma - agg. (n=6)",
      "ExtendedProperties": [
        {
          "Name": "DB Version",
          "Value": "OSP DATABASE"
        },
        {
          "Name": "ID",
          "Value": 664.0
        },
        {
          "Name": "Study Id",
          "Value": "Komoroski 2009"
        },
        {
          "Name": "Reference",
          "Value": "https://www.ncbi.nlm.nih.gov/pubmed/19129748"
        },
        {
          "Name": "Source",
          "Value": "Fig. 4c / Fig. 12 (202293Orig1s000ClinPharmR.pdf)"
        },
        {
          "Name": "Grouping",
          "Value": "MAD 2.5 mg (day 1)"
        },
        {
          "Name": "Data type",
          "Value": "aggregated"
        },
        {
          "Name": "N",
          "Value": 6.0
        },
        {
          "Name": "Molecule",
          "Value": "Dapagliflozin"
        },
        {
          "Name": "Species",
          "Value": "Human"
        },
        {
          "Name": "Organ",
          "Value": "Peripheral Venous Blood"
        },
        {
          "Name": "Compartment",
          "Value": "Plasma"
        },
        {
          "Name": "Route",
          "Value": "PO"
        },
        {
          "Name": "Dose",
          "Value": "2.5 mg"
        },
        {
          "Name": "Times of Administration [h]",
          "Value": "(S0-T24-R14)"
        },
        {
          "Name": "Formulation",
          "Value": "Capsule"
        },
        {
          "Name": "Food state",
          "Value": "."
        },
        {
          "Name": "Comment",
          "Value": "."
        }
      ],
      "Columns": [
        {
          "Name": "Avg",
          "QuantityInfo": {
            "Name": "Avg",
            "Path": "Komoroski 2009 - MAD 2.5 mg (day 1) - Dapagliflozin - PO - 2.5 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean"
          },
          "DataInfo": {
            "Origin": "Observation",
            "AuxiliaryType": "Undefined",
            "Date": "0001-01-01T00:00:00",
            "MolWeight": 408.87
          },
          "Values": [
            17.99987,
            24.87623,
            20.04969,
            13.59845,
            6.819046,
            5.378723,
            3.89192,
            2.816104,
            2.269718,
            2.082098,
            1.352532,
            1.352532,
            1.162984
          ],
          "Dimension": "Concentration (mass)",
          "Unit": "µg/l"
        }
      ],
      "BaseGrid": {
        "Name": "Time",
        "QuantityInfo": {
          "Name": "Time",
          "Path": "Komoroski 2009 - MAD 2.5 mg (day 1) - Dapagliflozin - PO - 2.5 mg - Plasma - agg. (n=6)|Time",
          "Type": "Time"
        },
        "DataInfo": {
          "Origin": "BaseGrid",
          "AuxiliaryType": "Undefined",
          "Date": "0001-01-01T00:00:00"
        },
        "Values": [
          0.5,
          1.0,
          1.5,
          2.0,
          4.0,
          6.0,
          8.0,
          10.0,
          12.0,
          14.0,
          18.0,
          22.0,
          24.0
        ],
        "Dimension": "Time",
        "Unit": "h"
      }
    },
    {
      "Name": "Komoroski 2009 - MAD 10 mg (day 1) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=6)",
      "ExtendedProperties": [
        {
          "Name": "DB Version",
          "Value": "OSP DATABASE"
        },
        {
          "Name": "ID",
          "Value": 665.0
        },
        {
          "Name": "Study Id",
          "Value": "Komoroski 2009"
        },
        {
          "Name": "Reference",
          "Value": "https://www.ncbi.nlm.nih.gov/pubmed/19129748"
        },
        {
          "Name": "Source",
          "Value": "Fig. 4c / Fig. 12 (202293Orig1s000ClinPharmR.pdf)"
        },
        {
          "Name": "Grouping",
          "Value": "MAD 10 mg (day 1)"
        },
        {
          "Name": "Data type",
          "Value": "aggregated"
        },
        {
          "Name": "N",
          "Value": 6.0
        },
        {
          "Name": "Molecule",
          "Value": "Dapagliflozin"
        },
        {
          "Name": "Species",
          "Value": "Human"
        },
        {
          "Name": "Organ",
          "Value": "Peripheral Venous Blood"
        },
        {
          "Name": "Compartment",
          "Value": "Plasma"
        },
        {
          "Name": "Route",
          "Value": "PO"
        },
        {
          "Name": "Dose",
          "Value": "10 mg"
        },
        {
          "Name": "Times of Administration [h]",
          "Value": "(S0-T24-R14)"
        },
        {
          "Name": "Formulation",
          "Value": "Capsule"
        },
        {
          "Name": "Food state",
          "Value": "."
        },
        {
          "Name": "Comment",
          "Value": "."
        }
      ],
      "Columns": [
        {
          "Name": "Avg",
          "QuantityInfo": {
            "Name": "Avg",
            "Path": "Komoroski 2009 - MAD 10 mg (day 1) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean"
          },
          "DataInfo": {
            "Origin": "Observation",
            "AuxiliaryType": "Undefined",
            "Date": "0001-01-01T00:00:00",
            "MolWeight": 408.87
          },
          "Values": [
            67.09619,
            98.9273,
            83.24817,
            68.55917,
            32.92793,
            21.39,
            15.81478,
            11.69272,
            8.833561,
            7.930442,
            5.15162,
            4.152092,
            3.808871
          ],
          "Dimension": "Concentration (mass)",
          "Unit": "µg/l"
        }
      ],
      "BaseGrid": {
        "Name": "Time",
        "QuantityInfo": {
          "Name": "Time",
          "Path": "Komoroski 2009 - MAD 10 mg (day 1) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=6)|Time",
          "Type": "Time"
        },
        "DataInfo": {
          "Origin": "BaseGrid",
          "AuxiliaryType": "Undefined",
          "Date": "0001-01-01T00:00:00"
        },
        "Values": [
          0.5,
          1.0,
          1.5,
          2.0,
          4.0,
          6.0,
          8.0,
          10.0,
          12.0,
          14.0,
          18.0,
          22.0,
          24.0
        ],
        "Dimension": "Time",
        "Unit": "h"
      }
    },
    {
      "Name": "Komoroski 2009 - MAD 20 mg (day 1) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=6)",
      "ExtendedProperties": [
        {
          "Name": "DB Version",
          "Value": "OSP DATABASE"
        },
        {
          "Name": "ID",
          "Value": 666.0
        },
        {
          "Name": "Study Id",
          "Value": "Komoroski 2009"
        },
        {
          "Name": "Reference",
          "Value": "https://www.ncbi.nlm.nih.gov/pubmed/19129748"
        },
        {
          "Name": "Source",
          "Value": "Fig. 4c / Fig. 12 (202293Orig1s000ClinPharmR.pdf)"
        },
        {
          "Name": "Grouping",
          "Value": "MAD 20 mg (day 1)"
        },
        {
          "Name": "Data type",
          "Value": "aggregated"
        },
        {
          "Name": "N",
          "Value": 6.0
        },
        {
          "Name": "Molecule",
          "Value": "Dapagliflozin"
        },
        {
          "Name": "Species",
          "Value": "Human"
        },
        {
          "Name": "Organ",
          "Value": "Peripheral Venous Blood"
        },
        {
          "Name": "Compartment",
          "Value": "Plasma"
        },
        {
          "Name": "Route",
          "Value": "PO"
        },
        {
          "Name": "Dose",
          "Value": "20 mg"
        },
        {
          "Name": "Times of Administration [h]",
          "Value": "(S0-T24-R14)"
        },
        {
          "Name": "Formulation",
          "Value": "Capsule"
        },
        {
          "Name": "Food state",
          "Value": "."
        },
        {
          "Name": "Comment",
          "Value": "."
        }
      ],
      "Columns": [
        {
          "Name": "Avg",
          "QuantityInfo": {
            "Name": "Avg",
            "Path": "Komoroski 2009 - MAD 20 mg (day 1) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean"
          },
          "DataInfo": {
            "Origin": "Observation",
            "AuxiliaryType": "Undefined",
            "Date": "0001-01-01T00:00:00",
            "MolWeight": 408.87
          },
          "Values": [
            101.0843,
            229.4329,
            155.61,
            105.5405,
            51.79475,
            33.64589,
            23.31747,
            20.48686,
            12.20818,
            11.44321,
            8.460587,
            6.121886,
            5.378723
          ],
          "Dimension": "Concentration (mass)",
          "Unit": "µg/l"
        }
      ],
      "BaseGrid": {
        "Name": "Time",
        "QuantityInfo": {
          "Name": "Time",
          "Path": "Komoroski 2009 - MAD 20 mg (day 1) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=6)|Time",
          "Type": "Time"
        },
        "DataInfo": {
          "Origin": "BaseGrid",
          "AuxiliaryType": "Undefined",
          "Date": "0001-01-01T00:00:00"
        },
        "Values": [
          0.5,
          1.0,
          1.5,
          2.0,
          4.0,
          6.0,
          8.0,
          10.0,
          12.0,
          14.0,
          18.0,
          22.0,
          24.0
        ],
        "Dimension": "Time",
        "Unit": "h"
      }
    },
    {
      "Name": "Komoroski 2009 - MAD 50 mg (day 1) - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=6)",
      "ExtendedProperties": [
        {
          "Name": "DB Version",
          "Value": "OSP DATABASE"
        },
        {
          "Name": "ID",
          "Value": 667.0
        },
        {
          "Name": "Study Id",
          "Value": "Komoroski 2009"
        },
        {
          "Name": "Reference",
          "Value": "https://www.ncbi.nlm.nih.gov/pubmed/19129748"
        },
        {
          "Name": "Source",
          "Value": "Fig. 4c / Fig. 12 (202293Orig1s000ClinPharmR.pdf)"
        },
        {
          "Name": "Grouping",
          "Value": "MAD 50 mg (day 1)"
        },
        {
          "Name": "Data type",
          "Value": "aggregated"
        },
        {
          "Name": "N",
          "Value": 6.0
        },
        {
          "Name": "Molecule",
          "Value": "Dapagliflozin"
        },
        {
          "Name": "Species",
          "Value": "Human"
        },
        {
          "Name": "Organ",
          "Value": "Peripheral Venous Blood"
        },
        {
          "Name": "Compartment",
          "Value": "Plasma"
        },
        {
          "Name": "Route",
          "Value": "PO"
        },
        {
          "Name": "Dose",
          "Value": "50 mg"
        },
        {
          "Name": "Times of Administration [h]",
          "Value": "(S0-T24-R14)"
        },
        {
          "Name": "Formulation",
          "Value": "Capsule"
        },
        {
          "Name": "Food state",
          "Value": "."
        },
        {
          "Name": "Comment",
          "Value": "."
        }
      ],
      "Columns": [
        {
          "Name": "Avg",
          "QuantityInfo": {
            "Name": "Avg",
            "Path": "Komoroski 2009 - MAD 50 mg (day 1) - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean"
          },
          "DataInfo": {
            "Origin": "Observation",
            "AuxiliaryType": "Undefined",
            "Date": "0001-01-01T00:00:00",
            "MolWeight": 408.87
          },
          "Values": [
            345.654144,
            532.1025,
            428.8629,
            323.9952,
            155.61,
            117.5595,
            74.73711,
            51.79475,
            39.98283,
            30.2060318,
            20.93356,
            15.81478,
            14.82382
          ],
          "Dimension": "Concentration (mass)",
          "Unit": "µg/l"
        }
      ],
      "BaseGrid": {
        "Name": "Time",
        "QuantityInfo": {
          "Name": "Time",
          "Path": "Komoroski 2009 - MAD 50 mg (day 1) - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=6)|Time",
          "Type": "Time"
        },
        "DataInfo": {
          "Origin": "BaseGrid",
          "AuxiliaryType": "Undefined",
          "Date": "0001-01-01T00:00:00"
        },
        "Values": [
          0.5,
          1.0,
          1.5,
          2.0,
          4.0,
          6.0,
          8.0,
          10.0,
          12.0,
          14.0,
          18.0,
          22.0,
          24.0
        ],
        "Dimension": "Time",
        "Unit": "h"
      }
    },
    {
      "Name": "Komoroski 2009 - MAD 100 mg (day 1) - Dapagliflozin - PO - 100 mg - Plasma - agg. (n=6)",
      "ExtendedProperties": [
        {
          "Name": "DB Version",
          "Value": "OSP DATABASE"
        },
        {
          "Name": "ID",
          "Value": 668.0
        },
        {
          "Name": "Study Id",
          "Value": "Komoroski 2009"
        },
        {
          "Name": "Reference",
          "Value": "https://www.ncbi.nlm.nih.gov/pubmed/19129748"
        },
        {
          "Name": "Source",
          "Value": "Fig. 4c / Fig. 12 (202293Orig1s000ClinPharmR.pdf)"
        },
        {
          "Name": "Grouping",
          "Value": "MAD 100 mg (day 1)"
        },
        {
          "Name": "Data type",
          "Value": "aggregated"
        },
        {
          "Name": "N",
          "Value": 6.0
        },
        {
          "Name": "Molecule",
          "Value": "Dapagliflozin"
        },
        {
          "Name": "Species",
          "Value": "Human"
        },
        {
          "Name": "Organ",
          "Value": "Peripheral Venous Blood"
        },
        {
          "Name": "Compartment",
          "Value": "Plasma"
        },
        {
          "Name": "Route",
          "Value": "PO"
        },
        {
          "Name": "Dose",
          "Value": "100 mg"
        },
        {
          "Name": "Times of Administration [h]",
          "Value": "(S0-T24-R14)"
        },
        {
          "Name": "Formulation",
          "Value": "Capsule"
        },
        {
          "Name": "Food state",
          "Value": "."
        },
        {
          "Name": "Comment",
          "Value": "."
        }
      ],
      "Columns": [
        {
          "Name": "Avg",
          "QuantityInfo": {
            "Name": "Avg",
            "Path": "Komoroski 2009 - MAD 100 mg (day 1) - Dapagliflozin - PO - 100 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean"
          },
          "DataInfo": {
            "Origin": "Observation",
            "AuxiliaryType": "Undefined",
            "Date": "0001-01-01T00:00:00",
            "MolWeight": 408.87
          },
          "Values": [
            385.0172,
            801.6435,
            892.9346,
            784.5373,
            368.7608,
            219.7457,
            152.2894,
            122.7419,
            79.73323,
            68.55917,
            51.79475,
            43.58572,
            39.98283
          ],
          "Dimension": "Concentration (mass)",
          "Unit": "µg/l"
        }
      ],
      "BaseGrid": {
        "Name": "Time",
        "QuantityInfo": {
          "Name": "Time",
          "Path": "Komoroski 2009 - MAD 100 mg (day 1) - Dapagliflozin - PO - 100 mg - Plasma - agg. (n=6)|Time",
          "Type": "Time"
        },
        "DataInfo": {
          "Origin": "BaseGrid",
          "AuxiliaryType": "Undefined",
          "Date": "0001-01-01T00:00:00"
        },
        "Values": [
          0.5,
          1.0,
          1.5,
          2.0,
          4.0,
          6.0,
          8.0,
          10.0,
          12.0,
          14.0,
          18.0,
          22.0,
          24.0
        ],
        "Dimension": "Time",
        "Unit": "h"
      }
    },
    {
      "Name": "Komoroski 2009 - MAD 2.5 mg (day 7 and day 14) - Dapagliflozin - PO - 2.5 mg - Plasma - agg. (n=6)",
      "ExtendedProperties": [
        {
          "Name": "DB Version",
          "Value": "OSP DATABASE"
        },
        {
          "Name": "ID",
          "Value": 685.0
        },
        {
          "Name": "Study Id",
          "Value": "Komoroski 2009"
        },
        {
          "Name": "Reference",
          "Value": "https://www.ncbi.nlm.nih.gov/pubmed/19129748"
        },
        {
          "Name": "Source",
          "Value": "Fig. 4c / Fig. 12 (202293Orig1s000ClinPharmR.pdf)"
        },
        {
          "Name": "Grouping",
          "Value": "MAD 2.5 mg (day 7 and day 14)"
        },
        {
          "Name": "Data type",
          "Value": "aggregated"
        },
        {
          "Name": "N",
          "Value": 6.0
        },
        {
          "Name": "Molecule",
          "Value": "Dapagliflozin"
        },
        {
          "Name": "Species",
          "Value": "Human"
        },
        {
          "Name": "Organ",
          "Value": "Peripheral Venous Blood"
        },
        {
          "Name": "Compartment",
          "Value": "Plasma"
        },
        {
          "Name": "Route",
          "Value": "PO"
        },
        {
          "Name": "Dose",
          "Value": "2.5 mg"
        },
        {
          "Name": "Times of Administration [h]",
          "Value": "(S0-T24-R14)"
        },
        {
          "Name": "Formulation",
          "Value": "Capsule"
        },
        {
          "Name": "Food state",
          "Value": "."
        },
        {
          "Name": "Comment",
          "Value": "."
        }
      ],
      "Columns": [
        {
          "Name": "Avg",
          "QuantityInfo": {
            "Name": "Avg",
            "Path": "Komoroski 2009 - MAD 2.5 mg (day 7 and day 14) - Dapagliflozin - PO - 2.5 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean"
          },
          "DataInfo": {
            "Origin": "Observation",
            "AuxiliaryType": "Undefined",
            "Date": "0001-01-01T00:00:00",
            "MolWeight": 408.87
          },
          "Values": [
            2.625031,
            14.36069,
            27.51918,
            22.78405,
            16.63247,
            9.439372,
            6.747722,
            5.13696,
            3.672149,
            3.376555,
            2.795563,
            1.654546,
            1.620195,
            1.586557,
            1.702594,
            10.525,
            31.14106,
            21.54435,
            16.51117,
            8.935341,
            6.440045,
            4.935525,
            3.94053817,
            3.705859,
            2.782559,
            1.96486807,
            1.84784985,
            1.416156
          ],
          "Dimension": "Concentration (mass)",
          "Unit": "µg/l"
        }
      ],
      "BaseGrid": {
        "Name": "Time",
        "QuantityInfo": {
          "Name": "Time",
          "Path": "Komoroski 2009 - MAD 2.5 mg (day 7 and day 14) - Dapagliflozin - PO - 2.5 mg - Plasma - agg. (n=6)|Time",
          "Type": "Time"
        },
        "DataInfo": {
          "Origin": "BaseGrid",
          "AuxiliaryType": "Undefined",
          "Date": "0001-01-01T00:00:00"
        },
        "Values": [
          144.25,
          144.5,
          145.0,
          145.5,
          146.0,
          148.0,
          150.0,
          152.0,
          154.0,
          156.0,
          158.0,
          162.0,
          166.0,
          168.0,
          312.25,
          312.5,
          313.0,
          313.5,
          314.0,
          316.0,
          318.0,
          320.0,
          322.0,
          324.0,
          326.0,
          330.0,
          334.0,
          336.0
        ],
        "Dimension": "Time",
        "Unit": "h"
      }
    },
    {
      "Name": "Komoroski 2009 - MAD 10 mg (day 7 and day 14) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=6)",
      "ExtendedProperties": [
        {
          "Name": "DB Version",
          "Value": "OSP DATABASE"
        },
        {
          "Name": "ID",
          "Value": 686.0
        },
        {
          "Name": "Study Id",
          "Value": "Komoroski 2009"
        },
        {
          "Name": "Reference",
          "Value": "https://www.ncbi.nlm.nih.gov/pubmed/19129748"
        },
        {
          "Name": "Source",
          "Value": "Fig. 4c / Fig. 12 (202293Orig1s000ClinPharmR.pdf)"
        },
        {
          "Name": "Grouping",
          "Value": "MAD 10 mg (day 7 and day 14)"
        },
        {
          "Name": "Data type",
          "Value": "aggregated"
        },
        {
          "Name": "N",
          "Value": 6.0
        },
        {
          "Name": "Molecule",
          "Value": "Dapagliflozin"
        },
        {
          "Name": "Species",
          "Value": "Human"
        },
        {
          "Name": "Organ",
          "Value": "Peripheral Venous Blood"
        },
        {
          "Name": "Compartment",
          "Value": "Plasma"
        },
        {
          "Name": "Route",
          "Value": "PO"
        },
        {
          "Name": "Dose",
          "Value": "10 mg"
        },
        {
          "Name": "Times of Administration [h]",
          "Value": "(S0-T24-R14)"
        },
        {
          "Name": "Formulation",
          "Value": "Capsule"
        },
        {
          "Name": "Food state",
          "Value": "."
        },
        {
          "Name": "Comment",
          "Value": "."
        }
      ],
      "Columns": [
        {
          "Name": "Avg",
          "QuantityInfo": {
            "Name": "Avg",
            "Path": "Komoroski 2009 - MAD 10 mg (day 7 and day 14) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean"
          },
          "DataInfo": {
            "Origin": "Observation",
            "AuxiliaryType": "Undefined",
            "Date": "0001-01-01T00:00:00",
            "MolWeight": 408.87
          },
          "Values": [
            6.075739,
            81.92937,
            129.9856,
            92.92003,
            67.83207,
            37.69726,
            24.77864,
            21.3942,
            14.06254,
            12.39921,
            10.48338,
            7.49402666,
            7.036884,
            6.075739,
            6.57321453,
            54.11695,
            106.3327,
            86.65184,
            72.07386,
            35.21005,
            26.43761,
            21.10787,
            16.85259,
            13.73339,
            10.96478,
            8.232951,
            6.57321453,
            6.056507
          ],
          "Dimension": "Concentration (mass)",
          "Unit": "µg/l"
        }
      ],
      "BaseGrid": {
        "Name": "Time",
        "QuantityInfo": {
          "Name": "Time",
          "Path": "Komoroski 2009 - MAD 10 mg (day 7 and day 14) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=6)|Time",
          "Type": "Time"
        },
        "DataInfo": {
          "Origin": "BaseGrid",
          "AuxiliaryType": "Undefined",
          "Date": "0001-01-01T00:00:00"
        },
        "Values": [
          144.25,
          144.5,
          145.0,
          145.5,
          146.0,
          148.0,
          150.0,
          152.0,
          154.0,
          156.0,
          158.0,
          162.0,
          166.0,
          168.0,
          312.25,
          312.5,
          313.0,
          313.5,
          314.0,
          316.0,
          318.0,
          320.0,
          322.0,
          324.0,
          326.0,
          330.0,
          334.0,
          336.0
        ],
        "Dimension": "Time",
        "Unit": "h"
      }
    },
    {
      "Name": "Komoroski 2009 - MAD 20 mg (day 7 and day 14) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=6)",
      "ExtendedProperties": [
        {
          "Name": "DB Version",
          "Value": "OSP DATABASE"
        },
        {
          "Name": "ID",
          "Value": 687.0
        },
        {
          "Name": "Study Id",
          "Value": "Komoroski 2009"
        },
        {
          "Name": "Reference",
          "Value": "https://www.ncbi.nlm.nih.gov/pubmed/19129748"
        },
        {
          "Name": "Source",
          "Value": "Fig. 4c / Fig. 12 (202293Orig1s000ClinPharmR.pdf)"
        },
        {
          "Name": "Grouping",
          "Value": "MAD 20 mg (day 7 and day 14)"
        },
        {
          "Name": "Data type",
          "Value": "aggregated"
        },
        {
          "Name": "N",
          "Value": 6.0
        },
        {
          "Name": "Molecule",
          "Value": "Dapagliflozin"
        },
        {
          "Name": "Species",
          "Value": "Human"
        },
        {
          "Name": "Organ",
          "Value": "Peripheral Venous Blood"
        },
        {
          "Name": "Compartment",
          "Value": "Plasma"
        },
        {
          "Name": "Route",
          "Value": "PO"
        },
        {
          "Name": "Dose",
          "Value": "20 mg"
        },
        {
          "Name": "Times of Administration [h]",
          "Value": "(S0-T24-R14)"
        },
        {
          "Name": "Formulation",
          "Value": "Capsule"
        },
        {
          "Name": "Food state",
          "Value": "."
        },
        {
          "Name": "Comment",
          "Value": "."
        }
      ],
      "Columns": [
        {
          "Name": "Avg",
          "QuantityInfo": {
            "Name": "Avg",
            "Path": "Komoroski 2009 - MAD 20 mg (day 7 and day 14) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean"
          },
          "DataInfo": {
            "Origin": "Observation",
            "AuxiliaryType": "Undefined",
            "Date": "0001-01-01T00:00:00",
            "MolWeight": 408.87
          },
          "Values": [
            92.92003,
            249.089478,
            163.728,
            112.2313,
            57.35115,
            50.56761,
            26.38835,
            25.30399,
            19.26363,
            19.67205,
            12.14178,
            9.051485,
            8.679538,
            10.7426405,
            97.97406,
            208.9296,
            160.1196,
            138.7466,
            67.78149,
            46.89333,
            35.93814,
            27.54229,
            22.90868,
            17.91981,
            11.65914,
            11.19151,
            8.754316
          ],
          "Dimension": "Concentration (mass)",
          "Unit": "µg/l"
        }
      ],
      "BaseGrid": {
        "Name": "Time",
        "QuantityInfo": {
          "Name": "Time",
          "Path": "Komoroski 2009 - MAD 20 mg (day 7 and day 14) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=6)|Time",
          "Type": "Time"
        },
        "DataInfo": {
          "Origin": "BaseGrid",
          "AuxiliaryType": "Undefined",
          "Date": "0001-01-01T00:00:00"
        },
        "Values": [
          144.5,
          145.0,
          145.5,
          146.0,
          148.0,
          150.0,
          152.0,
          154.0,
          156.0,
          158.0,
          162.0,
          166.0,
          168.0,
          312.25,
          312.5,
          313.0,
          313.5,
          314.0,
          316.0,
          318.0,
          320.0,
          322.0,
          324.0,
          326.0,
          330.0,
          334.0,
          336.0
        ],
        "Dimension": "Time",
        "Unit": "h"
      }
    },
    {
      "Name": "Komoroski 2009 - MAD 50 mg (day 7 and day 14) - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=6)",
      "ExtendedProperties": [
        {
          "Name": "DB Version",
          "Value": "OSP DATABASE"
        },
        {
          "Name": "ID",
          "Value": 688.0
        },
        {
          "Name": "Study Id",
          "Value": "Komoroski 2009"
        },
        {
          "Name": "Reference",
          "Value": "https://www.ncbi.nlm.nih.gov/pubmed/19129748"
        },
        {
          "Name": "Source",
          "Value": "Fig. 4c / Fig. 12 (202293Orig1s000ClinPharmR.pdf)"
        },
        {
          "Name": "Grouping",
          "Value": "MAD 50 mg (day 7 and day 14)"
        },
        {
          "Name": "Data type",
          "Value": "aggregated"
        },
        {
          "Name": "N",
          "Value": 6.0
        },
        {
          "Name": "Molecule",
          "Value": "Dapagliflozin"
        },
        {
          "Name": "Species",
          "Value": "Human"
        },
        {
          "Name": "Organ",
          "Value": "Peripheral Venous Blood"
        },
        {
          "Name": "Compartment",
          "Value": "Plasma"
        },
        {
          "Name": "Route",
          "Value": "PO"
        },
        {
          "Name": "Dose",
          "Value": "50 mg"
        },
        {
          "Name": "Times of Administration [h]",
          "Value": "(S0-T24-R14)"
        },
        {
          "Name": "Formulation",
          "Value": "Capsule"
        },
        {
          "Name": "Food state",
          "Value": "."
        },
        {
          "Name": "Comment",
          "Value": "."
        }
      ],
      "Columns": [
        {
          "Name": "Avg",
          "QuantityInfo": {
            "Name": "Avg",
            "Path": "Komoroski 2009 - MAD 50 mg (day 7 and day 14) - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean"
          },
          "DataInfo": {
            "Origin": "Observation",
            "AuxiliaryType": "Undefined",
            "Date": "0001-01-01T00:00:00",
            "MolWeight": 408.87
          },
          "Values": [
            355.8384,
            711.1091,
            420.8679,
            348.4506,
            185.6918,
            112.2313,
            101.0545,
            62.3718452,
            51.6397438,
            40.146225,
            30.56283,
            22.78405,
            22.78405,
            29.8920383,
            370.5859,
            630.9573,
            546.7361,
            370.5859,
            192.5061,
            122.712509,
            102.0678,
            69.1831,
            58.73391,
            43.20714,
            33.11311,
            21.54435,
            21.54435
          ],
          "Dimension": "Concentration (mass)",
          "Unit": "µg/l"
        }
      ],
      "BaseGrid": {
        "Name": "Time",
        "QuantityInfo": {
          "Name": "Time",
          "Path": "Komoroski 2009 - MAD 50 mg (day 7 and day 14) - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=6)|Time",
          "Type": "Time"
        },
        "DataInfo": {
          "Origin": "BaseGrid",
          "AuxiliaryType": "Undefined",
          "Date": "0001-01-01T00:00:00"
        },
        "Values": [
          144.5,
          145.0,
          145.5,
          146.0,
          148.0,
          150.0,
          152.0,
          154.0,
          156.0,
          158.0,
          162.0,
          166.0,
          168.0,
          312.25,
          312.5,
          313.0,
          313.5,
          314.0,
          316.0,
          318.0,
          320.0,
          322.0,
          324.0,
          326.0,
          330.0,
          334.0,
          336.0
        ],
        "Dimension": "Time",
        "Unit": "h"
      }
    },
    {
      "Name": "Komoroski 2009 - MAD 100 mg (day 7 and day 14) - Dapagliflozin - PO - 100 mg - Plasma - agg. (n=6)",
      "ExtendedProperties": [
        {
          "Name": "DB Version",
          "Value": "OSP DATABASE"
        },
        {
          "Name": "ID",
          "Value": 689.0
        },
        {
          "Name": "Study Id",
          "Value": "Komoroski 2009"
        },
        {
          "Name": "Reference",
          "Value": "https://www.ncbi.nlm.nih.gov/pubmed/19129748"
        },
        {
          "Name": "Source",
          "Value": "Fig. 4c / Fig. 12 (202293Orig1s000ClinPharmR.pdf)"
        },
        {
          "Name": "Grouping",
          "Value": "MAD 100 mg (day 7 and day 14)"
        },
        {
          "Name": "Data type",
          "Value": "aggregated"
        },
        {
          "Name": "N",
          "Value": 6.0
        },
        {
          "Name": "Molecule",
          "Value": "Dapagliflozin"
        },
        {
          "Name": "Species",
          "Value": "Human"
        },
        {
          "Name": "Organ",
          "Value": "Peripheral Venous Blood"
        },
        {
          "Name": "Compartment",
          "Value": "Plasma"
        },
        {
          "Name": "Route",
          "Value": "PO"
        },
        {
          "Name": "Dose",
          "Value": "100 mg"
        },
        {
          "Name": "Times of Administration [h]",
          "Value": "(S0-T24-R14)"
        },
        {
          "Name": "Formulation",
          "Value": "Capsule"
        },
        {
          "Name": "Food state",
          "Value": "."
        },
        {
          "Name": "Comment",
          "Value": "."
        }
      ],
      "Columns": [
        {
          "Name": "Avg",
          "QuantityInfo": {
            "Name": "Avg",
            "Path": "Komoroski 2009 - MAD 100 mg (day 7 and day 14) - Dapagliflozin - PO - 100 mg - Plasma - agg. (n=6)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean"
          },
          "DataInfo": {
            "Origin": "Observation",
            "AuxiliaryType": "Undefined",
            "Date": "0001-01-01T00:00:00",
            "MolWeight": 408.87
          },
          "Values": [
            61.0769043,
            552.8366,
            1037.398,
            895.7029,
            806.5029,
            386.9896,
            243.9179,
            201.9478,
            138.4299,
            122.05629,
            109.901207,
            67.83207,
            56.16044,
            54.99446,
            62.4533157,
            605.6507,
            1265.384,
            1031.177,
            743.2092,
            427.6723,
            284.0098,
            226.7543,
            163.4306,
            144.544,
            117.7907,
            72.07386,
            63.74476,
            62.4533157
          ],
          "Dimension": "Concentration (mass)",
          "Unit": "µg/l"
        }
      ],
      "BaseGrid": {
        "Name": "Time",
        "QuantityInfo": {
          "Name": "Time",
          "Path": "Komoroski 2009 - MAD 100 mg (day 7 and day 14) - Dapagliflozin - PO - 100 mg - Plasma - agg. (n=6)|Time",
          "Type": "Time"
        },
        "DataInfo": {
          "Origin": "BaseGrid",
          "AuxiliaryType": "Undefined",
          "Date": "0001-01-01T00:00:00"
        },
        "Values": [
          144.25,
          144.5,
          145.0,
          145.5,
          146.0,
          148.0,
          150.0,
          152.0,
          154.0,
          156.0,
          158.0,
          162.0,
          166.0,
          168.0,
          312.25,
          312.5,
          313.0,
          313.5,
          314.0,
          316.0,
          318.0,
          320.0,
          322.0,
          324.0,
          326.0,
          330.0,
          334.0,
          336.0
        ],
        "Dimension": "Time",
        "Unit": "h"
      }
    },
    {
      "Name": "Chang 2015 - Study 2 Treatment A (single oral doses) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=36)",
      "ExtendedProperties": [
        {
          "Name": "DB Version",
          "Value": "OSP DATABASE"
        },
        {
          "Name": "ID",
          "Value": 632.0
        },
        {
          "Name": "Study Id",
          "Value": "Chang 2015"
        },
        {
          "Name": "Reference",
          "Value": "https://www.ncbi.nlm.nih.gov/pubmed/26048185"
        },
        {
          "Name": "Source",
          "Value": "Fig. 3A"
        },
        {
          "Name": "Grouping",
          "Value": "Study 2 Treatment A (single oral doses)"
        },
        {
          "Name": "Data type",
          "Value": "aggregated"
        },
        {
          "Name": "N",
          "Value": 36.0
        },
        {
          "Name": "Molecule",
          "Value": "Dapagliflozin"
        },
        {
          "Name": "Species",
          "Value": "Human"
        },
        {
          "Name": "Organ",
          "Value": "Peripheral Venous Blood"
        },
        {
          "Name": "Compartment",
          "Value": "Plasma"
        },
        {
          "Name": "Route",
          "Value": "PO"
        },
        {
          "Name": "Dose",
          "Value": "10 mg"
        },
        {
          "Name": "Times of Administration [h]",
          "Value": 0.0
        },
        {
          "Name": "Formulation",
          "Value": "."
        },
        {
          "Name": "Food state",
          "Value": "."
        },
        {
          "Name": "Comment",
          "Value": "."
        }
      ],
      "Columns": [
        {
          "Name": "Avg",
          "QuantityInfo": {
            "Name": "Avg",
            "Path": "Chang 2015 - Study 2 Treatment A (single oral doses) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=36)|ObservedData|Peripheral Venous Blood|Plasma|Dapagliflozin|ArithmeticMean"
          },
          "DataInfo": {
            "Origin": "Observation",
            "AuxiliaryType": "Undefined",
            "Date": "0001-01-01T00:00:00",
            "MolWeight": 408.87
          },
          "Values": [
            68.98955,
            80.27875,
            61.46341,
            45.1568,
            29.47735,
            20.69686,
            13.17073,
            8.780488,
            6.89895439
          ],
          "Dimension": "Concentration (mass)",
          "Unit": "µg/l"
        }
      ],
      "BaseGrid": {
        "Name": "Time",
        "QuantityInfo": {
          "Name": "Time",
          "Path": "Chang 2015 - Study 2 Treatment A (single oral doses) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=36)|Time",
          "Type": "Time"
        },
        "DataInfo": {
          "Origin": "BaseGrid",
          "AuxiliaryType": "Undefined",
          "Date": "0001-01-01T00:00:00"
        },
        "Values": [
          1.0,
          2.0,
          3.0,
          4.0,
          6.0,
          8.0,
          12.0,
          16.0,
          24.0
        ],
        "Dimension": "Time",
        "Unit": "h"
      }
    }
  ],
  "ObservedDataClassifications": [
    {
      "Name": "Boulton 2013",
      "Classifiables": [
        "Boulton 2013 - Dapagliflozin po - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=7)",
        "Boulton 2013 - 14C-dapagliflozin iv - Dapagliflozin - IV - 0.08 mg - Plasma - agg. (n=7)"
      ]
    },
    {
      "Name": "Chang 2015",
      "Classifiables": [
        "Chang 2015 - Study 1 Treatment A (single oral doses) - Dapagliflozin - PO - 5 mg - Plasma - agg. (n=36)",
        "Chang 2015 - Study 2 Treatment A (single oral doses) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=36)"
      ]
    },
    {
      "Name": "Imamura 2013",
      "Classifiables": [
        "Imamura 2013 - Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=22)"
      ]
    },
    {
      "Name": "Kasichayanula 2011a",
      "Classifiables": [
        "Kasichayanula 2011a - fed - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=14)",
        "Kasichayanula 2011a - fasted - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=14)"
      ]
    },
    {
      "Name": "Kasichayanula 2011b",
      "Classifiables": [
        "Kasichayanula 2011b - Study 3: 20 mg Control (Perpetrator Placebo) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=18)",
        "Kasichayanula 2011b - Study 2: 20 mg Control (Perpetrator Placebo) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=18)",
        "Kasichayanula 2011b - Study 1: 50 mg Control (Perpetrator Placebo) - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=24)"
      ]
    },
    {
      "Name": "Kasichayanula 2012",
      "Classifiables": [
        "Kasichayanula 2012 - Study 1: Control (Perpetrator Placebo) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=24)"
      ]
    },
    {
      "Name": "Kasichayanula 2013a",
      "Classifiables": [
        "Kasichayanula 2013a - Study 2: Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=16)",
        "Kasichayanula 2013a - Study 1: Control (Perpetrator Placebo) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=14)"
      ]
    },
    {
      "Name": "Kasichayanula 2013b",
      "Classifiables": [
        "Kasichayanula 2013b - T2DM with severe renal impairment - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=4)",
        "Kasichayanula 2013b - T2DM with moderate renal impairment - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=8)",
        "Kasichayanula 2013b - T2DM with mild renal impairment - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=8)",
        "Kasichayanula 2013b - T2DM with normal kidney function - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=12)",
        "Kasichayanula 2013b - Healthy subjects with normal kidney function - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=8)"
      ]
    },
    {
      "Name": "Vakkalagadda 2016",
      "Classifiables": [
        "Vakkalagadda 2016 - Dapagliflozin - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=42)"
      ]
    },
    {
      "Name": "DeFronzo 2013",
      "Classifiables": [
        "DeFronzo 2013 - Healthy Subjects - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=12)"
      ]
    },
    {
      "Name": "Kasichayanula 2011c",
      "Classifiables": [
        "Kasichayanula 2011c - Healthy Volunteers - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=6)"
      ]
    },
    {
      "Name": "Komoroski 2009",
      "Classifications": [
        {
          "Name": "Urine",
          "Classifiables": [
            "Komoroski 2009 - SAD 2.5 mg (Urine) - Dapagliflozin - PO - 2.5 mg - Urine - agg. (n=6)",
            "Komoroski 2009 - SAD 5 mg (Urine) - Dapagliflozin - PO - 5 mg - Urine - agg. (n=6)",
            "Komoroski 2009 - SAD 10 mg (Urine) - Dapagliflozin - PO - 10 mg - Urine - agg. (n=6)",
            "Komoroski 2009 - SAD 20 mg (Urine) - Dapagliflozin - PO - 20 mg - Urine - agg. (n=6)",
            "Komoroski 2009 - SAD 50 mg (Urine) - Dapagliflozin - PO - 50 mg - Urine - agg. (n=6)",
            "Komoroski 2009 - SAD 100 mg (Urine) - Dapagliflozin - PO - 100 mg - Urine - agg. (n=6)",
            "Komoroski 2009 - SAD 250 mg fasted (Urine) - Dapagliflozin - PO - 250 mg - Urine - agg. (n=6)",
            "Komoroski 2009 - SAD 500 mg (Urine) - Dapagliflozin - PO - 500 mg - Urine - agg. (n=6)"
          ]
        },
        {
          "Name": "Plasma",
          "Classifications": [
            {
              "Name": "MAD",
              "Classifiables": [
                "Komoroski 2009 - MAD 2.5 mg (day 1) - Dapagliflozin - PO - 2.5 mg - Plasma - agg. (n=6)",
                "Komoroski 2009 - MAD 10 mg (day 1) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=6)",
                "Komoroski 2009 - MAD 20 mg (day 1) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=6)",
                "Komoroski 2009 - MAD 50 mg (day 1) - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=6)",
                "Komoroski 2009 - MAD 100 mg (day 1) - Dapagliflozin - PO - 100 mg - Plasma - agg. (n=6)",
                "Komoroski 2009 - MAD 2.5 mg (day 7 and day 14) - Dapagliflozin - PO - 2.5 mg - Plasma - agg. (n=6)",
                "Komoroski 2009 - MAD 10 mg (day 7 and day 14) - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=6)",
                "Komoroski 2009 - MAD 20 mg (day 7 and day 14) - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=6)",
                "Komoroski 2009 - MAD 50 mg (day 7 and day 14) - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=6)",
                "Komoroski 2009 - MAD 100 mg (day 7 and day 14) - Dapagliflozin - PO - 100 mg - Plasma - agg. (n=6)"
              ]
            },
            {
              "Name": "SAD",
              "Classifications": [
                {
                  "Name": "SAD 2.5 mg",
                  "Classifiables": [
                    "Komoroski 2009 - SAD 2.5 mg - Dapagliflozin - PO - 2.5 mg - Plasma - agg. (n=6)"
                  ]
                },
                {
                  "Name": "SAD 5 mg",
                  "Classifiables": [
                    "Komoroski 2009 - SAD 5 mg - Dapagliflozin - PO - 5 mg - Plasma - agg. (n=6)"
                  ]
                },
                {
                  "Name": "SAD 10 mg",
                  "Classifiables": [
                    "Komoroski 2009 - SAD 10 mg - Dapagliflozin - PO - 10 mg - Plasma - agg. (n=6)"
                  ]
                },
                {
                  "Name": "SAD 20 mg",
                  "Classifiables": [
                    "Komoroski 2009 - SAD 20 mg - Dapagliflozin - PO - 20 mg - Plasma - agg. (n=6)"
                  ]
                },
                {
                  "Name": "SAD 50 mg",
                  "Classifiables": [
                    "Komoroski 2009 - SAD 50 mg - Dapagliflozin - PO - 50 mg - Plasma - agg. (n=6)"
                  ]
                },
                {
                  "Name": "SAD 100 mg",
                  "Classifiables": [
                    "Komoroski 2009 - SAD 100 mg - Dapagliflozin - PO - 100 mg - Plasma - agg. (n=6)"
                  ]
                },
                {
                  "Name": "SAD 250 mg fasted",
                  "Classifiables": [
                    "Komoroski 2009 - SAD 250 mg fasted - Dapagliflozin - PO - 250 mg - Plasma - agg. (n=6)"
                  ]
                },
                {
                  "Name": "SAD 500 mg",
                  "Classifiables": [
                    "Komoroski 2009 - SAD 500 mg - Dapagliflozin - PO - 500 mg - Plasma - agg. (n=6)"
                  ]
                },
                {
                  "Name": "SAD 250 mg fed",
                  "Classifiables": [
                    "Komoroski 2009 - SAD 250 mg fed - Dapagliflozin - PO - 250 mg - Plasma - agg. (n=6)"
                  ]
                }
              ]
            }
          ]
        }
      ]
    },
    {
      "Name": "Kasichayanula 2008",
      "Classifiables": [
        "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin Feces - Dapagliflozin - PO - 50 mg - Feces - agg. (n=6)",
        "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin Urine - Dapagliflozin - PO - 50 mg - Urine - agg. (n=6)",
        "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin oxid Metab - Dapagliflozin oxidative metabolites - PO - 50 mg - Fraction - agg. (n=6)",
        "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin 2OG Gluc - Dapagliflozin-2-O-glucuronide - PO - 50 mg - Fraction - agg. (n=6)",
        "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin 3OG Gluc - Dapagliflozin-3-O-glucuronide - PO - 50 mg - Fraction - agg. (n=6)",
        "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin 3OG Gluc (incl. unchanged feces exret.) - Dapagliflozin-3-O-glucuronide - PO - 50 mg - Fraction - agg. (n=6)",
        "Kasichayanula 2008 - Mass Balance of 14C-dapagliflozin 2OG Gluc (incl. unchanged feces exret.) - Dapagliflozin-2-O-glucuronide - PO - 50 mg - Fraction - agg. (n=6)"
      ]
    }
  ],
  "SimulationClassifications": [
    {
      "Name": "model building",
      "Classifiables": [
        "IV 0.08 mg (perm)",
        "PO SD 10 mg (perm)",
        "PO SD 50 mg (perm)",
        "PO SD 2.5 mg (perm)",
        "PO SD 5 mg (perm)",
        "PO SD 20 mg (perm)",
        "PO SD 100 mg (perm)",
        "PO SD 250 mg (perm)",
        "PO SD 500 mg (perm)"
      ]
    },
    {
      "Name": "model verification",
      "Classifications": [
        {
          "Name": "multiple dose",
          "Classifiables": [
            "PO MD 10 mg (perm)",
            "PO MD 100 mg (perm)",
            "PO MD 2.5 mg (perm)",
            "PO MD 20 mg (perm)",
            "PO MD 50 mg (perm)"
          ]
        },
        {
          "Name": "tablet",
          "Classifiables": [
            "PO SD 20 mg IR tablet (perm)",
            "PO SD 5 mg IR tablet (perm)",
            "PO SD 250 mg fed (perm)",
            "PO SD 10 mg IR tablet (perm)"
          ]
        }
      ]
    }
  ],
  "ParameterIdentificationClassifications": [
    {
      "Name": "_tests",
      "Classifiables": [
        "PI full  (perm) (fe unchanged)",
        "PI [-logP]  (perm)",
        "PI [-Solub]  (perm)",
        "PI full  (perm) MSV"
      ]
    }
  ]
}